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ABSTRACT 
 
The PI3K-Akt signalling pathway is a well-established driver of cancer progression. 
One key process promoted by Akt phosphorylation is tumour cell motility; however 
the mechanism of VEGF-induced Akt phosphorylation leading to motility remains 
poorly understood. Previously, it has been shown that Akt phosphorylation, 
induced by different factors, causes both stimulation and inhibition of motility in 
different cell types. However, differential phosphorylation of Akt at T308 and S473 
residues by VEGF and its role in head and neck cancer cell motility and progression 
is unknown. The cell lines investigated in this study exhibited a change in 
phosphorylation of Akt in response to VEGF. However, in terms of motility, VEGF 
stimulated oral cancer and its associated cell lines, but not normal keratinocytes or 
oral mucosal fibroblasts. The addition of a PI3 kinase and mTOR inhibitor, inhibited 
the phosphorylation of Akt and also effectively blocked VEGF-induced oral cancer 
cell motility, whereas only the PI3 kinase inhibitor blocked oral cancer associated 
fibroblast cell motility. This study therefore discloses that two different mechanisms 
of Akt phosphorylation control the motility potential of different cell lines. Akt 
phosphorylated at both residues controls oral cancer cell motility. 
Tobacco, alcohol and HPV infection are associated with increased risk of HNSCC. 
However, little is known about the underlying signalling events influencing risk. It 
was also aimed to investigate the relationship between these risk factors and Akt 
phosphorylation, to determine prognostic value. VEGF-positive HNSCC biopsies, 
XIX 
 
with known HPV status, were analysed by immunohistochemistry (IHC) for Akt, 
phosphorylated at residues S473 and T308. Comparisons between the tissues were 
carried out using a Mann-Whitney U test. Associations between the variables and 
continuous immunohistochemical parameters were evaluated with general linear 
models. Patient characteristics and pAkt IHC score were analysed for possible 
association with overall survival by Cox proportional hazard models. 
Immunohistochemistry revealed that cancer patients had significantly higher levels 
of pAkt T308 than S473 (P < 0.001). Smoking and alcohol were found to be 
independent risk factors for Akt phosphorylation at T308 (P = 0.022 and 0.027, 
respectively). Patients with tumours positive for HPV or pAkt S473 had a poorer 
prognosis (P = 0.005, and 0.004, respectively). Patients who were heavy drinkers were 
more likely to die than non-drinkers (P = 0.003). Patients with low pAkt T308 were 
more likely to be HPV positive (P = 0.028). Non-drinkers were also found to have 
lower levels of pAkt T308 and were more likely to have tumours positive for HPV 
than heavy drinkers (P = 0.044 and 0.007, respectively). This study suggests different 
mechanisms of carcinogenesis are initiated by smoking, alcohol and HPV. The 
resultant data propose higher phosphorylation of Akt at T308 as a reliable biomarker 
for smoking and alcohol induced HNSCC progression and higher phosphorylation 
of Akt at S473 as a prognostic factor for HNSCC. 
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1.1  Introduction 
 
State-of-the-art laboratory research and clinical practice has significantly improved 
therapeutic regimens and early detection of cancer including HNSCC which have 
enhanced the prospect of cure and progression-free survival. However, patients with 
late-stage or metastasised cancer often get rewarded just a few months of survival 
advantage when treated by the latest molecular targeted therapy (Wan et al., 2013). 
The ability of cancer cells to metastasise from primary tumours contributes to a 
progressing tumour burden that is circulated across several sites in the body, 
causing death for many patients. Identifying the cellular and molecular steps that are 
used by cancer cells during metastasis and their interaction with the 
microenvironment can establish the basis of new ideas for prognostic, diagnostic and 
therapeutic approaches that might help restrain cancer metastasis (Wang et al., 
2005a, Yamaguchi et al., 2005, Quail and Joyce, 2013). Cell migration and invasion 
into neighbouring extracellular matrix, the lymphatic system and blood vessels is the 
critical step in metastasis. Controlling cell migration is critical in cancer treatment 
(Stracke et al., 1991) . However, the cascade of events leading to cell migration during 
cancer progression is still poorly understood. The role of the vascular endothelial 
growth factor (VEGF)-induced PI3K/Akt pathway in oral cancer cell migration, their 
control and identifying the prognostic value of phosphorylated Akt in HNSCC has 
been investigated and discussed in this project. 
 
3 
 
1.2 Cancer 
 
The generic term `cancer’ used to denote a group of about 200 diseases sharing 
common characteristics in which abnormal cells divide uncontrollably and can 
invade other tissues (Yarbro et al., 2005, Gabriel, 2008). There are over 100 different 
kinds of cancer. The majority of cancers are named for the organ or type of cell in 
which they originate- for example, cancer that starts in the head and neck region is 
called head and neck cancer, cancer that begins in the squamous cells of the skin is 
called squamous cell carcinoma. 
Different types of cancer can be grouped into broader categories. The main 
categories of cancer comprise (NCI, 2012): 
 Carcinoma- cancer that starts in the skin or in tissues that line or cover 
internal organs. 
 Sarcoma- cancer that starts in blood vessels, bone, muscle cartilage, fat or 
other connective or supportive tissue. 
 Leukaemia- cancer that begins in blood-forming tissue such as the bone 
marrow and initiates production of large numbers of abnormal blood which 
are released into the blood. 
 Lymphoma and myeloma- cancers that start in the immune system. 
 Central nervous system cancer- that starts in the cells of the brain and spinal 
cord. 
4 
 
All cancers start in cells, the body's fundamental unit of life. To understand cancer, it 
is helpful to be familiar with what happens when normal cells become cancer cells. 
The body comprises numerous types of cells. These cells grow and divide in a 
controlled manner to create more cells as they are essential to keep the body healthy. 
When cells become older or injured, they die and are restored with new cells. 
However, occasionally this orderly system becomes erroneous. DNA of a cell can 
become changed, generating mutations that influence normal cell growth and 
division. When this occurs, cells do not die when they should and new cells are 
made when the body does not require them. These additional cells may form a mass 
of tissue called a tumour (Ruddon, 2007, NCI, 2012). 
Tumours can be Benign and Malignant. 
 Benign tumours- Cells in benign tumours do not spread to other parts of the 
body. They can often be removed and in most cases, they do not reappear. 
 Malignant tumours- these cancerous tumours can invade local tissues and 
spread to other parts of the body. 
The spread of the cancerous cells expands outward from the original tumour and 
has been expressed as similar to the appearance of a crab. This is the basis of the 
term ‘cancer’, which was originated from the Latin meaning ‘crab’ (Walter, 1977). 
5 
 
The earlier a cancer is identified, the less likely it is to spread, and so the more 
positive the prognosis for the individual (DoH, 2000). 
1.2.1 Head and Neck cancer 
 
The majority of head and neck cancer begin in the cells lining the open cavities of the 
head and neck, such as the mouth, throat, sinuses and the nasal cavity. Other type of 
head and neck cancer can appear in the salivary glands. Cancers of the brain and 
thyroid are not categorised as head and neck cancer (Shah et al., 2001, Brockstein and 
Gregory, 2002). Head and neck squamous cell carcinomas (HNSCC) comprise the 
vast majority of head and neck cancers and appear from mucosal surfaces 
throughout this anatomic region. They comprise  tumours of the oral cavity, 
nasopharynx, oropharynx, hypopharynx, larynx, nasal cavities and paranasal 
sinuses (Figure 1.1)  (Barnes et al., 2005). 
These  cancers frequently spread to the lymph nodes of the neck, and this is often the 
first indication of the disease at the time of diagnosis (Samson et al., 2010).  
1.2.1.1 Oral cavity 
 
The oral cavity consists of the lips, the front two-thirds of the tongue, the gums, the 
lining within the cheeks and lips, the floor of the mouth under the tongue, the hard 
palate and the gum at the rear of the wisdom teeth (Hiatt and Gartner, 2009). 
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Figure 1.1 The region of head and neck. 
The figure shows different parts of the head and neck including nasal cavity, lips, 
tongue, floor of the mouth, nasopharynx and larynx (Eisenberg, 2010). 
 
1.2.1.2 Pharyngeal 
The pharynx is a hollow tube about 5 inches long that leads from the back of the 
nose to the oesophagus. It has three parts: 
Nasopharynx: The upper fraction of the pharynx, behind the nose.  
Oropharynx: The central part of the pharynx, extends from the soft palate to the 
superior border of the epiglottis. Oropharynx is surrounded superiorly by the soft 
palate, laterally by the palatoglossal arches and inferiorly by the tongue. 
Hypopharynx: The inferior part of the pharynx (Norton, 2007, Hiatt and Gartner, 
2009) 
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1.2.1.3 Laryngeal 
The larynx is also called the voicebox, a short passageway shaped by cartilage, just 
underneath the pharynx in the neck. The larynx contains the vocal cords. It also 
contains a small piece of tissue, called the epiglottis, which shifts to cover the larynx 
to stop food from entering the air passages (Norton, 2007). 
1.2.1.4 Paranasal sinuses and nasal cavity 
The paranasal sinuses are small void spaces in the bones of the head encircling the 
nose. The nasal cavity is the hollow space within the nose. 
1.2.1.5 Salivary glands 
The major salivary glands are in the floor of the mouth and next to the jawbone. The 
salivary glands generate saliva (Norton, 2007, Hiatt and Gartner, 2009). 
 
1.2.2 Oral cavity 
 
The oral cavity (Figure 1.2) is oval shaped and is divided into the oral vestibule and 
the oral cavity proper (Snow et al., 2009). It is connected by the lips anteriorly, the 
palate superiorly, the cheeks laterally, the oropharynx posteriorly and the floor of 
the mouth inferiorly (Probst et al., 2006). The bony base of the oral cavity is 
characterised by the maxillary and mandibular bones.  
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Figure 1.2 Graphical representation of oral cavity. 
 
It is showing hard palate, soft palate, tongue, uvula, tonsil, submandibular  gland, 
oropharynx, lips and teeth  (Dworken et al., 2012). 
 
The oral cavity consists of the lips, teeth, hard palate, cheek mucosa, tongue, floor of 
the mouth, gingivae and retromolar trigone. The major salivary glands are not part 
of oral cavity. The palatine tonsils, tongue base, soft palate and posterior pharyngeal 
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walls are components of the oropharynx which are not part of the oral cavity 
(Berkovitz et al., 2002, Shah et al., 2003, Edge, 2010).  
 
1.2.2.1 Normal histology of oral cavity 
 
The oral cavity is lined by the oral mucosa, a specialised tissue. This tissue is 
designed to offer defence to the body from infection and it is able to produce 
secretions such as mucus (Squier and Brogden, 2011). The oral mucosa (Figure 1.3) is 
comprised of stratified squamous epithelium, basement membrane, the lamina 
propria and submucosa. No hair follicles or sweat glands present in oral mucosa. It 
contains many sensory receptors including the taste receptors of the tongue.  
Keratinisation occurs in areas most exposed to mastication like hard palate, gingiva 
and dorsum of tongue (Shah et al., 2003). 
 
 
Figure 1.3 Cross section of oral 
mucosa. 
It is comprised of 
epithelium, basement 
membrane, lamina 
propria and sub mucosa 
(Shojaei, 1998). 
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The lamina propria is composed of loose connective tissue, mucous glands and 
serous minor salivary type glands. The submucosa has collagenous, dense, fibrous 
tissue (Pernick, 2012). 
1.2.3 Oral cancer 
 
Oral cancer, a subtype of head and neck cancer, is any cancerous tissue growth 
located in the oral cavity (Werning 2007). It may appear as a primary lesion 
originating in any of the oral tissues, by metastasis from a remote site of origin, or by 
expansion of an adjacent anatomic structure, such as the nasal cavity or the 
maxillary sinus (Pernick, 2012). An oral tumour may develop in any of the tissues of 
the mouth and may be of various histological types e.g., teratoma, adenocarcinoma 
originating from a major or minor salivary gland, lymphoma from tonsillar or other 
lymphoid tissue, or melanoma from the pigment generating cells of the oral mucosa. 
There are a number of different types of oral cancers, but about 90% are squamous 
cell carcinomas (OCF, 2012) deriving in the tissues that line the mouth and lips. 
These are malignant and likely to spread quickly.  Oral or mouth cancer most 
commonly involves the tongue. It may also occur on the floor of the mouth, cheek 
lining, gingiva (gums), lips, or palate (roof of the mouth)(Werning, 2007). 
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1.2.4 Clinical presentations of oral cancer 
 
Ulceration and indurated margin are two very characteristic features of almost all 
oral cancer, except those in the earliest stages. However  there are certain variations 
in different sites (Bagan et al., 2010). 
Lip cancer usually refers to the cancer of vermilion border with the lower lip (Figure 
1.4) being much more frequently affected than the upper lip. Vermilion border 
cancers in contrast to oral mucosa cancer often have their origin in a tissue which is 
altered by ageing or UV radiation: actinic keratosis and elastosis. This assumes a 
paler colour, which characterised by narrowing of vermilion border. Cancer of the 
skin has more similarity to this cancer of modified mucosa and pre cancer in the 
form of actinic keratosis than that of oral mucosa (Pindborg et al., 1997, Barnes et al., 
2005). 
 
 
 
Figure 1.4 Lip cancer. 
 
A ulcerated area with indurated and firm margin (Reifman, 2012). 
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Cancer of the labial commissures are often associated with candidal infection and 
preceded by nodular leukoplakia. 
The majority of buccal mucosa cancers are located posteriorly. Sometimes the cancer 
extends into the upper or lower sulcus. The buccal mucosa is the major location of 
oral cancer in some areas of South and South-eastern Asia. This may be due to high 
occurrence of betel quid chewing with tobacco. 
Cancer of the floor of the mouth is often sited anteriorly near or in the midline 
(Figure 1.5). In advanced cases, adjacent structures such as extension into tongue are 
common. Leukoplakia( pre-cancerous white patches) or erythroplakia (pre-
cancerous red patches) may also be present (Pindborg et al., 1997, Shah et al., 2003, 
Barnes et al., 2005). 
 
Figure 1.5 Cancer of the floor of the mouth. 
 
A sharply defined margin and raw ulcerated area (Levison et al., 2008). 
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Tongue cancer often is exophytic and linked with ulceration (Figure1. 6). Sometimes 
the only presentation of carcinoma is leukoplakia in tongue cancer. The main 
location of  tumour growth is in the lateral border and ventral surface of anterior 
tongue (Pindborg et al., 1997, Neville et al., 2002). 
 
Figure 1.6 Cancer of lateral border of tongue. 
 
Red and white and warty growth enclosed by leukoplakia (Pindborg et al., 1997). 
 
Palatal cancer develops as swelling that later ulcerates with deep growth (Figure 
1.7). Reverse smokers ( who smokes a cigarette from the lit end) are at high risk of 
hard palate cancer which develops as an ulcer lateral to the midline (Bagan et al., 
2010). 
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Figure 1.7 Mouth cancer on hard palate.  
                                                                     
Squamous cell carcinoma on the hard palate characterised by growing mass 
(Sadeghi, 2015). 
 
 
The term gum cancer is commonly used to describe both cancer in gingiva and 
edentulous alveolar ridge, although the mucosal structure of both the sites is 
different. The carcinoma begins as ulceration, often associated with leukoplakia at 
either site (Figure 1.8) (Pindborg et al., 1997, Barnes et al., 2005). 
 
Figure 1.8 Cancer of the gingiva. 
 
Ulceration with leukoplakia (Buquot, 1992). 
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Cancer of the vermilion border of lower lip has a lower tendency to produce cervical 
lymph node metastases. Even though the cancer of the tongue and floor of the 
mouth are smaller in size, they have a high frequency of spreading to cervical nodes. 
Cancer located close to or extending to the midline may spread to contra lateral or 
bilateral lymph nodes but usually to the ipsilateral side of the neck (Pindborg et al., 
1997). 
1.2.5 Oral pre-cancerous lesion 
 
Histologically oral pre-cancerous lesions are divided into three classes: 
i. Epithelial hyperplasia 
ii. Squamous epithelial dysplasia 
iii. Squamous cell carcinoma in situ 
 
1.2.5. i Epithelial hyperplasia 
 
Cytologically  no changes occur in the hyperplasia but architecturally they are 
characterised by thickened epithelium, hyperkeratosis and normal maturation 
(Figure 1.9) (Speight, 2007). 
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Figure 1.9 Epithelial hyperplasia. 
 
Thickened epithelial layer with normal maturation (Speight, 2007). 
 
 
 
1.2.5. ii Squamous epithelial dysplasia 
 
Squamous epithelial dysplasia is a pre-cancerous condition of stratified squamous 
epithelium. It is characterised by cellular atypia and loss of normal cell maturation 
and stratification short of carcinoma in situ. The general disorder of the epithelium is 
designated as dysplasia and the possibility for progressing to invasive carcinoma 
increases with the severity of dysplasia (Pindborg et al., 1997, Speight, 2007). Table 1 
lists the changes that may occur in epithelial dysplasia. 
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Table 1 Histological transformations to the diagnosis of epithelial dysplasia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. The more aggressive or more numerous the changes are, the more severe the grade of 
dysplasia (Speight, 2007, Ramadas et al., 2012). 
 
Any degree of dysplasia (Figure 1.10-1.12), even a mild form, designates an 
increased risk for the patient. Severe dysplasia signifies that there is a very high risk 
of the consequent growth of cancer. Dysplasia is often seen synchronised with 
invasive carcinoma. 
Architecture Cytology 
Drop-shaped rete-ridges 
Polarity loss of basal cells 
Irregularity of epithelial stratification 
Number of mitotic figures increases 
Mitotic figures present in the superficial 
half of the epithelium 
Dyskeratosis ( Premature keratinisation 
in single cells) 
Keratin pearls with rete pegs 
Loss of intercellular adherence 
Abnormal form ( Atypical) of mitotic 
figures 
Anisonucleosis( abnormal variation of 
nuclear size) 
Nuclear pleaomorphism ( abnormal 
variation in nuclear shape) 
Anisocytosis ( abnormal variation in 
cellular size) 
Cellular pleomorphism ( abnormal 
variation in cellular shape) 
Nuclear-cytoplasmic ratio increases 
Increased nuclear size 
Nuclear hyperchromatism 
Increased number and size of nucleoli 
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Figure 1.10 Mild dysplasia. 
 
Basal cell atypia including  hyperchromatism and pleomorphism  is common 
without any architectural changes. Stratification is also normal (Speight, 2007). 
 
 
Figure 1.11 Moderate dysplasia. 
 
A considerable cellular atypia extends into the middle third of the epithelium 
(Speight, 2007). 
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Figure 1.12 Severe dysplasia. 
 
Cellular atypia spreads into the upper third of the epithelium. Basal cell hyperplasia 
is common. Disruption of the normal architecture of the epithelium and spherical 
rete pegs are noticeable (Speight, 2007). 
 
1.2.5. iii Squamous cell carcinoma in situ 
 
Carcinoma in situ is a lesion in which full thickness or almost the full thickness of 
squamous epithelium demonstrates the cellular characteristics of carcinoma without 
stromal invasion (Figure 1.13). 
Severe grades of dysplasia are amalgamated into lesions routinely regarded as 
carcinoma in situ in which the whole or almost the whole of the epithelium is 
involved. 
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However, differentiating between severe dysplasia and carcinoma in situ is often 
tricky and does not appear to be of practical value in the case of the oral mucosa 
(Pindborg et al., 1997). 
 
 
Figure 1.13 Carcinoma in situ. 
 
Hyperproliferation of epithelial cells. The cells have not acquired the required 
genetic lesions that would assist basement membrane diffusion and invasion (Regezi 
and Jordan, 2001). 
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1.2.6 Oral Carcinomas 
 
According to WHO tumour classification (2005) Oral carcinomas can be classified 
into the following types (Barnes et al., 2005):  
i. Squamous Cell Carcinoma 
ii. Verrucous Carcinoma 
iii. Basaloid Squamous Cell Carcinoma 
iv. Acantholytic Squamous Cell Carcinoma 
v. Spindle Cell Carcinoma 
vi. Adenosquamous Carcinoma 
vii. Papillary Squamous Cell Carcinoma 
viii. Carcinoma Cuniculatum 
 
1.2.6.i Squamous cell carcinoma 
 
Squamous cell carcinoma is the malignant neoplasm of epithelium displaying 
squamous differentiation as distinguished by the development of keratin and/or the 
existence of intercellular bridges (Pindborg et al., 1997).  
To establish a prognosis for the patient or an indicator for the most successful 
treatment and in an attempt to forecast their aggressiveness it has been usual to 
grade this neoplasm. This grading is based on the subjective measurement of the 
degree of keratinisation, cellular and nuclear pleomorphism and mitotic activity 
(Pindborg et al., 1997, Bhargava et al., 2010). The grades are: 
22 
 
 Grade 1: Well differentiated carcinoma that closely resemble to normal 
squamous epithelial lining of the oral mucosa, histologically and 
cytologically. Keratinisation is the outstanding feature in this grade where 
there is varying extent of basal and squamous cells with intercellular 
bridges. Cellular and nuclear pleomorphism is negligible, atypical mitoses 
and multinucleated epithelial cells are extremely rare. A small number of 
mitotic figures are also seen (Pindborg et al., 1997, Woolgar and 
Triantafyllou, 2009, Bhargava et al., 2010) (Figure 1.14). 
 
  
Figure 1.14 Well differentiated squamous cell carcinoma. 
 
Infiltrating nests and sheets of keratinising cells are presents (IARC, 2015) .  
 
 
 Grade 2: Moderately differentiated neoplasm which has less keratinisation 
and more cellular and nuclear pleomorphism than well-differentiated 
squamous cell carcinoma. There are more mitotic figures with some 
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abnormal form and less obvious intercellular bridges are also present 
(Pindborg et al., 1997, Woolgar and Triantafyllou, 2009, Bhargava et al., 
2010) (Figure 1.15). 
 
Figure 1.15 Moderately differentiated squamous cell carcinoma. 
 
Characterised by limited keratin configuration (IARC, 2015). 
 
 Grade 3: Poorly differentiated carcinoma which has rare keratinisation and 
extremely scarce intercellular bridges. Mitotic activity and multinucleated 
cells are frequent. Cellular and nuclear pleomorphism and atypical 
mitoses are obvious (Pindborg et al., 1997, Woolgar and Triantafyllou, 
2009, Bhargava et al., 2010) (Figure 1.16). 
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Figure 1.16 Poorly differentiated oral squamous cell carcinoma. 
Non-keratinising sheets of infiltrating carcinoma (IARC, 2015). 
 
There are no known differences between oral squamous cell carcinoma and those 
found elsewhere in terms of capacity to extend by invasion into neighbouring 
tissues. Tumour infiltration into bone and intra-vascular spread is common as much 
of the oral mucosa is closely related to blood vessels and underlying bone. Invasion 
may occur sometimes by dissociated individual cancer cells and in the form of solid 
sheets, cords or islands of malignant cells. The basement membrane may be more or 
less discrete or completely absent. The term microinvasive squamous cell carcinoma 
is often used when invasion by islands or strands of squamous carcinoma engages 
only the most superficial regions of primary connective tissue, just below the 
basement membrane (Pindborg et al., 1997, Barnes et al., 2005, Wang et al., 2005b, 
Harrison et al., 2008). 
25 
 
When squamous cell carcinoma infiltrates through stromal tissue, this may show an 
uneven chronic inflammatory reaction and in some instances a desmoplastic 
response is aggravated. Extensive spreading through lymphatics and blood vessel 
also occurs (Pindborg et al., 1997, Barnes et al., 2005). 
 
1.2.6.ii Verrucous Carcinoma 
 
Verrucous carcinoma(VC)  is exophytic, warty, slowly growing variant of well 
differentiated keratinising epithelium with minimal atypia and limited pushing 
margins at its interface with underlying connective tissues (Pindborg et al., 1997, 
Barnes et al., 2005) (Figure 1.17). Hyperplastic well-differentiated stratified 
epithelium is arranged into bulbous rete-ridges that demonstrate no or little 
cytological atypia or mitotic activity. A considerable endophytic component may be 
present and the invading boundary is typically below the level of the surrounding 
mucosa. The advancing epithelial margin is wide and the basement membrane is 
usually undamaged. Strong inflammatory cell reaction can be seen in adjacent 
connective tissues and local destruction of the connective tissues occurs in advance 
of the deep epithelial margin. Pure verrucous carcinoma‘s growth is normally slow 
and metastasis is very rare. However, hybrid VC (non-verruous SCC that arises 
synchronously with VC) has the potential to metastasise. Although very uncommon, 
75% of all cases are found in the oral cavity and usually occurs in older males 
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(Grinspan and Abulafia, 1979, Tornes et al., 1985, Pindborg et al., 1997, Barnes et al., 
2005). 
 
 
Figure 1.17 Verrucous carcinoma. 
Exophytic hyperkeratinised SCC with atypical cytology and extended epithelial rete-
ridges (Barnes et al., 2005). 
 
 
 
1.2.6.iii Basaloid Squamous Cell Carcinoma 
 
Basaloid squamous cell carcinoma is an aggressive and high grade variant of SCC 
with a mixed composition of basaloid and squamous cells (Pindborg et al., 1997, 
Barnes et al., 2005)( Figure 1.18). The basaloid components of this type of oral 
carcinoma are comprised of hyperchromatic nuclei and scant cytoplasm which are 
crowded together into lobulated sheets or strands. These sheets are usually 
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connected focally to the surface epithelium. Palisaded cells are often seen at the 
periphery of the lobules. More centrally, sometimes there may be cystic spaces 
containing mucin-like materials and focal squamous differentiation. Mitotic figures 
are common with variable hyalinisation of surrounding stroma and chronic 
inflammatory cell infiltration. Larynx, hypopharynx and base of the tongue are the 
most common areas where basaloid carcinoma occurs (Banks et al., 1992, Barnes et 
al., 1996, Pindborg et al., 1997, Barnes et al., 2005). 
 
 
Figure 1.18 Basaloid squamous cell carcinoma. 
Small cell with hyperchromatic nuclei demonstrate peripheral palisading and 
surround areas of cystic necrosis (Pindborg et al., 1997). 
 
1.2.6.iv Acantholytic Squamous Cell Carcinoma 
 
Pseudoglandular spaces or lumina containing squamous cell carcinoma are termed 
acantholytic squamous cell carcinoma (Figure 1.19), also known as pseudoglandular 
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squamous carcinoma. Keratinocyte acantholysis and degeneration within islands of 
a SCC are the major characteristics of this variant. It appears as 
pseudoadenocarcinoma, but there is no sign of glandular differentiation or of 
secretory products or functions (Pindborg et al., 1997, Barnes et al., 2005). 
 
Figure 1.19 Acantholytic squamous cell carcinoma. 
Characterised by pseudoglandular spaces and acantholysis (Pindborg et al., 1997). 
 
1.2.6.v Spindle Cell Carcinoma 
 
This type of carcinoma contains some elements that resemble squamous cell 
carcinoma which are associated with spindle cell components (Figure 1.20). This 
type of carcinoma is also called sarcomatoid carcinoma. The malignant spindle- 
shaped cells are epithelial in origin and derived from squamous cell sections of the 
carcinoma. Most of the carcinoma contains thin elongated cells with occasional 
pleomorphic cell and frequent mitotic figures. Spindle cell carcinoma should be 
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distinguished very carefully from squamous cell carcinoma that has activated 
stromal fibroblastic proliferation (Pindborg et al., 1997, Barnes et al., 2005). 
 
Figure 1.20 Spindle cell carcinoma. 
Characterised by thin elongated cells (Barnes et al., 2005). 
 
1.2.6.vi Adenosquamous Carcinoma 
 
Adenosquamous carcinoma is a malignant carcinoma which is histologically 
characterised by both adenocarcinoma and squamous cell carcinoma (Figure 1.21). 
The tumour may appear from the surface epithelium of minor salivary glands or 
from the ducts of the glands. The component found as squamous cell carcinoma may 
be in situ or invasive. On the other hand, adenocarcinomatous components may 
include glandular structures lined by columnar, basaloid and mucin-secreting cells 
(Barnes et al., 2005, Fonseca et al., 2012). 
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Figure 1.21 Adenosquamous carcinoma. 
Characterised by both adenocarcinoma and squamous cell carcinoma (Pindborg et 
al., 1997). 
 
1.2.6.vii  Papillary Squamous Cell Carcinoma 
 
 
Papillary SCC is a distinctive  variant of squamous cell carcinoma characterised by 
exopphytic papillary(filliform) growth pattern.These filliform growth have thin 
fibrovascular core covered by neoplastic, immature basaloid cells or more 
pleomorphic cells (Figure 1.22) . Larynx and hypopharyns are the most common site 
of this variant of SCC (Barnes et al., 2005). 
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Figure 1.22 Papillary Squamous Cell Carcinoma. 
 
A, Papillary growth with finger-like projections and distinguishable fibrovascular 
core. B, Markedly pleomorphic cells (Wenig, 2002).  
 
 
1.2.6.viii Carcinoma Cuniculatum 
 
This is a rare variant of oral cancer which infiltrates deeply into the bone. The keratin 
filled crypts are surrounded by well-differentiated squamous epithelium along with 
broad epithelial processes (Figure 1.23). Tumour cells exhibit frequent mitosis and 
mild cytologic atypia in this type of carcinoma (Allon et al., 2002, Barnes et al., 2005). 
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Figure 1.23 Carcinoma Cuniculatum. 
 
Invasive tumour underneath the oral epithelium (arrow) with keratin filled crypts 
surrounded by well-differentiated squamous cell epithelium (A) (Allon et al., 2002) 
 
 
 
1.3 TNM staging system and datasets for reporting oral cancer 
 
Measurement of the mass of the primary tumour (T), the number of local lymph 
node metastasis (N) and the incidence of distant metastasis(M),  collectively called 
TNM system  are broadly used to describe the degree of tumour load and decide 
treatment options for patients with oral squamous cell carcinoma (Deschler and Day, 
2008). Table 2 (Deschler and Day, 2008) describes the TNM staging system for head 
and neck cancer. 
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Table 2 TNM staging system of head and neck cancer 
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 TNM system often has faced the criticism that it overlooks individual histological 
features of tumours. It has been suggested that a combined assessment of 
histological grading along with clinical staging might offer a more precise measure 
for envisaging the outcome of the neoplasms and determining the best treatment for 
each patient (Anneroth et al., 1987, Sawair et al., 2003).  The histological 
characteristics of oral cancer may vary widely from site to site within the same 
tumour, and it is understood that the most valuable prognostic data can be 
determined from the invasive front of the tumours, where the innate and apparently 
most aggressive cells reside (Bryne et al., 1989, Bryne et al., 1998). According to ‘the 
dataset for histopathology reporting of mucosal malignancies of the oral cavity’ 
published by the Royal College of Pathologists the following pathological core data 
items should be included in the histopathology report for oral cancer (Helliwell and 
Woolgar, 2013): 
 Maximum diameter of tumour: The macroscopic diameter in millimetres 
should be used. If the histological degree is greater than macroscopic 
extent then the microscopic diameter is used. 
 Maximum depth of invasion: For non-ulcerated tumour the maximum 
depth of invasion underneath the luminal aspect of surface should be 
documented. For ulcerated tumour the reconstructed surface should be 
used. A more detailed nature of the tissues invaded (mucosa, muscle etc.) 
should be commented. Depth of invasion has a good evidence for the 
prognostic value in oral cancer. 
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 Histological type of carcinoma: Subtypes of squamous carcinoma, such as 
basaloid, papillary, verrucous, adenosquamous etc. should be identified 
and listed in the dataset. 
 Degree of differentiation (grade): Tumour is graded according to the 
degree of resemblance of the carcinoma to the normal epithelium and the 
most aggressive area is graded as poorly, moderately and well 
differentiated. Grading is useful for prognostication. 
 Pattern of invasion: Two groups for the pattern of invasion are identified 
for the purposes of prognostication: ‘carcinomas composed of broad 
cohesive sheets of cells or strands of cells >15 cells across’ and ‘carcinomas 
composed of narrow strands, non-cohesive small groups of single cells’. 
 Distance from invasive carcinoma to surgical margins: Distance for both 
mucosal and deep margins should be measured histologically. >5mm is 
clear, 1-5mm is close and <1mm is involved, from a surgical point of view. 
 Vascular invasion: If vascular invasion is an obvious feature on medium 
magnification examination of the tumour, the presence or absence of it 
should be mentioned. 
 Nerve invasion: Perineural invasion in front of the invasive front of the 
carcinoma should be documented, regardless of the size of the nerve. 
Nerve invasion predicts more aggressive disease. 
 Bone invasion: The presence or absence of carcinoma at the bone margins 
should be listed, if bone invasion is present. 
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 Severe dysplasia/carcinoma in-situ: The presence of moderate or severe 
dysplasia next to to the primary carcinoma and inside 5mm of the 
resection margins should be noted. Severe dysplasia and carcinoma in-situ 
often used interchangeably and linked with a high risk of progression to 
carcinoma. 
 
 
1.4 Epidemiology of Head and Neck cancer 
 
The world cancer report 2014 published that there were around 15 million new 
cancer cases, 8.5 million cancer deaths and 33 million people living with cancer 
within 5 years of diagnosis in 2012 worldwide. 58% of new cancer cases, 66% of the 
cancer deaths and 49% of the 5-year prevalent cancer cases appeared in the less 
developed countries (Stewart and Wild, 2014). In 2014, the International Agency for 
Research on Cancer (IARC) estimated that there are approximately 630,000 new 
cases of head and neck cancer and 300,000 deaths every year worldwide, which 
makes it the 6th most prevalent cancer in the world. The most common sites of head 
and neck cancer are the oral cavity with 400,000 cases a year, the larynx with 160, 000 
cases a year and the pharynx with 65,000 a year (Stewart and Wild, 2014). 
There is an approximately 20-fold geographical variation in the incidence of this 
cancer. South and Southeast Asia (e.g. India, Bangladesh, Sri Lanka, Taiwan), parts 
of Latin America and the Caribbean (e.g. Brazil, Puerto Rico, Uruguay), parts of 
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Western (e.g., France,  Eastern Europe: Hungary, Slovakia, Slovenia) and in Pacific 
regions (e.g. Papua New Guinea, Melanesia) are the areas characterised by high 
incidence rates for oral cancer. This cancer is the most common cancer in men in 
high-risk countries such as India, Bangladesh, Pakistan and Sri Lanka and may 
represent up to 25% of all new cancer cases (Warnakulasuriya, 2009). WHO 
projections estimated mortality statistics from oral and oropharyngeal cancer in 2008 
to be 371, 000 worldwide. Because there is a predicted rise in mortality in Southeast 
Asia (182,000 in 2008 to 324,000 in 2030) this is projected to increase to 595,000 by 
2030 worldwide (Mathers and Loncar, 2006, Mehanna et al., 2010). 
A recent study however revealed that, rates of oral cavity cancer have decreased in 
Canada and the US, remained stable or decreased in a number of Asian countries 
and increased in a number of European countries. Oropharyngeal cancer rates also 
decreased for men and women in China (Hong Kong) and India (Mumbai) and rates 
rise among men and women in some eastern (Belarus, Czech Republic) and in some 
northern European countries (the UK, Sweden, Norway, Finland) as well as some 
Asian countries (Japan, India[Chennai]). The difference in trends in incidence rates 
among countries by head and neck cancer sub-site and gender probably indicate the 
differences in the prevalence of known risk factors (Simard et al., 2014). 
In the UK, around 6,500 people were diagnosed with oral cancer in 2010 that equates 
to 18 people every day. Among them, 4,300 were men and 2,200 were women. The 
incidence rate of oral cancer has increased by a third in the last decade. The most 
common age group is 65 and over for oral cancer cases in the UK. On the other hand, 
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around 2,400 people were diagnosed with laryngeal cancer in 2011, more than 6 
people a day. 1,900 were men and 400 were women were diagnosed with laryngeal 
cancer, i.e. it is four times more common in men that women. 
In 2011, around 2,100 people died of oral cancer (more than five people a day) and 
800 people died of laryngeal cancer in the UK. Around two-thirds of oral cancer 
deaths and 8 in 10 laryngeal cancer deaths were in men. The mortality rates of oral 
cancer have remained stable since 1970, whereas the laryngeal cancer mortality rate 
have fallen by around a fifth in the last decade (CRUK, 2014a, b). 
Scotland has the highest occurrence of oral cancer in the UK (Table 3)(CRUK, 2014c) 
and this incidence is rising alarmingly (Robinson and Macfarlane, 2003, Mendez, 
2007). Taken together, oral and laryngeal cancer incidence  occurs in 2.7% of all 
malignancies which rank head and neck cancer the 10th most prevalent cancer in the 
UK (CRUK, 2014c). 
Table 3 UK Head and Neck cancer incidence rate (2011) by country 
 
HNSCC by 
site 
Incidence rate per 100,000 
England Wales Scotland Northern Ireland UK 
Oral 8.6 10.1 11.8 9.3 9.0 
Larynx 2.7 3 4.2 4.3 2.9 
 
Notes: Rates are European age-standardised and given per 100,000 populations 
(CRUK, 2014c). 
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1.5 Aetiology and risk factors 
 
A number of risk factors have been characterised as being associated with oral 
cancer with substantial evidence (Ram et al., 2011). Not all individuals exposed to 
these risk factors develop oral cancer; on the contrary, oral cancer may also develop 
without exposure to these risk factors. This observation proposes that additional 
causes, for example genetic susceptibility, may also play a part in the variable 
individual susceptibility to oral cancer (Mehrotra and Yadav, 2006). Cancer is the 
eventual consequence of the transformation of normal cells to mutated cells with 
uncontrolled growth by enhancing factors, DNA-reactive and genotoxic carcinogens. 
Thus, cancer is the product of interaction of environmental exposures and genetic 
factors which progresses over a long time and goes through many steps (Taghavi 
and Yazdi, 2007). Some well characterised risk factors are described below:  
 
1.5.1 Tobacco use 
 
There is plenty of evidence to suggest that tobacco in different forms, including 
smoking and smokeless have a carcinogenic impact in the oral cavity. Smoking is the 
commonest form of tobacco use and the most important risk factor for oral cancer. 
Smoking of tobacco as factory-made cigarettes, cigars and cheroots and loose 
tobacco in pipes or hand-made cigarettes is familiar to all (Johnson, 2001). The risk is 
higher for heavy smokers, long-term smokers and smokers of black or high tar 
cigarettes. Cigar and pipe smoking also pose a risk. (Kjaerheim et al., 1998). Smoking 
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of bidis (small filter-less cigarettes common in India and Bangladesh) seems to have 
a higher risk for cancer of the hypo-pharynx and larynx than smoking of the Western 
type cigarettes (Sapkota et al., 2007). Hookah or chillum, a clay pipe used to keep the 
burning tobacco are other common forms of smoking in some countries of Asia 
including India (Ram et al., 2011). Among men in industrialised countries, smoking 
is estimated to be the cause of 40-45 percent of all cancer deaths, over 85 percent of 
oral cancer deaths, in those aged thirty-five to sixty-nine years (Boyle and Levin, 
2008). It is estimated that smoking tobacco causes around 70% of oral and 
pharyngeal cancers in men, and around 55% in women in the UK (Parkin, 2011a). 
Smokeless tobacco is consumed orally or nasally, without burning the product. Oral 
smokeless products are placed in the mouth, cheek or lip and are sucked (dipped) or 
chewed. Chewing tobacco can be classified as loose leaf, plug and twist. Snuff is a 
common term for finely cut or powdered, flavoured tobacco, which can be prepared 
as moist or dry snuff. Tobacco pastes or powders are also used orally and rub on to 
the gums or teeth. Dry snuff can also be inhaled through the nasal passages (Boffetta 
et al., 2008). In developing countries smokeless tobacco is mostly used mixed with 
other constituents (Table 4) (Figure 1.23) (Johnson, 2001). 
Table 4 Some conventional forms of oral smokeless tobacco 
 
Habit Ingredients Population 
Pan/Paan/betel 
quid 
Areca nut, betel leaf, slaked 
lime, catechu, condiments, 
Indian subcontinent, Southeast 
Asia, Papua New Guinea, part 
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with or without tobacco of South America 
Khaini Tobacco and lime Bihar (India) 
Mishri Burned tobacco Maharashtra (India) 
Zarda Boiled tobacco India, Bangladesh and Arab 
countries 
Gudkha/Gudakhu Tobacco and molasses Central India, Pakistan 
Mawa Tobacco, lime and areca India 
Nass Tobacco, ash, cotton or 
seasame oil 
Central Asia, Iran, Afganistan, 
Pakistan 
Naswar/niswar Tobacco, lime, indigo, 
cardamom, oil, menthol, etc. 
Central Asia, Iran, Afganistan, 
Pakistan 
Shammah Tobacco, ash and lime Saudi Arabia 
Toombak Tobacco and Sodium 
bicarbonate 
Sudan 
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Figure 1.24 Some common forms of smokeless tobacco product. 
(A) Betel quid with tobacco, (B) Bidi, (C) Dry snuff and (D) Zarda. 
 
IARC categorises smokeless tobacco as a cause of oral cavity cancer. Oral cancer risk 
varies by geographical location, possibly due to variances in the composition and 
format (e.g. chewing or inhaling nasally) of smokeless tobacco (IARC, 2014). In India 
and Sudan, over 50% of oral cancers are attributable to smokeless tobacco products 
used in these countries, so are about 4% of oral cancers in US men and 20% of 
oesophageal cancers in Swedish men (Boffetta et al., 2008). 
Tobacco is the most common source of carcinogens to human, including polycyclic 
aromatic hydrocarbons (i.e. benzo[a] pyrene) and tobacco specific nitrosamines (i.e. 
NNK). It introduces a linear dose-response carcinogenic effect in which duration is 
more significant than the intensity of exposure. The most important carcinogenic 
effect of tobacco resides in the tar fraction, which comprises a composite 
46 
 
mixture of interacting cancer initiators, promoters, and co-carcinogens (Sturgis et al., 
2004). The chronic exposure of this mixture to the airway epithelial cells, through 
continued smoking, can cause molecular lesions which, in the presence of reduced 
metabolic detoxification, can weaken repair capability, overwhelming cellular 
defences and lead to oral cancer (Boffetta et al., 2008, Boyle and Levin, 2008) . 
1.5.2 Alcohol 
 
Alcohol is also an important promoter of carcinogenesis and contributes in at least 
75% of Head and Neck cancer (Blot et al., 1988). WCRF/AIRC and IARC classify 
alcohol as a risk factor of oral cavity, tonsil and pharyngeal cancer (Wiseman, 2008, 
IARC, 2014). It is estimated that alcohol drinking causes around 37% of oral and 
pharyngeal cancers in men and around 17% in women in the UK (Parkin, 2011b). A 
meta-analysis showed that regular alcohol drinkers have around 2.5 times the risk of 
oral and pharyngeal cancer compared with non-drinkers and occasional drinkers. 
The same study also showed that heavy drinkers who drink around 6 units or more 
per day increase the risk of oral and pharyngeal cancer more than five- fold (Turati et 
al., 2013). It has been suggested that alcohol may have additive effects and it 
facilitates the entry of carcinogens into the exposed cells, altering the metabolism of 
mucosal cells (McCoy, 1978). The meta-analysis of Turati (2013) has also revealed 
that alcohol increases the risk of oral and pharyngeal cancer in current smokers 
rather than never/former smokers. Heavy drinking smokers have an almost 7-fold 
higher risk than heavy-drinking non-smokers (Turati et al., 2013). Alcohol in 
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conjunction with smokeless tobacco also increases oral cancer risk (Znaor et al., 2003, 
Lin et al., 2011). 
1.5.3 Human Papilloma Virus (HPV) 
 
IARC classifies HPV-16 and HPV-18 as a cause for oral cavity, tonsil and pharynx 
cancer and probable cause of oral cancer, respectively (IARC, 2014). It is estimated 
that around 8% of oral cavity cancers and 14% of oropharyngeal cancer is caused by 
HPV infection in the UK (Parkin, 2011c). A meta-analysis shows that around 40% of 
oropharyngeal cancer cases in Europe are HPV-positive. Data obtained from 2005 
onwards suggest that the HPV prevalence rate in oropharyngeal cancer has 
increased and reached over 70%. For oral cavity, hypopharynx and larynx cancer 
(non-oropharyngeal head & neck cancer), HPV prevalence in European cases has not 
significantly increased over time and its rate is 24% (Mehanna et al., 2013). Sexual 
activity is the main cause of HPV infection. A pooled-analysis showed that multiple 
past sex partners, especially oral sex partners and sexual activity at a younger age 
have increased the risk of oropharyngeal, tongue and base of tongue cancer (Heck et 
al., 2010). 
1.5.4 Epstein-Barr Virus (EBV) 
 
IARC classifies EBV infection as a main cause of nasopharyngeal cancer. It is 
estimated that 90% of nasopharyngeal cases in the UK involved EBV infection 
equating 6% of overall oral cavity and pharynx cancer (Parkin, 2011c). 
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1.5.5 HIV/AIDS 
 
Meta-analyses have shown that HIV positive patients have doubled the risk of oral 
cavity, oropharyngeal and pharynx cancer compared to the general population 
(Grulich et al., 2007, Shiels et al., 2009). There is also a positive relationship between 
HIV and HPV infection (Houlihan et al., 2012). 
1.5.6 Immunosuppression 
 
A meta-analysis and several large cohort studies have shown that people who have 
undergone organ transplants have 2 to 5 times the risk of oral cavity and pharynx 
cancer compared to general population (Grulich et al., 2007, Engels et al., 2011, 
Krynitz et al., 2013). The risk of lip cancer increases by 17-46 times in transplant 
recipients (Grulich et al., 2007, Engels et al., 2011, Krynitz et al., 2013). Kidney, heart 
and lung recipients are particularly prone to lip cancer and which is increased with 
current immunosuppressant medication and smoking. The possible explanations for 
increased risk of lip cancer include continued HPV infection and increased 
sensitivity to UV radiation as a function of immunosuppressant medication (van 
Leeuwen et al., 2009, Krynitz et al., 2013). 
 
1.5.7 Radiation 
 
According to IARC solar radiation is the probable cause of lip cancer. IARC also 
classifies X-Ray and Gamma radiation as the causes of salivary gland cancer and 
radioiodine as a probable cause (IARC, 2014). Most modern evidence of the effect of 
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ionising radiation comes from studies of people exposed to diagnostic or therapeutic 
medical radiation, whereas early evidence came from atomic bomb survivors (Saku 
et al., 1997). Studies have shown that survivors of childhood cancer and Hodgkin 
Lymphoma possess 17 and 39-fold higher risk of salivary gland cancer, respectively 
due to the use of radiation to eradicate the primary tumour (Boukheris et al., 2008, 
Boukheris et al., 2013). Thyroid cancer survivors have between 3 to 11 times the 
higher risks of salivary gland cancer, attributable to radioiodine treatment (Sawka et 
al., 2009, Iyer et al., 2011). 
1.5.8 Oral condition and medication 
 
Oral epithelial dysplasia and oral leucoplakia has the potential to undergo malignant 
transformation to OSCC (Nankivell et al., 2012).  The transformation rate published 
in literature varied from 5 to 36 % (Silverman et al., 1984, Hsue et al., 2007). A meta-
analysis showed that around 12% of these conditions will transform into cancer 
(Mehanna et al., 2009). Another meta-analysis has shown that patients with gum 
disease have 2.6-fold higher risk of head and neck cancer (Zeng et al., 2013a). A meta-
analysis also showed that people who lose 6 or more teeth have at least a 60% 
increased risk of head and neck cancer and the risk is positively correlated with the 
number of teeth lost (Zeng et al., 2013b). White people who used 
hydrochlorothiazide for five years or more, which has a photosensitising effect had a 
4-fold increased risk of lip cancer compared to non-users, a US cohort study showed 
(Friedman et al., 2012). 
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1.5.9 Familial and genetic predisposition 
 
Previous cancer can precede increased risk of oral cancer due to shared aetiological 
factors (HPV, smoking etc.) and the effect of radiotherapy for the first cancer. A 
pooled-analysis showed that people with previous head and neck cancer have 12-16 
times increased risk of subsequent head and neck cancer (Bosetti et al., 2011). 
Survivors of oesophageal squamous cell carcinoma have almost 7-times increased 
risk of oral cavity and pharynx cancers (Chuang et al., 2008). Lung cancer survivors 
have 1.5 to 5.7 times increased risk of developing head and neck cancer varying by 
sex and lung cancer histology (Chuang et al., 2010). Previous cervical cancer patients 
also have increased risk of mouth and pharynx cancer (Chaturvedi et al., 2009). 
A pooled-analysis showed that a family history of head and neck cancer particularly 
in siblings have almost 70% increased risk of head and neck cancer. Individuals who 
smoke tobacco and drink alcohol with a family history of head and neck cancer have 
more than a 7-times increased risk (Negri et al., 2009). 
1.5.10 Occupational hazards 
 
It is estimated that in Great Britain in 2004 occupational exposure to formaldehyde 
and wood dust caused around 11% of nasopharyngeal cancer in men and around 2% 
in women (Slack et al., 2012). A US cohort study showed that embalmers and funeral 
directors who were heavily exposed to formaldehyde have twice the risk of dying 
from nasopharyngeal cancer (Hauptmann et al., 2004). A pooled- analysis also 
showed that furniture and plywood workers have around a 140% increased risk of 
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nasopharyngeal cancer (Demers et al., 1995). A meta-analysis also revealed that 
people exposed to asbestos and printing processes (polycyclic aromatic 
hydrocarbons and mineral oils) have a 25% and 14% increased risk of oral and 
pharyngeal cancer, respectively (Paget-Bailly et al., 2012). 
1.5.11 Dietary habit 
 
IARC classifies Chinese-style salted fish as a cause of nasopharyngeal cancer (IARC, 
2014). There is a higher amount of nitrosamines found in the Chinese-style salted 
fish than other type of salted fish. A case-control study showed that people who 
intake the highest amount of Chinese-style salted fish in childhood exhibited an 
increased risk, 2.5 times the risk of nasopharyngeal cancer in adulthood (Jia et al., 
2010). However, another study found that after controlling the tobacco use and 
vegetable intake, salted fish intake was not associated with the risk of 
nasopharyngeal cancer (Lau et al., 2013). Drinking hot maté, a traditional Latin 
American infused drink is found to be a risk factor for pharyngeal cancer (Wiseman, 
2008, IARC, 2014). A meta-analysis from case-control studies from Latin America 
showed that maté users have around twice the risk of oropharyngeal cancer that low 
or never-users, although it remains unclear whether this is due to the hot 
temperature of the drink or any carcinogenic compounds present in the drink 
(Dasanayake et al., 2010). 
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1.5.12 Socio-economic factors 
 
The complex association between the risk of head and neck cancer and socio-
economic classes were explored in a study in Scotland. People living in the most 
deprived areas and those who were unemployed had a significantly higher risk of 
head and neck cancer than those with high level of educational accomplishment, 
however smoking dominated the overall profile of risk (Conway et al., 2010). 
The oral cancer risk factors evaluated by IARC and WCRF/AICR are summarised in 
the following table. 
 
Table 5 IARC and WCRF/AICR evaluations of oral cancer risk factors 
 
Increases risk May increase risk 
 Alcohol (oral cavity, tonsil, pharynx) 
 Betel quid with tobacco (oral cavity, 
tonsil, pharynx) 
 Betel quid without tobacco ( oral 
cavity) 
 HPV-16 (oral cavity, tonsil, pharynx) 
 Smokeless tobacco (oral cavity) 
 Tobacco smoking (oral cavity, tonsil, 
pharynx, nasopharynx) 
 X-radiation, gamma-radiation 
(salivary gland) 
 Hydrochlorothiazide (lip) 
 Solar radiation (lip) 
 HPV-18 (oral cavity) 
 Radioiodines, including iodine-
131(salivary gland) 
 Asbestos (pharynx) 
 Hot Maté drinking (pharynx) 
 Printing processes (pharynx) 
 Passive smoking (pharynx) 
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 EBV (nasopharynx) 
 Formaldehyde (nasopharynx) 
 Chinese-style salted fish 
(nasopharynx) 
 Wood dust (nasopharynx) 
Adapted from CR-UK website (CR-UK, 2013) 
 
1.6 General overview of signal transduction 
 
Communication between cells, tissues and organs is controlled by internal and 
external signals that either stimulate or inhibit biological processes. One of the 
fundamental issues in current cell biological research is the mechanism by which 
cells identify and react to these signals. Signal transduction is a series of collective 
reactions by which the biological effects of different regulatory molecules are 
transmitted from the cell membrane to intracellular targets such as the nucleus, 
mitochondria and the endoplasmic reticulum. This transmission of signals from 
membrane to internal targets leads to a series of molecular events that translate into 
the eventual biological effects (Mohan, 2009). 
Cells continuously communicate with each other. This communication takes place 
through both electrical and chemical signals.  
Electrical signals pass directly from one cell to its neighbour through the gap 
junction and this is very fast. This type of signal can be found mainly in the brain 
and heart. The major form of information transfer between cells is the 
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communication through chemical signals. When the cell releases the chemical 
stimulus such as a growth factor, it then changes the action of target cells. Target 
cells have receptors able to sense the incoming signal and transmit the information 
to the appropriate internal cell signalling pathway which results in a change in 
cellular activity (Berridge, 2009, Powar, 2010) (Figure 1.24). 
 
 
Figure 1.25 Cell communication through electrical and chemical signalling 
mechanisms. 
Cells that are linked through the low-resistance gap junctions can communicate 
quickly with each other by transmitting electrical current or through the circulation 
of low-molecular-mass second messengers such as cyclic AMP and inositol 1,4,5-
trisphosphate (InsP3). In the case of chemical communication, the cell discharges a 
stimulus, which is dispersed to a target cell that has receptors to sense the stimulus 
and to pass the information along a range of cell signalling pathways to trigger 
effectors either in the nucleus (Enucl) or cytoplasm (Ecyto) (Berridge, 2009). 
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The fundamental theory of a cellular transduction pathway, therefore, concerns the 
mechanisms liable for accepting the external signal and transmitting it through 
internal cell signalling pathways to trigger the sensor and effector mechanisms that 
lead to transforming in cellular activities (Figure 1.25). This pathway transduces 
signals to different parts of the cells, but most frequently to the genes. The term 
‘transduce’ is employed here in the sense of to send or carry. 
Cell communication by extracellular signals typically contains the following series of 
steps: 
 
Figure 1.26 The fundamental theory of a cellular transduction pathway.  
Stimuli are bound to cell-surface receptors which pass the information through 
intracellular signalling pathways that can have a number of different mechanisms. 
They typically start with the activation of transducers that employ amplifiers to 
produce internal messengers that either operate locally or can disperse throughout 
the cell. These messengers then employ sensors that are attached to the effectors that 
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are liable to trigger the cellular responses. The green and red arrows point out that 
cell signalling is a dynamic process comprised of ON mechanisms (green arrows) 
through which information flows down the pathway, opposite to the OFF 
mechanisms (red arrows) that turn off the diverse steps of the signalling pathway 
(Berridge, 2009). 
 
Synthesis of the signalling molecules or ligands: Cells communicate with each 
other by extracellular physical or chemical signals in multicellular organisms. 
Signalling cells synthesise the chemical signals. Proteins and peptides, hormones 
and neurotransmitters are the predominant forms of chemical signals. Heat and 
lights are the physical signals and are not produced by the signalling cells (Powar, 
2010). 
Release of the ligands: These signalling molecules are then secreted by the cells and 
generate a specific response in target cells  (Powar, 2010). 
Transport of the ligands: Transfer of the signalling molecules to the target cells 
occurs over varying distances. Signalling molecules such as hormones, acts on target 
cells distant from the cell they are produced by and this is termed as endocrine 
signalling. In paracrine signalling, ligands act locally on nearby cells. In autocrine 
signalling the molecules act on the same cells that synthesise them. Juxtacrine refers 
to direct cell to cell contact dependent signalling (Berridge, 2009, Powar, 2010). 
Signal detection by receptors: Ligands interact with signalling pathways by 
specifically binding with protein receptors. Lipid soluble amphiphilic ligands diffuse 
across the cell plasma membrane and bind with intracellular receptors. In contrast, 
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low lipid soluble ligands cannot cross the plasma membrane and therefore, bind 
with the membrane receptors. Upon binding of ligands, receptors may undergo 
conformational change in their structure and transfer the signal into the cell. Intrinsic 
or associated catalytic activity of the receptors may modify intracellular target 
proteins (Lauffenburger and Linderman, 1993, Lodish et al., 2007). 
Receptor-Signal complex: Alteration in the cells triggered by receptor-signal 
complex may be in the form of metabolism, development or function. Chains of 
intercommunicating proteins of signalling pathways convey the signal in a stepwise 
manner. The signalling pathway may end in the nucleus with DNA-binding proteins 
that repress or trigger replication or transcription (Nelson, 2008, Powar, 2010). 
Signal termination: Termination of the signals can occur by removal of the ligands, 
down-regulation or desensitisation of the receptors (Dennis and Bradshaw, 2011). 
 
1.6.1 Signalling molecules or ligands 
 
Ligands are a chemically varied group of molecules that transmit signals between 
the cells by binding to plasma membrane receptors. Ligands are primarily classified 
into three categories based upon the distance they travel. 
I. Hormones: They are secreted by specific endocrine cells into the blood stream 
and act on the target cells remote from the site of production. Based on their 
solubility and their receptor location in the cells they are grouped into three 
categories. 
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i. Lipophilic hormones with intracellular receptors: They are small 
lipid soluble molecules that can cross the plasma membrane 
and bind with intracellular receptors either in the cytoplasm or 
in the nucleus. Examples include steroid hormones like 
oestrogen and progesterone, Vitamin D and thyroxine 
(Berridge, 2009).  
ii. Lipophilic hormones bind to plasma membrane receptors: This type 
of hormone such as the Prostaglandins can act both as 
autocrine and paracrine signalling molecules (Berridge, 2009, 
Powar, 2010). 
iii. Hydrophilic hormones bind to plasma membrane receptors: These 
are water soluble hormones that cannot diffuse across the lipid 
bilayer of the plasma membrane and so therefore bind with 
the plasma membrane receptors. Examples includes peptide 
hormones (insulin and glucagon), and biogenic amines 
(adrenaline and histamine) (Marks et al., 2008, Gomperts et al., 
2009). 
II. Neurotransmitter: They are released into the synapses of the nerve cells and 
travel a very short distance from pre-synaptic to post-synaptic neurons. So 
therefore they act as paracrine signalling molecules (Dennis and Bradshaw, 
2011). 
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III. Local mediators: This type of signalling molecules are secreted by various 
types of cells and act on close by neighbouring cells. Examples of local 
mediators include protein growth factors, amino acid derivatives, 
lymphokines and fatty acid derivatives (Nelson, 2008). 
 
1.6.2. Signalling receptors 
 
Ligand binding to the receptors causes conformational change of the receptors that 
initiates a series of reactions and ultimately causes cellular response. Receptors are 
protein molecules that have binding specificity for a specific ligand. Different cell 
types may have different sets of receptors for the same type of ligand inducing 
different cellular responses. In contrast, different cell types may have the same 
receptors and upon binding of the same ligand can cause different cellular activity. 
Based on their location, receptors are primarily classified by two types which are 
then sub-divided into different categories (Table  6) (Lauffenburger and Linderman, 
1993, Gomperts et al., 2009). 
 
Table 6 Different types of signalling receptors 
 
I. Cell Surface Signalling Receptors 
IA. Ion Channel linked Receptors 
IA 1. Ligand-gated ion channel 
IA 2. Voltage-gated ion channel 
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IA 3. Second-messenger gated ion channel 
   IB. Metabotropic Receptors 
   IB 1. G protein-coupled Receptors (GPCRs) 
   IB 2. Enzyme-linked Cell surface receptors  
    IB2a. Receptors with Intrinsic enzymatic activity 
             IB2a i. Receptor Tyrosine Kinases (RTKs) 
             IB2a ii. Receptor Serine/Threonine Kinases 
             IB2a iii. Receptor guanylyl cyclises (RGCs) 
             IB2a iv. Receptor-like protein tyrosine phoshphatases (PTPs) 
   IB 2b. Receptors with associated enzymatic activity 
             IB2b i. Receptors with associated tyrosine kinase activity 
             IB2b ii. Receptors with associated histidine kinase activity 
II. Intracellular Signalling Receptors 
IIA. Cytosolic Receptors 
IIB. Nuclear Receptors 
 
I. Cell surface signalling receptors 
Most of the ligands are hydrophilic in nature and so they cannot cross the lipid 
bilayer of the plasma membrane. These ligands interact with transmembrane or 
membrane spanning or membrane associated receptors. Upon binding, ligands can 
change the structure of the receptors which initiates the signal transduction 
pathway. Ion channel-linked and metabotropic receptors are two broad classes of the 
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cell surface receptors which can activates a series of enzymes in the ligand-bound 
state (Nelson, 2008, Powar, 2010). 
IA. Ion channel-linked or Ionotropic receptors 
Ion channel linked receptors have inherent channels which are closed in the default 
state and unlock in response to a particular signal. This channel is controlled by 
closing and opening which allows or prevents ions or small molecules in or out of 
the cell. These channels can be voltage gated, ligand gated or second-messenger 
gated (Lauffenburger and Linderman, 1993, Powar, 2010). 
IA 1. Ligand-gated ion channel 
This type of ion channels open in response to a particular type of ligand e.g. 
neurotransmitter which may be excitatory and inhibitory. Excitatory 
neurotransmitters include glutamate, acetylcholine and ATP. Inhibitory 
neurotransmitters include GABA (Dennis and Bradshaw, 2011). 
IA 2. Voltage-gated ion channel 
This type of ion channel opens in response to electrical changes related to an action 
potential in neurons (Hancock, 2010). 
IA 3. Second-messenger gated ion channel 
This type of channel receptors acts in response to second messengers such as cAMP 
and Ca2+ in the cell (Berridge, 2009). 
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IB. Metabotropic Receptors 
Metabotropic receptors can activate a particular series of enzymes in the ligand 
bound state. They can be GPCR and enzyme-coupled receptors (Berridge, 2009, 
Sitaramayya, 2009). 
IB 1. G protein-coupled receptor 
These types of receptors are integral membrane proteins composed of a single 
polypeptide which forms seven transmembrane domain structures. The ligand 
binding site is in an extracellular N-terminal region, the seven transmembrane 
domain structure is a central hydrophobic region which forms a helical wheel 
structure and the cytosolic C terminal is associated with a heterotrimeric G protein. 
GPCRs activate a GTP binding protein called G-protein, which then activates 
enzymes in the cytosol or loosely associated with the inner side of the plasma 
membrane. G-proteins act as intermediates in the signal transduction pathway 
which can determine whether a signal will be stimulatory or inhibitory (Gomperts et 
al., 2009, Powar, 2010). 
IB 2. Enzyme-linked cell surface receptors 
These types of receptors are the second major type of metabotropic receptors. In 
contrast to GPCRs, they have a single transmembrane domain structure. The N-
terminal region is in the extracellular part and is for ligand binding. The cytosolic C 
–terminal region either has intrinsic enzymatic activity or is directly associated with 
enzymes. These types of receptors are collectively called growth-factor receptors, 
because the ligands which bind to these receptors are responsible for cellular 
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growth, differentiation and proliferation. The responses mediated by these receptors 
normally are slow because a number of intracellular signalling steps are involved. 
However, these receptors also mediate a direct and rapid effect on the cellular 
cytoskeleton which control cell movement and shape (Lauffenburger and 
Linderman, 1993, Gomperts et al., 2009, Powar, 2010). 
There are six types of enzyme-linked cell surface receptors among which four of 
them have intrinsic enzymatic activity and two have associated enzymatic activity. 
 
IB2a. Receptors with enzymatic activity 
i. Receptors Tyrosine Kinases (RTKs): RTKs phosphorylate specific tyrosine 
residues on a restricted set of intracellular signalling proteins 
(Lauffenburger and Linderman, 1993, Powar, 2010). 
ii. Receptor Guanylyl Cyclases (RGCs): RGCs catalyse cGMP production in 
the cytosol(Lauffenburger and Linderman, 1993). 
iii. Receptor Serine/Threonine kinases: This type of receptors phosphorylate 
specific serine/threonine residues on related gene regulatory proteins 
(Lauffenburger and Linderman, 1993, Berridge, 2009). 
iv. Receptor like protein tyrosine phoshphatases (PTPs): They can 
dephosphorylate phosphotyrosine (Powar, 2010). 
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IB2b. Receptors with associated enzymatic activity 
i. Receptors with associated tyrosine kinase activity are linked with 
intracellular proteins containing tyrosine kinase activity. For example, 
JAK-STAT pathway (Lauffenburger and Linderman, 1993, Powar, 2010). 
ii. Receptors with associated histidine kinase activity autophosphorylate 
histidine in the two compartment signalling pathway (Berridge, 2009, 
Powar, 2010). 
 
1.6.3. Transducers and amplifiers 
 
They are regarded as together because their activities are closely connected and 
every so often, the two functions exist in the same molecule. They are linked with 
the receptors, accept information coming in from the outside and transform it into 
the internal messengers. One of the typical examples of information transduction is 
GPCRs that use heterotrimeric G proteins to transmit information to amplifiers such 
as Adenylyl cyclase or phospholipase C (PLC).The monomeric G-proteins like SoS 
(Son of Sevenless) function as transducers for the tyrosine kinase-linked receptors. 
The ion channel receptors are receptors where a single protein combines the role of 
receptor, transducer and amplifier. Different transducers and amplifiers generate 
different second messengers that transmit information to the internal sensors and 
effectors (Berridge, 2009, Powar, 2010, Dennis and Bradshaw, 2011). 
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1.6.4. Intracellular messenger 
 
Intracellular messengers are the agents that transmit the information within the cell. 
They can take many different forms.  
a. One of the major intracellular messengers is Ca2+ that carries 
information for the Ca2+ signalling pathway (Berridge, 2009, Hancock, 
2010). 
b. cAMP that transmit information for the cAMP signalling pathway 
(Berridge, 2009, Dennis and Bradshaw, 2011). 
c. Ca2+ mobilising messengers: 
 Inositol 1, 4, 5 tri phosphate (IP3) acts as a messenger 
connecting receptors to the Ca2+ signalling pathway (Lodish et 
al., 2007, Dennis and Bradshaw, 2011). 
 Cyclic ADP ribose that discharges Ca2+ from internal stores 
(Hancock, 2010, Powar, 2010).  
d. Lipid messengers:  
 DAG (Diacyl Glycerol) connects receptor activation to protein 
kinase C and protein phosphorylation of the phosphoinositide 
pathway (Berridge, 2009). 
 PI3,4,5P3 acts as a lipid messenger in the PI3-kinase pathway 
(Lodish et al., 2007, Berridge, 2009). 
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 PI4,5P2 acts as a membrane messenger to trigger various 
cellular processes (Berridge, 2009, Dennis and Bradshaw, 
2011). 
 Phosphatidic acid (PA) is a messenger for Phospholipase D 
signalling pathway (Berridge, 2009). 
e. Protein kinase messengers: Particular protein kinases can transmit 
information to diverse area of the cells. 
 ERk1/2 and JNK active kinases generated by MAPK signalling 
pathway can transmit information into the cell and very often 
into the nucleus (Berridge, 2009, Dennis and Bradshaw, 2011). 
f. Some transcription factors activated at the membrane or in the      
cytoplasm can act as messengers that transmit information into the 
nucleus. 
 NFkB and STATs can transmit information from the cell 
surface to the nucleus (Berridge, 2009, Dennis and Bradshaw, 
2011). 
 Smads carry signals from the TGFβ- superfamily receptors 
into the nucleus (Berridge, 2009, Hancock, 2010). 
 β-catenin acts as a messenger in the canonical Wnt pathway 
(Marks et al., 2008, Berridge, 2009). 
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1.6.5. Sensors and effectors 
 
Intracellular messengers can carry information to the sensors and effectors that are 
responsible for the final task of the cell signalling pathways to trigger a whole host of 
cellular processes. For example, Ca2+ binding proteins can detect increasing levels of 
Ca2+ and convey this signal to diverse effector molecules which control the processes 
of contraction and secretion. Some of the effectors are somewhat simple consisting of 
a single downstream effector system, but some of them are more complicated being 
made up of various components such as those that limit the processes of gene 
transcription, actin remodelling, phagocytosis and exocytosis. The activation of these 
sensors and effectors terminates the passage of the information down the cell 
signalling pathway (Marks et al., 2008, Berridge, 2009, Powar, 2010, Dennis and 
Bradshaw, 2011).  
 
1.7 Growth factors in HNSCC 
 
Growth factors and their specific cell surface receptors harbouring a tyrosine kinase 
activity offer us profound knowledge in identifying the mechanism of development, 
homeostasis and diseases (Higashiyama et al., 2008). Various growth factors and 
their signalling pathways give us remarkable advantages in developing intriguing 
molecular targeted therapy in various cancers including HNSCC. 
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1.7.1 The Epidermal Growth Factor (EGF) family 
 
The EGF family of growth factors are characterised by the existence of an EGF-like 
domain which is composed of three disulphide-bonded intramolecular groups 
conferring binding specificity and supplementary structural motifs such as 
immunoglobulin-like motifs, glycosylation sites and heparin-binding sites 
(Normanno et al., 2005). The EGF family includes 13 members: EGF, TGF-α 
(transforming growth factor-α). Amphiregulin, HB-EGF (heparin-binding EGF-like 
growth factor), epiregulin, epigen, betacellulin, NRG-1 (neuregulin-1), NRG-2, NRG-
3, NRG-4, NRG-5 and NRG-6. EGF family growth factors bind to the specific 
receptor family named as EGFR which includes four members: EGFR (ErbB1),  
ErbB2, ErbB3 and ErbB4 (Cohen, 1964, Harris et al., 2003, Normanno et al., 2005, 
Cohen, 2008, Higashiyama et al., 2008). Human EGF is a 60-kDa protein with 53 
amino acid residues and three intramolecular disulphide bonds (Carpenter and 
Cohen, 1990, Harris et al., 2003). The epidermal growth factor receptor is a 
cytoplasmic transmembrane protein encoded by the EGFR gene belonging to the 
HER (ErbB) family of RTKs (receptor tyrosine kinases). The structure of the EGFR 
receptor consists of an extracellular ligand-binding domain, a single transmembrane 
hydrophobic helix and a cytoplasmic carboxy-terminal motif, which is restricted to 
tyrosine kinase function.  The EGFR receptor undergoes a conformational change,  
once the ligand binds to the extracellular domain, which permits homodimerisation 
or heterodimerisation with another activated receptor of the HER family. Following 
dimerisation, autophosphorylation occurs in the intracellular tyrosine residues and 
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triggers various signal transduction pathways. The Ras/Raf/MAPK pathway, 
PI3K/Akt pathway and JAK/STAT pathways have been identified as three major 
signalling pathways that are activated by EGFR. Once activated, these pathways 
promote normal tissue homeostasis and over-activation may progress to a malignant 
cellular phenotype, including resistance to apoptosis, enhanced proliferation, 
invasion, metastasis and stimulation of angiogenesis in many cancer including 
HNSCC (Hackel et al., 1999, Moghal and Sternberg, 1999, Nicholson et al., 2001, 
Hynes and Lane, 2005, Bublil and Yarden, 2007, Uribe and Gonzalez, 2011). 
Overexpression of EGFR and TGF-α mRNA are prevalent and found to be elevated 
in 92% and 87% of HNSCC cases (Grandis and Tweardy, 1993). Studies also revealed 
that EGFR protein is overexpressed in 38-47% HNSCC (Bei et al., 2004, Ongkeko et 
al., 2005).  Upregulation of EGFR have been seen in the normal epithelium adjacent 
to tumour  dysplasia in late-stage tumours and in poorly differentiated tumours 
which supports the field cancerisation hypothesis in HNSCC (Grandis and Tweardy, 
1993, Shin et al., 1994). A study showed that EGFR expression was found to be low in 
laryngeal cancer as compared with tumours from the pharynx and oral cavity and 
suggested that EGFR expression may be site-specific (Takes et al., 1998). Several 
studies suggested that other ErbB family members in addition to EGFR are 
overexpressed in HNSCC (ErbB2, 3% to 29%; ErbB3, 21%; ErbB4, 26%) (Bei et al., 
2001, Bei et al., 2004, Schartinger et al., 2004). EGFR, ErbB2, and ErbB4 were 
upregulated in invasive and in situ carcinoma, whereas ErbB3 was upregulated only 
in invasive carcinoma (Bei et al., 2001). In most of these cases, two or more of these 
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receptors were upregulated concurrently, proposing the development of receptor 
heterodimers (Kalyankrishna and Grandis, 2006). 
 
1.7.2 Transforming Growth Factor-beta (TGF-β) superfamily 
 
The transforming growth factor-beta superfamily of proteins contains the TGF-β 
ligands (TGF-β1, 2, and 3), bone morphogenic proteins (BMPs) and activins/inhibins 
(Shi and Massague, 2003). TGF-β ligands bind to and induce signals through two 
types of transmembrane serine/threonine kinase receptors: TGFβR1 and TGFβRII. 
Seven TGFβRI and five TGFβRII family members have been defined so far 
(Massague, 2008). Canonical TGFβ signalling is mediated through SMAD family 
members which are grouped into three classes (receptor activated R-SMADs, 
inhibitory SMADs and the common SMAD4) and act as a transcription factors 
(Massague, 2008). After TGF-β binding, TGFβRI is phosphorylated by TGFβRII, 
which then phosphorylates and activates R-SMADs. TGFβ1, 2 and 3 signals through 
R-SMAD 2 and 3, whereas BMPs utilise R-SMAD 1, 5 and 8 (Massague, 2000). 
Activated R-SMADs then heterodimerise with SMAD4, translocate to the nucleus 
and control gene expression at SMAD binding elements (Massague et al., 2005). 
Inhibitory SMADs mitigate TGFβ signalling by challenging R-SMADs for binding at 
TGFβRI and by engaging ubiquitin ligases to disintegrate TGFβRI and R-SMADs 
(Ebisawa et al., 2001, Massague et al., 2005). Ligand bound TGFβ receptors induce 
other signalling pathways such as the MAP kinases, PI3K/Akt and Rho-GTPases in 
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SMAD-independent non-canonical TGFβ signalling, which probably increase 
tumour growth after disruption of SMAD-dependent signalling (Zhang, 2009). 
TGFβ1 is overexpressed in around 80% of human HNSCCs and associates with more 
aggressive disease and worse survival (Lu et al., 2004, Levy and Hill, 2006). Loss of 
functional TGFβ signalling triggers a compensatory amplification in TGFβ 1 
production that ironically stimulates tumour growth by altering the tumour stroma, 
enhancing invasion, inflammation and angiogenesis in HNSCC (Lu et al., 2006, Bian 
et al., 2009, Bornstein et al., 2009). Several studies have showed that TGFβRII may be 
down-regulated in around 70% of HNSCC (Lu et al., 2006) and is linked with poorly 
differentiated tumours and more aggressive clinical behaviour (Muro-Cacho et al., 
1999, Fukai et al., 2003). Not much is known about the association between TGFβRI 
loss and clinical behaviour in HNSCC, yet TGFβRI mutation has been discovered in 
around 19% of HNSCC metastases (Chen et al., 2001). X-J Wang group revealed in 
their study that 86% of tumours and 67% of adjacent non-malignant mucosa in 
HNSCC had more than 50% SMAD4 reduction, proposing that SMAD4 down-
regulation is an early event in HNSCC development (Bornstein et al., 2009). 
 
1.7.3 The Fibroblast Growth Factor (FGF) family 
 
The FGFs are heparin-binding proteins and associations with cell-surface-associated 
heparan sulphate proteoglycans (HSPGs) have been shown to be vital in FGF-
mediated intracellular signalling (Ornitz and Itoh, 2001). To date, 22 structurally 
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related FGF family members have been identified in humans (Eswarakumar et al., 
2005). FGF binds to a group of FGF receptors (FGFR1- 4) to transduce signals in 
target cells which share a common domain structure. HSPGs are linked with FGFR 
to regulate the binding of FGF to FGFR (Itoh and Ornitz, 2011).  The FGFRs are 
comprised of three Ig-type extracellular domains, a transmembrane domain and a 
cytoplasmic tyrosine kinase domain (Beenken and Mohammadi, 2009, Turner and 
Grose, 2010). FGFR genes are regarded as proto-oncogenes activated in various 
human cancers as a result of point mutation, gene amplification and chromosomal 
translocation. Various signal transduction pathways are activated through 
FGF/FGFR system such as Ras-MAPK, PI3K/Akt, DAG-PKC and IP3/Ca2+. FGF 
signals are engaged in anti-apoptosis, proliferation, drug resistance, angiogenesis, 
EMT (epithelial to mesenchymal transition) and invasion (Wesche et al., 2011, Katoh 
and Nakagama, 2014). 
FGFR1 gene amplification and protein overexpression have been observed in 17% 
and 12% of oral squamous cell tumours, respectively (Freier et al., 2007). Several 
studies also revealed that, FGFR1/2/3 are overexpressed in 12-100% of HNSCC 
tissues (Drugan et al., 1998, Wakulich et al., 2002, Hase et al., 2006, Freier et al., 2007, 
Marshall et al., 2011). While elevated FGFR1 expression has only been found in 12% 
of HNSCC cell lines, FGFR2 and FGFR3 overexpression has been found in the 
majority of HNSCC cell lines (Henson and Gollin, 2010, Marshall et al., 2011). A 
decrease of FGFR3 levels in HNSCC cell lines leads to a 35% reduction in 
proliferation in vitro (Henson and Gollin, 2010). 
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1.7.4 The Vascular Endothelial Growth Factor (VEGF) family 
 
Vascular endothelial growth factor (VEGF) represents a family of homodimeric 
glycoproteins, which at present comprises five mammalian and one parapox-virus 
encoded member. The VEGFs bind to three VEGF-receptor tyrosine kinases in an 
overlapping manner. Binding of  VEGF to the receptors stimulates receptor 
dimerisation and activation and thus, induces signal transduction that causes 
cellular activities (Cross et al., 2003). VEGFs were initially discovered as vascular 
permeability factor, VPF, a factor released by tumour cells that stimulates vascular 
leakage (Senger et al., 1983). It is now evident that VPF corresponded to a biological 
function attributable to a family of polypeptide growth factors controlling blood and 
lymph vessel formation during embryonic development, providing vessel 
homeostasis and in wound healing in adult organisms. Imbalanced formation of 
blood and lymphatic vessels caused by excessive or decreased production of VEGF, 
results in many human diseases. VEGFs particularly interact with differentiating and 
mature endothelial cells and hematopoietic and endothelial precursor cells like 
angioblasts (Grunewald et al., 2010). 
VEGF-A (commonly termed as, VEGF) is a heparin-binding, dimeric polypeptide, 
which belongs to the platelet-derived growth factor family previously known as 
VPF. Besides VEGFA there are other members of this family which includes 
placental growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E (Senger et 
al., 1983, Tischer et al., 1989, Maglione et al., 1991, Joukov et al., 1996, Lee et al., 1996, 
Olofsson et al., 1996, Ferrara and Davis-Smyth, 1997, Achen et al., 1998, Meyer et al., 
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1999). Among these members, VEGF plays a vital role in vasculogenesis and 
angiogenesis (Beck and D'Amore, 1997). The human VEGF gene is organised in eight 
exons, separated by seven introns and its coding region spans approximately 
14 kb(Houck et al., 1991, Tischer et al., 1991). At least six VEGF isoforms with 
different number of amino acids are generated through alternative exon splicing: 
VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206 (Robinson and Stringer, 2001) 
(Figure 1.26). VEGF121, VEGF 165 and VEGF189 are the predominant form. The isoforms 
vary in their capacity to bind to the extracellular matrix (ECM) and heparin sulphate 
(Cross et al., 2003). 
 
Figure 1.27 Various isoforms of VEGF. 
Alternative exon splicing causes at least six human VEGF isoforms of which VEGF121, 
VEGF165 and VEGF189 are the predominant form (Cross et al., 2003).  
 
VEGF121 lacks the region encoded by exons six and seven, so does not bind to 
heparin sulphate and is freely diffusible. It is a 28.4 kDa disulfide‐linked 
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homodimeric protein consisting of two 121 amino acid polypeptide chains .VEGF165 
binds to cell surface heparin sulphate proteoglycans and VEGF189 is almost 
completely sequestered in the ECM making a reservoir of VEGF that can be 
mobilised through proteolysis (Cross et al., 2003, Ferrara et al., 2003). The secreted 
forms of VEGF can stimulate the proliferation of endothelial cells and in vivo 
angiogenesis, on the other hand, the heparin-binding forms of VEGF can bind to the 
cell surface and ECM and enable the release of other angiogenic factors stored on 
heparin sulphate from the ECM (Christopoulos et al., 2011). 
Initially VGEF receptors were identified on the cell surface of vascular ECs in vitro 
and in vivo. Consequently, it became obvious that VEGF binding sites also occurs on 
bone-marrow derived cells and in cancer cells (Ferrara and Davis-Smyth, 1997, 
Shibuya, 2013). VEGF binds with two receptor tyrosine kinases (RTKs), VEGFR1 
(Flt1) and VEGFR2 (Flk1/KDR). Both of these receptors have seven extracellular Ig-
like domains, a single transmembrane region and a consensus intracellular tyrosine 
kinase domain. These receptors are expressed in most blood vessel endothelial cells 
(Shibuya et al., 1990, Terman et al., 1991). In contrast, VEGFC and VEGFD bind to 
VEGFR2 and also to VEGFR3 (Flt-4) which  are largely restricted to lymphatic 
endothelial cells (Karkkainen et al., 2002). PlGF and VEGFB binds only with VEGFR1 
(Anisimov et al., 2013). Most evidence suggests that, VEGFR2 is the major mediator 
of angiogenesis, microvascular permeability, endothelial cell mitogenesis and 
survival. In contrast, VEGFR1 plays an inhibitory role by sequestering VEGF and 
preventing its interaction with VEGFR2 especially during early embryonic 
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development. Yet, VEGFR1 has a recognised signalling role in mediating monocyte 
chemotaxis. Both VEGFR1 and VEGFR2 may mediate chemotactic and survival 
signal in hematopoietic stem cells (Ferrara et al., 2003). The role of different tyrosine 
kinase receptors on different cell types is summarised in Figure 1.27. 
 
 
 
Figure 1.28 Different VEGF receptors function differently. 
Varied activities of VEGF receptors largely depends on the ligands binds to them 
and on different cell types (Ferrara et al., 2003). 
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It is now a well-accepted fact that angiogenesis is indispensable for the proliferation 
and metastasis of solid tumours, including head and neck squamous cell carcinoma. 
VEGF and its receptors are the main factor responsible for angiogenesis (Hoeben et 
al., 2004). It has been confirmed that VEGFRs are also existent on tumour cells 
themselves and other components of tumour microenvironments, other than 
tumoural endothelial cells. Therefore, abundant and different interactions take place 
between these cells mediated via autocrine/paracrine pathways that stimulate 
angiogenesis, uncontrolled growth and metastasis (Mittal et al., 2014). Consequently, 
assessment of VEGF expression and its receptors became a dependable prognostic 
tool in HNSCCs predicting the poor survival and metastasation (Margaritescu et al., 
2009). However, studies regarding VEGF-expression in HNSCC and the potential 
role of cancer progression are contradictory. The percentage of VEGF-positive OSCC 
cases differs from 25% to 100% with mean positivity of 78% (Margaritescu et al., 
2009). Table 7 summarise the data collected from the studies that shows the 
differential expression of VEGF isoforms and their associated receptors in HNSCC.  
 
Table 7 Overexpression of different VEGF isoforms and their receptors in HNSCC 
 
VEGF/VEGFR 
Type 
Cell type /region 
/stage in HNSCC 
References 
A Invasion depth (Kyzas et al., 2005a, Chuang et al., 2006) 
C, D Infiltrating 
tumour front 
(Shintani et al., 2004) 
A Necrotic region (Shweiki et al., 1992, Mohamed et al., 2004) 
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B, C > A OSCC (Shintani et al., 2004) 
C, R3 OSCC (Fernandez Pujol et al., 2001) 
C Perivascular 
stroma 
(Zangani et al., 1999, Ziegler et al., 1999, 
Fernandez Pujol et al., 2001) 
C Early stage (Shintani et al., 2004, Ohno et al., 2007, 
Warburton et al., 2007, Faustino et al., 2008, 
Siriwardena et al., 2008) 
Decreasing C Superficial to deep 
invasion 
(Ohno et al., 2007) 
Increasing C Superficial to deep 
invasion 
(Nakaya et al., 2005) 
R1, R2, R3 OSCC (Neuchrist et al., 2001, Lalla et al., 2003, Kyzas 
et al., 2005b) 
R3 Endothelial cells (Matsuura et al., 2009, Sugiura et al., 2009) 
R1, R2, R3 Macrophage (Lalla et al., 2003) 
R1, R3 Fibroblast (Lalla et al., 2003) 
 
Several studies have shown that overexpression of VEGF is associated with worse 
survival (Kim et al., 2006, Tse et al., 2007, Shao et al., 2008, Joo et al., 2009), whereas 
two studies found no correlation with these two factors (Salven et al., 1997, Li et al., 
2005b). Most studies regarding the association between VEGF overexpression in 
HNSCC and clinicopathological predictors (e.g., TNM stage, tumour grade, tumour 
site, pattern of invasion, vascular invasion, lymph node metastasis, smoking, sex, 
age etc.) have also revealed contradictory results (Table 8). 
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Table 8 Association between VEGF overexpression in HNSCC and clinical 
parameter 
 
Parameter Correlated? References 
Differentiation No (Smith et al., 2000, Kyzas et al., 2005b, 
Shang and Li, 2005, Chuang et al., 2006) 
Differentiation Yes (Shintani et al., 2004, Li et al., 2005b, 
Johnstone and Logan, 2007) 
Angiogenesis No (Tae et al., 2000, Carlile et al., 2001, Wong et 
al., 2003) 
Angiogenesis Yes (Arora et al., 2005, Li et al., 2005b, Shang et 
al., 2006, Shao et al., 2008, Joo et al., 2009) 
Clinical stage Yes (Uehara et al., 2004, Kyzas et al., 2005c, Shao 
et al., 2008) 
Clinical stage No (Maeda et al., 1998, Shintani et al., 2004, 
Chuang et al., 2006) 
Lymph node metastasis Yes (Tae et al., 2000, Gallo et al., 2002, Shang 
and Li, 2005, Chien et al., 2006, Kim et al., 
2006, Joo et al., 2009) 
Lymph node metastasis No (Maeda et al., 1998, Homer et al., 2003, 
Uehara et al., 2004, Kyzas et al., 2005c, Li et 
al., 2005b, Tse et al., 2007) 
Lymph node metastasis, 
recurrence, distant 
metastasis 
Yes (Shao et al., 2008) 
Lymph node metastasis, 
tumour grade, smoking 
No (Kyzas et al., 2005c) 
 
Note. Data from literature regarding the association between the clinical parameters and 
VEGF overexpression are disputed. 
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1.8 Signalling Pathways in HNSCC 
 
There has been a recent upsurge in our understanding on how the flow of 
information through intercellular signalling networks controls cellular bioactivity. 
Indeed, the emerging knowledge of the basic mechanisms regulating intercellular 
and cell-to-cell communication is offering an extraordinary opportunity to 
understand physiological and pathological processes at the organismal, cellular and 
molecular levels, thereby recognising novel targets for pharmacological intervention 
in a multitude of diseases. In this regard, the evolving information on the nature of 
the deregulated signalling mechanisms in HNSCC and their potential involvement 
to disease progression is discussed below. 
1.8.1 p53/Rb pathway 
 
The tumour suppressor protein p53 maintains genomic stability by regulating cell 
cycle and growth arrest, DNA repair or apoptosis (Vogelstein et al., 2000). p53 can 
arrest the cell cycle and activate repair or initiate apoptosis in response to DNA 
damage. Mouse double minute 2 homolog (MDM2), an E3 ubiquitin protein ligase 
can bind to p53 and causes its degradation. p14ARF is encoded by the gene CDKN2A, 
inhibits MDM2, thus protecting p53 from degradation (Vogelstein et al., 2000, Sherr 
and McCormick, 2002). ATM (ataxia telangiectasia mutated) and ATR (ataxia 
telangiectasia and rad3-related) pathways activate p53 by sensing DNA damage and 
phosphorylating the cell cycle checkpoint kinases CHK1 and CHK2. p53 thus trans-
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activates a number of proteins which are involved in apoptosis and cell cycle arrest 
(Brady et al., 2011). 
Retinobalstoma (Rb) is also regarded as the tumour suppressor protein that 
regulates the expression of genes which are involved in cell cycle progression 
through the G1 restriction point. pRb inhibits E2F transcription factors that induce 
expression of S-phase genes and cell proliferation. Cyclin D1/CDK4/CDK6 
complexes phosphorylates and activates pRb, resulting in the release of E2F. p16INK4A  
and p21 binds to the complexes, inhibits them and prevents them from 
phosphorylating pRb (Di Fiore et al., 2013).  
Limitless replicative potential and immortalisation can result from the mutations in 
p53 and pRb pathways. It is reported that in around 50-80% cases of HNSCC, 
mutation in TP53 gene occurs which is one of the earliest and most frequently 
detectable genetic alteration. p53 mutation can also be detected in premalignant 
dysplastic lesions and in histopathologically negative tumour margins (Brennan et 
al., 1995b, Poeta et al., 2007, Ebrahimi et al., 2008).  Use of tobacco and alcohol and 
increased TP53 mutations are closely associated in HNSCC and this association 
increased the risk of progression to cancer (Boyle et al., 1993, Brennan et al., 1995a). 
Mutations (7-9% cases of HNSCC) and copy number losses (20-30% cases of 
HNSCC) of CDKN2A gene inactivates pRb pathway and is observed early in the 
carcinogenesis of HNSCC (Agrawal et al., 2011, Stransky et al., 2011, Gaykalova et al., 
2014). The CCND1 gene, which encodes cyclin D1 in overexpressed in over 80% of 
HNSCC (Smeets et al., 2006). Reduced survival in HNSCC is linked with TP53 
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mutation, cyclin D1 overexpression and p16INK4A loss (Bova et al., 1999, Poeta et al., 
2007). 
1.8.2 Ras/Raf/MEK/MAPK pathway 
 
Guanosine nucleotide binding protein, Ras is a proto-ocnogene. There are three Ras 
genes: HRAS, KRAS and NRAS, the proteins are localised on the plasma membrane. 
When Ras is bound to guanosine diphosphate (GDP) it regarded as inactive. Upon 
activation Ras converts to GTP (guanosine triphosphate) bound form. Thus Ras-GTP 
forms then binds to and activates Raf-1. Raf-1 then phosphorylates MEK1 and MEK2 
kinases which in turn activate the MAPkinases ERK1 and EKR2. These kinases 
translocate to the nucleus and target genes which are involved in cell growth, 
proliferation and survival (Bos, 1989, Schmukler et al., 2014). HRAS mutation has 
been found in 4-5% of HNSCC cases (Agrawal et al., 2011, Stransky et al., 2011). 
1.8.3 NOTCH pathway 
 
NOTCH1 signalling is responsible for a variety of biological activities including 
survival, differentiation and self-renewal capacity. This pathway consists of two 
families of ligands, Delta-like 1, 3, 4 and Jagged 1, 2 and four receptors, NOTCH 1-4. 
Upon ligand binding, TNF-α converting enzyme (TACE) and γ–secretase cleaves 
NOTCH1 in two parts and releases NOTCH1 intracellular domain (NCID). NCID 
then translocates to the nucleus and induces transcription of HRT and NES family 
target genes. NOTCH1 is partly degraded by the ubiquitination pathway that 
involves FBXW7 (Egloff and Grandis, 2012). A recent whole-genome sequencing 
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study revealed that the NOTCH1 gene mutation is the second most common 
mutation in HNSCC, accounting for 14-15%. Mutations in other NOTCH family 
members account for 3-5% of HNSCC (Agrawal et al., 2011, Stransky et al., 2011). A 
new finding regarding FBXW7 reported that this gene is mutated in 5% of HNSCC 
cases (Agrawal et al., 2011). A recent study has also suggested that chromosomal 
aberrations in NOTCH signalling modulators JAG1, JAG2, MUMB and MAML1 are 
frequent along with the mutations in NOTCH itself (Pickering et al., 2013). 
1.8.4 JAK/STAT pathway 
 
The JAKs are non-receptor tyrosine kinases and they bind with the cytokine receptor 
of the plasma membrane. Upon binding, receptors are activated by 
transphosphorylation. Activated cytokine receptors then employ STAT protein 
which is phosphorylated by JAKs, facilitating dimerisation and translocation to the 
nucleus to activate transcription of their target genes. The RTKs (receptor tyrosine 
kinases) such as EGFR can also phosphorylate JAKs which then activates the Ras 
and PI3K pathways. The JAK/STAT pathway is responsible for the bioactivities such 
as cell proliferation, survival, angiogenesis and inhibiting immune surveillance 
(Aaronson and Horvath, 2002). A study suggests that STAT3 is overexpressed in 
both cultured HNSCC cells and tumour specimens (Grandis et al., 2000). Increased 
STAT3 expression is associated with increased Ras in tobacco-associated HNSCC 
and STAT5 promotes tumour growth, EMT and resistance to treatment-induced 
apoptosis in HNSCC (Xi et al., 2003, Arredondo et al., 2006, Koppikar et al., 2008).  
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1.8.5 NFkB pathway 
 
NFkB is a transcription factor which has five family members: p50 (NFkB1), p52 
(NFkB2), p65 (RELA), c-Rel (REL) and RelB (RELB). NFkB is assembled by the 
polymerisation of these five members and upon activation translocates to the 
nucleus (Karin, 2006). Activation of NFkB involves the phosphorylation of IkB on Ser 
32 and Ser36 residues. Phosphorylated IkB triggers rapid ubiquitination and 
degradation in the proteasome with consequent nuclear translocation and activation 
of NFkB. Activated NFkB participates in the expression of genes involved in 
inflammatory and immune responses, as well as in cell proliferation and survival 
(Hayden and Ghosh, 2008).The IkB kinase has a regulatory subunit, NEMO (IKKc) 
and two catalytic kinase subunits, IKKa (IKK1) and IKKb(IKK2) (Karin and Greten, 
2005), all of which are activated by pro-inflammatory cytokines, tumour necrosis 
factor (TNF)-α and can readily be detected in HNSCC (Squarize et al., 2006). 
Deregulation of NFkB stimulates tumour angiogenesis and metastasis and represses 
the apoptotic potential of chemotherapeutic agents and radiation, thus indicating 
treatment resistance (Karin and Greten, 2005, Nakanishi and Toi, 2005). The 
constitutive activation of NFkB is a common event in a variety of human cancers 
including HNSCC (Ondrey et al., 1999, Karin and Greten, 2005). NFkB signalling 
plays a vital role at the early stages of HNSCC carcinogenesis because the expression 
and activity of NFkB is often upregulated and its protein levels increases gradually 
from premalignant lesions to invasive head and neck cancer (Ondrey et al., 1999, 
Bindhu et al., 2006, Mishra et al., 2006, Sawhney et al., 2007). A study also showed 
85 
 
that, NFkB stimulates the expression of the antiapoptotic protein Bcl-2 in HNSCC 
and restricting NFkB function leads to a significant reduction in cell survival and 
tumour growth in HNSCC (Jordan et al., 1996, Chen et al., 1999). 
1.8.6 PI3K/Akt/mTOR pathway 
 
The PI3K (phosphoinositide-3-kinases) pathway has appeared to be one of the most 
common targeted pathways in all sporadic human cancer, as proposed by the fact 
that mutation in one or more PI3K pathway components accounts for up to 30% of 
all cancers (Cully et al., 2006). Genomic abnormalities such as mutation, 
amplification and rearrangements in a number of constituents of the PI3K signalling 
pathway, cause the deregulation of cellular growth and survival, which promotes a 
competitive growth advantage, metastatic potential and resistance to therapy 
(Hennessy et al., 2005). According to the substrate preference and sequence 
homology PI3Ks are classified into three subclasses (I-III) (Cantley, 2002). The Class 
1A PI3Ks are activated by EGFR or VEGFR and class IB PI3Ks are activated by 
GPCRs. Class IA PI3Ks consists of a p85 regulatory subunit and a p110 catalytic 
subunit. The P85 regulatory subunit binds and incorporates signals from a number 
of cellular proteins, including oncogenic proteins such as Ras and Src and growth 
factor tyrosine kinase-linked receptors, offering an integration point for activation of 
PI3K and its downstream signalling molecules (Cui et al., 2014).  
Activated PI3K converts the phospholipid component PIP2 (phosphatidylinositol 4, 
5-bisphosphate) to PIP3 (phosphatidylinositol 3, 4, 5-triphosphate) by donating a 
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phosphate group. PIP3 is a component of the inner leaflet of the plasma membrane 
and serves as docking sites for proteins that contains PH (pleckstrin homology) 
domain, including Akt (protein kinase B) and PDK1 (phosphoinositide-dependent 
kinase 1). The Akt family of kinases has three family members; Akt1, Akt2 and Akt3. 
All three Akt isoforms retain two highly conserved threonine/serine 
phosphorylation sites that along with the PH domain are critical for Akt bioactivity. 
PDK1 phosphorylates Akt1 at Threonine 308 residue which lies in the T-loop of the 
catalytic domain, resulting in its activation (Alessi and Cohen, 1998, Cantley, 2002). 
The second phosphorylation residue (Serine 473) lies within a hydrophobic motif 
proximal to the C-terminus and is activated by a distinct protein kinase, most likely 
the mammalian target of rapamycin-rictor complex (mTOR complex 2) (Hennessy et 
al., 2005, Sarbassov et al., 2005).  Strong evidence supports a vital role for Akt in the 
transmission of the pro-proliferative and transforming pathways induced by growth 
factors and oncogenes that stimulate PI3K (Luo et al., 2003). Thus, the detection of 
Akt substrates has been the focus of many studies to determine the mechanisms by 
which this kinase controls insulin signalling, cell growth, apoptosis and cancer (Luo 
et al., 2003). Amongst them, Akt inactivates pro-apoptotic factors including FOXOs     
(Forkhead transcription factors), BAD and procaspase-9, activates some transcription 
factors that upregulate anti-apoptotic genes, comprising NFkB, thus prevents cell 
death. It also inactivates p53 through MDM2 and activates CDK inhibitors p21 
CIP1/WAF1 and p27KIP1, causing their elimination from the nucleus and subsequent 
cytoplasmic degradation, resulting in an increase in cell proliferation (Hennessy et 
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al., 2005). Akt also enhances β-catenin and cyclin D1 stabilisation by phosphorylating 
and inhibiting GSK-3β (glycogen synthase kinase-3 beta) (Vivanco and Sawyers, 
2002). Akt is constitutively activated by frequent mutations in the small GTPase Ras, 
PI3K and receptor and non-receptor tyrosine kinases and inactivated by many 
tumour suppressor proteins like PTEN, TSC1, TSC2 and LKB1, highlighting the 
significant role of the dysregulation of the Akt pathway in cancer (Brazil et al., 2004, 
Inoki et al., 2005a). 
Numerous works suggest that Akt is persistently activated in a number of HNSCC 
cases. Active phosphorylated Akt is identified in a vast majority of human HNSCC 
tissues and HNSCC-derived cell lines (Patel et al., 2002, Amornphimoltham et al., 
2004). Furthermore, AKT activation is an early event in HNSCC progression, as it is 
identified in nearly 50% of tongue preneoplastic lesions (Massarelli et al., 2005),  and 
its activation signifies an independent prognostic marker of poor clinical outcome in 
tongue and oropharyngeal HNSCC (Massarelli et al., 2005). Activating mutations 
and amplification in the PI3KI gene (PI3KCA) can be observed in around 10% and 
40% cases of HNSCC, respectively (Woenckhaus et al., 2002, Pedrero et al., 2005, 
Murugan et al., 2008). Additionally, lipid phosphatase, PTEN which inactivates PIP3 
rapidly, is mutated or epigenetically inactivated in a large number of cancer 
including HNSCC, rivalling only p53 as one of the most significant tumour 
suppressor proteins (Sulis and Parsons, 2003). Loss of PTEN expression can be 
observed in around 30% of HNSCC cases and studies showed that this lack of 
expression may be an independent prognostic factor for poor clinical outcome (Lee 
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et al., 2001a, Squarize et al., 2002). Thus, augmented Akt activity by the presence of 
several convergent pathways may explain why enhanced Akt function represents 
one of the most regular events in HNSCC (Molinolo et al., 2007). 
Despite the fact that Akt plays an important role in the development of HNSCC the 
downstream pathway(s) through which Akt acts, in this tumour type, is still not 
fully understood. Recent studies suggested that, tumour suppressor protein, TSC2 
(tuberous sclerosis complex 2) is inactivated by Akt phosphorylation which 
associates with TSC1. This complex of TSC1/2 acts like a GTPase activating protein 
(GAP) for the Rheb1 (a small GTPase) (Inoki et al., 2003, Inoki et al., 2005b). The 
inactive TSC2 leads to the accumulation of active (GTP-bound) form of Rheb1 which 
in turn induces the phosphorylation and activation of mTOR (mammalian target of 
rapamycin) (Manning and Cantley, 2003). mTOR is an atypical serine/threonine 
kinase that phosphorylates p70-S6 kinase (eukaryotic translation regulators) and 
4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) (Hay and 
Sonenberg, 2004). Phosphorylated 4EBP1 then stimulates eukaryotic initiation factor 
4E (eIF 4E) and ultimately results in increased translation from a group of genes that 
are involved in cell growth (Hay and Sonenberg, 2004). In HNSCC, it has been 
observed that eIF 4E gene amplification and protein overexpression are significantly 
associated with cancer progression and there is six-fold rise in risk of developing 
local recurrences in eIF 4E-positive surgical margins (Sorrells Jr et al., 1999, Nathan et 
al., 2002, Nathan et al., 2004). Recent works by the S. Gutkind group have revealed 
that activation of mTOR is an early and one of the most frequent events in HNSCC 
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(Amornphimoltham et al., 2005, Molinolo et al., 2007, Molinolo et al., 2009). Figure1. 
28 below illustrate the most dysregulated signalling pathways in HNSCC. 
 
Figure 1.29 Dysregulated signalling pathways in HNSCC. 
Ras/Raf, PI3k/Akt and JAK/STAT’s are the most frequently altered  signalling 
pathways in HNSCC (Bose et al., 2013). 
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1.9 Akt and its role in metastasis 
 
1.9.1 Metastasis cascade 
  
Metastatic diseases remain the primary reason for cancer-related deaths (Siegel et al., 
2013). Whether it exists at the time of diagnosis, progresses during treatment, or 
happens at the time of disease relapse, the spreading of tumour cells from the 
primary lesion is the main reason for the mortality and morbidity of cancer patients  
(Palmer et al., 2011). The metastatic process comprises a series of successive, 
interrelated steps including: detachment of tumour cells from the primary tumour 
and invasion of neighbouring, healthy tissue, intrusion into the blood and lymphatic 
vessels, circulation through the bloodstream (circulating tumour cells) to other sites 
and tissues in the body, extravasation from the vessel of distribution, and metastasis 
growth in specific distant organs and building a secondary tumour (Figure 1.29) 
(Woodhouse et al., 1997, Leber and Efferth, 2009, Robert, 2013). 
Many of these stages are dependent on cell motility and invasion, which permit the 
cells to change location within the tissues. To spread within the tissues, tumour cells 
apply similar migration mechanisms with those that happen in normal or non-
neoplastic cells during physiological courses such as embryonic morphogenesis, 
inflammatory immune responses, wound healing, and angiogenesis (Friedl and 
Brocker, 2000). 
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Figure 1.30 The metastasis cascade. 
Sequential steps of metastasis include cell migration and invasion, intravasation, 
circulation, extravasion and homing. 
 
Yet, distinct from the physiological processes of cell migration, tumour cell 
migration appears to be stimulated by a range of pro-migratory factors without 
responding stop signals, including autocrine motility factors generated by tumour 
cells, plus the soluble factors present at the secondary site (Friedl and Wolf, 2003, 
Zhou and Huang, 2011). Due to this imbalance of signals, cancer cells become 
unceasingly migratory and invasive, causing tumour expansion across tissue 
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boundaries and the development of cancer metastasis (Friedl and Wolf, 2003, Robert, 
2013). 
Cell migration through tissues results from highly integrated multistep cellular 
events (Lauffenburger and Horwitz, 1996, Friedl and Brocker, 2000, Ridley et al., 
2003). First, reacting to a migration-promoting agent, the moving cell polarises and 
elongates, extending protrusions in the way of migration. These protrusions, which 
can be spike-like filopodia, or large and broad lamellipodia, are typically driven by 
actin polymerisation and are steadied by adhering to the extracellular matrix or 
adjacent cells via transmembrane receptors associated with the actin cytoskeleton 
(Mitchison and Cramer, 1996). Consequently, forward extension of a lamellipodium 
and retraction of the trailing edge causes the translocation of the cell body 
(Mitchison and Cramer, 1996, Friedl and Wolf, 2003). Reorganisation of the actin 
cytoskeleton is the most important process of cell motility and is vital for most types 
of cell migration (Schmidt and Hall, 1998). In the course of cell migration, the actin 
cytoskeleton is dynamically remodelled, and this reorganisation creates the force 
indispensable for cell migration (Pollard and Borisy, 2003). 
Variable experimental behaviour and histological patterns of tumour cells propose 
that tumour cells can utilise different cellular and molecular modes of migration 
based on cell-type specific autonomous mechanisms and reactive mechanisms 
stimulated by the local microenvironments (Ellis et al., 2012). In malignant cancer 
patients, tumour cells are observed as both single cells and organised collective 
sheets indicating that cancer cells in vivo display the plasticity to switch between 
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single and collective cell migration. A range of studies on single cell migration 
develops a cellular and molecular basis which has furnished substantial 
understanding into the dissemination of the tumours whose cells migrate 
constitutively as single cells such as lymphomas and leukaemia or, after detachment 
from cohesive lesions through the epithelial to mesenchymal transition (EMT). 
Migration as collective sheets or clusters occurs when the junctions between cells are 
retained over an extended time period where cells are adherent to their neighbours. 
Although metastatic efficiency is enhanced by the transition to single cell migration, 
the basic requirements for the intra-vasation process can also be performed by a cell 
cluster as indicated by circulating grouped tumour cells from patient peripheral 
blood samples. Cell invasion is connected to and involves cell migration, but cells do 
more than migrate. Invasive cells degrade the extracellular matrix by ECM 
degradation and proteolysis and invade into neighbouring tissues (Ridley et al., 2003, 
Friedl, 2004, Rorth, 2011, Inaki et al., 2012). 
Cell migration and invasion through tissues results from highly integrated multistep 
cellular events that are regulated by various signalling pathways, including the 
PI3K-Akt pathway. The serine/threonine kinase Akt (also known as protein kinase B 
or PKB) was initially discovered as a proto-oncogene. It plays a critical regulatory 
role in various cellular processes including, cancer progression, survival, insulin 
metabolism, protein synthesis etc. which is why it has become a focus of major 
attention. The Akt signalling pathway is activated by receptor tyrosine kinases 
(RTK), cytokine receptors, G-protein coupled receptor, integrin, B and T cell 
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receptors and other stimuli that stimulate the production of phosphatidylinositol 
3,4,5 triphosphates (PtdIns(3,4,5)P3) through phosphoinositide 3-kinase (PI3K) 
(Figure 1.30). 
 
Figure 1.31 PI3K/Akt Signalling pathways. 
The PI3k/Akt pathway is activated by many growth factors including VEGF. The 
central mediator of this pathway is Akt, which is activated or phosphorylated at 
Thr308 and Ser 473 residues by PI3K and mTOR C2, respectively. Once Akt is 
phosphorylated and activated, it is capable of phosphorylating multiple substrates 
generating diverse cellular processes, such as metabolism, proliferation, survival and 
protein synthesis. 
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The Class 1 PI3 kinases are a set of lipid kinases that phosphorylate the relatively 
abundant membrane phospholipid, phosphatidylinositol 4, 5 biphosphate (PIP2), 
generating small quantities of phosphatidylinositol 3, 4, 5 triphosphate (PIP3). This 
latter lipid signal controls a diverse set of effector molecules including the Akt group 
of oncogenic kinases termed as Akt1, Akt2 and Akt3. (Ellis et al., 2010a). Activation 
of Akt1, a 60kDa kinase, depends on PI3K (Datta et al., 1999). Increase of cellular 
PIP3 by PI3K eventually allows the activation of Akt1 by phosphorylation at T308 
and S473 residues (Alessi and Cohen, 1998). This activation is completed by 
structural modification stimulated by PI3K-dependent kinase-1 (PDK-1)-dependent 
phosphorylation at T308 and stabilisation by mTORC2 or DNA-PK (DNA activated 
protein kinase) dependent phosphorylation at S473 (Feng et al., 2004, Sarbassov et al., 
2005, Bozulic and Hemmings, 2009). A third phosphorylation site on Akt1 has been 
identified at T450 (Bellacosa et al., 1998). This site is referred to as the turn 
phosphorylation site and is controlled by mTORC2 activity (Ikenoue et al., 2008, Hart 
and Vogt, 2011). Activation of the three Akt isoforms plays a pivotal role in 
fundamental cellular functions by phosphorylating a variety of substrates. Recent 
studies have suggested that frequent alterations of the PI3K-Akt pathway occur in 
various types of human cancers. Constitutive activation of the PI3K-Akt pathway 
occurs due to amplification of the PIK3C gene encoding PI3K or the Akt gene, or as a 
result of mutations in components of the pathway, for example PTEN (phosphatase 
and tensin homologue deleted on chromosome 10), which inhibit the activation of 
Akt (Gonzalez-Angulo et al., 2011, De Marco et al., 2013, Wu et al., 2013). Recent 
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evidence also suggested that Akt plays an important role in cancer cell migration 
and invasion (Yoeli-Lerner and Toker, 2006, Xue and Hemmings, 2013). 
1.9.2 Akt in cytoskeletal rearrangements 
 
The cytoskeleton is the cellular scaffolding or skeleton which is composed of a  
filamentous network of micro filaments (actin, myosin etc.), intermediate filaments 
(vimentin, keratin etc.) and microtubules (tubulin) (Frixione, 2000). The cytoskeleton 
is necessary for cellular structure maintenance, intracellular transport, cell division 
and many other functions. Cytoskeletal rearrangements occur in physiological 
events like cell movements and also in some pathological conditions like wound 
healing and cancer metastasis (Bonello et al., 2012). Cellular motility either in 
physiological events or in pathological conditions is driven by cytoskeletal 
remodelling adapted by various signalling pathways. Migration potential arises 
because of a synergistic effect of all the three basic elements - filamentous actin, 
microtubule and the intermediate filament vimentin (Xue and Hemmings, 2013). 
Wide-ranging studies have focused on how stabilisation of intracellular filaments 
and dynamic polymerisation controls cell migration (Pollard and Borisy, 2003, Bugyi 
and Carlier, 2010). A broad spectrum of key factors associated with the cytoskeletal 
filaments are likely to be activated by Akt-mediated phosphorylation.  
For the metastatic spread of cancer tissue, growth of the vascular network is 
important. The processes whereby new vessels form are called angiogenesis and this 
has an essential role in the supply of nutrients, oxygen and immune cells and also to 
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remove waste products (Folkman, 1995). Angiogenic factors are increasingly getting 
attention, especially in the field of neoplastic vascularisation. Vascular endothelial 
cell migration is a key step for angiogenic process. Microvascular endothelial cells 
display enhanced actin polymerisation upon stimulation by vascular endothelial 
growth factor (VEGF), linked with elevated motility and Akt activation. Inhibition of 
Akt activity by expression of a kinase-dead mutant abrogated actin bundle 
formation and blocked cell locomotion. This effect was increased when myristylated 
Akt was expressed (Morales-Ruiz et al., 2000), demonstrating that Akt is a critical 
mediator of VEGF-induced endothelial cell migration through actin reorganisation. 
Data also suggests that eNOS activation via phosphorylation of Ser-1177 by Akt is 
necessary and sufficient for VEGF-mediated EC migration (Dimmeler et al., 1999, 
Dimmeler et al., 2000).  
Interfering with Akt activity in chicken embryonic fibroblasts (CEF) also successfully 
blocked PI3K-transduced migratory signals. Overexpression of an active form of 
p70S6K1 was adequate to induce actin filament remodelling and cell migration in 
CEF cells, which requires Rac activity. This study establishes that activation of PI3K 
activity alone is sufficient to remodel actin filaments to enhance cell migration 
through the activation of Akt and p70S6K1 in CEF cells (Qian et al., 2004). Another 
study showed, overexpression of the Integrin linked kinase (ILK) pathway is 
sufficient to induce PI3K dependent Rac1 activation. Inhibition of Akt, Rac1, or 
p70S6K1 inhibited the effects of ILK on actin filaments and cell migration, 
suggesting a regulatory role of the PI3K/Akt/p70S6K1/Rac1 signalling pathway in 
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response to ILK signalling (Qian et al., 2005). In ovarian cancer, p70S6K1, 
downstream of PI3K/Akt pathway stimulated the rapid activation of Rac1 and cdc42 
and their downstream effector molecule p21 activated kinase (PAK1). This regulates 
actin cytoskeleton in the metastatic phenotype (Ip et al., 2011) .  In neutrophils, 
activation of G-protein coupled receptors regulates F-actin polymerisation and 
cytoskeleton contraction through PIP3 signalling. This reorganisation pattern of actin 
ensures pseudopod extension in human neutrophils during chemo-attractant 
stimulation, which is dependent on Akt activity (Chodniewicz and Zhelev, 2003). 
Breast cancer cell migration and invasion often occurs in an Akt dependent manner 
which is characterised by enhanced filopodia production. A specific Akt inhibitor 
named API-2 (Akt phosphorylation inhibitor 2) blocks human breast cancer cell 
migration by blocking filopodia formation (Yang et al., 2004). These observations of 
Akt activation and its role, suggest that Akt can potentially regulate cell migration 
through direct modulation of actin. Other studies showed that actin preferentially 
binds to phosphorylated Akt at pseudopodia with enriched bundles (Cenni et al., 
2003, Amiri et al., 2007). Ho et al (2011) further confirmed that Akt can phosphorylate 
actin and therefore cortical reorganisation of actin associated with cell migration is 
strongly dependent on Akt activation (Ho et al., 2011). Studies with HeLa cells 
revealed that Akt phosphorylates PAK1, a protein which belongs to the p21-
activated serine/threonine kinase family and facilitates its binding with non-catalytic 
region of tyrosine kinase adaptor protein (Nck) and promote chemotaxis (Zhou et al., 
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2003). This effect of Akt through PAK1 may be mediated by enhanced myosin 2 
assembly and polarity (Chung et al., 2001). 
The actin-rich structure of highly motile cells such as invadopodia, filopodia and 
pseudopodia need to be stabilised to function properly. Actin-associated proteins are 
responsible for stabilising this actin structure by blocking the degradation of newly 
formed actin filaments (Chhabra and Higgs, 2007). One of the best example of this 
type of protein is APE (the Akt phosphorylation enhancer), also termed as girders of 
actin filaments (girdin). APE/girdin maintains the integrity of actin filaments, 
especially the actin meshwork at the leading edge of migrating cells. Decrease of 
APE/girdin destabilises the actin bundles, causing ablation of stress fibres and 
cortical actin structure. This leads to loss of directional migratory capacity and 
demonstrates the crucial activity of APE/girdin in the organised regulation of cell 
migration. Enomoto and colleagues established that APE/girdin is phosphorylated 
by Akt on serine 1416 (S1416) (Enomoto et al., 2005). Upon stimulation by EGF, S1416 
phosphorylation initiates the translocation of APE/girdin from the junctions between 
actin filament to the leading edge, co-localised with pAkt. This form of activation of 
APE/girdin is critical for cell migration. Indeed, recent observations have 
demonstrated that APE/girdin regulates actin reconstruction and Akt controlled cell 
motility in fibroblasts, human breast cancer and oesophageal squamous cell 
carcinoma (Jiang et al., 2008, Weng et al., 2010, Natsume et al., 2012, Shibata et al., 
2013) . Akt has also been shown to promote actin organisation and cell motility 
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mediated by the mechano-protein and Akt-substrate ANKRD2 (Ankyrin repeat 
domain protein 2, also known as ARPP). 
Actin-associated structural (cross-linker) protein, filamin A (Stossel et al., 2001, Feng 
and Walsh, 2004) is phosphorylated by Akt on S2152 site (Ravid et al., 2008) . In turn, 
phosphorylated filamin A mediates caveolin-1 induced cancer cell migration 
through the IGF signalling pathway (Ravid et al., 2005, Nallapalli et al., 2012). 
Besides, insulin and PDGF induce the sodium-hydrogen exchanger isoform 1 
(NHE1) which is a key mediator of stress fibre disassembly. Akt is shown to 
phosphorylate NHE1 on S648 and it has been suggested that it is critical for the 
growth factor induced cytoskeletal rearrangements that favours cell migration and 
invasion (Meima et al., 2009). Different studies have demonstrated the migration of 
different cell types by modulating the cytoskeleton through NHE1 although the role 
of Akt was not elucidated (Denker and Barber, 2002, Stock and Schwab, 2006, Stuwe 
et al., 2007, Martin et al., 2011). Another study showed that NHE1 interacts with an 
actin regulatory protein, cortactin, in invasive breast cancer cells and stabilise the 
newly formed invadopodia (Magalhaes et al., 2011). A recent study in fibroblast cells 
demonstrated that the Akt pathway is necessary for the translocation of NHE1 to the 
leading edge and actin nucleation at the lamellipodium that supports directional cell 
migration (Clement et al., 2013). 
Extensive studies were carried out to investigate the role of intermediate filaments in 
cell motility (Chang and Goldman, 2004, Helfand et al., 2004). Vimentin, a type 3 
filamentous protein is the most abundant intermediate protein that supports normal 
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cell and tissue integrity. Vimentin is shown to be highly expressed in motile cells 
both in physiological and pathological conditions. It is phosphorylated by Akt1 on 
S39, stabilised and thereby regulates cancer cell invasion in aggressive sarcoma (Zhu 
et al., 2011). It has also been shown that vimentin is highly expressed in breast cancer 
and lung metastases (Lahat et al., 2010, Satelli and Li, 2011) but the specific 
mechanism by which some of the Akt substrates control cell migration is still 
uncertain. For example, a component of E3 ligase named S-phase kinase-associated 
protein 2 (Skp2) is phosphorylated by Akt on S72, activates Skp-2 dependent ligase 
activity and stimulates cell migration through maintaining Skp2 in the cytoplasm 
(Gao et al., 2009, Lin et al., 2009). Akt also promotes cell migration by regulating 
microtubule dynamics through Akt/GSK3β axis-dependent activation of microtubule 
binding protein, APC (adenomatous polyposis coli) (Onishi et al., 2007, McPhee et al., 
2008, Hong et al., 2009). 
Akt also interacts with pro-migratory proteins, in addition to targeting cytoskeletal 
proteins thus facilitating crosstalk between associated signalling axes. VEGFR/eNOS 
signalling pathway controlled cell migration is dependent on Akt mediated 
phosphorylation on S1177 (Dimmeler et al., 2000). Accumulating evidence has 
pointed out the importance of NO in pathological situations, especially in malignant 
tumours (Xu et al., 2002, Ridnour et al., 2012). Furthermore, VEGFR signalling often 
cooperates with a G-protein coupled receptor named sphingosine-1 phosphate 
receptor 1(SIPR1, also known as endothelial differentiation gene 1, EDG-1). eNOS 
activates upon binding of SIP in SIP receptor 1. Thus SIP/SIPR1 activation leads to 
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the phospho-activation of VEGFR which is facilitated through phospho Src kinase, 
thus consequently activates the PI3k/Akt/eNOS axis (Spiegel and Milstien, 2003). Akt 
mediated phosphorylation of SIPR1 on T236 further enhanced this activity, 
stimulates cortical actin assembly, angiogenesis and chemotaxis (Lee et al., 2001b, 
Ozaki et al., 2003). Thus, Akt plays a central role in regulating VEGFR and 
SIP/SIPR1pathway and actively controls cell migration. 
A member of the largest tyrosine kinase protein family named, EphA2 (Ephrin 
receptor tyrosine kinase A2) has also been shown to be phosphorylated by Akt on 
S897. In human brain cancer cells S897 phosphorylation is responsible for Akt 
mediated migration and invasion due to effects on dendritic actin cytoskeleton 
rearrangement and lamellipodia formation (Miao et al., 2009, Pasquale, 2010). In a 
recent study, scientists have shown that EphA2 recruits Ephexin4 (a guanine 
nucleotide exchange factor for the small GTPase RhoG) upon phosphorylation on 
S896 and promotes breast cancer and colorectal cancer cell migration and anoikis 
resistance (Kawai et al., 2013). 
It is now well established that membrane redistribution of integrins by various 
signalling pathways is a critical mediator of cellular movement. ANK repeat and 
pleckstrin homology domain-containing protein 1 (ACAP1) is a GTPase activating 
protein (GAP) for ADP ribosylation factor 6 (ARF6) which participates in integrin β 
recycling. ACAP1 is phosphorylated by Akt on S554 and stimulates integrin 
recycling and therefore promotes cell migration (Li et al., 2005a). Another GTPase 
activating protein, RhoGAP22 is shown to be phosphorylated by Akt on S16 upon 
103 
 
stimulation by insulin or possibly PDGF, playing a vital role in regulating cell 
migration, leading to modulation of Rac1 activity (Rowland et al., 2011). 
Several studies have demonstrated the role of mammalian target of rapamycin 
complex 1 (mTORC1) in cellular movement and their relationship with Akt (Berven 
et al., 2004, Sakakibara et al., 2005). Akt may positively regulate mTORC1 and in turn, 
increase the phosphorylation of p70S6K1 (S6K1) and inhibit eukaryotic initiation 
factor 4E binding protein 1(4EBP1). It has been published that a tumour suppressor 
gene, tuberous sclerosis complex 1/2 (TSC1/2) inhibits the S6K1 and activates 4EBP1 
and this function of TSC1/2 is mediated by inhibiting mTORC1. It has also been 
shown that TSC2 is inhibited by Akt-mediated phosphorylation which destabilises 
the complex and activates mTORC1 (Inoki et al., 2002). In the single cell motility 
assay, IGF-1 stimulated cell motility was inhibited by down regulation of S6K1 by 
using lentiviral and by ectopic expression of constitutively hypophosphorylated 
4EBP1 (Liu et al., 2006a). S6K1 regulates cell motility, perhaps related to its 
regulating phosphorylation of the focal adhesion proteins, such as focal adhesion 
kinase (FAK), paxillin and p130Cas, and F-actin reorganisation (or lamellipodia 
formation) (Liu et al., 2008). Furthermore, mTORC1 mediates phosphorylation of 
ERK1/2 (extracellular-signal related kinase) on T202 through direct or indirect 
regulation of PP2A (Protein phosphatase 2A). Inhibition of PP2A activates EKR1/2 
which promotes motility in a number of transformed cells and cancer cell lines 
(Benefield et al., 1997, Jackson and Young, 2003, Wlodarski et al., 2006, Liu et al., 2010, 
Li et al., 2013). 
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A number of studies have also demonstrated that transforming growth factor β1 
(TGF β1) increases the migration of human chondrosarcoma and lung cancer cells 
through the PI3K/Akt signalling pathway. Akt activated IKKαβ (IkB kinase) can 
phosphorylate IkBα and p65 on S536 residue. NFkB thus dissociates from IkBα and 
activates β1 integrin and αvβ3 integrin which promotes human lung cancer and 
chondrosarcoma cell migration (Yeh et al., 2008, Fong et al., 2009). 
Studies with human trophoblast cells have shown that abrogation of mTOR 
signalling, leading to the lack of functional mTORC1 is involved in a tightly 
regulated network of the intracellular JAK/STAT signalling pathway and contributes 
to the invasiveness of trophoblast cells by regulating matrix-remodelling enzymes 
such as MMP9 ( matrix metalloproteinase), MMP2, uPA (urokinase plasminogen 
activator) and PAI-1 (plasminogen activator inhibitor) (Busch et al., 2009, Zhou and 
Huang, 2011). 
The opposing roles of Akt in cell migration have also been discussed in different 
studies. Akt phosphorylates kidney ankyrin repeat-containing protein (kank) which 
consequently lead to negative regulation of stress fibre assembly and RhoA 
activation, thus attenuating cell migration (Kakinuma et al., 2008). An actin binding 
protein, palladin, phosphorylated by Akt1 on S507 inhibits breast cancer cell 
migration by disrupting F-actin bundles (Chin and Toker, 2010a). On the other hand, 
Akt2 contributes to palladin stability independent of S507 phosphorylation (Chin 
and Toker, 2010b). Similarly, Akt phosphorylates TSC2 (tuberous sclerosis complex 
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2), a Rho GTPase regulator that inhibits breast cancer cell migration due to impaired 
F-actin assembly (Liu et al., 2006b). 
 
1.9.3 Akt in EMT 
 
Epithelial cells are tightly connected with their adjacent cells and with actin 
filaments via E-cadherin-containing adherent junctions and α or β-catenin, 
respectively. Before migrating as single cells, carcinoma cells must break these 
intercellular junctions and invade stromal tissues. To facilitate this type of cellular 
invasion epithelial tumour cells undergo a process termed as epithelial to 
mesenchymal transition (EMT). EMT can be stimulated either by extracellular 
cytokines, for example EGF, TGF α and β, FGF, or by intracellular cues, such as 
oncogenic Ras (Yang and Weinberg, 2008, Thiery et al., 2009, Nieto, 2011). During 
EMT, epithelial cells gain mesenchymal phenotypes by losing their polarity and cell-
cell contacts. Characteristics of EMT are the functional loss of E-cadherin and down-
regulation of epithelial markers such as, cytokeratin and ZO-1, and the 
overexpression of mesenchymal or fibroblast markers N-cadherin, vimentin and 
fibronectin (Figure 1.31) (Larue and Bellacosa, 2005, Zheng and Kang, 2013). 
EMT is reversible and sometimes, cells undergo the reciprocal mesenchymal to 
epithelial transition (MET). During the development process, 
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Figure 1.32 Epithelial to Mesenchymal Transition (EMT) and associated biological 
markers. 
Upon growth factor stimulation epithelial cells undergo a morphological change to a 
mesenchymal phenotype, which is characterised by its motile and invasive 
behaviour. 
 
EMT plays a vital role in the formation of various tissues and organs such as the 
neural crest, heart, musculoskeletal and peripheral nervous systems. Only a few cells 
in adult organisms hold the ability to undergo EMT in specific physiological or 
pathological events like wound healing. However, tumour cells often gain the ability 
to reactivate the EMT process during cancer progression and confer selective 
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advantages like enhanced migration and invasiveness (Thompson and Williams, 
2008, Zheng and Kang, 2013). 
A number of studies have reported that Akt is frequently activated in human 
carcinoma (Ringel et al., 2001, Testa and Bellacosa, 2001, Fresno Vara et al., 2004, 
Bellacosa et al., 2005, Wu et al., 2009). Akt2 has been shown to be activated in ovarian 
carcinoma affecting epithelial cell morphology, tumourigenicity, cell motility and 
invasiveness which is characterised by the loss of histological features of epithelial 
differentiation (Bellacosa et al., 1995). The first study that reported the definitive role 
of Akt in EMT was published in 2003, in which squamous cell carcinoma lines 
overexpressing activated mutants of Akt were shown to undergo EMT and down 
regulate E-cadherin (Grille et al., 2003). Loss of E-cadherin and relocalisation of β-
catenin from the membrane to the nucleus is frequently detected in tumour cells 
undergoing EMT (Kalluri and Weinberg, 2009, Thiery et al., 2009). A number of 
transcription factors have been identified that can commence and maintain this 
process, including Snail, Twist and Zeb. The definitive signalling mechanism of 
normal regulation of these factors at a molecular level are still poorly understood, 
yet they are apparently deregulated in many invasive cancers (Larue and Bellacosa, 
2005, Bellacosa and Larue, 2010). Recent evidence suggests a strong relationship 
between Akt and EMT-inducing transcription factors. The first evidence was that 
Snail is phosphorylated by GSK3β (glycogen synthase kinase 3 beta) in normal 
epithelial cells but is very unstable and hardly detectable. Expression of Snail in 
epithelial cells strongly induces morphological change associated with enhanced 
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migratory capacity (Zhou et al., 2004, Katoh and Katoh, 2006). 
Hyperphosphorylation of Akt down regulates GSK3β activity depending on S9 
phosphorylation. Because GSK3β-dependent phosphorylation of β-catenin and Snail 
leads to ubiquitination and degradation, down regulation of GSK3β results in the 
stabilisation and the nuclear accumulation of β-catenin and Snail. Nuclear Snail 
represses transcription of CDH1 gene encoding E-cadherin, to induce the EMT 
program. Stabilisation of Snail by phospho-inhibiting GSK3β also increases the 
expression of vimentin, N-cadherin and MMP-9. Nuclear β-catenin activates the 
transcription of cMYC and cyclin D1 gene, which also plays a significant role in the 
EMT. This is perhaps consistent with the situation in invasive cancers, in which high 
Akt phosphorylation leads to negative GSK3β expression and Snail overexpression. 
(Wu et al., 2012, Ha et al., 2013, Smith et al., 2013, Wang et al., 2013).  
A transcription/translation regulatory protein named Y-box binding protein-1 (YB-1) 
is reported to be phosphorylated by Akt and translocated to the nucleus. Nuclear 
YB-1 thus activates Snail and reduces E-cadherin expression, which in turn promotes 
EMT in invasive breast carcinoma (Evdokimova et al., 2009). Furthermore, 
upregulated Snail could in turn, increase Akt activity (Cho et al., 2007). An 
unexpected role of Akt2 in transcriptional control is also revealed. Snail1 increases 
the binding of Akt2 to the E-cadherin (CDH1) promoter and Akt2 interference 
inhibits Snail1 repression of CDH1 gene (Villagrasa et al., 2012). Akt2 could also be 
activated by another EMT-inducer, Twist, in invasive breast cancer cells (Cheng et 
al., 2007). Inhibition of Akt also down-regulates Twist in cancer cells (Hong et al., 
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2009). Furthermore, Akt phosphorylates and activates Twist1, which in turn 
enhances the phosphorylation of Akt because of increased TGFβ signalling in human 
breast cancer (Yao et al., 2008, Xue et al., 2012, Yokoyama et al., 2012). Recent data 
also suggests that the polycomb group protein named B lymphoma Mo-MLV 
insertion region 1 homolog (Bmi1) is a downstream target of Twist1 and is crucial for 
EMT and cancer metastasis (Yang et al., 2010). Akt, remarkably, could directly 
phosphorylate Bmi1 in high grade prostate tumours (Nacerddine et al., 2012). 
Promotion of Akt activity by Bmi1 was also found to promote EMT by blocking 
GSK3β-mediated degradation of Snail in HNSCC and breast cancer (Song et al., 2009, 
Guo et al., 2011). Twist and Bmi1 also mediate suppression of the miR let-7i which 
results in NEDD9 and DOCK3 overexpression and promotes mesenchymal motility 
in HNSCC, melanoma and breast cancer via Rac1 (Ahn et al., 2012, Sanz-Moreno, 
2012, Yang et al., 2012). In many cases breast cancer metastasis may be under the 
control of a balance between Akt1 and Akt2 and their link with MiR-200/Zeb/E-
cadherin axis (Iliopoulos et al., 2009, Hill et al., 2013). Taken together, several studies 
demonstrate an important interaction between Akt and EMT inducer-associated 
signalling. This synergistic interaction has critical and unfortunate pathological 
effects: 1) it stops stress-induced cell cycle arrest in cancer cells, 2) it stimulates pro-
invasive/metastatic gene expression, and 3) it maintains up regulation of PI3K/Akt 
signalling, which further increases the anti-apoptotic potential of cancer cells (Smith 
et al., 2013, Xue and Hemmings, 2013, Zheng and Kang, 2013). Figure 1.32 
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summarises the role of Akt in metastasis with its possible association with 
substrates. 
1.9.4 Akt in HNSCC metastasis 
 
The term HNSCC (Head and Neck Squamous Cell Carcinoma) refers to epithelial 
tumours that arise in the oral cavity, pharynx, larynx and nasal cavity, with the main 
risk factors being alcohol and/or tobacco use and HPV infection (Gillison et al., 2000, 
Neville and Day, 2002). It is the sixth most common type of cancer by incidence and 
around 500000 new cases a year worldwide (Kamangar et al., 2006). It has recently 
been shown that Akt is persistently activated in the vast majority of HNSCC cases. 
Active forms of Akt (as phosphorylated) can readily be detected in both 
experimental and human HNSCCs and HNSCC-derived cell lines 
(Amornphimoltham et al., 2004). Akt can be activated due to the overactivity of 
different growth factors, chemokines, integrin etc. and their respective receptors, ras 
mutations, PI3Ka gene amplification, overexpression, or activating mutations, 
together with aberrant PTEN activity due to genetic alterations or decreased 
expression in HNSCC (Amornphimoltham et al., 2011). Akt activation is an early 
event in HNSCC progression which can be identified in as many as 50% of tongue 
preneoplastic lesions  
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Figure 1.33 Role of Akt in metastasis 
Phosphorylated Akt activates a range of signalling molecules responsible for 
cytoskeletal rearrangements and EMT. These two biological phenomena are the 
mechanism for cell migration and invasion. 
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Akt activation also represents an independent prognostic marker of poor clinical 
outcome in both tongue and oropharyngeal HNSCCs (Massarelli et al., 2005, Yu et al., 
2007) and has recently been linked with the conversion of a potentially malignant 
oral lesions to OSCC (Pontes et al., 2009). Akt is known to induce morphological 
changes associated with EMT, loss of cell-cell adhesion and increased motility and 
invasion in HNSCC (Larue and Bellacosa, 2005). Oral carcinoma cells of epithelial 
origin ectopically express a mesenchyme-specific transcription factor (HMGA2) at 
the invasive front, which has a significant impact on tumour progression and patient 
survival (Miyazawa et al., 2004). However, the definitive evidence that EMT was 
induced by Akt was provided by a study in which oral squamous cell carcinoma 
lines overexpressing activated mutants of Akt were shown to undergo EMT and 
down-regulate E-cadherin (Grille et al., 2003). Snail and SIP1 exhibit an inverse 
correlation with E-cadherin expression levels in oral carcinoma cells (Yokoyama et 
al., 2001, Maeda et al., 2005). The stably Snail overexpressing OSCC clones showed 
spindle morphology, increased expression of vimentin and decreased expression of 
E-cadherin (Taki et al., 2003). Julien reported that activation of NF-κB by Akt up 
regulates Snail expression and induces EMT in OSCC and expression of the NF-κB 
subunit p65 is enough for EMT induction (Julien et al., 2007). Recently, Bmi1 was 
found to inhibit Akt inhibitor, PTEN and thus promotion of Akt activity by Bmi1 
promotes EMT. Interestingly, Bmi1 depends on Snail for E-cadherin repression. Thus 
Bmi1 found to be a player in EMT by activation of Akt, stabilisation of Snail and 
repression of E-cadherin in HNSCC (Song et al., 2009, Smith et al., 2013). Increased 
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Twist expression is associated with down- regulation of E-cadherin and also may 
influence the Akt pathway through unclear mechanism in nasopharyngeal 
carcinoma cells (Zhang et al., 2007). Another study reported that p-Akt inhibition 
could induce the mesenchymal to epithelial transition (MET) through its interaction 
with NF-κB and down regulation of Twist in OSCC cells, suggesting that there may 
be a positive interaction between Twist and p-Akt during the EMT in OSCC (Hong et 
al., 2009). Moreover, recent work suggests that EMT induced by SDF-1/CXCR4 
system might be involved in the lymph node metastasis of OSCC via activation of 
PI3K/Akt signalling pathway (Onoue et al., 2006).  
Work from our laboratory has indicated that PI3 kinase and Akt pathways are 
essential for migration of fibroblasts in response to added factors such as Migration 
stimulating factor (MSF), Epidermal growth factor (EGF) and Transforming growth 
factor alpha (TGFα) (Schor et al., 2003, Ellis et al., 2007, Ellis et al., 2010a). The 
addition of PI3 kinase inhibitors blocks the migration stimulating activity of MSF 
and EGF. The data indicates differences in Akt phosphorylation with different 
growth factors, for example; MSF reduces and EGF and TGFα both increase 
phosphorylation. The data also reveals that when an Akt inhibitor (Akti 1/2) is 
added to fibroblasts, in the collagen gel assay, there is a stimulation of cell migration. 
The data indicate that MSF promoted fibroblast migration, at least in part, by 
inhibiting Akt activity (Ellis et al., 2010a). 
Extensive studies have demonstrated that activation of three Akt isoforms by 
phosphorylating different residues determines the substrate selectivity and thus 
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exerts different biological activity in different cell types. Three highly homologous 
Akt isoforms have opposing functions in different cancer types (Hutchinson et al., 
2001, Hutchinson et al., 2004, Irie et al., 2005, Wyszomierski and Yu, 2005, Yoeli-
Lerner et al., 2005, Fayard et al., 2011). As Akt is the central signalling node that 
incorporates membrane, cytoplasmic and nuclear signals regulating cell fate, 
analysing Akt isoform and cell type specific signalling pathways and targeting them 
will contribute to personalise targeted cancer therapy. 
1.10 Conventional chemotherapy, their limitations and overcome 
1.10.1 Conventional chemotherapeutic agents 
 
There are three aims associated with the use of most regularly used 
chemotherapeutic drugs (Ophardt, 2003): 
1. To damage the DNA of the cancer cells. 
2. To stop the cell from replicating by inhibiting the synthesis of new DNA. 
3. To stop splitting of the original cell into two new cells or to stop mitosis. 
The most commonly used chemotherapy agents and their mechanism of actions are 
illustrated in the Figure 1.33. The chemotherapeutic agents used for advanced 
HNSCC include platinums (cisplatin and carboplatin), anthracyclines (adriamycin, 
epirubicin, and pirarubicin), taxanes (paclitaxel and docetaxel) and antimetabolites 
(e.g., methotrexate and 5- fluorouracil). 
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Figure 1.34 Name and mechanism of action of some conventional chemotherapy 
agents. 
Alkylating agents, anti-metabolites, anti-tumour antibiotics, topoisomerase inhibitor 
and mitotic inhibitors are the most used chemotherapy  classes (Ophardt, 2003). 
 
The usefulness of many chemotherapeutic agents is limited by their toxicity to 
normal cells because there are a very few obvious biochemical differences between 
cancerous and normal cells. Thus nonspecific actions of conventional anti-cancer 
agents lead to many side effects.  These chemotherapy drugs, whether given alone or 
in combination, have produced clinical benefits in terms of significant improvement 
of the overall survival in HNSCC, in comparison to other cancers such as renal and 
colorectal carcinomas (Lebwohl and Canetta, 1998, Giaccone, 2000, Blackhall et al., 
2005). Yet, in most cases, patients unavoidably experience tumor progression or 
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relapses owing to the development of cells with acquired drug resistance, or 
appearance of cell subpopulations genetically unmanageable to the drugs (intrinsic 
drug resistance) (Greenberg et al., 2003). 
1.10.2 Mechanisms of chemotherapy drug resistance 
 
The drawbacks of chemotherapy are recognised to be mechanisms that facilitate 
drug resistance at a cellular level or factors innate to tumour microenvironment and 
the host. For example, a number of intracellular mechanisms have been associated 
with reduced drug transport or enhanced efflux including overexpression of plasma 
membrane efflux proteins such as LRP (lung resistance protein), MRP( MDR-related 
proteins) and Pgp-170 (P-glycoprotein-170) that inhibit drugs from reaching 
intracellular targets (Minchinton and Tannock, 2006, Tredan et al., 2007). 
Mutations in drug target-encoding genes that decrease the attraction of a drug to the 
active site (e.g. mutations in topoisomerase-coding genes and tubulin that diminish 
camptothecin and taxanes activity, respectively), improved drug detoxification via 
upregulation of  phase II detoxifying enzymes (e.g. GST, glutathione S-transferases), 
enriched DNA repair mechanisms that neutralise drug-induced DNA damage, along 
with a variety of other mechanisms that make the cells more resistant to pro-
apoptotic signals ranging from cell cycle checkpoints, chromatin and transcriptional 
modifications and abnormal function of growth factor receptors and tumour 
suppressor proteins to deregulated intracellular signal transduction pathways 
(Rudolf and Cervinka, 2003, Dwarakanath et al., 2004). 
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Tumour microenvironment is a crucial determining factor and transformer of 
therapeutic response; especially angiogenesis and hypoxia have been broadly 
studied as options to overcome drug resistance (Folkman, 2007, Maione et al., 2012, 
Sebens and Schafer, 2012, Semenza, 2012). Even though primary optimism 
surrounding the targeting of angiogenesis was based on the idea that endothelial 
cells are genetically stable and therefore less susceptible to develop drug resistance, 
it is now recognised that tumor blood vessels are unstable and vary from their 
normal counterparts regarding structural abnormalities in the basement membrane 
and in pericyte activity, leakiness, morphological characteristics and blood flow 
(Morikawa et al., 2002, Baluk et al., 2003, Kawamoto et al., 2012). This may explain 
why tumor endothelial cell become resistant to anti-angiogenic drugs, including the 
anti-VEGF antibody bevacizumab  (Ma and Waxman, 2008). 
A recent study revealed that anti-angiogenic agents can decrease the growth of 
primary tumours, but also can stimulate distant metastases and therefore worsen 
prognosis. This was mainly because they induced cell invasion signalling, including 
EMT (epithelial-mesenchymal transition) and hypoxia in tumours. Hypoxia is well- 
known to stimulate resistance to chemotherapy and radiation. (Braybrooke et al., 
2000, Semenza, 2010, Cooke et al., 2012, Semenza, 2012).  
Induction of cell heterogeneity and selection of rare cancer stem cell (CSC) variants 
with intrinsic resistance to chemotherapy are another explanation for chemotherapy 
failure (da Silva et al., 2012). CSC’s are a small subpopulation of tumour cells having 
tumour- initiating ability and the capability to reconstruct the cellular heterogeneity 
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of the primary tumour. A number of studies have involved cancer stem cells in 
cancer progression, invasion process, distant metastasis and loco-regional recurrence 
after therapy (Prince et al., 2007, Prince and Ailles, 2008, Zhang et al., 2012). Also, it 
has been reported that cancer cell variants expressing CSC markers are more 
resistant to chemotherapy than cells that do not express CSC markers (Dean et al., 
2005). This suggests that chemotherapy drugs, by targeting the more sensitive non- 
CSC can contribute to enhancement of the chemotherapy-resistant CSC and 
therefore stimulate recurrences (Frame and Maitland, 2011). 
EMT can regulate cellular plasticity and produce multiple, distinct cellular 
subpopulations contributing cellular heterogeneity. It also contributes to 
selection/enhancement of cancer stem cells from well-differentiated epithelial cells 
(Mani et al., 2008, Polyak and Weinberg, 2009). In this case, well-differentiated cancer 
cells need to have a higher plasticity and invasive ability via a transformation to 
non-polarised and poorly differentiated mesenchymal cells (Thiery, 2002, Thiery and 
Sleeman, 2006). Activation of Wnt/β-catenin, PI3K-Akt, MAPK and Notch signalling 
pathway can activate  EMT and  is well-known to occur in OSCC (Boyer et al., 2000, 
Conacci-Sorrell et al., 2002, Nelson and Nusse, 2004, Larue and Bellacosa, 2005, 
Nawshad et al., 2005, Barker, 2008, Agarwal et al., 2010, Courtney et al., 2010, Falasca, 
2010, Ihle and Powis, 2010). Studies have also revealed a significant correlation 
between EMT phenotype, drug resistance, and relapses (Zeisberg and Neilson, 2009, 
Scanlon et al., 2013) including in OSCC patients (Machiels and Schmitz, 2011, Raza et 
al., 2011). 
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Figure 1.34 below explains the factors that are responsible for chemotherapy drug 
resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.35 Important biological and pharmacological factors implicated in 
chemotherapy resistance. 
Apart from intracellular, tissue micro-environmental and host factors cell 
heterogeneity plays vital role in drug resistance and relapses (da Silva et al., 2012). 
 
 
 
 
EMT MET 
CSC 
Susceptibility to drug response  
and relapses 
Tissue microenvironment, e.g. angiogenesis, 
hypoxia, inflammatory cell infiltration 
Intracellular factors, e.g. enhanced drug 
efflux, decreased drug-target affinity 
Cell heterogeneity, e.g. transition 
to EMT 
Host factors, e.g. altered 
pharmacodistribution and metabolism 
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1.10.3 Molecular targeted therapy 
 
Researchers have been working relentlessly to produce drugs that target the 
mechanism of cancer cells specifically, so as to leave healthy cells undamaged, 
although certain conventional anti-cancer drugs are quite successful treatments for 
many forms of cancer. The build-up of knowledge about the specific molecular 
differences between normal and cancerous cells has allowed for the development of 
molecular targeted cancer therapy (Li et al., 2014). 
Exploiting molecular and cell biology to study carcinogenesis developed a greatly 
increased understanding of the cellular signalling pathways contributing to tumour 
growth and survival. The detection of tumour suppressors that can be stopped and 
oncogenes that can be dysregulated to stimulate tumour cell proliferation, 
uncovered crucial targets specific to tumour cells. Our knowledge has prospered 
through basic life science research to show that tumour growth also requires the 
escape of cell death programs, encouraging replicative immortality, initiating 
angiogenesis and stimulating invasion and metastasis (Hanahan and Weinberg, 
2011). Even though many of these processes are facilitated by genetic alteration 
within the tumour cells, the non-tumour cells and tumour microenvironment as well 
as the immune system are also associated in this multifaceted process. These 
biology-based progressions have strongly expanded the prospective selection of 
anti-cancer strategies. Furthermore, as well as offering novel targets, they have also 
opened the gate to molecular-targeted agents that selectively interrupt key signalling 
pathways and, thus potentially have less nonspecific side-effects (Tsantoulis et al., 
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2007, Papaspyrou et al., 2011, Rao et al., 2012). Many of these drugs are now in 
clinical use for specific cancer such as Erlotinib (EGFR-tyrosine kinase inhibitor) for 
invasive pancreatic and NSCLC (Rosell et al., 2012, Troiani et al., 2012), Bevacizumab 
(anti-VEGF monoclonal antibody) for metastatic cancer of the kidney, lung and 
colon (Kerr, 2004), Cetuximab and Trastuzumab (anti-EGFR monoclonal antibody) 
for colorectal carcinoma and HER-2/neu+ breast cancer, respectively (Chang, 2010, 
Debucquoy et al., 2010), Imatinib (BCR-Abl inhibitors) for chronic myeloid leukaemia 
(Waller, 2014) and Vorinostat (the proteasome inhibitor) for cutaneous lymphoma 
(Lansigan and Foss, 2010). Cetuximab is the only US FDA approved drug for use in 
locally advanced HNSCC in combination with radiotherapy and as a single agent or 
in combination with platinum based chemotherapy for recurrent or metastatic 
HNSCC (Dorsey and Agulnik, 2013). 
It is clear that a better knowledge of the molecular and biological profile of HNSCC 
should accelerate the development of more effective targeted therapies. Existing 
clinical trials with targeted agents in HNSCC are likely to bring encouraging 
strategies reducing the risk of tumor recurrence and improving survival of patients 
with HNSCC.  
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Chapter 2 Aims and hypothesis 
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2.1 Aims of the project 
 
The aim of this project was to study the role of VEGF-induced phosphorylated Akt 
on the migration and prognosis of head and neck cancer. The overall objectives of 
this project were: 
a. To investigate the effect of different concentrations of VEGF and incubation 
time on the phosphorylation of Akt (pAkt) at Thr 308 and Ser 473 residues in 
normal and cancer cell lines. 
b. To determine the effect of VEGF-induced Akt phosphorylation on the 
migration of different cell lines. 
c. To identify the prognostic significance of VEGF-induced Akt phosphorylation 
in head and neck squamous cell carcinoma. 
The specific studies carried out towards these objectives included: 
 VEGF-induced phosphorylation of Akt and PTEN were elucidated by SDS-
PAGE and Western blotting in normal keratinocytes (HaCaT), normal oral 
mucosal fibroblasts (MM1), cells from a dysplastic lesion (PM1), mouth 
cancer-associated fibroblasts (COM D25), oral adeno-squamous cell 
carcinoma (TYS) and oral squamous cell carcinoma (TR 146). The effect of 
PI3K/Akt pathway inhibitors (LY294002 and PI103) was also identified in 
terms of blocking Akt phosphorylation. 
 To investigate the effect of VEGF on cell migration, a number of in vitro cell 
migration and invasion assays were carried out for example, modified 
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Boyden chamber, 3D collagen gel, wound healing and live cell chemotaxis 
assay. To determine the different role of pAkt Thr308 and pAkt Ser473 in 
terms of migration, LY294002 (a specific PI3K inhibitor) and PI103 (dual 
inhibitor of PI3K and mTOR) were used.  
 To elucidate the status of phosphorylation of Akt at both residues, 
immunohistochemistry was performed using a phospho-site-specific 
antibody on the collected head and neck cancer tissue samples.  A statistically 
significant association among the patient’s behavioural and histopathological 
characteristics including smoking and alcohol with the Akt phosphorylation 
was identified. The prognostic significance of pAkt in HNSCC was also 
determined. 
2.2 Hypothesis of the study 
 
 It was hypothesised that VEGF-induced Akt phosphorylation would be 
dependent on cell type, VEGF concentration and duration of VEGF treatment. 
It was also hypothesised that PI3K/Akt pathway inhibitors would effectively 
inhibit Akt phosphorylation regardless of the cell type and PTEN would not 
be expressed in cancer cells. 
 Akt phosphorylated at both residues would be responsible for oral cancer cell 
migration and PI103, a dual inhibitor of PI3K and mTOR could effectively 
inhibit that migration. 
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 It was also hypothesised that Akt phosphorylated at both residues would be 
found highly activated in VEGF positive HNSCC and would be associated 
with at least one of the risk factors, if not all. Lymph node metastasis in 
HNSCC patients would be associated with phosphorylation of Akt at both 
residues as pAkt would be responsible for head and neck cancer cell 
migration. pAkt would also be an effective prognostic marker. 
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Chapter 3 Phosphorylation of Akt and its regulation in 
different cell lines 
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3.1 Background 
 
Protein phosphorylation is a post-translational modification in which a covalently 
bound phosphate group from ATP,  is transferred to serine, threonine or tyrosine 
residue of the protein mediated by protein kinases (O'Connor and Adams, 2010). It is 
the most common mechanism of controlling protein function and transmitting 
signals through the cells. Thus phosphorylation plays essential functions in the 
regulation of a number of cellular processes, including signal transduction 
pathways, cell cycle, growth, apoptosis and differentiation. It is approximated that 
30% of  human proteins are the substrates for phosphorylation at some time (Cohen, 
2000). Additionally, aberrant protein phosphorylation events are associated with 
many disease states (Huang, 2010). 
Serine, threonine and tyrosine have a nucleophilic hydroxyl (-OH) group that 
attracts the phosphate group on the universal phosphoryl donor adenosine 
triphosphate (ATP), causing the transfer of the phosphate group to the amino acid 
side chain and forming adenosine diphosphate (ADP). This process is mediated by 
protein kinases and magnesium (Mg+2). Phosphorylation is a reversible process in 
which kinase can phosphorylate and phosphatases can dephosphorylate the 
substrates. Thus, these two families of enzymes regulate the dynamic character of 
phosphorylated proteins in a cell. Phosphorylation causes the conformational 
changes in the phosphorylated proteins and this change can either activate or 
deactivate the protein (Figure 3.1). The conformational change can also recruit the 
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neighbouring proteins that have structurally conserved domains that recognise and 
bind to phosphomotifs. This recruitment is essential for signal transduction, in 
which downstream effector proteins are recruited to phosphorylated signalling 
proteins and initiate the signalling pathway (Johnson and Lewis, 2001). 
 
Figure 3.1 Protein phosphorylation. 
It is a reversible post-translation modification that controls protein function. Kinases 
transfers a phosphate group from ATP to the amino acid side chain and 
phosphatases hydrolyses the phosphate group (left panel). Phosphorylation triggers 
conformational changes in proteins that either activate (top) or inactivate (bottom) 
their function (right panel). 
 
Vascular endothelial growth factor (VEGF) mediates its biological effects by binding 
to specific receptors, leading to receptor dimerisation and following signal 
transduction by activating PI3kinases .  The Class 1 PI3 kinases are a set of lipid 
kinases that phosphorylate the relatively abundant membrane phospholipid, 
phosphatidylinositol 4, 5 biphosphate (PIP2), generating small quantities of 
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phosphatidylinositol 3, 4, 5 triphosphate (PIP3) (Ferrara, 2004). This latter lipid 
signal controls a diverse set of effector molecules including the Akt group of 
oncogenic kinases (also known as protein kinase B) (Ellis et al., 2010a). Activation of 
Akt, a 60 kDa serine/threonine kinase, depends on PI3K (Datta et al., 1999) . Increase 
of cellular PIP3 by PI3K eventually allows the activation of Akt by phosphorylation 
at residues T308 (Threonine 308) and S473 (Serine 473) (Alessi and Cohen, 1998). This 
activation is completed by structural modification stimulated by PI3K-dependent 
kinase-1 (PDK-1)-dependent phosphorylation at T308 and stabilisation by mTORC2-
dependent phosphorylation at S473 (Sarbassov et al., 2005). PTEN ((phosphatase and 
tensin homologue deleted on chromosome 10) inhibits the activation of Akt by 
dephosphorylating PIP3. 
3.2 Aims and hypothesis 
 
The specific aim of this study was to observe the status of Akt phosphorylation at 
both T308 and S473 residues in VEGF-treated different cell lines, ranging from 
normal to cancerous cells. It also aimed to explore the effect of PI3K/Akt pathway 
inhibitors and the duration of VEGF treatment on the phosphorylation of Akt. PTEN 
status was also investigated in normal and cancerous cell line. 
It was hypothesised that VEGF-induced Akt phosphorylation would be dependent 
on cell type, VEGF concentration and duration of VEGF treatment. It was also 
hypothesised that PI3K/Akt pathway inhibitors would effectively inhibit the Akt 
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phosphorylation regardless of the cell type and PTEN would not be expressed in 
cancer cells.  
3.3 Cell lines  
 
In this study, the following six cell lines were used (Table 9). Validation and 
justification of using the following cells are described in Appendix 1. 
Table 9 Details of the cell lines used 
 
Name Cell type Derived/originated 
from 
Secondary 
Source 
Primary 
source 
HaCaT Normal adult 
keratinocyte 
Normal skin Prof. S. L. 
Schor (Late), 
DDS 
(Boukamp et 
al., 1988) 
TYS Oral Adeno-
squamous cell 
carcinoma 
Derived from minor 
salivary gland 
Dr. Koji 
Harada 
University of 
Tokushima, 
Japan 
(Yanagawa et 
al., 1986) 
TR 146 Oral squamous 
cell carcinoma 
Originated from buccal 
mucosa and derived 
from lymph node 
Dr. Sam 
Crouch, DDS 
(Boukamp et 
al., 1985) 
MM1 Normal oral 
mucosal 
fibroblast 
Normal oral mucosa - Dr. M. 
Macluskey, 
In-house 
explant culture 
of a biopsy, 
Oral Surgery 
Clinic, 
Ninewells 
COM 
D25 
Mouth cancer-
associated 
fibroblast 
Oral  mucosa - 
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Hospital, 
Dundee. 
PM1 Stromal cell line Originated from 
forehead skin and 
derived from dysplastic 
lesion 
Dr. Sam 
Crouch, DDS 
(Proby et al., 
2000) 
 
3.4 Materials 
Table 10 lists all the equipment, reagents and antibodies used in this study. 
Table 10 List of equipment 
 
Name of the equipment Make/Origin 
Class II biological safety cabinet Medical Air Technology, Manchester, UK 
Incubator Thermo Scientific, Waltham, MA, USA 
Water bath Grant Instruments, Cambridge, UK 
Centrifuge machine (Mistral 1000) MSE, London, UK 
Hot Plate Photax Inc. 
Pipette Thermo Scientific, Waltham, MA, USA 
Pipette boy Integra bioscience, Zizers, Switzerland 
Nunclone cell culture dish Thermo Fisher Scientific, Denmark 
Automated cell counter, TC10 Bio-Rad, Hercules, CA, USA 
Light Microscope, IX50 Olympus, Tokyo, Japan 
Orbital shaker Stuart Scientific, Staffordshire, UK 
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Magnetic stirrer Stuart Scientific, Staffordshire, UK 
Mini PROTEAN Tetra System Bio-Rad, Hercules, CA, USA 
Semi-dry transfer cell Bio-Rad, Hercules, CA, USA 
Centrifuge (Sigma 1-13)  Sigma, Osterode am Harz, Germany 
Power Pac 300 Bio-Rad, Hercules, CA, USA 
ChemiDoc® MP imaging system Bio-Rad, Hercules, CA, USA 
 
Table 11 List of reagents and antibodies 
 
Cell culture reagents Company Catalogue no. 
FCS (Foetal Calf Serum) Sigma-Aldrich, St. Louis, MO, USA F-2442 
MEM (Minimum Essential 
Medium Eagle) 
Sigma-Aldrich, St. Louis, MO, USA M-0275 
EGTA Sigma-Aldrich, St. Louis, MO, USA E-8145 
Trypsin Sigma-Aldrich, St. Louis, MO, USA T-4549 
L-Glutamine Sigma-Aldrich, St. Louis, MO, USA G-7513 
PBS Sigma-Aldrich, St. Louis, MO, USA P-4417 
HBSS (HANK’S balanced salt 
solution) 
Sigma-Aldrich, St. Louis, MO, USA H-4641 
Sodium bicarbonate Merck, Darmstadt, Germany 301515V 
DMSO Sigma-Aldrich, St. Louis, MO, USA D-5859 
Protease inhibitor Roche Applied Science, Bavaria, 04693116001 
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Germany 
Phosphatase inhibitor Roche Applied Science, Bavaria, 
Germany 
04906845001 
SDS-PAGE & WB reagents 
Laemmli loading buffer Bio-Rad, Hercules, CA, USA 161-0737 
2-Mercaptoethanol Sigma-Aldrich, St. Louis, MO, USA M-7522 
Running buffer (TGS) Bio-Rad, Hercules, CA, USA 161-0772 
Mini-PROTEAN precast gel Bio-Rad, Hercules, CA, USA 456-1026 
Magic Mark XP western std. Invitrogen, Carlsbad, CA, USA LC 5602 
Immun-Star Western C 
substrate 
Bio-Rad, Hercules, CA, USA 170-5070 
Semi-skimmed milk powder Marvel, London, UK - 
Tris Boehringer, Mannheim, Germany 708976 
Glycine Sigma-Aldrich, St. Louis, MO, USA G-8898 
SDS VWR BDH, PA, USA 108073J 
Methanol VWR BDH, PA, USA 101586B 
Sodium Chloride Sigma-Aldrich, St. Louis, MO, USA S-3014 
Hydrochloric acid VWR BDH, PA, USA 101254H 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA P1379 
Nitrocellulose 
transmembrane 
Whatman, GE Healthcare, 
Buckinghamshire, UK 
10401396 
134 
 
Extra thick filter paper Bio-Rad, Hercules, CA, USA 1703960 
Antibodies, proteins and inhibitors 
Phospho-Akt (Ser473)(D9E) 
XP Rabbit mAb 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
4060 
Phospho-Akt (Thr 308) 
(C31E5E) Rabbit mAb 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
2965 
Akt (pan) (C67E7) Rabbit 
mAb 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
4691 
Phospho-PTEN (Ser380) 
antibody 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
9551 
Goat anti-rabbit IgG, HRP-
linked antibody 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
7074 
LY294002 Merck Calbiochem, Darmstadt, 
Germany 
9901 
PI103 Merck Calbiochem, Darmstadt, 
Germany 
528100 
Human Recombinant 
VEGF121 
Insight Biotechnology, Middlesex, 
UK 
10-1296 
Anti-GAPDH mouse mAb Millipore, Darmstadt, Germany MAB374 
Rabbit anti-mouse IgG, HRP-
linked antibody 
Dako, Cambridgeshire, UK P-0260 
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3.5 Experimental Procedure 
 
3.5.1 Cell Culture 
 
All the cells were cultured at 37 °C and 5% CO2 in MEM medium supplemented 
with 10% (v/v) foetal calf serum (FCS) and 200 mM glutamine. All the cell culture 
related tasks (including sub-culturing, farming, cryopreservation and resuscitation) 
were performed according to the standard laboratory protocol prepared by the unit 
of Cell and Molecular Biology, The Dental School, University of Dundee, UK. The 
cells were sub-cultured 1-2 time/s a week either 1:3 or 1:4 format. Growth medium 
was changed every third day. All the cells were grown on 90 mm dishes (Nunclon). 
To sub-culture, old medium was aspirated off first, washed with 4mls of HBBS, and 
trypsinised by 2 ml of EGTA at 370C for 5 minutes. Floated cells were then 
neutralised by 2 ml of growth medium and collected in a universal tube. The cell 
suspension was then spun for 5 minutes at 900 rpm, supernatant was aspirated off 
and the pellet was re-suspended in growth medium. Cell suspension was then split 
in required number of dishes and placed in the incubator. 
To cryopreserve the cells, steps of sub-culturing were followed up until the re-
suspension of the pellets. In this case, pellets were resuspended in freeze mix instead 
of growth medium and collected in 2 ml cryovials. Vials were then stored in -800 C. 
To resuscitate the cells, cryovials were first placed in a 370 C water bath to defrost. In 
the meantime, cell culture dishes were prepared by adding 5 ml of growth medium. 
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Defrosted cells were then placed in the culture dishes containing growth medium 
and incubated. After 3-4 hours dishes were checked for cell attachment. If cells 
attached in the dishes, a fresh medium was added. The cell culture log book was 
maintained in all cases.  
 
3.5.2 Cell treatment and Lysis 
 
Cells were grown on (around 80% confluent) 60 mm culture dishes and then 
transferred to serum free (SF) medium overnight, prior to the experiment. They were 
then transferred to the test conditions. Cells were treated with different 
concentrations of VEGF121 (100 pg/ml, 1 ng/ml, 10ng/ml and 100 ng/ml), LY294002 (1 
µM and 6 µM) and PI103 (75 nM and 125 nM) for 15 minutes.  Cells were also 
treated with 10 ng/ml of VEGF121 for 15 minutes, 5 hours and 24 hours to study the 
effect of the duration of the treatment on phosphorylation of Akt and PTEN. 5 hours 
and 24 hours treatment time was selected to compare the status of Akt 
phosphorylation with cell’s migratory behaviour in different migration assays i.e., in 
the Boyden chamber migration assay (5 hours experiment) and in the scratch and 
live cell chemotaxis assay (24 hours experiment). Cells were then washed with ice-
cold PBS and lysed on ice with RIPA buffer (50 mM Tris HCl, 150 mM NaCl, pH 7.4; 
0.1% w/v SDS, 1% v/v Triton x-100, 1% w/v sodium deoxycholate and 5 mM EDTA) 
containing protease inhibitors for 10 minutes. RIPA buffer containing protease 
inhibitors with added phosphatase inhibitors was only used to lyse the cells treated 
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with different concentrations of VEGF121 for 15 minutes. Cells were scraped off the 
dishes after 10 minute and the cell lysates were collected into Eppendorf tubes and 
frozen at -200C.  
 
3.5.3 SDS-PAGE (Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis) 
 
SDS-PAGE was used to separate proteins according to their size. Prior to SDS-PAGE, 
proteins were denatured by heating at 950C in a loading buffer containing SDS and a 
reducing agent, 2-Mercaptoethanol. Heating in this buffer causes denaturation of the 
proteins and loss of their 3D structures. SDS, an anionic detergent, binds to the 
denatured proteins. The amount of bound SDS is relative to the size and proteins 
therefore migrate according to their size when the current is applied. Protein 
molecular weight markers were also run on each gel for reference, to allow 
molecular weight estimation of the fractionated protein. For Western blotting 
Magicmark XP western standard was used. The separated proteins were transferred 
to inert nitrocellulose membranes by Western blotting followed by probing the blot 
with antibodies to identify specific proteins. 
The specific procedures of SDS-PAGE are briefly discussed below: 
Prior to use in SDS-PAGE cell lysates were thawed and spun at 13,000 rpm for 5 
minutes. Samples were then mixed with equal volume of Laemmli sample loading 
buffer including 5% (v/v) 2-mercaptoethanol. Samples were then heated at 950C in a 
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water bath for 5 minutes and loaded onto 10% or Any kD Biorad TGX precast gels. 
Gels were then connected to a power pack set at the voltage of 140-180V and run for 
approximately 40-45 minute.  After removing the gels from the cassette they were 
placed into transfer buffer to be blotted.  
 
3.5.4 Western Blot 
 
Western blot is a method used to transfer the protein bands from SDS-PAGE onto a 
membrane using an electric current. After transfer, the non-specific binding sites on 
the blot were blocked by incubation in blocking buffer. The immobilised bands were 
then probed with specific antibodies against the target proteins (primary antibodies). 
The primary antibody, which recognises the target protein, was then added. Excess 
and unbound antibody was removed by thorough washing of the blot. The 
secondary antibody which recognises the primary antibody was then added and 
labelled with the enzyme horse radish peroxide for visualisation. The location of this 
antibody was visualised by adding a substrate to the enzyme HRP generating 
chemiluminescence. 
The procedures of western blotting are briefly discussed below: 
After completion of SDS-PAGE, proteins from the gels were electro-transferred onto 
the nitrocellulose membranes at a constant voltage of 15Vfor 42 minutes. Blots were 
then blocked by incubation in blocking buffer (1% w/v dried milk in 1X TBST) for 10-
30 minutes. Blots were then incubated with the primary antibodies anti-pAkt T308 
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(1:1000), anti-pAkt S473 (1:2000), anti-pan Akt (1:1000), anti-pPTEN (1: 1000) and 
anti-GAPDH (1:500) overnight at 190C. After washing with TBST blots were then 
incubated with the secondary antibodies goat anti-rabbit (1:2000) and rabbit anti-
mouse (1:10,000) for 60 minute at room temperature. Immunoblots were then 
developed using a Western C substrate kit and chemiluminescence was detected 
using a ChemiDoc imaging system.  
3.5.5 Statistical Analysis 
 
The data was analysed using the statistical package IBM SPSS 19.0. Differences in the 
phosphorylation between the negative control and different concentration of 
VEGF121 were carried out using 1-way ANOVA with Bonferroni’s post-test. 
Differences were considered significant when the p value was less than 0.05. 
3.6 Results 
 
3.6.1 Akt phosphorylation at S473 (Serine 473) is cell type and VEGF concentration 
dependent 
All the cell lines were treated with different concentrations of VEGF121 for 15 minutes 
and analysed for phosphorylation of Akt at S473 (60 kDa). Phosphorylation was 
increased in normal oral mucosal fibroblasts (MM1) and OSCC (TR 146) in 
comparison to the negative control (p<0.05) and also with increasing VEGF121 
concentration (Appendix 2). Phosphorylation was increased in OASCC (TYS) in 
comparison to the negative control (p<0.05) but constant with increasing VEGF121 
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concentration. On the other hand, phosphorylation at S473 was constant in normal 
keratinocytes (HaCaT) and mouth cancer-associated fibroblasts (COM D25) 
compared to the negative control (p>0.05) and with increasing VEGF121 concentration 
of 100 pg/ml, 1 ng/ml, 10 ng/ml and 100 ng/ml. Akt S473 phosphorylation was either 
similar or increased compared to that of negative control in all the cell lines except in 
cells from the dysplastic lesion (PM1). The VEGF121-induced AktS473 
phosphorylation in PM1 cells was decreased compared to the negative control 
(p<0.05) but increased with different concentrations. The highest increase in Akt 
phosphorylation at S473 was stimulated by VEGF121 concentration of 10 ng/ml in oral 
cancer cells. Serum free treated cells were used as a negative control and FCS media 
treated cells were used as a positive control.  Figure 3.2 illustrates the status of 
VEGF121-induced Akt phosphorylation at S473 in different cell lines and Table 12 
represents the quantification of the phosphorylation. 
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Figure 3.2 Western blot experiments for Akt phosphorylation at Serine 473 in 6 
different cell lines with a spectrum of VEGF concentrations. 
pAkt S473 phosphorylation in normal keratinocytes (HaCaT), normal oral fibroblasts 
(MM1), mouth cancer-associated fibroblasts (COM D25), cells from a dysplastic 
lesion (PM1), OASCC (TYS) and OSCC (TR 146) with VEGF concentrations of 
100 pg/ml, 1 ng/ml, 10 ng/ml and 100 ng/ml. All the cells were treated with VEGF for 
15 minutes. All the blots were cropped from the original images and the figure 
shows the representative images from triplicate experiment. (+) denotes the positive 
control (FCS media) and (−) denotes the negative control (serum free media). 
GAPDH was used as loading control which showed constant pAkt S473 with all the 
factors. 
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Table 12 Quantification of Akt phosphorylation at S473 
 
Note: Each value represents % phosphorylation and (*) denotes significant at p<0.05 level 
compared with negative control. 
 
3.6.2 VEGF121-induced pAkt T308 (Threonine 308) is also dependent on cell type 
and concentration. 
pAkt T308 was also analysed in cells after 15 minutes of VEGF121 treatment.  
Akt phosphorylation at T308 in normal keratinocytes (HaCaT), mouth cancer-
associated fibroblasts (COM D25) and OASCC (TYS) was constant in comparison to 
negative control (p>0.05) and with increasing VEGF121 concentrations. 
Phosphorylation was increased in oral cancer cells (TR 146) (Appendix 2) and 
decreased in those from a dysplastic lesion (PM1) compared to the negative control 
(p<0.05) and with increasing VEGF121 concentration. pAkt T308 was constant at 100 
pg/ml and 1 ng/ml VEGF121, but increased (p<0.05) compared to negative control. 
The highest increase in Akt phosphorylation at T308 was at a VEGF121 concentration 
of 10 ng/ml in oral cancer cells. Serum free treated cells were used as negative 
pAkt Ser473 quantification,% 
Cell name (-)ve 
control 
(+)ve 
control 
100pg/ml 
VEGF 
1 ng/ml 
VEGF 
10 ng/ml 
VEGF 
100 ng/ml 
VEGF 
HaCaT 100 207* 99 105 103 106 
MM1 100 142* 59* 129* 427* 281* 
COM D25 100 642* 95 101 79 99 
PM1 100 633* 34* 51* 31* 50* 
TYS 100 152* 155* 149* 145* 129* 
TR146 100 116 451* 632* 678* 600* 
GAPDH 
 100 109 104 95 90 106 
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control and FCS treated cells were used as a positive control.  Figure 3.3 illustrates 
the status of VEGF121-induced Akt phosphorylation at T308 in different cell lines and 
Table 13 represents the quantification of the phosphorylation.  
 
 
Figure 3.3 Differential phosphorylation of Akt at T308 in different cell lines. 
VEGF121-induced pAkt T308 was dependent on cell type and concentration. All the 
cells were treated with VEGF for 15 minutes. All the blots were cropped from the 
original images and the figure shows the representative images from triplicate 
experiment. (+) denotes the positive control (FCS media) and (−) denotes the 
negative control (serum free media). GAPDH was used as loading control. 
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Table 13 Quantification of Akt phosphorylation at T308 
 
 Note: Each value represents % phosphorylation and (*) denotes significant at p<0.05 
level compared with negative control. 
 
 
3.6.3 Pan Akt is constant in both normal and cancer cells 
VEGF121-induced pan (total) Akt was constant in both normal keratinocytes (HaCaT) 
and in OASCC (TYS) compared to the negative control (p>0.05) and with different 
VEGF concentrations. Serum free treated cells were used as negative control and FCS 
media treated cells were used as positive control. Figure 3.4 illustrates the status of 
VEGF121-induced Pan Akt in different cell lines and Table 14 represents the 
quantification of the phosphorylation. 
 
pAkt Thr308 quantification, %  
Cell name (-)ve 
control 
(+)ve 
control 
100pg/ml 
VEGF 
1 ng/ml 
VEGF 
10 ng/ml 
VEGF 
100 ng/ml 
VEGF 
HaCaT 100 215* 102 86 87 82 
MM1 100 492* 95 112 486* 455* 
COM D25 100 451* 95 100 114 116 
PM1 100 1015* 44* 60* 36* 25* 
TYS 100 132* 97 113 94 118 
TR146 100 180* 155* 771* 1036* 954* 
GAPDH 
 100 110 101 92 99 95 
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Figure 3.4 Pan Akt status in VEGF121 treated cells. 
All the blots were cropped from the original images and the figure shows the 
representative images from triplicate experiment. (+) denotes the positive control 
(FCS media) and (−) denotes the negative control (serum free media). 
 
Table 14 Quantification of phosphorylation of pan Akt 
 
 
Note: Each value represents % phosphorylation. 
 
 
3.6.4 VEGF121-induced Akt phosphorylation both at S473 and T308 is time and cell 
type dependent 
Cell lines were treated with 10 ng/ml VEGF for 15 minutes, 5 hours and 24 hours. 
Western blot experiments show various level of phosphorylation of Akt at both T308 
and S473 residues in different cells. Figure 3.5 illustrates the level of Akt 
phosphorylation in a time-course manner, whereas Table 15 statistically quantifies 
the level of phosphorylation compared to the respective negative control at different 
Pan Akt quantification, %  
Cell name (-)ve 
control 
(+)ve 
control 
100pg/ml 
VEGF 
1 ng/ml 
VEGF 
10 ng/ml 
VEGF 
100 ng/ml 
VEGF 
HaCaT 100 108 106 107 112 106 
TYS 100 104 91 100 115 89 
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times. Table 16 compares the VEGF-induced phosphorylation at different times 
instead of comparing to the respective negative control. Table 16 shows  
VEGF (10 ng/ml) treatment of COM D25, TYS and TR146 cells (Appendix 3) for 
various times (15 minutes, 5 hours and 24 hours) caused a gradual increase in the 
level of Akt phosphorylation at both S473 and T308 (p<0.05). By contrast, after 24 h 
of VEGF exposure either a decrease or a constant level of phosphorylation of Akt at 
residues T308 and S473 was observed in HaCaT, MM1 and PM1 cells (Figure 3.5) 
(Table 16). 
 
Figure 3.5 Time-course Western blot experiment. 
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VEGF-induced Akt phosphorylation at both T308 and S473 residues are VEGF 
incubation time and cell type dependent. All the blots were cropped from the 
original images and the figure shows the representative images from triplicate 
experiment. (+) denotes the positive control (FCS media) and (−) denotes the 
negative control (serum free media). 
 
 
Table 15 Quantification of Akt phosphorylation at different incubation times 
 
pAkt Ser473 quantification, % 
 15 minutes 5 hours 24 hours 
Cell 
name 
(-)ve 
control 
(+) 
control 
10 
ng/ml 
VEGF 
(-)ve 
control 
(+) 
control 
10 
ng/ml 
VEGF 
(-)ve 
control 
(+) 
control 
10 
ng/ml 
VEGF 
HaCaT 100 365* 78 100 807* 113 100 209* 27* 
MM1 100 142* 427* 100 518* 87 100 383* 99 
COMD25 100 589* 103 100 380* 109 100 292* 112 
PM1 100 633* 61* 100 830* 182* 100 216* 18* 
TYS 100 155* 152* 100 118 92 100 128* 135* 
TR146 100 619* 148* 100 92 115 100 108 82 
pAkt Thr308 quantification, % 
HaCaT 100 133* 90 100 233* 103 100 146* 91 
MM1 100 492* 386* 100 587* 85 100 195* 12* 
COMD25 100 982* 98 100 465* 118 100 326* 190* 
PM1 100 1015* 85 100 585* 80 100 131* 21* 
TYS 100 125* 98 100 126* 103 100 101 113 
TR146 100 173* 55* 100 99 130* 100 96 104 
 
Note: Each value represents % phosphorylation. (*) indicates significant changes 
compared with respective negative control. 
 
Table 16 pAkt quantification compared with VEGF-treatment at different times 
 
Time course, 10ng/ml VEGF-induced pAkt S473 quantification, Mean volume 
Cell name 15 minutes 5 hours 24 hours 
HaCaT 781 867 259 (**↓)/ (***↓) 
MM1 5825 2059 (*↓) 2047 (***↓) 
COM D25 562 2872 (*↑) 2602(***↑) 
PM1 13984 28168 (*↑) 1934 (**↓)/ (***↓) 
TYS 8261 8185 11049 (**↑)/(***↑) 
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TR146  9224 43122 (*↑) 36334 (***↑) 
Time course, 10ng/ml VEGF-induced pAkt T308 quantification, Mean volume 
HaCaT 4444 4283 3618 
MM1 31570 5709 (*↓) 5032 (***↓) 
COM D25 480 762 (*↑) 992 (**↑)/(***↑) 
PM1 6889 7494 1224 (**↓)/ (***↓) 
TYS 5633 6779 (*↑) 9499 (**↑)/(***↑) 
TR146 8160 29713 (*↑) 26500 (***↑) 
 
Note: Time-course Western blot experiment revealed that VEGF-induced Akt 
phosphorylation is time and cell type dependent. Each value represents mean 
volume. (*) indicates significant changes in phosphorylation compared to 15 
minutes, (**) indicates significant changes in phosphorylation compared to 5 hours 
(***) indicates significant changes in phosphorylation compared to 15 minutes. (↑) 
indicates increase and (↓) indicates t decrease in phosphorylation. 
 
3.6.5 LY294002 cannot inhibit Akt phosphorylation at S473 in cancer and cancer-
associated fibroblast cells 
LY2904002 [2-(4-Morpholinyl)-8-phenyl-4 H-1-benzopyran-4-one] is a specific and 
potent inhibitor of PI3 Kinases, which competitively inhibits ATP binding to the 
catalytic subunit of the PI3Ks. To elucidate the effects of PI3K inhibitor on the 
phosphorylation of Akt, cells were treated with LY294002 (1 µM and 6 µM) for 15 
minutes. Akt phosphorylation at T308 was effectively blocked by both 
concentrations of LY294002 in all cells, which was statistically significant (p<0.05). 
Both the concentrations of LY294002 on the other hand, did not block the 
phosphorylation of Akt at S473  in cancer (Appendix 4)and cancer-associated 
fibroblast cells either alone or in combination with VEGF (p>0.05). pAkt S473 was 
only blocked by 6 µM LY in normal keratinocytes (p<0.05) (Figure 3.6) (Table 17). 
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Figure 3.6 Effect of LY294002 on Akt phosphorylation. 
pAkt S473 was not blocked by LY in cancer and cancer-associated fibroblast cells. All 
the blots were cropped from the original image. 
 
Table 17 Quantification of Akt phosphorylation in LY294002 treated cells 
 
pAkt Ser473 quantification, %  
Cell name VEGF 1 µM LY 6 µM LY 1 µM LY 
+ 
VEGF 
6 µM LY 
+ 
VEGF 
HaCaT 100 25* 2* 32* 1* 
TYS 100 2* 2* 4* 1* 
TR146 100 112 116 124* 129* 
MM1 100 3* 2* 4* 2* 
COM D25 100 52* 65* 59* 62* 
pAkt Thr308 quantification, %  
HaCaT 100 2* 1* 3* 1* 
TYS 100 1* 1* 2* 2* 
TR146 100 2* 3* 1* 2* 
MM1 100 2* 1* 1* 2* 
COM D25 100 1* 2* 1* 1* 
Note:  Each value represents % changes and (*) denotes significant changes in 
phosphorylation. 
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3.6.6 PI103 effectively blocked pAkt at both residues in all cells 
PI 103 is a cell permeable pyridinylfuranopyrimidine compound (3-(4-(4-
Morpholinyl)pyrido[3′,2′ :4,5]furo[3,2-d]pyrimidin-2-yl)phenol) that acts as a potent 
and ATP competitive inhibitor of PI3K, mTOR and DNA-PK. Cells were treated with 
PI103 (75 nM and 125 nM) for 15 minutes. All the cells were effectively and 
significantly blocked by PI103 (p<0.05) with 125 nM being the most effective 
concentration (Figure 3.7) (Table 18) (Appendix 4). 
 
Figure 3.7 Effect of PI103 on Akt phosphorylation. 
pAkt was blocked by PI103 in all cells. All the blots were cropped from the original 
image.  
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Table 18 Quantification of Akt phosphorylation in PI103 treated cells 
 
pAkt Ser473 quantification, %  
Cell name VEGF 75 nM 
PI103 
125 nM 
PI103 
75 nM + 
VEGF 
125 nM + 
VEGF 
HaCaT 100 2* 1* 3* 1* 
TYS 100 2* 1* 1* 2* 
TR146 100 43* 5* 19* 25* 
MM1 100 2* 1* 1* 2* 
COM D25 100 35* 38* 23* 42* 
pAkt Thr308 quantification, %  
HaCaT 100 2* 4* 3* 1* 
TYS 100 2* 3* 1* 5* 
TR146 100 3* 2* 1* 1* 
MM1 100 2* 1* 1* 1* 
COM D25 100 19* 15* 25* 10* 
 
Note:  Each value represents % changes and (*) denotes significant changes in 
phosphorylation. 
 
3.6.7 PTEN is inactivated in cancer cells 
Phosphatase and Tensin homologue (PTEN) (57 kDa) status was assessed in normal 
and cancerous cells treated with SF (negative control), FCS (positive control) and 
VEGF for 15 minutes, 5 hours and 24 hours.  Phosphorylated PTEN at S380 residue 
was constant in normal keratinocytes (HaCaT) and normal oral fibroblasts (MM1) 
cells over the treatment period. Oral squamous cell carcinoma (TR 146) treated with 
all the controls and VEGF, expressed very low or no phosphorylated PTEN in 
different incubation time (Appendix 5). pPTEN at Ser 380 was gradually decreased 
by increasing incubation time in  VEGF-treated mouth-cancer associated fibroblast 
cells (Figure 3.8).  
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Figure 3.8  Phosphorylated PTEN at S380 in normal and cancerous cells.  
pPTEN was inactivated in cancer cells (TR146). All the blots were cropped from the 
original images. SF treated cell were used as (-)ve control and FCS treated cells were 
treated with (+)ve control. 
 
3.7 Discussion 
 
To our knowledge, the study of Akt activation by VEGF121 in different cell lines 
ranging from normal epithelial to oral cancer cells as well as normal fibroblasts to 
oral cancer-associated fibroblasts is the first of its kind. Due to its increased acidity, 
VEGF121 circulates more freely than the other VEGF isoforms, which bind more 
tightly with vascular heparin sulphate (Ferrara and Davis-Smyth, 1997). VEGF165 is 
the most extensively studied among the other VEGFA isoforms, although VEGF121 
isoform is also predominant. Exposure of six different cell types to various 
concentrations of VEGF121 resulted in phosphorylation of Akt both at T308 and S473 
residues. The phosphorylation at both residues and its intensity and duration 
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depends on VEGF concentration, duration of exposure and cell type. LY294002, a 
selective class I PI3K inhibitor is still used extensively in experimental models 
although it failed in clinical trials due to its poor solubility and high toxicity (Knight, 
2011). It inhibited the phosphorylation of Akt at T308 in all the cell lines used in this 
study. This confirms the highly conserved PI3K-dependent mechanism of Akt 
phosphorylation at T308. Conversely, LY294002 was able to inhibit the 
phosphorylation of Akt at S473 only in normal keratinocytes, normal oral mucosal 
fibroblasts and oral adeno-squamous cell carcinoma, but not in oral cancer and oral 
cancer-associated fibroblasts.  A selective class I PI3K, mTOR (C1 & C2) and DNA-
PK inhibitor, PI103, inhibited Akt phosphorylation both at T308 and S473 in all the 
cell lines. A number of studies have revealed the different mechanisms of Akt 
phosphorylation at S473.  Depending on the context, phosphorylation of Akt at S473 
is recognised by a number of different kinases namely, PDK2 (Phosphoinositide-
dependent kinase 2) (Chan and Tsichlis, 2001), MAPKAP-K2 (Mitogen-activated 
protein kinase associated protein kinase 2) (Alessi et al., 1996), ILK1 (Integrin-linked 
kinase 1)(Lynch et al., 1999) which has been the subject of considerable debate. 
Sarvassov et al in 2005 confirmed that phosphorylation of Akt at S473 in response to 
growth factors is dependent on Rictor-mTOR complex, mTORC2 (Sarbassov et al., 
2005). A number of studies have also proposed that a member of the PI3K-like 
family of kinases, the DNA-dependent protein kinase (DNA-PK) triggers 
phosphorylation of Akt at the S473 in response to genotoxic stimuli (Feng et al., 2004, 
Bozulic et al., 2008). It has also been suggested that Akt can be autophosphorylated at 
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S473 residue (Toker and Newton, 2000). A recent review by Alex Toker (2014) has 
suggested that most of these mechanisms are anecdotal and are likely to be cell type-
dependent (Toker and Marmiroli, 2014). This theory is proven by this study but the 
hypothesis is proven incorrect. It has been shown that phosphorylation of Akt at 
S473 in oral cancer and cancer-associated fibroblast cells depend upon mTORC2 
and/or DNA-PK, whereas S473 phosphorylation in normal keratinocytes, normal 
mucosal fibroblasts and oral adeno-carcinoma was not mTORC2-dependent but 
PI3K-dependent. Akt phosphorylation is also targeted by dual lipid and protein 
phosphatase and tensin homologue (PTEN) by dephosphorylating PIP3. 
Importantly, loss of PTEN expression or inactivating mutations leads to constitutive 
activation of Akt signalling, characterised by increased cell proliferation and 
resistance to apoptosis, turning a normal cell to cancerous one (Leslie et al., 2009, 
Barata, 2011). It has been observed that Akt phosphorylation is higher and there is 
no PTEN phosphorylation in the oral cancer cell line (TR146) in this study. These 
characteristics of oral cancer cells here and in other studies with cancer (but not oral 
cancer) (LoPiccolo et al., 2008, Newton and Trotman, 2014) prompted us to study Akt 
hyper-phosphorylation and its association with metastasis in the next stage of this 
project. 
 
 
 
 
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 Is there a pAkt between VEGF and motility in oral 
cancer? 
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4.1 Background 
There has been a significant progress in cancer treatment over the past few decades 
but oral cancer still has a poor survival rate, with a high occurrence of metastases 
(Tankere et al., 2000). Cell migration is an essential part of most tumour metastasis. 
Cells need to migrate away from their microenvironment to enable the tumour to 
spread or metastasise. Growth factors and matrix macromolecules are essential for 
the movement of cells (Schor, 1994). Such movement requires a reorganisation of the 
actin cytoskeleton, which is under the control of many pathways including the PI3 
kinase/Akt signal transduction pathway. Previous work in this laboratory showed 
that the PI3 kinase and Akt pathways are essential for the migration of fibroblasts in 
response to added factors such as Epidermal growth factor (EGF) and Transforming 
growth factor alpha (TGFα) (Ellis et al., 2007). The addition of PI3 kinase inhibitors 
blocks the migration stimulating activity of EGF and TGFα, the data indicating that 
both growth factors increase phosphorylation of Akt. Inhibition of PI3K activity 
blocks migration stimulated by G protein-coupled receptors or by receptor tyrosine 
kinases, signifying that PI3K has a vital function in cell migration (Barber and Welch, 
2006). Vascular endothelial growth factor (VEGF) has been reported to stimulate the 
proliferation of endothelial cells and to  enhance vascular permeability and survival 
(Ferrara et al., 2003). Over-expressed VEGF  acts as an effective angiogenic cytokine, 
stimulating endothelial cells thus promoting angiogenesis in solid tumours such as 
breast or ovarian carcinomas (Sia et al., 2013). Apart from angiogenic function, VEGF 
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was also found to be responsible for the migration of breast carcinoma (Bachelder et 
al., 2003, Mercurio et al., 2005), colon carcinoma (Oommen et al., 2011), 
hepatocarcinoma (Xu et al., 2012) and skin cancer (Beck et al., 2011). But the role of 
VEGF and its downstream PI3K/Akt signalling pathway in oral cancer metastasis is 
not known. 
4.2 Aims and Hypothesis 
 
The aim of this study was to establish the role of the PI3K-Akt pathway in VEGF121 
induced migration of oral cancer cells. It was also aimed to investigate the role of 
phosphorylated Akt at both T308 and S473 on oral cancer cell migration. A novel 
class I PI3K, mTOR and DNA-PK inhibitor, PI103 was also used in this study to 
investigate its inhibitory effect on the migration of oral cancer. The resultant data 
would help extend the spectrum of known biological activities of this pathway and 
support the proposal that inhibition of this pathway would be a suitable target for 
chemotherapeutic drug design to control oral cancer cell metastasis. It would also 
help to understand why the current used treatments targeting the VEGF pathway in 
cancer are not universally effective in inhibiting metastasis tumours. 
It was hypothesised that Akt phosphorylated at both residues would be responsible 
for oral cancer cell migration and PI103, a dual inhibitor of PI3K and mTOR would 
effectively inhibit that migration. 
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4.3 Materials 
 
The cell lines that were used in this study were as described earlier in Chapter 3 
(Table 9). Table 19 and 20 lists all the equipment, reagents and antibodies used in 
this study. 
 
 
Table 19 List of equipment 
 
Name of the equipment Make/Origin 
Class II biological safety cabinet Medical Air Technology, Manchester, 
UK 
Incubator Thermo Scientific, Waltham, MA, USA 
Water bath Grant Instruments, Cambridge, UK 
Centrifuge machine (Mistral 1000) MSE, London, UK 
Hot Plate Photax Inc., UK 
Pipette Thermo Scientific, Waltham, MA, USA 
Pipette boy Integra bioscience, Zizers, Switzerland 
Nunclone cell culture dish Thermo Fisher Scientific, Denmark 
Automated cell counter, TC10 Bio-Rad, Hercules, CA, USA 
Light Microscope, IX50 Olympus, Tokyo, Japan 
Chemotaxis chamber (48 well) Neuroprobe Inc., Gaithersburg, MD, 
USA 
Membrane filter (8 µm) Costar, UK 
µ-slide Chemotaxis 2D IBIDI GmbH, Munich, Germany 
Heated stage IBIDI GmbH, Munich, Germany 
Inverted fluorescence microscope 
(IX70) 
Olympus, Tokyo, Japan 
Immunopen Dako, Cambridgeshire, UK 
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Table 20 List of reagents and antibodies 
 
Name Company Catalogue 
no. 
FCS (Foetal Calf Serum) Sigma-Aldrich, St. Louis, MO, USA F-2442 
MEM (Minimum Essential 
Medium Eagle) 
Sigma-Aldrich, St. Louis, MO, USA M-0275 
EGTA Sigma-Aldrich, St. Louis, MO, USA E-8145 
Trypsin Sigma-Aldrich, St. Louis, MO, USA T-4549 
L-Glutamine Sigma-Aldrich, St. Louis, MO, USA G-7513 
PBS Sigma-Aldrich, St. Louis, MO, USA P-4417 
HBSS (HANK’S balanced 
salt solution) 
Sigma-Aldrich, St. Louis, MO, USA H-4641 
Sodium bicarbonate Merck, Darmstadt, Germany 301515V 
DMSO Sigma-Aldrich, St. Louis, MO, USA D-5859 
BSA Sigma-Aldrich, St. Louis, MO, USA A-9418 
Methanol VWR BDH, PA, USA 101586B 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA P1379 
Mayer’s Haematoxylin Sigma-Aldrich, St. Louis, MO, USA MHS-32 
Gills 3 Haematoxylin Brunel Microscope, Wiltshire, UK 095903, 
Aqueous mounting media Sigma-Aldrich, St. Louis, MO, USA M-1289 
Native Type 1 Collagen In-house  
Normal goat serum Vactor laboratories, Burlingame, 
CA, USA 
S1000 
Phospho-Akt 
(Ser473)(D9E) 
XP Rabbit mAb 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
4060 
Phospho-Akt (Thr 308) Cell Signaling Technology Inc., 2965 
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(C31E5E) Rabbit mAb Danvers, MA, USA 
Akt (pan) (C67E7) Rabbit 
mAb 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
4691 
Anti-Rabbit IgG (H+L), 
F(ab')2 Fragment (Alexa 
Fluor® 488 Conjugate) 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
4412 
LY294002 Merck Calbiochem, Darmstadt, 
Germany 
9901 
PI103 Merck Calbiochem, Darmstadt, 
Germany 
528100 
Human Recombinant 
VEGF121 
Insight Biotechnology, Middlesex, 
UK 
10-1296 
 
4.4 Experimental Procedure 
 
4.4.1 Cell Culture 
 
All the cells were cultured at 37 °C and 5% CO2 in MEM medium supplemented 
with 10% (v/v) foetal calf serum (FCS) and 200 mM glutamine. All the cell culture 
related tasks (including sub-culturing, farming, cryopreservation and resuscitation) 
were performed according to the standard laboratory protocol prepared by the unit 
of Cell and Molecular Biology, The Dental School, University of Dundee, UK. The 
cell culture log book was maintained in all cases. 
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4.4.2 Boyden Chamber Migration Assay 
 
The Boyden chamber assay is based on the chemotaxis mode of cell migration in 
which cells  migrate towards the concentration gradient of a chemoattractant (Chen, 
2005). 
A 48-well Boyden chamber (Neuroprobe) (Figure 4.1 A) was used for the in vitro 
migration assays as previously described (Ellis et al., 2010b). In brief, cells suspended 
in serum-free MEM with bovine serum albumin (2µg/ml) (SF-BSA) were seeded into 
the upper compartment of the chamber. The lower compartment was filled with 
different concentrations of VEGF121 and inhibitors, diluted with SF-BSA. The two 
compartments were separated by a porous membrane filter (8µm, Costar, UK) 
coated with type 1 native collagen. The chambers were incubated for 5 hours at 37˚C. 
The filter was then washed twice in PBS, fixed in cold methanol and stained either 
with Mayer’s (Sigma-Aldrich) or Gills 3 (Brunel Microscope) haematoxylin 
overnight. The cells on the upper surface of the filter were scraped off with a cotton 
swab. The membrane was then mounted onto a glass slide and examined under 
bright field illumination at a magnification of x200. Six replicate wells were used per 
variable. The numbers of migrated cells adherent to the lower surface of the 
membrane was counted in 3 random fields per well i.e. 18 fields per variable. Data 
were expressed as mean cell number per field ± SEM. When comparing different 
variables, results were expressed as a percentage of the controls.  
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4.4.3 Collagen gel migration assay 
 
The collagen gel migration assay was performed as previously described (Ellis et al., 
2010a). Type I collagen from rat tail tendons was used to make 2 ml collagen gels in 
35 mm plastic tissue culture dishes as described earlier (Schor et al., 1980). Collagen 
gels were overlaid with 1 ml of either serum-free MEM (SF-MEM) or SF-MEM 
containing 4× the final concentration of VEGF121 and/or with the inhibitors. 
Confluent stock cultures of cells were then harvested, resuspended in growth 
medium containing 4% (v/v) FCS at the desired concentration and 1 ml aliquots were 
added to the overlaid gels. Considering the 2 ml volume of gel, 1 ml medium overlay 
and 1 ml cell inoculum, this procedure gives a final concentration of 1% (v/v) serum 
in both control and test cultures. Cells attached to the surface of the gel within 1 hour 
and started to migrate into the underlying 3D gel within 24 hours. Four days after 
plating, the number of cells remaining on the surface or that had migrated into the 
gel were determined by microscopic observation of 10 randomly selected fields in 
each of the duplicate cultures. Cell migration was expressed by the number of cells 
that migrated into the 3D gel, as a percentage of the total number of cells present 
(Mean ± SEM). When comparing different variables, results were expressed as a 
percentage of the controls.  
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4.4.4 Live cell chemotaxis assay 
 
Live cell imaging during chemotaxis was captured while cells were in the µ-slide 
(IBIDI) (Figure 4.1B). The μ-Slide Chemotaxis 2D is a tool for investigating 
chemotaxis of adherent migrating cells in 2D over extended periods of time. The 
linear concentration profile which is necessary for chemotactical movement is 
produced by diffusion and stable for at least 48 hours. Detailed experimental 
procedures are described in Appendix 6 and 7. In brief, live cell migration was 
observed for 24 hours in a heated stage fitted onto an inverted microscope (Olympus 
IX70). Cells (HaCaT and TR146) were plated in the observation area of the µ-slide 
chemotaxis 2D (IBI-treat) (IBIDI GmbH) with the control in one reservoir and 
chemo-attractant with or without the inhibitors in the other reservoir. Time-lapse 
images were captured every 15 minutes by Metamorph v6.1 software (Molecular 
Devices). Cells were tracked by the manual tracking plug-in of ImageJ software and 
analysed by different chemotaxis parameters e.g. centre of mass, forward migration 
index (FMI) and directness by IBIDI’s Chemotaxis and Migration tool. Video of live 
cell migration and animation movie was also prepared using the ImageJ software 
(See attached CD). 
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A 
 
B  
 
Figure 4.1 Equipment for migration assay. 
(A) Boyden chamber (B) µ-slide chemotaxis 2D 
 
4.4.5 Wound healing (Scratch assay) and Immunofluorescence assay 
 
The scratch assay, a directional in vitro 2D migration assay, was performed as 
described earlier (Rodriguez et al., 2005). A cell monolayer was serum starved 
overnight and then a wound was made in the monolayer using a 100µl pipette tip, 
the assays were then incubated in test conditions (VEGF ± inhibitors) for 24 hours. 
Images were captured at the starting point and at regular periods throughout the 
assay to monitor the cell migration causing wound closure. After 24 hours, the cells 
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were fixed with cold methanol for 15 minutes and then washed with PBS. Cells were 
then treated with 0.2% Triton X-100 in PBS for 5 minutes, the area into which cells 
migrated was ringed with Immunopen (DAKO) and blocked with 5% (v/v) normal 
goat serum (NGS) (Vector Lab) in PBST (phosphate buffered solution with 0.1% 
Tween 20) for 30 minutes. The cells were then washed with PBS and incubated with 
pAkt S473 or pAkt T308 diluted in 5% (v/v) NGS in PBST at 4˚C for overnight. They 
were then washed twice with PBST, once with PBS and incubated with secondary 
antibody conjugated with Alexa Fluor 488 (1:1000) for 30 minutes at room 
temperature. After washing twice with PBST and once with PBS, sections were cover 
slipped with aqueous mounting medium (Sigma). Sections were then viewed with 
an Olympus IX70 inverted fluorescent microscope using x10 or x40 objective lenses. 
Images were collected using an Olympus SC35 digital camera. All devices were 
controlled through Metamorph v6.1 software (Molecular Devices) and images were 
then processed and analysed by ImageJ software (NIH). 
 
4.4.6 Statistical Analysis 
 
The data was analysed using the statistical package IBM SPSS 19.0. Differences in 
cell migration were analysed by Kruskal-Wallis test and Bonferroni with Dunn’s 
post-test. Differences were considered significant when the p value was less than 
0.05. The Rayleigh test was applied for unimodal clustering of directions in live cell 
chemotaxis assay and a p<0.05 was chosen as the criterion for rejecting the null 
hypothesis of random directionality. 
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4.5  Results 
 
4.5.1 VEGF can stimulate oral adeno-squamous cancer and cancer-associated 
fibroblast cell migration and can be blocked by LY294002 and PI103 
Cell migration experiments were performed using a modified Boyden chamber 
assay. Different concentrations of VEGF were used to investigate the role of this 
growth factor in the migration of normal adult keratinocytes (HaCaT), normal oral 
mucosal fibroblasts (MM1), mouth cancer-associated fibroblast (COM D25) and 
OASCC (TYS). HaCaT (Appendix 8) and MM1cells were not stimulated to migrate in 
response to VEGF (Figure 4.2 A, B). However, VEGF stimulated the migration of TYS 
and COM D25 cells (Figure 4.2 C, D) and this migration displayed a dose response 
effect with maximal stimulation at approximately 10 ng/ml VEGF (p<0.05) 
(Appendix 9 & 10). A cell permeable, potent, reversible and specific PI3K inhibitor, 
LY294002, which acts on the ATP binding site of the enzyme, had no effect on the 
migration of these cells either alone or in combination with VEGF (Figure 4.2 C, D). 
A blocking effect of LY294002 was observed at concentrations between 1µM to 6µM. 
No effect on the migration of MM1 and HaCaT was observed in response to 
LY294002 alone or in combination with VEGF (Figure 4.2 A, B).  PI103, another 
potent, cell-permeable, ATP-competitive PI3K and mTORC1/2 inhibitor was added 
at 75 nM-250 nM and its effect on cell migration was observed. PI103 reduced 
HaCaT, MM1 and TYS (Appendix 11) cell migration from baseline to below the 
baseline level (p<0.05) and showed no effect in combination with VEGF (Figure 4.2 
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A, B, C). PI103 alone had no effect and stimulated COM D25 cell migration in 
combination with VEGF (Figure 4.2 D). A representative statistical report is attached 
in Appendix 12. 
 
 
 
Figure 4.2 Boyden chamber migration assay. 
Variable migratory responses of different cell lines treated with VEGF and PI3K-Akt 
pathway inhibitors obtained by Boyden chamber migration assay compared with 
negative control. (A) Normal keratinocytes (HaCaT) (n=35) and (B) Oral mucosal 
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fibroblasts (MM1) (n=40) were not stimulated to migrate by VEGF (baseline, n =32 & 
38, respectively) (p>0.05). LY294002 had no effect either alone or in combination with 
VEGF on the migration of HaCaT (n=30 & 33, respectively) and MM1 cells (n=37 & 
38, respectively). PI103 alone inhibits the migration of HaCaT (n=10) and MM1 
(n=21) to below the baseline (baseline, n=14 & 21, respectively) and has no effect in 
combination with VEGF (n=13 & 27, respectively). (C) OASCC (TYS) (n=90) and (D) 
Mouth cancer-associated fibroblast (COM D25) (n=50) were stimulated to migrate 
through the filters by VEGF (baseline, n=34 & 30, respectively) (p<0.05). There is no 
effect of LY294002 alone or in combination with VEGF on TYS (n= 35 & 34, 
respectively) and COM D25 (n= 29 & 32, respectively) on cell migration. PI103 alone 
reduced TYS (n= 13) cell migration from baseline to below the baseline (baseline, n= 
24) and showed no effect in combination with VEGF (n=25). However, PI103 had no 
effect alone on COM D25 cell migration (n=26) and stimulated migration (n=31) 
(p<0.05) in combination with VEGF (baseline, n=25). n= number of cells migrated. 
Asterisk (*) indicates the significant changes compared with negative control. 
Double asterisk (**) indicates the significant changes compared with VEGF. 
 
 
4.5.2 VEGF can stimulate oral cancer cells and cells from a dysplastic lesion to migrate 
and can be blocked by PI103 
Some of the cells lines (TR 146 and PM1) investigated here did not migrate in the 
modified Boyden chamber assay and therefore, a 3D collagen gel migration assay, 
developed in other studies, was used. After initial experiments to determine suitable 
concentrations of VEGF and the Akt inhibitors, the following concentrations were 
used in the collagen gel assay: 10 ng/ml VEGF121, 6 µM LY294002 and 125 nM PI103. 
Normal oral fibroblasts (MM1) were not stimulated to migrate in response to VEGF 
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(Figure 4.3 A), whereas VEGF stimulated the migration of cancer-associated 
fibroblasts (COM D25) (Figure 4.3 B, p<0.05), cells from a dysplastic lesion (PM1) 
(Figure 4.3 C, p<0.05) and OSCC (TR146) (Figure 4.3 D, p<0.05) after 4 days of 
treatment.  
 
Figure 4.3 3D Collagen gel assay. 
VEGF stimulated cells from a dysplastic lesion and oral cancer cells to migrate in the 
collagen gel assay compared with the negative control. (A) Normal oral mucosal 
fibroblasts (MM1) were not stimulated to migrate into the collagen gel in response to 
VEGF and the inhibitors (baseline, n =30) (p>0.05). (B) Mouth cancer-associated 
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fibroblasts (COM D25) were stimulated to migrate (n=33) significantly by VEGF 
(baseline, n= 8) (p<0.05). There was no effect of LY294002 and PI103 alone (n= 9 & 8, 
respectively) or in combination with VEGF (n=9 & 10, respectively) on COM D25 cell 
migration. (C) PM1 were stimulated to migrate by VEGF alone (n=7) and in 
combination with LY294002 (n=6) (p<0.05) (baseline, n=2), and no effect with 
LY294002 & PI103. (D) TR146 were also stimulated to migrate by VEGF alone (n=15) 
and in combination with LY294002 (n=13) (p<0.05) (baseline, n=7), and LY294002 and 
PI103 had no effect. n= number of cells migrated. Asterisk (*) indicates the significant 
changes compared with negative control. Double asterisk (**) indicates the 
significant changes compared with VEGF. 
 
 
LY294002 and PI103 alone and in combination with VEGF had no effect on the MM1 
and COM D25 cell migration (Figure 4.3 A, B). These two inhibitors alone also had 
no effect on the migration of PM1 (Figure 4.3 C) and TR 146 cells (Figure 4.3 D). 
LY294002, not PI103, in combination with VEGF stimulated the migration of these 
cells (p<0.05). 
 
4.5.3 Oral cancer cells showed directive cell migration towards VEGF and can be 
blocked by PI103 
Trajectory plots were developed after taking images of a 24 hour period of migration 
of HaCaT and TR146 cells (Figure 4.4).  The plots were showed the directive oral 
cancer (TR146) cell migration towards VEGF (Figure 4.4 B) (Video clip 4.1 and 4.2) 
unlike the HaCaT which showed no migration (Figure 4.4 A) (Video clip 4.3 and 4.4) 
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or TR146 with inhibitors (Video clip 4.5-4.8) which showed random migration 
(Figure 4.4 B, C). Legends of the video clips are described in the Appendix 13. 
 
Figure 4.4 Trajectory plot of the live cell chemotaxis assay. 
(A) HaCaT cell showed no migration (B) OSCC showed directional migration 
towards VEGF (C) and (D) OSCC cells with the inhibitors showed random and 
inhibited migration. 
 
The centre of mass and forward migration index was higher towards 
chemoattractants (VEGF) than that towards negative control for OSCC. This 
suggested the directive cell migration towards VEGF which is significant (P<0.001) 
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(Table 21). However, HaCaT cells showed insignificant migration towards VEGF 
(P>0.05) and PI103 effectively blocks OSCC cell migration (P>0.05). Although 
LY294002 blocks VEGF-induced OSCC cell migration, it rather showed higher 
migration towards negative control (P<0.05). 
 
Table 21 Chemotaxis parameter of live cell chemotaxis assay 
 
Chemotaxis 
parameters 
HaCaT TR 146 
-ve vs VEGF -ve vs VEGF -ve vs VEGF+LY -ve vs VEGF+PI 
Centre of mass 
(µm) 
X = 2.88 X= -84.55 X=-250.59 X= 60.31 
Y =-1.41 Y= -1379.85 Y=132.62 Y= 34.875 
xFMI or FMI  0.087 -0.024 -0.082 0.026 
yFMI or FMI II -0.051 -0.381 0.039 0.006 
Directness 0.257 0.399 0.140 0.102 
Rayleigh test P>0.05 P<0.001 P<0.05 P>0.05 
 
Note: FMI-Forward migration index, xFMI- a direction perpendicular to the 
gradient, yFMI- a direction parallel to the gradient 
 
4.5.4 pAkt Thr308 was strongly expressed and localised in the nucleus of serum 
 and VEGF-induced migrated cells 
24 hour observation of cell migration in the scratch assay (Figure 4.5) showed that 
VEGF stimulated the migration of cancer-associated fibroblasts, cells from dysplastic 
lesion and oral cancer cells, whereas normal fibroblasts and keratinocytes were not 
stimulated to migrate in response to VEGF. LY294002 cannot block the VEGF-
induced migration of oral cancer cells in this assay and upon addition of VEGF, 
cancer cells were stimulated to migrate significantly. On the other hand, LY294002 
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blocked the migration of cells from dysplastic lesion and this migration can be 
rescued upon addition of VEGF. No migration of oral fibroblast, cancer-associated 
fibroblasts and keratinocytes were observed in response to LY294002 alone or in 
combination with VEGF. PI103 blocks VEGF-induced migration of oral cancer cells 
insignificantly, whereas these cells were stimulated to migrate upon addition of 
VEGF. No effect on the migration of oral fibroblasts, cancer-associated fibroblasts, 
keratinocytes and dysplastic cells was observed in response to PI103 alone and in 
combination with VEGF. Serum-free MEM was used as negative control, 10% FCS 
was used as positive control and 10ng/ml VEGF as a stimulant in this study. 
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Fig 4.5 
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Figure 4.5 Scratch assay. 
Images have shown variable migratory behaviour of different cell lines. Scratch 
assays of keratinocytes and normal fibroblasts showed no migratory response upon 
treatment with VEGF and/or PI3K-Akt pathway inhibitors. Whereas cancer-
associated fibroblasts, cells from a dysplastic site and oral cancer cells were 
stimulated to migrate in response to VEGF. Oral cancer cells showed migration even 
in serum-free condition and in response to the inhibitors alone or in combination 
with VEGF. All the images were taken at X100 magnification. 
 
After 24 hours of scratch assay observation, immunocytochemistry of the fixed cells 
showed the expression and localisation of phosphorylated Akt in the cells. Serum-
induced migrated cells of all the cell lines assayed showed strong expression and 
nuclear localisation of pAkt T308 (Figure 4.6 B), whereas a very weak or diffused 
expression of pAkt S473 was observed in these migrated cells (Figure 4.6 A). VEGF-
induced migration of cancer- associated fibroblasts, dysplastic and oral cancer cells 
also showed strong expression and nuclear staining for pAkt T308 (Figure 4.6 B) and 
very weak or diffused staining for pAkt S473 (Figure 4.6 A). LY294002 alone or in 
combination with VEGF effectively blocks the expression of pAkt S473 in the 
keratinocytes, normal fibroblasts, cancer-associated fibroblasts and dysplastic lesion 
cells and showed diffused expression in the cancer cells (Figure 4.6 A). On the other 
hand, pAkt T308 expression was found to be effectively blocked by LY294002 alone 
and in combination with VEGF in the keratinocytes, normal fibroblasts and cancer-
associated fibroblasts cells and showed nuclear staining in the dysplastic and cancer 
cells in combination with VEGF (Figure 4.6 B). Both pAkt S473 and pAkt T308 were 
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found to be expressed very weakly or diffusely by PI103 alone and in combination 
with VEGF in all the cells (Figure 4.6 A & B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.6 (A) 
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Fig 4.6 (B) 
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Figure 4.6 Immunofluorescence assay. 
Cells were fixed after 24 hours and immunolocalised for pAkt with a fluorescent 
labelled antibody. VEGF and serum-induced migration showed strong nuclear 
localisation of pAkt T308 (B) in contrast to weak cytoplasmic or diffused localisation 
of pAkt S473 (A). All the fluorescent images were taken at x400 magnification. 
 
4.6  Discussion 
 
We have investigated the relationship between VEGF treatment, Akt activity and cell 
migration in human cell lines. In summary, we have tested six different cell lines in 
this study to represent the stages of tumour progression ranging from normal to 
metastatic cells. Our findings indicate that migration, in response to the addition of 
exogenous VEGF121, is only upregulated in cell lines originating from dysplastic 
lesions and tumours. Cancer-associated fibroblasts (CAF) were also stimulated to 
migrate. In contrast, however, VEGF121 did not stimulate normal keratinocytes and 
normal oral mucosal fibroblast cell migration.  
Our migration data is in agreement with previously published studies, where 
tumour-associated cells such as endothelial cells (Wang et al., 2011) and monocytes 
(Barleon et al., 1996) were stimulated to migrate in response to VEGF. However, our 
data for the epithelial cell line, HaCaT, is contrary to data from Yang et al, (2009) 
who demonstrated that VEGF165 enhanced HaCaT cell migration (Yang et al., 2009). 
Response of cancer cells to VEGF in terms of Akt activation is summarised in Figure 
4.7. It should be noted that this is a much simplified view of events. Two cell lines, 
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TR146 and COM D25, were stimulated to migrate in response to VEGF. These cell 
lines also displayed an increase in phosphorylation of Akt at S473 and T308 in 
response to VEGF. The addition of the inhibitor PI103 caused a decrease in the 
migration of these cell lines.   
Tumour progression requires both positive and reciprocal feedback between CAF 
and cancer cells. Initially, this is manifest by a change in phenotype of normal 
fibroblasts to that of CAF, which occurs in response to various growth factors, 
including VEGF, which are secreted by the tumour cells (Cirri and Chiarugi, 2011). 
However, it may be that these stromal cells themselves are predisposed to respond 
in a certain way to these growth factors and normal fibroblasts are not (Schor et al., 
1991).  The CAF act as a source of various types of protease activity (Joyce and 
Pollard, 2009, Pietras and Ostman, 2010) allowing the cells to play a role in the 
invasive and metastatic process by remodelling the extracellular matrix. The CAF 
may also stimulate epithelial to mesenchymal transition (EMT) of tumour cells 
through secretion of various growth factors or the response to breakdown products 
of the extracellular matrix (Bhowmick et al., 2004, Pietras and Ostman, 2010). The 
data presented here is the first evidence that oral cancer-associated fibroblasts are 
stimulated to migrate by exogenous VEGF treatment.  
Experiments using different migration assays and the small molecule PI3K-Akt 
pathway inhibitors, LY294002, show that treatment of cancer-associated fibroblasts, 
cells from a dysplastic lesion and adeno squamous carcinoma cells with LY294002 
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alone, is sufficient to inhibit VEGF-induced migration but not to inhibit oral cancer 
cells. PI103 appears to be a better inhibitor of oral cancer cell migration and 
phosphorylation of Akt. This may be due to the fact that PI103 can act at multiple 
places on the PI3K-Akt pathway. PI103 also blocks mTORC2 from phosphorylating 
Akt at S473 and mTORC1 further downstream (Dowling et al., 2010). This suggests 
that PI103 has three chances of blocking activity on one pathway. However, the 
affects seen here could be PI103 affecting other pathways. In the long term, when 
considering PI103 as a possibly therapeutic agent, the multi-target effects may be 
fortuitous and ultimately represent an efficacious strategy for blocking metastases.   
 
Figure 4.7 Proposed PI3K-Akt signal transduction pathway in oral cancer cell 
migration. 
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Akt is phosphorylated at Thr 308 residue by PI3K and at Ser 473 residue by 
mTORC2. Phosphorylated Akt then stimulates oral cancer cell migration. RTK-
Receptor Tyrosine Kinase, PIP2-Phosphoinositide 4,5- biphosphate, PIP3-
Phosphoinositide 3,4,5- triphosphate, PI3K- Phosphoinositide 3-kinase, PTEN-
Phosphatase and tensin homologue, PDK1-Phosphoinositide-dependent kinase-1, 
mTORC2- Mammalian target of rapamycin complex-2 (Islam et al., 2014). 
 
Our data support a model where the stimulation of PI3K-Akt activity by VEGF is a 
mechanism that drives cell migration in CAF and cancerous cells. Akt has been 
shown to be critically involved in VEGF-induced endothelial cell migration 
(Morales-Ruiz et al., 2000). Full Akt kinase activity is dependent upon 
phosphorylation at residues T308 and S473 and this is greatly increased by growth 
factor receptor signalling (Bozulic and Hemmings, 2009). Regardless of the 
activation mechanism, once phosphorylated, Akt  loses its PIP3 binding requirement 
and translocates to distinct subcellular compartments, including the nucleus, 
mitochondria and other organelles (Chin and Toker, 2009). Akt then transduces the 
signal by phosphorylating numerous substrate proteins, including both cytoplasmic 
and nuclear proteins. Accordingly, it is not unexpected that Akt activity can be 
found in both the cytoplasm and nucleus (Rosner et al., 2007). Although it has been 
suggested that differential phosphorylation of T308 and S473 may modulate the 
substrate selectivity of Akt, a clear picture of this is yet to emerge (Bozulic and 
Hemmings, 2009). In this study we have also found nuclear localisation of pAkt T308 
in VEGF induced migrated oral adeno-carcinoma cells, whereas pAkt S473 was 
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mostly diffuse or localised in the cytoplasm. The Ringel group showed that the 
localisation of activated Akt differs between the two forms of thyroid cancer, but 
nuclear localisation is associated with tumour invasion in both subtypes (Vasko et 
al., 2004). Although Akt has been reported to be rich in the nucleus in many cancer 
cells, the mechanism of translocation, biological importance and activity have not yet 
been confirmed (Wang and Brattain, 2006).  
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Chapter 5 . Phosphorylation of Akt in alcohol, tobacco and 
HPV-induced HNSCC 
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5.1 Background 
HNSCC (Head and Neck Squamous Cell Carcinoma) includes cancers that involve 
the oral cavity, pharynx and larynx. Each year there are approximately 400 000 cases 
of cancer of the oral cavity and pharynx, with 160 000 cancers of the larynx, resulting 
in approximately 300 000 deaths (Boyle and Levin, 2008). It is the sixth most 
common type of cancer worldwide with a five year survival rate of 40-50%, which 
has shown only moderate improvement over the last two decades (Al-Sarraf, 2002). 
Head and neck cancer is strongly associated with lifestyle and certain environmental 
risk factors such as alcohol and tobacco use, some chemical used in workplaces, UV 
light and some strains of viruses including HPV (Ridge et al., 2008). Alcohol and 
tobacco play significant role which have  a synergistic effect  on HNSCC (up to 100 
times higher for both) (Neville and Day, 2002). HPV infection  has been detected in 
around 20% of all cases (Gillison et al., 2013). 
Recent studies have focused on the genetic and epigenetic alterations of HNSCC, 
providing a better understanding of the molecular events underlying the 
pathogenesis of HNSCC (Mao et al., 2004, Tan et al., 2013). One of the most 
frequently altered signaling pathways in HNSCC is the PI3K/Akt cascade (Tan et al., 
2013). Akt, also known as PKB, is a serine-threonine protein kinase and is central to 
the phosphatidylinositol 3’ kinase (PI3K) signaling pathway (Altomare et al., 1995, 
Fresno Vara et al., 2004, Bellacosa et al., 2005). PI3K is activated by tyrosine-kinase 
transmembrane receptors and other signaling intermediates, such as Ras oncogenes 
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and G proteins (Rodriguez-Viciana et al., 1994). PI3K then phosphorylates PtdIns 
(4,5) P2 (PIP2) yielding PtdIns (3,4,5) P3 (PIP3), which serves as an anchor for 
intracellular proteins (primarily mediated by pleckstrin homology domains), 
including Akt amongst others. Membrane-bound Akt is phosphorylated at T308 in 
the catalytic domain by the kinase PDK1 and at S473 in the regulatory domain by 
mTORC2 (Alessi and Cohen, 1998, Sarbassov et al., 2005). Full Akt kinase activity is 
dependent upon phosphorylation at both T308 and S473 residues and this is greatly 
increased by growth factor receptor signaling (Bozulic and Hemmings, 2009). PIP3 is 
converted back into PIP2 through the action of the lipid phosphatase PTEN, thus 
terminating the PI3K-initiated signal and avoiding further Akt activation (Song et al., 
2012). Growth factor receptor over-expression (Sweeny et al., 2012, Thariat et al., 
2012), mutation and down-regulation of PTEN protein (Squarize et al., 2013)  and 
amplification of the PIK3CA gene (the gene coding for the catalytic unit of PI3K) 
(Pedrero et al., 2005) can lead to increased Akt activity. Enhanced Akt activity has 
indeed been found in 20 to 60% of tumour samples and in the majority of HNSCC-
derived cell lines (Pedrero et al., 2005, Mandal et al., 2006, Moral and Paramio, 2008, 
Amornphimoltham et al., 2011). Once Akt is phosphorylated and activated, it is 
capable of phosphorylating multiple substrates generating diverse cellular processes, 
such as metabolism, proliferation, survival and protein synthesis (Lindsley, 2010). 
An increasing number of mucosal changes and cellular atypia occur over large areas 
of the carcinogen-exposed upper aero-digestive tract epithelium, which initiate the 
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stepwise carcinogenesis process in HNSCC. Acquisition of a transformed phenotype 
and accumulation of specific molecular genetic events are associated with this 
process (Slaughter et al., 1953, Liotta et al., 1991, Mao et al., 1996, Grandis et al., 2000, 
Rosin et al., 2000, Papadimitrakopoulou et al., 2001); yet histopathological evaluation 
remains the time honoured method in risk assessment of carcinoma lesions. In a 
search for better biological models of risk, Akt activation was recently identified as 
an early cellular response to carcinogen exposure and may be a significant step in 
environmental carcinogenesis (West et al., 2003). Akt activation has also been found 
to correlate with squamous cell carcinoma progression from normal epithelium to 
invasive cancer (Amornphimoltham et al., 2004). 
5.2 Aims and Hypothesis 
The aim of this study was to investigate the role of demographic, pathological and 
major risk factors (Smoking, alcohol and HPV) on the activation of Akt 
(phosphorylation of Akt at Threonine 308 and Serine 473) in HNSCC and to 
determine their prognostic role.  
It was hypothesised that lymph node metastasis in HNSCC patients would be 
associated with phosphorylation of Akt at both residues as they were found to be 
responsible for head and neck cancer cell migration. It was also hypothesised that 
Akt at both residues would be found to be highly activated in VEGF positive 
HNSCC and associated with at least one of the risk factors, if not all. 
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5.3 Materials 
The following materials were used in this study. 
Table 22 List of materials 
 
Name Source Catalogue 
number 
Orbital shaker Stuart Scientific, Staffordshire, UK - 
Water bath Grant Instrument, Cambridge, UK - 
Immuno pen Dako, Cambridgeshire, UK S200230-2 
Xylene VWR BDH, PA, USA 28975.325 
Ethanol , denatured VWR BDH, PA, USA 20827.365 
Sodium citrate trisodium 
dihydrate 
Sigma-Aldrich, St. Louis, MO, USA S4641 
Hydrogen peroxide Sigma-Aldrich, St. Louis, MO, USA H1009 
Trizma® Base Sigma-Aldrich, St. Louis, MO, USA T1503 
Sodium chloride Sigma-Aldrich, St. Louis, MO, USA S3014 
Tween-20 Sigma-Aldrich, St. Louis, MO, USA P1379 
DAB Sigma-Aldrich, St. Louis, MO, USA D5637 
Mayer’s Haematoxyline Sigma-Aldrich, St. Louis, MO, USA S3309 
Shandon Bluing agent Thermo Scientific, Waltham, MA, USA 6769001 
DPX mounting media VWR BDH, PA, USA 360294H 
Normal goat serum Vactor laboratories, Burlingame, CA, USA S1000 
Phospho-Akt 
(Ser473)(D9E) 
XP Rabbit mAb 
Cell Signaling Technology Inc., Danvers, 
MA, USA 
4060 
Phospho-Akt (Thr 308) 
(C31E5E) Rabbit mAb 
Cell Signaling Technology Inc., Danvers, 
MA, USA 
2965 
Akt (pan) (C67E7) Rabbit Cell Signaling Technology Inc., Danvers, 4691 
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mAb MA, USA 
SignalStain® Boost IHC 
detection reagent (HRP, 
Rabbit) 
Cell Signaling Technology Inc., Danvers, 
MA, USA 
8114 
Blocking peptide for 
#4060 
Cell Signaling Technology Inc., Danvers, 
MA, USA 
1140 
Blocking peptide for 
#2965 
Cell Signaling Technology Inc., Danvers, 
MA, USA 
1145B 
 
5.4 Experimental procedure 
5.4.1 Patients 
Ethical approval (ID: LEC271/03) was granted for the prospective collection of 
tissues which were stored at the Tayside Tissue Bank. In total 64 HNSCC and 11 
normal oral mucosal tissues (from non-tumour patients) were collected from 
patients treated at Ninewells Hospital, Tayside. Baseline data obtained from patient 
charts included age, sex, histology, site, drinking and smoking status, nodal 
involvement, survival and follow-up data. Patients were followed-up for a total of 66 
months (median, 40 months) after diagnosis. 
Some continuous variables (such as age, drinking and smoking status) were changed 
into categorical variables in this study with clear justification (statistical and/or 
clinical reasons). Age was grouped as ‘<65 years of age’ and ‘≥65 years’ because 
approximately 50% patients were above/below 65 and a growing number of patients 
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with Head and Neck Squamous Cell Carcinoma (HNSCC) are age 65 and older 
(VanderWalde et al., 2013). Patients who consumed alcohol were referred to as 
‘drinkers’ throughout this study. Drinkers are categorised as non-drinkers, medium 
or moderate drinkers (less than 7 units per week for women and 14 units per week 
for men or occasional or social, regarded as low risk group by NIAAA), and heavy 
drinkers (over 7 units per week for women and 14 units per week for men) 
according to National Institute of Alcohol Abuse and Alcoholism (Niaaa, 2014). 
Smoking status was also classified as non- or light smokers (less than 5 cigarettes per 
day) and smokers (more than 5 cigarettes per day) after reviewing the literature 
(Fagan and Rigotti, 2009, Husten, 2009, Shiffman, 2009). 
HNSCC tissues were stained for VEGFA expression by IHC (Islam et al., 2014) and 
tissues with IHC scores of more than 3 were selected and regarded as positive. 
Tissues were also analysed for HPV (6, 16 &18) DNA by PCR, automated DNA 
sequencing and the SPF10-LiPA25 method (Sailan, 2010). 
5.4.2 Immunohistochemistry 
 
The paraffin-embedded tissues were cut into 5-μm sections, dewaxed in xylene and 
then rehydrated in serial ethanol solutions, before washing in distilled water for 5 
minutes. 58 VEGFA positive HNSCC and 11 normal mucosal samples were then 
probed with pAkt T308 (#2965) and pAkt S473 (#4060) antibodies according to the 
manufacturer’s instructions (Cell Signaling Technology Inc., Danvers, MA, USA). In 
brief, after the deparaffinisation and rehydration process, antigens were unmasked 
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by boiling in 10mM Sodium citrate buffer (pH 6.0) using a microwave, followed by 
maintenance at a sub-boiling temperature for 10 minutes and then cooling for 30 
minutes on the bench top. 3% (v/v) H2O2 was then used as a peroxidase blocker and 
TBST (Tris buffered saline with 0.1% v/v Tween 20) for washing. Sections were then 
blocked with 5% (v/v) normal goat serum (NGS) plus TBST for 1 hour at room 
temperature. Sections were then incubated with antibodies against pAkt S473 (1: 50) 
and pAkt T308 (1:50) diluted in 5% (v/v) NGS/TBST in a humidified chamber 
overnight at 4°C. After equilibration, sections were then washed three times with 
TBST and then incubated in signal stain boost detection reagent (HRP, rabbit # 8114, 
Cell Signaling Technology) for 30 minutes at room temperature. Visualisation was 
achieved by incubation with 3, 3’-diaminobenzidine (DAB) (Sigma-Aldrich, MO, 
USA) for 5 minutes and counterstaining with Mayer’s haematoxylin (Sigma) and 
eosin. Rehydration and mounting processes were then followed as described in the 
instruction manual (Cell Signaling Technology). Normal oral mucosal tissues were 
used as negative controls. The pAkt S473 and pAkt T308 antibodies were blocked 
using the respective blocking peptide (#1140 and 1145B, respectively, Cell Signaling 
Technology) by adding twice the volume of peptide as volume of antibody used, in a 
total volume of 100 μl. These tissues were also used as negative control.  A detail 
optimisation method is described in Appendix 14. 
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5.4.3 IHC score 
 
According to the scoring systems that have been reported previously in the literature 
(Malik et al., 2002, Tang et al., 2006) with some modifications, pAkt staining scoring 
was performed as follows: stained sections were visualised using a light microscope 
at high power field and were evaluated by three observers without prior knowledge 
of the patients’ characteristics. An intra-class correlation (inter-observer correlation) 
analysis using a mixed model and testing for consistency gave a Chronbach’s alpha 
of more than 0.8. The cells showing cytoplasmic and /or nuclear staining were 
judged as positive. Five high power fields were selected randomly under the 
microscope. The average percentage of positive staining was calculated for each 
field. The average percentage of tissue staining was designated as 0 when less than 
10% was stained, 1 when 10-25%, 2 when 25-50%, 3 when 50-75% and 4 when >75% 
of tissues stained. The intensity of tissue staining positively was categorised as 
follows: 0, no appreciable staining in tissues; 1, barely detectable staining as 
compared with stromal elements; 2, readily appreciable brown staining distinctly 
marking cell cytoplasm and/or nucleus; and 3, dark brown staining in tissues 
completely obscuring cytoplasm and/or nucleus. Scoring was performed according 
to the product of staining intensity and average percentage of tissue staining 
positively ranging from 0–12. In the following analysis, the level of Akt 
phosphorylation was evaluated using the pAkt index either as a continuous variable 
directly or categorised as no phosphorylation (IHC score 0), low phosphorylation 
(IHC score 0.1-2.0), medium phosphorylation (IHC score 2.1-5.0), high 
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phosphorylation (IHC score 5.1-12.0) after reviewing a number of studies (Stal et al., 
2003, Kirkegaard et al., 2005, Lim et al., 2005, Messersmith et al., 2005, Ogino et al., 
2005, Schmitz et al., 2005, Bose et al., 2006, Tokunaga et al., 2006, Wu et al., 2008, 
Glynn et al., 2010, Scartozzi et al., 2012). 
5.4.4 Statistics 
Data were analysed using the statistical package IBM SPSS 19.0. Comparisons 
between the tissues (HNSCC and normal) regarding the Akt phosphorylation were 
carried out using a Mann–Whitney U test. Associations between categorical 
demographic, pathological and behavioural factors were investigated using cross 
tabulation and Pearson chi-square test. Associations between these variables and 
continuous immunohistochemical parameters were evaluated with general linear 
models (both univariate and multivariate). Bonferroni’s correction for multiple 
comparisons was applied where appropriate. 
Patients’ characteristics and pAkt IHC score were analysed for possible association 
with overall survival by univariate and multivariate Cox proportional hazard 
models. Overall survival was defined as the time between diagnosis date and death 
or last follow-up date. Initially, explanatory factors were screened for univariate 
associations with death, using a method appropriate to the distribution of the data. If 
the two-sided P value was <0.300 for any variable it was considered as a candidate in 
multiple regression models (Hosmer-Lemeshow criterion). Variables with P ≥0.300 
were discarded at this stage. The assumption of proportional hazards was checked 
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for independent variables by plotting the logarithm of the cumulative hazards 
functions. Starting with the set of variables identified for inclusion from the previous 
steps, a multiple Cox regression model was built using a step-wise approach. All 
tests were two-sided, using the 5% significance level. All the statistical results were 
summarised in Appendix 16. 
5.5 Results 
5.5.1 Analysis of patient details 
58 HNSCC patient details were analysed in this study (patient details can be found 
in Appendix 13). 33 (57%) were male and 25 (43%) female with ages ranging from 36 
to 97 years (median age 64 years). 42 (72%) were smokers and 16 (28%) non-smokers. 
7 patients (12%) were non-drinkers, 21 (36%) medium or moderate drinkers and 30 
(52%) were heavy drinkers. 31 (53%) patients had negative and 27 (47%) had positive 
nodal metastasis. Half of the cohort was HPV positive. 43 (74%) patients had T1/T2 
and 15 (26%) had T3/T4 tumour size with 5 (9%) of them grade I, 39 (67%) of them 
grade II and 14 (24%) of them grade III. These data are summarised in Table 23. 
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Table 23 Demographic, behavioural and pathological data by pAkt status 
 
  Akt T308 phosphorylation status Akt S473 phosphorylation status 
n High Medium Low p Medium Low None p 
(n = 40) (n = 8) (n = 10) (n = 5) (n = 30) (n = 23) 
% % % % % % 
Gender 
Male 
Female 
 
33 
25 
 
62 
38 
 
63 
37 
 
30 
70 
 
0.109 
 
60 
40 
 
50 
50 
 
65 
35 
 
0.737 
Age 
<65 years 
≥65 years 
 
30 
28 
 
50 
50 
 
50 
50 
 
60 
40 
 
0.233 
 
80 
20 
 
43 
57 
 
57 
43 
 
0.376 
Location 
FOM 
RMT 
SP 
Tong 
Alv 
Other 
 
10 
8 
5 
27 
4 
4 
 
15 
10 
10 
53 
5 
7 
 
25 
13 
0 
50 
0 
12 
 
20 
30 
10 
20 
20 
0 
 
 
 
0.217 
 
20 
0 
40 
20 
0 
20 
 
17 
10 
10 
47 
10 
6 
 
17 
22 
0 
53 
4 
4 
 
 
0.094 
Tumour size 
T1-T2 
T3-T4 
 
43 
15 
 
70 
30 
 
25 
75 
 
90 
10 
 
0.173 
 
60 
40 
 
73 
27 
 
78 
22 
 
0.213 
Grade 
I 
II 
III 
 
5 
39 
14 
 
8 
65 
27 
 
12 
75 
13 
 
10 
70 
20 
 
 
0.523 
 
0 
80 
20 
 
7 
66 
27 
 
13 
65 
22 
 
 
0.788 
Lymph node metastasis 
Positive 
Negative 
 
27 
31 
 
58 
42 
 
12 
88 
 
30 
70 
 
0.018 
 
40 
60 
 
50 
50 
 
43 
57 
 
0.327 
HPV status 
Positive 
Negative 
 
29 
29 
 
40 
60 
 
63 
37 
 
80 
20 
 
0.028 
 
40 
60 
 
43 
57 
 
61 
39 
 
0.301 
Smoking 
Yes 
No 
 
42 
16 
 
82 
18 
 
50 
50 
 
50 
50 
 
0.022 
 
80 
20 
 
70 
 
74 
26 
 
0.449 
30 
Alcohol 
Non-drinker 
Med drinker 
Heavy drinker 
 
7 
21 
30 
 
10 
27 
63 
 
0 
62 
38 
 
30 
40 
30 
 
0.027 
 
0 
40 
60 
 
17 
33 
50 
 
9 
39 
52 
 
0.968 
 
Note: The general linear model was used for hypothesis testing of the relationship 
between categorical variables and pAkt. The P value was obtained from univariable 
analysis. Percentages represent the column percentages within variable so that the 
balance between the pAkt groups can be assessed.  
 
5.5.2 Immunohistochemistry for Akt phosphorylation 
Both normal and VEGF-positive carcinoma patient samples were stained with pAkt 
S473 and pAkt T308 antibodies. Some samples which were highly stained for pAkt 
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S473 and pAkt T308 were then selected and tested with the blocking peptide for the 
respective antibody and were used as negative controls (Figure 5.1A). No staining 
was observed in the blocking peptide treated tissues and this confirmed the specific 
binding of the antibodies. Normal tissue samples were also regarded as negative 
controls and the level of Akt phosphorylation at T308 was higher in the HNSCC 
group than the control (median 5.8 vs 2.0, P < 0.001) (Figure 5.1B). Normal tissue 
adjacent to the tumours was also tested and the resultant data indicated that there 
was very low or no pAkt T308/pAkt S473 presents (Figure 5.1C). There is also some 
evidence to suggest higher levels of pAkt S473 in the cancer group than the controls 
(P = 0.054) (Figure 5.1B). There is a statistically significant difference between pAkt 
T308 and pAkt S473 levels in the cancer patients (pAkt T308, median 5.8 vs pAkt 
S473, median 0.3, P < 0.001) (Figure 5.1B). VEGFA is not correlated with pAkt T308 (r 
= 0.062, P = 0.644) and pAkt S473 (r = 0.181, P = 0.175). A stepwise progression of 
cancer including epithelial to mesenchymal transition (EMT) (Figure 5.2A & 5.2B) 
and migrated cells in stroma (Figure 5.2C) is observed in pAkt T308 stained sections. 
Table 1 compares the characteristics between pAkt expression groups. All the 
samples were found to be phosphorylated at Akt T308 so there is no ‘no 
phosphorylation’ group for this residue. On the other hand, there is no ‘high 
phosphorylation’ group for pAkt S473. 
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Figure 5.1VEGF positive carcinoma tissues were stained with pAkt antibodies. 
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Blocking peptides were used to test the efficacy of the antibodies and were tested on 
duplicate sections of those that had been highly stained for pAkt S473 and pAkt 
T308 using the antibodies alone. These were used as negative controls. Normal 
tissues were also used as negative controls, where no staining was observed. All the 
representative images were taken at x200 magnification except for those stained for 
pAkt T308, which were taken at x100. (A) pAkt S473 and pAkt T308 showed more 
intense staining in HNSCC tissues compared to normal tissues (P < 0.05). (B) 
Phosphorylation of Akt at residue T308 was found to be significantly higher in 
HNSCC patient samples compared to phosphorylation at S473 (P < 0.001). (C) 
Phosphorylation status of Akt in non-tumour part of cancer tissues. Very weak or no 
phosphorylation of Akt both at T308 and S473 was observed in the non-tumour part 
of HNSCC tissues. The arrow indicates the non-tumour area of the tissues. Images 
were captured at x200 magnification. Scale bar= 5mm. 
 
 
Figure 5.2 EMT in pAkt T308 stained HNSCC. 
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Akt T308 phosphorylated cancer cells that had undergone epithelial to mesenchymal 
transition. (A) Attached cancer cells were detached by breaking cell-cell junctions 
and changed their shape from epithelial to mesenchymal like cells (EMT) before 
migrating to the stroma. 1, 2 and 3 showed the stepwise transition whereas 1 
represents cells with tight junction, 2 represents cells with loose junctions and 3 
represents mesenchymal type cells. (B) EMT of cancer cells before migration. Arrows 
in (A) and (B) represents mesenchymal type cancer cells that had undergone EMT. 
(C) Migrated cancer cells in stroma (arrows). All the representative images were 
taken at ×400 magnification. 
 
5.5.3 Association of patient characteristics with Akt phosphorylation 
Smoking and alcohol were found to be independent risk factors for phosphorylation 
of Akt at T308 (P = 0.022 and 0.027, respectively) but not for pAkt S473 (P = 0.449 and 
0.968, respectively). HNSCC with nodal metastasis was associated with a higher 
level of pAkt T308 than HNSCC without nodal metastasis (P = 0.018). Smokers and 
HNSCC with nodal metastasis were found to have higher levels of Akt 
phosphorylated at T308 than non-smokers (P = 0.022) and HNSCC without modal 
metastasis (P = 0.018) patients, respectively. HPV-negative patients exhibited higher 
levels of pAkt T308 compared to those who were HPV positive (P = 0.028). There is 
some evidence to suggest that heavy drinking patients had higher levels of pAkt 
T308 than medium drinkers (P = 0.063). 
Adjusted by four independent variables, smoking, drinking, nodal status and age, 
the general linear model accounts for 65.2% (R2 = 0.652) of the total variation in pAkt 
T308 levels (Table 24). This model’s significance statistics for the F-statistic (P < 0.001) 
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indicate that there is only a very small chance that the observed correlation between 
one or more of the independent variables and the dependent variable is due solely to 
random sampling error. 
Smoking (P = 0.027), drinking habit (P < 0.001) and age (P = 0.031) showed a 
significant effect on the phosphorylation of Akt at T308. Alcohol and age, alcohol 
and nodal involvement, smoking and nodal involvement and smoking and alcohol 
are strongly correlated with the phosphorylation of Akt at T308 in pairwise 
combination (P = 0.009, 0.038, 0.049 and 0.052, respectively). Moreover, smoking, 
nodal involvement, age and alcohol, nodal involvement, age also have a strong 
correlation with the phosphorylation of Akt T308 (P = 0.019 and 0.022, respectively). 
None of these independent variables correlated with the phosphorylation of Akt at 
S473 (univariate and multivariate, P > 0.05). 
Non-drinking patients had lower levels of Akt phosphorylated at T308 and were 
more likely to be infected by HPV than heavy drinkers (χ2 P = 0.044 and 0.007, 
respectively). Also, HPV infected patients were shown to have lower levels of Akt 
phosphorylated at T308 than the non-infected patients (χ2 P = 0.028). 
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Table 24 General Linear Model (Multivariate analysis) 
 
Independent variables F P 
Corrected Model 4.06 <0.001 
Smoking 5.30 0.027 
Alcohol 10.56 <0.001 
Nodal Status 1.31 0.260 
Age 4.98 0.031 
Smoking * Alcohol 3.20 0.052 
Smoking * Nodal status 4.12 0.049 
Smoking * Age 0.01 0.919 
Alcohol * Nodal status 3.56 0.038 
Alcohol * Age 5.31 0.009 
Nodal status * Age 2.80 0.102 
Smoking * Alcohol * Nodal status 0.17 0.682 
Smoking * Alcohol * Age 0.08 0.774 
Smoking * Nodal status * Age 6.00 0.019 
Alcohol * Nodal status * Age 5.73 0.022 
R2 = 0.652 
 
Note: After adjusting Smoking, Alcohol, Nodal Status and Age, this model accounts 
for 65.2% of the total variations in pAkt T308 level. R2 = Coefficient of determination, 
F = F-statistics. Dependent variable: pAkt T308 score. 
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5.5.4 Survival Analysis 
Levels of pAkt S473 and pAkt T308, as determined by IHC, were examined for 
association with overall survival using Cox’s proportional hazard model (Table 25). 
In multivariate analysis, pAkt S473 level, tumour size, alcohol consumption, age and 
patients’ HPV status had significant effects on overall survival (P = 0.005, 0.005, 
0.021, 0.007 and 0.004, respectively). The rate of deaths in this small cohorts of 
HNSCC patients with medium levels of phosphorylated Akt S473 was higher than in 
those with none and in those with low levels (P = 0.001 and P = 0.036, respectively, 
Table 3). However, this is an observation of a marker and cannot be attributed to the 
case of why and how they died. Patients with tumours of size T3/T4 died more 
rapidly than patients with tumours T1/T2 (HR = 15.2, P = 0.005). Death rates in heavy 
drinkers were higher than those who consumed no alcohol (P = 0.006). Older 
patients (65 years of age or over) were more likely to die than those of 65 years of age 
(P = 0.007). HPV positive patients were more likely to die in this small cohort than 
those with a negative status (P = 0.004).  A number of recent studies however, 
revealed that  the prognosis for HPV-positive patients (especially in oropharyngeal 
cancer) is better than that for patients with HPV negative tumour independent of  
age, gender, stage, nodal status and tumour differentiation (Weinberger et al., 2006, 
Lindquist et al., 2007, Fakhry et al., 2008). 
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Table 25 COX proportional hazard model- time to death 
 
  Unadjusted HR Adjusted HR 
HR 95% CI P HR 95% CI P 
pAkt S473 Overall   0.168   0.005 
Med : No 6.27 0.87, 45.3 0.069 438 10.9, 
1755 
0.001 
Med : Low 1.83 0.38, 8.88 0.456 21.5 1.23, 376 0.036 
Tumour size T3/T4 : T1/T2 4.59 1.39, 15.2 0.013 15.2 2.28, 102 0.005 
Alcohol Overall   0.005   0.021 
Heavy : Non-
drinker 
15.4 2.74, 86.7 0.002 49.4 3.04, 801 0.006 
Heavy : Moderate 3.19 0.62, 16.5 0.166 2.69 0.35, 20.8 0.343 
Age ≥65 : <65 5.41 1.17, 25.05 0.031 46.8 2.81, 781 0.007 
HPV +ve : −ve    89.4 4.05, 
1973 
0.004 
Gender F : M 1.40 0.42, 4.63 0.581    
Tumour size Overall   0.310    
Nodal status +ve : −ve 1.49 0.43, 5.10 0.529    
Smoking No : Yes 1.45 0.42, 4.95 0.556    
pAkt T308 Overall   0.984    
Low : High 1.02 0.21, 4.92 0.985    
Med : High 1.16 0.24, 5.63 0.858    
Note: Unadjusted HR obtained from univariable analysis and adjusted HR from 
multivariable analysis after adjusting tumour size, alcohol, age, HPV and pAkt S473. 
All the variables are categorical and HR = exp (B). Abbreviations- HR, Hazard ratio, 
95% CI, 95% confidence interval. 
 
5.6 Discussion 
To our knowledge this is the first report to show the relationships between the major 
risk factors for HNSCC (alcohol, smoking and HPV) and Akt activation (both at 
residues T308 and S473) at the protein level using an immunohistochemical staining 
method (IHC), in surgically resected specimens. Most studies to date have used IHC 
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to assess the prognostic value of Akt activation in HNSCC, but have focused only on 
phosphorylation of residue S473. As the differential phosphorylation of Akt at the 
two sites may modulate downstream substrate selectivity and subsequent bioactivity 
(Bozulic and Hemmings, 2009), it is not surprising that Akt phosphorylated at any 
single site could perform certain cellular bioactivities. Two different mechanisms are 
involved in phosphorylating Akt, therefore overexpression or amplification of any 
components in these mechanisms may result in over-phosphorylation at any one of 
the two sites. It is therefore worth studying the phosphorylation status of Akt at both 
sites in HNSCC specimens to elucidate their different roles. 
As only VEGFA positive HNSCC biopsy samples were selected in this study, no 
statistically significant correlation was found between VEGF and pAkt. The present 
study showed that Akt was significantly phosphorylated at T308 in VEGF positive 
HNSCC rather than S473. Alcohol and smoking were positively correlated with 
pAkt T308 activation but not with pAkt S473. Moreover, Akt activated at T308 
showed a significant relationship with lymph node metastasis, which suggests that 
pAkt T308 may be concerned with invasion and metastasis. This data is similar to 
our in vitro data concerning the migration of tumor cells in response to VEGF, which 
suggests that migration of oral adeno-squamous cancer cells is dependent on Akt 
T308 phosphorylation. Our study also disclosed that Akt phosphorylated at both 
residues controls oral cancer cell motility (Islam et al., 2014), but it should be 
remembered that studies performed with cultured cells or tissue models may 
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produce different results. In vivo, tumor progression requires both positive and 
reciprocal feedback between the components of the tissue microenvironment and 
cancer cells (Cirri and Chiarugi, 2011). 
The activation of Akt in response to alcohol exposure is an important contributor to 
the molecular effects of excessive alcohol consumption (Neasta et al., 2011). In 2003, 
West showed that redundant Akt activation by nicotine and nicotine-derived 
nitrosamine ketone (NNK) could contribute to tobacco-related carcinogenesis (West 
et al., 2003). A study by the Gonzalez group in 2005 revealed that Akt activation was 
correlated with concomitant PI3K accumulation and PTEN down-regulation in 
HNSCC, reflecting an early biochemical effect in response to nicotine (Pedrero et al., 
2005). Combined with these data, our study supports the basic hypothesis that Akt 
activation (especially at T308) is a key step in the progression of HNSCC caused by 
alcohol and smoking. HPV infection, another risk factor for HNSCC, was found to be 
negatively correlated with Akt activation at T308, as HPV positive HNSCC patients 
showed lower levels of pAkt T308. Non-drinking patients had lower levels of 
activated Akt at T308 too and there were more HPV positive patients among non-
drinkers than amongst the heavy drinkers. Earlier epidemiological research supports 
this data, that is non-smokers and light or non-drinkers are more likely to have 
tumours positive for HPV than are heavy smokers and drinkers (Lindel et al., 2001). 
Molinolo et al. (2012) showed in their study that HPV positive HNSCC patients 
over-activate Akt at S473 and mTOR (Molinolo et al., 2012). Although we have not 
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found any association between HPV infection and pAkt S473 activation, this may 
suggest that there are two different mechanisms of cancer progression initiated by 
alcohol, smoking and HPV. The study by Kelsey group (2007) strongly supports the 
emerging view that the aetiology of HPV related HNSCC is distinct from that of 
HNSCC tumours associated with smoking and drinking (Applebaum et al., 2007). 
Increased Akt activation at T308 by excessive alcohol and smoking may be 
responsible for cancer development and progression, including metastasis, whereas 
HNSCC by HPV infection may over-activate Akt at S473 and be responsible for poor 
survival. 
In this study we show that increased pAkt S473 levels in HNSCC are a strong 
predictor for poor patient outcome. In the multivariate Cox proportional hazard 
model, adjusted for well recognised prognostic indicators (e.g. tumor size and age), 
pAkt S473 status remained a strong predictor. This is corroborated by three other 
studies which have shown that pAkt activated at S473 is associated with poor 
prognosis in oral cancer (Lim et al., 2005, Massarelli et al., 2005, Yu et al., 2007). 
Although further molecular analysis is needed to investigate the mechanism of 
smoking and alcohol related HNSCC development, we can propose pAkt T308 as a 
reliable biomarker for smoking and alcohol induced HNSCC progression. A large 
cohort with a longer follow-up of pre-neoplastic and HNSCC lesions is needed to 
more accurately define the role of Akt activation in carcinogenesis and to integrate 
this data into a risk model for carcinoma development and progression.  
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Chapter 6 General discussion, conclusion and further 
investigations 
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6.1 General discussion 
 
EGFR is overexpressed in 90% of HNSCC and correlated with poor prognosis (Pablo 
Uribe and Sergio Gonzalez, 2011). Cetuximab which inhibits EGFR is the first 
molecular targeted agent approved for the treatment of both locally advanced and 
recurrent/metastatic HNSCC (Specenier and Vermorken, 2013, Schmitz et al., 2014). 
However, only 13% of patients respond to cetuximab (single agent), despite its great 
clinical promise (Cohen, 2014). New studies have revealed that aberration of 
Ras/MAPK/ERK and PI3K/Akt pathway is the central mediator of cetuximab 
resistance in HNSCC (Rebucci et al., 2011, Rampias et al., 2014). Activation of the 
PI3K/Akt signalling pathway  is also found to be responsible for radio-resistance in 
HNSCC (Saki et al., 2013). Recent studies suggest that the dynamics of a variable 
clonal sub-population due to tumour heterogeneity may also modify the cellular 
response to cetuximab (Greaves and Maley, 2012, Kreso et al., 2013). One of the 
interesting developments in the recent cancer research, is the discovery that tumour 
cells exhibit both autocrine and paracrine VEGF signalling (Goel and Mercurio, 2013) 
and that this signalling participates in vital aspects of cancer progression, especially 
in the function of cancer stem cells and angiogenesis (Beck et al., 2011, Perrot-
Applanat and Di Benedetto, 2012, Mittal et al., 2014) . In addition, VEGF can affect 
the function of fibroblasts and immune cells in the tumour stroma and consequently, 
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it can affect the host response to tumours (Pietras and Ostman, 2010, Junttila and de 
Sauvage, 2013). 
Studies in this project into the role of Akt in VEGF-induced cancer cell migration 
have produced potentially conflicting results, which reveal both positive and 
negative effects of the inhibitors. For example, a specific PI3K inhibitor, LY294002 
inhibited the migration of mouth cancer associated fibroblast and oral-adeno 
squamous cell carcinoma but was unable to inhibit the oral squamous cell carcinoma 
migration. This paradox could be, in part, explained by different cell types and 
experimental design i.e. the migration assay format (2D and 3D, concentration 
gradient and non-gradient environment) and  treatment period employed (4 hours, 
24 hours and 4 days). LY294002 did not inhibit oral-adeno carcinoma cell migration 
in the 2D non-gradient format (scratch assay, 24 hours) but effectively inhibited the 
migration in 2D gradient format (Boyden chamber, 4 hours). PI103 (PI3K and mTOR 
inhibitor), on the other hand, effectively inhibited the migration of oral cancer cells 
both in 3D non-gradient (collagen gel assay, 4 days) and 2D gradient (live cell 
chemotaxis, 24 hours) format, but was unable to inhibit the migration of oral adeno-
carcinoma cell in 2D non-gradient format (scratch assay, 24 hours). In addition, intra-
tumoural variation reflective of the existence of multiple sub-clonal tumour 
populations may also contribute. This variation might correspond to an essential, yet 
unrecognised, determinant for the appearance of secondary drug resistance (Sinha et 
al., 2013). In general, the data obtained from the in-vitro migration assays have 
revealed that Akt needs to be phosphorylated at both the Thr308 and Ser473 residue 
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for oral cancer cells to be migrated by VEGF and this stimulation of migration can be 
blocked by PI103. Thus, VEGF-induced oral cancer cell migration is PI3K and 
mTROC2 dependent as they are responsible for phosphorylation of Akt at Thr 308 
and Ser 473 residues, respectively. 
Results obtained from the experiments using cell and tissue systems have also 
produced conflicting results. Cell migration assays  revealed that Akt 
phosphorylated at both Thr308 and Ser473 residues is responsible for oral cancer cell 
migration, whereas analysis of HNSCC tissue samples   revealed that Akt 
phosphorylated at Thr308 only is positively correlated with lymph node metastasis. 
The over-activation of Akt Ser473 only is responsible for patient’s worse survival. 
This contradiction can be explained by the role of the tumour microenvironment 
(TME). Interaction between cancer cells and the associated components of tumour 
microenvironment characterise a powerful connection that stimulates cancer 
initiation, progression and patient prognosis (Joyce and Pollard, 2009). TME 
continually changes over the course of cancer progression in response to oncogenic 
signals such as VEGF overexpression by growing tumours and evolving 
environmental conditions. The influences of TME on metastasis is thus considered as 
a dynamic process (Quail and Joyce, 2013).  
Inconsistent responses to targeted therapies illustrate the requisite for personalised 
cancer treatment, where the importance of recognising and appreciating the specific 
intricacy and variability of a tumour is paramount. The data presented exemplify 
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that to enable the design of efficacious chemotherapeutic regimes, there is an 
absolute requirement for individual tumours to be precisely characterised.  
6.2 Conclusion 
 
In conclusion, the following list summarises the main findings of this project: 
1. Phosphorylation of Akt is VEGF concentration, treatment period and cell type 
dependent. 
2. VEGF-induced phosphorylation of Akt and subsequent motility behaviour is cell 
type and incubation time dependent. 
3. VEGF-induced in vitro cell migration is also dependent on assay format. 
4. Akt needs to be phosphorylated at both the Thr308 and Ser473 residue for oral cancer 
cells to be effectively stimulated to migrate by VEGF. 
5. pAkt Thr308 can be used as a potential biomarker for smoking and alcohol-induced 
HNSCC and lymph node metastasis. 
6. The predictive role of Akt activation in HNSCC and cell migration studies suggests 
that targeting PI3K/Akt and mTORC2/Akt pathway might be a useful strategy for 
therapy in this disease. So, PI103 can be used as a potential therapeutic inhibitor in 
metastatic HNSCC. 
In conclusion, our findings suggest that targeting Akt activation might be of interest 
as part of a combination therapy in HNSCC. 
6.3 Further investigations 
 
1. To elucidate the downstream signalling pathway of Akt responsible for oral 
cancer cell migration. 
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2. To identify the cellular mechanism of VEGF-induced oral cancer cell 
migration e.g., EMT or actin re-organisation and understand the associated 
molecular pathway. 
3. To recognise the possible substrates of Akt in the migration of other cell types. 
4. To use GFP-pAkt transfected cells in the live cell chemotaxis assay to clarify 
the localisation of phosphorylated Akt during cell migration. 
5. To use 3D organotypic assay to illustrate the possible role of tumour 
microenvironment on the migration and invasion of oral cancer cells. 
6. To apply in vivo migration and invasion assays to analyse the invasive cells 
from the primary tumour and to better understand the cell types and 
signalling events involved in the tumour microenvironment. 
7. To use PI103 in a mouse model of oral cancer to elucidate its therapeutic 
benefit. 
8. To study the role and mechanism of CSCs and the tumour 
microenvironments on head and neck cancer drug resistance. 
9. A large cohort with a longer follow-up of pre-neoplastic and HNSCC lesions 
is needed to more accurately define the role of Akt activation in 
carcinogenesis and to integrate this data into a risk model for carcinoma 
development and progression.  
10. Establishing new ways of destroying head and neck cancer cells using nano-
particles, or modification of viruses e.g. herpes simplex. 
 
212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
213 
 
Aaronson, D. S. and Horvath, C. M. (2002) A road map for those who don't know 
JAK-STAT. Science, 296(5573), 1653-1655. 
 
Achen, M. G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A. F., Alitalo, K. 
and Stacker, S. A. (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand 
for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl 
Acad Sci U S A, 95(2), 548-553. 
 
Agarwal, R., Carey, M., Hennessy, B. and Mills, G. B. (2010) PI3K pathway-directed 
therapeutic strategies in cancer. Curr Opin Investig Drugs, 11(6), 615-628. 
 
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., 
Fakhry, C., Xie, T. X., Zhang, J., Wang, J., Zhang, N., El-Naggar, A. K., Jasser, S. A., 
Weinstein, J. N., Trevino, L., Drummond, J. A., Muzny, D. M., Wu, Y., Wood, L. D., 
Hruban, R. H., Westra, W. H., Koch, W. M., Califano, J. A., Gibbs, R. A., Sidransky, 
D., Vogelstein, B., Velculescu, V. E., Papadopoulos, N., Wheeler, D. A., Kinzler, K. 
W. and Myers, J. N. (2011) Exome sequencing of head and neck squamous cell 
carcinoma reveals inactivating mutations in NOTCH1. Science, 333(6046), 1154-1157. 
 
Ahn, J., Sanz-Moreno, V. and Marshall, C. J. (2012) The metastasis gene NEDD9 
product acts through integrin beta3 and Src to promote mesenchymal motility and 
inhibit amoeboid motility. J Cell Sci, 125(Pt 7), 1814-1826. 
 
Al-Sarraf, M. (2002) Treatment of locally advanced head and neck cancer: historical 
and critical review. Cancer Control, 9(5), 387-399. 
 
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and 
Hemmings, B. A. (1996) Mechanism of activation of protein kinase B by insulin and 
IGF-1. Embo J, 15(23), 6541-6551. 
214 
 
Alessi, D. R. and Cohen, P. (1998) Mechanism of activation and function of protein 
kinase B. Curr Opin Genet Dev, 8(1), 55-62. 
 
Allon, D., Kaplan, I., Manor, R. and Calderon, S. (2002) Carcinoma cuniculatum of 
the jaw: A rare variant of oral carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, 
Oral Radiology, and Endodontology, 94(5), 601-608. 
 
Altomare, D. A., Guo, K., Cheng, J. Q., Sonoda, G., Walsh, K. and Testa, J. R. (1995) 
Cloning, chromosomal localization and expression analysis of the mouse Akt2 
oncogene. Oncogene, 11(6), 1055-1060. 
 
Amiri, A., Noei, F., Jeganathan, S., Kulkarni, G., Pinke, D. E. and Lee, J. M. (2007) 
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and 
migration. Oncogene, 26(21), 3027-3040. 
 
Amornphimoltham, P., Patel, V., Molinolo, A. and Gutkind, J. S. (2011) Head and 
Neck Cancer and PI3K/Akt/mTOR Signaling Network: Novel Molecular Targeted 
Therapy. in Glick, A. B. and Van Waes, C., (eds). Signaling Pathways in Squamous 
Cancer. New York, Springer Science+Business Media, pp. 407-430. 
 
Amornphimoltham, P., Patel, V., Sodhi, A., Nikitakis, N. G., Sauk, J. J., Sausville, E. 
A., Molinolo, A. A. and Gutkind, J. S. (2005) Mammalian target of rapamycin, a 
molecular target in squamous cell carcinomas of the head and neck. Cancer Res, 
65(21), 9953-9961. 
 
Amornphimoltham, P., Sriuranpong, V., Patel, V., Benavides, F., Conti, C. J., Sauk, J., 
Sausville, E. A., Molinolo, A. A. and Gutkind, J. S. (2004) Persistent activation of the 
Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-
01. Clin Cancer Res, 10(12 Pt 1), 4029-4037. 
215 
 
Anisimov, A., Leppanen, V. M., Tvorogov, D., Zarkada, G., Jeltsch, M., Holopainen, 
T., Kaijalainen, S. and Alitalo, K. (2013) The basis for the distinct biological activities 
of vascular endothelial growth factor receptor-1 ligands. Sci Signal, 6(282), ra52. 
 
Anneroth, G., Batsakis, J. and Luna, M. (1987) Review of the literature and a 
recommended system of malignancy grading in oral squamous cell carcinomas. 
Scand J Dent Res, 95(3), 229-249. 
 
Applebaum, K. M., Furniss, C. S., Zeka, A., Posner, M. R., Smith, J. F., Bryan, J., 
Eisen, E. A., Peters, E. S., McClean, M. D. and Kelsey, K. T. (2007) Lack of Association 
of Alcohol and Tobacco with HPV16-Associated Head and Neck Cancer. Journal of 
the National Cancer Institute, 99(23), 1801-1810. 
 
Arora, S., Kaur, J., Sharma, C., Mathur, M., Bahadur, S., Shukla, N. K., Deo, S. V. and 
Ralhan, R. (2005) Stromelysin 3, Ets-1, and vascular endothelial growth factor 
expression in oral precancerous and cancerous lesions: correlation with microvessel 
density, progression, and prognosis. Clin Cancer Res, 11(6), 2272-2284. 
 
Arredondo, J., Chernyavsky, A. I., Jolkovsky, D. L., Pinkerton, K. E. and Grando, S. 
A. (2006) Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-
1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor 
in oral keratinocytes. FASEB J, 20(12), 2093-2101. 
 
Bachelder, R. E., Lipscomb, E. A., Lin, X., Wendt, M. A., Chadborn, N. H., Eickholt, 
B. J. and Mercurio, A. M. (2003) Competing autocrine pathways involving alternative 
neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res, 63(17), 5230-
5233. 
 
216 
 
Bagan, J., Sarrion, G. and Jimenez, Y. (2010) Oral cancer: clinical features. Oral Oncol, 
46(6), 414-417. 
 
Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. and McDonald, D. M. (2003) 
Abnormalities of basement membrane on blood vessels and endothelial sprouts in 
tumors. Am J Pathol, 163(5), 1801-1815. 
 
Banks, E. R., Frierson, H. F., Jr., Mills, S. E., George, E., Zarbo, R. J. and Swanson, P. 
E. (1992) Basaloid squamous cell carcinoma of the head and neck. A 
clinicopathologic and immunohistochemical study of 40 cases. Am J Surg Pathol, 
16(10), 939-946. 
 
Barata, J. T. (2011) The impact of PTEN regulation by CK2 on PI3K-dependent 
signaling and leukemia cell survival. Adv Enzyme Regul, 51(1), 37-49. 
 
Barber, M. A. and Welch, H. C. (2006) PI3K and RAC signalling in leukocyte and 
cancer cell migration. Bull Cancer, 93(5), E44-52. 
 
Barker, N. (2008) The canonical Wnt/beta-catenin signalling pathway. Methods Mol 
Biol, 468, 5-15. 
 
Barleon, B., Sozzani, S., Zhou, D., Weich, H. A., Mantovani, A. and Marme, D. (1996) 
Migration of human monocytes in response to vascular endothelial growth factor 
(VEGF) is mediated via the VEGF receptor flt-1. Blood, 87(8), 3336-3343. 
 
Barnes, L., Eveson, J. W., Reichart, P. and Sidransky, D. (2005) Pathology and Genetics 
of Head and Neck Tumours., Lyon: IARC press. 
 
217 
 
Barnes, L., Ferlito, A., Altavilla, G., MacMillan, C., Rinaldo, A. and Doglioni, C. 
(1996) Basaloid squamous cell carcinoma of the head and neck: clinicopathological 
features and differential diagnosis. Ann Otol Rhinol Laryngol, 105(1), 75-82. 
 
Beck, B., Driessens, G., Goossens, S., Youssef, K. K., Kuchnio, A., Caauwe, A., 
Sotiropoulou, P. A., Loges, S., Lapouge, G., Candi, A., Mascre, G., Drogat, B., 
Dekoninck, S., Haigh, J. J., Carmeliet, P. and Blanpain, C. (2011) A vascular niche and 
a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature, 
478(7369), 399-403. 
 
Beck, L., Jr. and D'Amore, P. A. (1997) Vascular development: cellular and molecular 
regulation. FASEB J, 11(5), 365-373. 
 
Beenken, A. and Mohammadi, M. (2009) The FGF family: biology, pathophysiology 
and therapy. Nat Rev Drug Discov, 8(3), 235-253. 
 
Bei, R., Budillon, A., Masuelli, L., Cereda, V., Vitolo, D., Di Gennaro, E., Ripavecchia, 
V., Palumbo, C., Ionna, F., Losito, S., Modesti, A., Kraus, M. H. and Muraro, R. (2004) 
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell 
carcinoma contrasts with rare antibody immunity in patients. J Pathol, 204(3), 317-
325. 
 
Bei, R., Pompa, G., Vitolo, D., Moriconi, E., Ciocci, L., Quaranta, M., Frati, L., Kraus, 
M. H. and Muraro, R. (2001) Co-localization of multiple ErbB receptors in stratified 
epithelium of oral squamous cell carcinoma. J Pathol, 195(3), 343-348. 
 
Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S., Stokoe, D., 
McCormick, F., Feng, J. and Tsichlis, P. (1998) Akt activation by growth factors is a 
multiple-step process: the role of the PH domain. Oncogene, 17(3), 313-325. 
218 
 
Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., 
Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti Panici, P., 
Mancuso, S., Neri, G. and Testa, J. R. (1995) Molecular alterations of the AKT2 
oncogene in ovarian and breast carcinomas. Int J Cancer, 64(4), 280-285. 
 
Bellacosa, A., Kumar, C. C., Di Cristofano, A. and Testa, J. R. (2005) Activation of 
AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res, 94, 29-
86. 
 
Bellacosa, A. and Larue, L. (2010) PI3K/AKT Pathway and the Epithelial–
Mesenchymal Transition. in Thomas-Tikhonenko, A., (ed). Cancer Genome and Tumor 
Microenvironment. New York, Springer Science+Business Media, pp. 11-31. 
 
Benefield, J., Meisinger, J., Petruzzelli, G. J. and Young, M. R. (1997) Endothelial cell 
response to human head and neck squamous cell carcinomas involves 
downregulation of protein phosphatases-1/2A, cytoskeletal depolymerization and 
increased motility. Invasion Metastasis, 17(4), 210-220. 
 
Berkovitz, B. K. B., Holland, G. R. and Moxham, B. J. (2002) Oral Anatomy, 
Embryology and Histology. California, Mosby. 
 
Berridge, M. J. (2009) Cell Signalling Biology, Portland Press Limited [online], 
available: http://www.biochemj.org/csb/default.htm [accessed 14 January 2011]. 
 
Berven, L. A., Willard, F. S. and Crouch, M. F. (2004) Role of the p70(S6K) pathway 
in regulating the actin cytoskeleton and cell migration. Exp Cell Res, 296(2), 183-195. 
 
Bhargava, A., Saigal, S. and Chalishazar, M. (2010) Histopathological Grading 
Systems In Oral Squamous Cell Carcinoma: A Review. J. Int Oral Health, 2(4), 1-9. 
219 
 
Bhowmick, N. A., Neilson, E. G. and Moses, H. L. (2004) Stromal fibroblasts in 
cancer initiation and progression. Nature, 432(7015), 332-337. 
 
Bian, Y., Terse, A., Du, J., Hall, B., Molinolo, A., Zhang, P., Chen, W., Flanders, K. C., 
Gutkind, J. S., Wakefield, L. M. and Kulkarni, A. B. (2009) Progressive tumor 
formation in mice with conditional deletion of TGF-beta signaling in head and neck 
epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res, 69(14), 
5918-5926. 
 
Bindhu, O. S., Ramadas, K., Sebastian, P. and Pillai, M. R. (2006) High expression 
levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral 
squamous cell carcinoma. Head Neck, 28(10), 916-925. 
 
Blackhall, F. H., Shepherd, F. A. and Albain, K. S. (2005) Improving survival and 
reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a 
realistic goal? Treat Respir Med, 4(2), 71-84. 
 
Blot, W. J., McLaughlin, J. K., Winn, D. M., Austin, D. F., Greenberg, R. S., Preston-
Martin, S., Bernstein, L., Schoenberg, J. B., Stemhagen, A. and Fraumeni, J. F., Jr. 
(1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res, 
48(11), 3282-3287. 
 
Boffetta, P., Hecht, S., Gray, N., Gupta, P. and Straif, K. (2008) Smokeless tobacco and 
cancer. Lancet Oncol, 9(7), 667-675. 
 
Bonello, T., Coombes, J., Schevzov, G., Gunning, P. and Stehn, J. (2012) Therapeutic 
Targeting of the Actin Cytoskeleton in Cancer. in Kavallaris, M., (ed). Cytoskeleton 
and Human Disease. New York, Humana Press, pp. 181-200. 
220 
 
Bornstein, S., White, R., Malkoski, S., Oka, M., Han, G., Cleaver, T., Reh, D., 
Andersen, P., Gross, N., Olson, S., Deng, C., Lu, S. L. and Wang, X. J. (2009) Smad4 
loss in mice causes spontaneous head and neck cancer with increased genomic 
instability and inflammation. J Clin Invest, 119(11), 3408-3419. 
 
Bos, J. L. (1989) ras oncogenes in human cancer: a review. Cancer Res, 49(17), 4682-
4689. 
 
Bose, P., Brockton, N. T. and Dort, J. C. (2013) Head and neck cancer: from anatomy 
to biology. Int J Cancer, 133(9), 2013-2023. 
 
Bose, S., Chandran, S., Mirocha, J. M. and Bose, N. (2006) The Akt pathway in human 
breast cancer: a tissue-array-based analysis. Mod Pathol, 19(2), 238-245. 
 
Bosetti, C., Scelo, G., Chuang, S. C., Tonita, J. M., Tamaro, S., Jonasson, J. G., Kliewer, 
E. V., Hemminki, K., Weiderpass, E., Pukkala, E., Tracey, E., Olsen, J. H., Pompe-
Kirn, V., Brewster, D. H., Martos, C., Chia, K. S., Brennan, P., Hashibe, M., Levi, F., 
La Vecchia, C. and Boffetta, P. (2011) High constant incidence rates of second 
primary cancers of the head and neck: a pooled analysis of 13 cancer registries. Int J 
Cancer, 129(1), 173-179. 
 
Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A. and 
Fusenig, N. E. (1988) Normal keratinization in a spontaneously immortalized 
aneuploid human keratinocyte cell line. J Cell Biol, 106(3), 761-771. 
 
Boukamp, P., Rupniak, H. T. and Fusenig, N. E. (1985) Environmental modulation of 
the expression of differentiation and malignancy in six human squamous cell 
carcinoma cell lines. Cancer Res, 45(11 Pt 2), 5582-5592. 
 
221 
 
Boukheris, H., Ron, E., Dores, G. M., Stovall, M., Smith, S. A. and Curtis, R. E. (2008) 
Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin 
lymphoma: a population-based analysis. Cancer, 113(11), 3153-3159. 
 
Boukheris, H., Stovall, M., Gilbert, E. S., Stratton, K. L., Smith, S. A., Weathers, R., 
Hammond, S., Mertens, A. C., Donaldson, S. S., Armstrong, G. T., Robison, L. L., 
Neglia, J. P. and Inskip, P. D. (2013) Risk of salivary gland cancer after childhood 
cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol 
Phys, 85(3), 776-783. 
 
Bova, R. J., Quinn, D. I., Nankervis, J. S., Cole, I. E., Sheridan, B. F., Jensen, M. J., 
Morgan, G. J., Hughes, C. J. and Sutherland, R. L. (1999) Cyclin D1 and p16INK4A 
expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer 
Res, 5(10), 2810-2819. 
 
Boyer, B., Valles, A. M. and Edme, N. (2000) Induction and regulation of epithelial-
mesenchymal transitions. Biochem Pharmacol, 60(8), 1091-1099. 
 
Boyle, J. O., Hakim, J., Koch, W., van der Riet, P., Hruban, R. H., Roa, R. A., Correo, 
R., Eby, Y. J., Ruppert, J. M. and Sidransky, D. (1993) The incidence of p53 mutations 
increases with progression of head and neck cancer. Cancer Res, 53(19), 4477-4480. 
 
Boyle, P. and Levin, B., eds. (2008) World Cancer Report 2008. Lyon, France, IARC. 
 
Bozulic, L. and Hemmings, B. A. (2009) PIKKing on PKB: regulation of PKB activity 
by phosphorylation. Current Opinion in Cell Biology, 21(2), 256-261. 
 
222 
 
Bozulic, L., Surucu, B., Hynx, D. and Hemmings, B. A. (2008) PKBalpha/Akt1 acts 
downstream of DNA-PK in the DNA double-strand break response and promotes 
survival. Mol Cell, 30(2), 203-213. 
 
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., 
Kenzelmann Broz, D., Basak, S., Park, E. J., McLaughlin, M. E., Karnezis, A. N. and 
Attardi, L. D. (2011) Distinct p53 transcriptional programs dictate acute DNA-
damage responses and tumor suppression. Cell, 145(4), 571-583. 
 
Braybrooke, J. P., O'Byrne, K. J., Propper, D. J., Blann, A., Saunders, M., Dobbs, N., 
Han, C., Woodhull, J., Mitchell, K., Crew, J., Smith, K., Stephens, R., Ganesan, T. S., 
Talbot, D. C. and Harris, A. L. (2000) A phase II study of razoxane, an antiangiogenic 
topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate 
markers of angiogenesis. Clin Cancer Res, 6(12), 4697-4704. 
 
Brazil, D. P., Yang, Z. Z. and Hemmings, B. A. (2004) Advances in protein kinase B 
signalling: AKTion on multiple fronts. Trends Biochem Sci, 29(5), 233-242. 
 
Brennan, J. A., Boyle, J. O., Koch, W. M., Goodman, S. N., Hruban, R. H., Eby, Y. J., 
Couch, M. J., Forastiere, A. A. and Sidransky, D. (1995a) Association between 
cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the 
head and neck. N Engl J Med, 332(11), 712-717. 
 
Brennan, J. A., Mao, L., Hruban, R. H., Boyle, J. O., Eby, Y. J., Koch, W. M., 
Goodman, S. N. and Sidransky, D. (1995b) Molecular assessment of 
histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J 
Med, 332(7), 429-435. 
 
223 
 
Brockstein, B. and Gregory, M., eds. (2002) Head and Neck Cancer. Secaucus, NJ, USA, 
Kluwer Academic Publishers. 
 
Bryne, M., Boysen, M., Alfsen, C. G., Abeler, V. M., Sudbo, J., Nesland, J. M., 
Kristensen, G. B., Piffko, J. and Bankfalvi, A. (1998) The invasive front of carcinomas. 
The most important area for tumour prognosis? Anticancer Res, 18(6B), 4757-4764. 
 
Bryne, M., Koppang, H. S., Lilleng, R., Stene, T., Bang, G. and Dabelsteen, E. (1989) 
New malignancy grading is a better prognostic indicator than Broders' grading in 
oral squamous cell carcinomas. J Oral Pathol Med, 18(8), 432-437. 
 
Bublil, E. M. and Yarden, Y. (2007) The EGF receptor family: spearheading a merger 
of signaling and therapeutics. Curr Opin Cell Biol, 19(2), 124-134. 
 
Bugyi, B. and Carlier, M. F. (2010) Control of actin filament treadmilling in cell 
motility. Annu Rev Biophys, 39, 449-470. 
 
Buquot, J. (1992) Oral effects of tobacco abuse. [online], available: 
http://www.maxillofacialcenter.com/TobaccoEffects.html#Figures [accessed 10 May 
2012]. 
 
Busch, S., Renaud, S. J., Schleussner, E., Graham, C. H. and Markert, U. R. (2009) 
mTOR mediates human trophoblast invasion through regulation of matrix-
remodeling enzymes and is associated with serine phosphorylation of STAT3. Exp 
Cell Res, 315(10), 1724-1733. 
 
Cantley, L. C. (2002) The phosphoinositide 3-kinase pathway. Science, 296(5573), 
1655-1657. 
 
224 
 
Carlile, J., Harada, K., Baillie, R., Macluskey, M., Chisholm, D. M., Ogden, G. R., 
Schor, S. L. and Schor, A. M. (2001) Vascular endothelial growth factor (VEGF) 
expression in oral tissues: possible relevance to angiogenesis, tumour progression 
and field cancerisation. J Oral Pathol Med, 30(8), 449-457. 
 
Carpenter, G. and Cohen, S. (1990) Epidermal growth factor. J Biol Chem, 265(14), 
7709-7712. 
 
Cenni, V., Sirri, A., Riccio, M., Lattanzi, G., Santi, S., de Pol, A., Maraldi, N. M. and 
Marmiroli, S. (2003) Targeting of the Akt/PKB kinase to the actin skeleton. Cell Mol 
Life Sci, 60(12), 2710-2720. 
 
Chan, T. O. and Tsichlis, P. N. (2001) PDK2: a complex tail in one Akt. Sci STKE, 
2001(66), pe1. 
 
Chang, H. R. (2010) Trastuzumab-based neoadjuvant therapy in patients with HER2-
positive breast cancer. Cancer, 116(12), 2856-2867. 
 
Chang, L. and Goldman, R. D. (2004) Intermediate filaments mediate cytoskeletal 
crosstalk. Nat Rev Mol Cell Biol, 5(8), 601-613. 
 
Chaturvedi, A. K., Kleinerman, R. A., Hildesheim, A., Gilbert, E. S., Storm, H., 
Lynch, C. F., Hall, P., Langmark, F., Pukkala, E., Kaijser, M., Andersson, M., Fossa, S. 
D., Joensuu, H., Travis, L. B. and Engels, E. A. (2009) Second cancers after squamous 
cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol, 27(6), 967-973. 
 
Chen, H. C. (2005) Boyden chamber assay. Methods Mol Biol, 294, 15-22. 
 
225 
 
Chen, T., Yan, W., Wells, R. G., Rimm, D. L., McNiff, J., Leffell, D. and Reiss, M. 
(2001) Novel inactivating mutations of transforming growth factor-beta type I 
receptor gene in head-and-neck cancer metastases. Int J Cancer, 93(5), 653-661. 
 
Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Smith, C. W., 
Enamorado, I., Yeh, N. T., Kroog, G. S., Rudy, S., McCullagh, L., Mousa, S., Quezado, 
M., Herscher, L. L. and Van Waes, C. (1999) Expression of proinflammatory and 
proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res, 5(6), 
1369-1379. 
 
Cheng, G. Z., Chan, J., Wang, Q., Zhang, W., Sun, C. D. and Wang, L. H. (2007) Twist 
transcriptionally up-regulates AKT2 in breast cancer cells leading to increased 
migration, invasion, and resistance to paclitaxel. Cancer Res, 67(5), 1979-1987. 
 
Chhabra, E. S. and Higgs, H. N. (2007) The many faces of actin: matching assembly 
factors with cellular structures. nature cell biology, 9(10), 1110-1121. 
 
Chien, C. Y., Su, C. Y., Hwang, C. F., Chuang, H. C., Chen, C. M. and Huang, C. C. 
(2006) High expressions of CD105 and VEGF in early oral cancer predict potential 
cervical metastasis. J Surg Oncol, 94(5), 413-417. 
 
Chin, Y. R. and Toker, A. (2009) Function of Akt/PKB signaling to cell motility, 
invasion and the tumor stroma in cancer. Cell Signal, 21(4), 470-476. 
 
Chin, Y. R. and Toker, A. (2010a) The Actin-Bundling Protein Palladin Is an Akt1-
Specific Substrate that Regulates Breast Cancer Cell Migration. Molecular Cell, 38(3), 
333-344. 
 
226 
 
Chin, Y. R. and Toker, A. (2010b) Akt2 regulates expression of the actin-bundling 
protein palladin. FEBS Lett, 584(23), 4769-4774. 
 
Cho, H. J., Baek, K. E., Saika, S., Jeong, M.-J. and Yoo, J. (2007) Snail is required for 
transforming growth factor-β-induced epithelial–mesenchymal transition by 
activating PI3 kinase/Akt signal pathway. Biochemical and Biophysical Research 
Communications, 353(2), 337-343. 
 
Chodniewicz, D. and Zhelev, D. V. (2003) Chemoattractant receptor-stimulated F-
actin polymerization in the human neutrophil is signaled by 2 distinct pathways. 
Blood, 101(3), 1181-1184. 
 
Christopoulos, A., Ahn, S. M., Klein, J. D. and Kim, S. (2011) Biology of vascular 
endothelial growth factor and its receptors in head and neck cancer: Beyond 
angiogenesis. Head & Neck, 33(8), 1220-1229. 
 
Chuang, H. C., Su, C. Y., Huang, H. Y., Chien, C. Y., Chen, C. M. and Huang, C. C. 
(2006) High expression of CD105 as a prognostic predictor of early tongue cancer. 
Laryngoscope, 116(7), 1175-1179. 
 
Chuang, S. C., Hashibe, M., Scelo, G., Brewster, D. H., Pukkala, E., Friis, S., Tracey, 
E., Weiderpass, E., Hemminki, K., Tamaro, S., Chia, K. S., Pompe-Kirn, V., Kliewer, 
E. V., Tonita, J. M., Martos, C., Jonasson, J. G., Dresler, C. M., Boffetta, P. and 
Brennan, P. (2008) Risk of second primary cancer among esophageal cancer patients: 
a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev, 17(6), 1543-
1549. 
 
 
227 
 
Chuang, S. C., Scelo, G., Lee, Y. C., Friis, S., Pukkala, E., Brewster, D. H., Hemminki, 
K., Tracey, E., Weiderpass, E., Tamaro, S., Pompe-Kirn, V., Kliewer, E. V., Chia, K. S., 
Tonita, J. M., Martos, C., Jonasson, J. G., Boffetta, P., Brennan, P. and Hashibe, M. 
(2010) Risks of second primary cancer among patients with major histological types 
of lung cancers in both men and women. Br J Cancer, 102(7), 1190-1195. 
 
Chung, C. Y., Potikyan, G. and Firtel, R. A. (2001) Control of cell polarity and 
chemotaxis by Akt/PKB and PI3 kinase through the regulation of PAKa. Mol Cell, 
7(5), 937-947. 
 
Cirri, P. and Chiarugi, P. (2011) Cancer associated fibroblasts: the dark side of the 
coin. Am J Cancer Res, 1(4), 482-497. 
 
Clement, D. L., Mally, S., Stock, C., Lethan, M., Satir, P., Schwab, A., Pedersen, S. F. 
and Christensen, S. T. (2013) PDGFRalpha signaling in the primary cilium regulates 
NHE1-dependent fibroblast migration via coordinated differential activity of 
MEK1/2-ERK1/2-p90RSK and AKT signaling pathways. J Cell Sci, 126(Pt 4), 953-965. 
 
Cohen, P. (2000) The regulation of protein function by multisite phosphorylation--a 
25 year update. Trends Biochem Sci, 25(12), 596-601. 
 
Cohen, R. B. (2014) Current challenges and clinical investigations of epidermal 
growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of 
head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev, 40(4), 567-577. 
 
Cohen, S. (1964) Isolation and biological effects of an epidermal growth-stimulating 
protein. Natl Cancer Inst Monogr, 13, 13-37. 
 
228 
 
Cohen, S. (2008) Origins of growth factors: NGF and EGF. J Biol Chem, 283(49), 33793-
33797. 
 
Conacci-Sorrell, M., Zhurinsky, J. and Ben-Ze'ev, A. (2002) The cadherin-catenin 
adhesion system in signaling and cancer. J Clin Invest, 109(8), 987-991. 
 
Conway, D. I., McMahon, A. D., Smith, K., Black, R., Robertson, G., Devine, J. and 
McKinney, P. A. (2010) Components of socioeconomic risk associated with head and 
neck cancer: a population-based case-control study in Scotland. Br J Oral Maxillofac 
Surg, 48(1), 11-17. 
 
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, 
M. B., Xie, L., Maeda, G., Vong, S., Sugimoto, H., Rocha, R. M., Damascena, A., 
Brentani, R. R. and Kalluri, R. (2012) Pericyte depletion results in hypoxia-associated 
epithelial-to-mesenchymal transition and metastasis mediated by met signaling 
pathway. Cancer Cell, 21(1), 66-81. 
 
Courtney, K. D., Corcoran, R. B. and Engelman, J. A. (2010) The PI3K pathway as 
drug target in human cancer. J Clin Oncol, 28(6), 1075-1083. 
 
CR-UK (2013) Oral cancer risk factors. [online], available: 
http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/oral/riskfactors/#source51 [accessed 25 February 2014]. 
 
Cross, M. J., Dixelius, J., Matsumoto, T. and Claesson-Welsh, L. (2003) VEGF-
receptor signal transduction. Trends Biochem Sci, 28(9), 488-494. 
 
229 
 
CRUK (2014a) Laryngeal cancer key facts. [online], available: 
http://publications.cancerresearchuk.org/cancerstats/statslaryngeal/keyfactslarynx.ht
ml [accessed 01 May 2014]. 
 
CRUK (2014b) Oral cancer key facts. [online], available: 
http://publications.cancerresearchuk.org/cancerstats/stats_mouth/oralkeyfacts.html 
[accessed 01 May 2014]. 
 
CRUK (2014c) UK cancer incidence (2011) by country summary. [online], available: 
http://publications.cancerresearchuk.org/publicationformat/formatstats/dtinccountri
es.html [accessed 05 May 2014]. 
 
Cui, W., Cai, Y. and Zhou, X. (2014) Advances in subunits of PI3K class I in cancer. 
Pathology, 46(3), 169-176. 
 
Cully, M., You, H., Levine, A. J. and Mak, T. W. (2006) Beyond PTEN mutations: the 
PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev 
Cancer, 6(3), 184-192. 
 
da Silva, S. D., Hier, M., Mlynarek, A., Kowalski, L. P. and Alaoui-Jamali, M. A. 
(2012) Recurrent oral cancer: current and emerging therapeutic approaches. Front 
Pharmacol, 3, 149. 
 
Dasanayake, A. P., Silverman, A. J. and Warnakulasuriya, S. (2010) Mate drinking 
and oral and oro-pharyngeal cancer: a systematic review and meta-analysis. Oral 
Oncol, 46(2), 82-86. 
 
Datta, Brunet, A. and Greenberg, M. E. (1999) Cellular survival: a play in three Akts. 
Genes Dev, 13(22), 2905-2927. 
230 
 
De Marco, C., Rinaldo, N., Bruni, P., Malzoni, C., Zullo, F., Fabiani, F., Losito, S., 
Scrima, M., Marino, F. Z., Franco, R., Quintiero, A., Agosti, V. and Viglietto, G. (2013) 
Multiple genetic alterations within the PI3K pathway are responsible for AKT 
activation in patients with ovarian carcinoma. PLoS One, 8(2), e55362. 
 
Dean, M., Fojo, T. and Bates, S. (2005) Tumour stem cells and drug resistance. Nat 
Rev Cancer, 5(4), 275-284. 
 
Debucquoy, A., Machiels, J. P., McBride, W. H. and Haustermans, K. (2010) 
Integration of epidermal growth factor receptor inhibitors with preoperative 
chemoradiation. Clin Cancer Res, 16(10), 2709-2714. 
 
Demers, P. A., Boffetta, P., Kogevinas, M., Blair, A., Miller, B. A., Robinson, C. F., 
Roscoe, R. J., Winter, P. D., Colin, D., Matos, E. and et al. (1995) Pooled reanalysis of 
cancer mortality among five cohorts of workers in wood-related industries. Scand J 
Work Environ Health, 21(3), 179-190. 
 
Denker, S. P. and Barber, D. L. (2002) Cell migration requires both ion translocation 
and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol, 159(6), 1087-
1096. 
 
Dennis, E. A. and Bradshaw, R. A., eds. (2011) Transduction Mechanisms in Cellular 
Signaling. 1 ed., New York, Academic Press. 
 
Deschler, D. D. and Day, T., eds. (2008) Pocket guide to neck dissesction classification and 
TNM staging of head and neck cancer. 3rd ed., Alexandria, VA, American academy of 
otolaryngology-head and neck surgery foundation, Inc. 
 
231 
 
Di Fiore, R., D'Anneo, A., Tesoriere, G. and Vento, R. (2013) RB1 in cancer: different 
mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J 
Cell Physiol, 228(8), 1676-1687. 
 
Dimmeler, S., Dernbach, E. and Zeiher, A. M. (2000) Phosphorylation of the 
endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced 
endothelial cell migration. FEBS Lett, 477(3), 258-262. 
 
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A. M. 
(1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent 
phosphorylation. Nature, 399(6736), 601-605. 
 
DoH (2000) The NHS Cancer plan: a plan for investment, a plan for reform, London: 
Department of Health. 
 
Dorsey, K. and Agulnik, M. (2013) Promising new molecular targeted therapies in 
head and neck cancer. Drugs, 73(4), 315-325. 
 
Dowling, R. J., Topisirovic, I., Fonseca, B. D. and Sonenberg, N. (2010) Dissecting the 
role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta, 1804(3), 433-439. 
 
Drugan, C. S., Paterson, I. C. and Prime, S. S. (1998) Fibroblast growth factor receptor 
expression reflects cellular differentiation in human oral squamous carcinoma cell 
lines. Carcinogenesis, 19(6), 1153-1156. 
 
Dwarakanath, B. S., Khaitan, D. and Mathur, R. (2004) Inhibitors of topoisomerases 
as anticancer drugs: problems and prospects. Indian J Exp Biol, 42(7), 649-659. 
 
232 
 
Dworken, H. J., Hightower, N. C. and Sircus, W. (2012) Human digestive system. 
[online], available: http://www.britannica.com/EBchecked/topic/1081754/human-
digestive-system/45314/The-tongue [accessed 19 April 2012]. 
 
Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T. and 
Miyazono, K. (2001) Smurf1 interacts with transforming growth factor-beta type I 
receptor through Smad7 and induces receptor degradation. J Biol Chem, 276(16), 
12477-12480. 
 
Ebrahimi, M., Boldrup, L., Coates, P. J., Wahlin, Y. B., Bourdon, J. C. and Nylander, 
K. (2008) Expression of novel p53 isoforms in oral lichen planus. Oral Oncol, 44(2), 
156-161. 
 
Edge, S. (2010) AJCC Cancer staging manual. New York, Springer. 
 
Egloff, A. M. and Grandis, J. R. (2012) Molecular pathways: context-dependent 
approaches to Notch targeting as cancer therapy. Clin Cancer Res, 18(19), 5188-5195. 
 
Eisenberg, R. M. (2010) Understanding Radiotherapy for Head and Neck Cancer 
A Guide for Adults and Their Caregivers, Barthesda, MD, USA: Agency for Healthcare 
Research and Quality. 
 
Ellis, I. R., Islam, M. R., Aljorani, L. and Jones, S. J. (2012) Fibronectin: the N-terminal 
region and its role in cell migration- implications for disease and healing. in Beattie, 
J., (ed). Fibronectin: Current Concepts in Structure, Function and Pathology. New York, 
Nova Science publishers, pp. 35-69. 
 
233 
 
Ellis, I. R., Jones, S. J., Lindsay, Y., Ohe, G., Schor, A. M., Schor, S. L. and Leslie, N. R. 
(2010a) Migration Stimulating Factor (MSF) promotes fibroblast migration by 
inhibiting AKT. Cell Signal, 22(11), 1655-1659. 
 
Ellis, I. R., Jones, S. J., Staunton, D., Vakonakis, I., Norman, D. G., Potts, J. R., Milner, 
C. M., Meenan, N. A., Raibaud, S., Ohea, G., Schor, A. M. and Schor, S. L. (2010b) 
Multi-factorial modulation of IGD motogenic potential in MSF (migration 
stimulating factor). Exp Cell Res, 316(15), 2465-2476. 
 
Ellis, I. R., Schor, A. M. and Schor, S. L. (2007) EGF AND TGF-alpha motogenic 
activities are mediated by the EGF receptor via distinct matrix-dependent 
mechanisms. Exp Cell Res, 313(4), 732-741. 
 
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Jr., Kasiske, B. L., Israni, A. K., Snyder, J. 
J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., Copeland, G., Finch, J. 
L., Fleissner, M. L., Goodman, M. T., Kahn, A., Koch, L., Lynch, C. F., Madeleine, M. 
M., Pawlish, K., Rao, C., Williams, M. A., Castenson, D., Curry, M., Parsons, R., Fant, 
G. and Lin, M. (2011) Spectrum of cancer risk among US solid organ transplant 
recipients. JAMA, 306(17), 1891-1901. 
 
Enomoto, A., Murakami, H., Asai, N., Morone, N., Watanabe, T., Kawai, K., 
Murakumo, Y., Usukura, J., Kaibuchi, K. and Takahashi, M. (2005) Akt/PKB 
regulates actin organization and cell motility via Girdin/APE. Dev Cell, 9(3), 389-402. 
 
Eswarakumar, V. P., Lax, I. and Schlessinger, J. (2005) Cellular signaling by 
fibroblast growth factor receptors. Cytokine Growth Factor Rev, 16(2), 139-149. 
 
 
234 
 
Evdokimova, V., Tognon, C., Ng, T., Ruzanov, P., Melnyk, N., Fink, D., Sorokin, A., 
Ovchinnikov, L. P., Davicioni, E., Triche, T. J. and Sorensen, P. H. (2009) 
Translational activation of snail1 and other developmentally regulated transcription 
factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell, 15(5), 
402-415. 
 
Fagan, P. and Rigotti, N. A. (2009) Light and intermittent smoking: The road less 
traveled. Nicotine & Tobacco Research, 11(2), 107-110. 
 
Fakhry, C., Westra, W. H., Li, S., Cmelak, A., Ridge, J. A., Pinto, H., Forastiere, A. 
and Gillison, M. L. (2008) Improved survival of patients with human 
papillomavirus-positive head and neck squamous cell carcinoma in a prospective 
clinical trial. J Natl Cancer Inst, 100(4), 261-269. 
 
Falasca, M. (2010) PI3K/Akt signalling pathway specific inhibitors: a novel strategy 
to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des, 16(12), 1410-1416. 
 
Faustino, S. E., Oliveira, D. T., Nonogaki, S., Landman, G., Carvalho, A. L. and 
Kowalski, L. P. (2008) Expression of vascular endothelial growth factor-C does not 
predict occult lymph-node metastasis in early oral squamous cell carcinoma. Int J 
Oral Maxillofac Surg, 37(4), 372-378. 
 
Fayard, E., Xue, G., Parcellier, A., Bozulic, L. and Hemmings, B. (2011) Protein 
Kinase B (PKB/Akt), a Key Mediator of the PI3K Signaling Pathway. in Rommel, C., 
Vanhaesebroeck, B. and Vogt, P. K., (eds). Phosphoinositide 3-kinase in Health and 
Disease. Springer Berlin Heidelberg, pp. 31-56. 
 
235 
 
Feng, Park, J., Cron, P., Hess, D. and Hemmings, B. A. (2004) Identification of a 
PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase. 
Journal of biological chemistry, 279(39), 41189-41196. 
 
Feng, Y. and Walsh, C. A. (2004) The many faces of filamin: a versatile molecular 
scaffold for cell motility and signalling. Nat Cell Biol, 6(11), 1034-1038. 
 
Fernandez Pujol, B., Lucibello, F. C., Zuzarte, M., Lutjens, P., Muller, R. and 
Havemann, K. (2001) Dendritic cells derived from peripheral monocytes express 
endothelial markers and in the presence of angiogenic growth factors differentiate 
into endothelial-like cells. Eur J Cell Biol, 80(1), 99-110. 
 
Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical 
progress. Endocr Rev, 25(4), 581-611. 
 
Ferrara, N. and Davis-Smyth, T. (1997) The biology of vascular endothelial growth 
factor. Endocr Rev, 18(1), 4-25. 
 
Ferrara, N., Gerber, H. P. and LeCouter, J. (2003) The biology of VEGF and its 
receptors. Nat Med, 9(6), 669-676. 
 
Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. 
Nat Med, 1(1), 27-31. 
 
Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev 
Drug Discov, 6(4), 273-286. 
 
 
236 
 
Fong, Y.-C., Hsu, S.-F., Wu, C.-L., Li, T.-M., Kao, S.-T., Tsai, F.-J., Chen, W.-C., Liu, S.-
C., Wu, C.-M. and Tang, C.-H. (2009) Transforming growth factor-β1 increases cell 
migration and β1 integrin up-regulation in human lung cancer cells. Lung Cancer, 
64(1), 13-21. 
 
Fonseca, F. P., Ramos, L. M., Vargas, P. A., de Almeida, O. P., Lopes, M. A. and 
Santos-Silva, A. R. (2012) Oral adenosquamous carcinoma: evidence that it arises 
from the surface mucosal epithelium. Histopathology, 61(2), 321-323. 
 
Frame, F. M. and Maitland, N. J. (2011) Cancer stem cells, models of study and 
implications of therapy resistance mechanisms. Adv Exp Med Biol, 720, 105-118. 
 
Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Muhling, J., Hofele, C., 
Radlwimmer, B., Lichter, P. and Joos, S. (2007) Recurrent FGFR1 amplification and 
high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol, 
43(1), 60-66. 
 
Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C. and Gonzalez-
Baron, M. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev, 30(2), 
193-204. 
 
Friedl, P. (2004) Prespecification and plasticity: shifting mechanisms of cell 
migration. Curr Opin Cell Biol, 16(1), 14-23. 
 
Friedl, P. and Brocker, E. B. (2000) The biology of cell locomotion within three-
dimensional extracellular matrix. Cell Mol Life Sci, 57(1), 41-64. 
 
Friedl, P. and Wolf, K. (2003) Tumour-cell invasion and migration: diversity and 
escape mechanisms. Nat Rev Cancer, 3(5), 362-374. 
237 
 
Friedman, G. D., Asgari, M. M., Warton, E. M., Chan, J. and Habel, L. A. (2012) 
Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch Intern Med, 
172(16), 1246-1251. 
 
Frixione, E. (2000) Recurring views on the structure and function of the cytoskeleton: 
a 300-year epic. Cell Motil Cytoskeleton, 46(2), 73-94. 
 
Fukai, Y., Fukuchi, M., Masuda, N., Osawa, H., Kato, H., Nakajima, T. and Kuwano, 
H. (2003) Reduced expression of transforming growth factor-beta receptors is an 
unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J 
Cancer, 104(2), 161-166. 
 
Gabriel, J. A., ed. (2008) Biology of Cancer 2ed., Hoboken, NJ, USA, Wiley. 
 
Gallo, O., Masini, E., Bianchi, B., Bruschini, L., Paglierani, M. and Franchi, A. (2002) 
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and 
neck squamous cell carcinoma. Hum Pathol, 33(7), 708-714. 
 
Gao, D., Inuzuka, H., Tseng, A., Chin, R. Y., Toker, A. and Wei, W. (2009) 
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs 
APCCdh1-mediated Skp2 destruction. Nat Cell Biol, 11(4), 397-408. 
 
Gaykalova, D. A., Mambo, E., Choudhary, A., Houghton, J., Buddavarapu, K., 
Sanford, T., Darden, W., Adai, A., Hadd, A., Latham, G., Danilova, L. V., Bishop, J., 
Li, R. J., Westra, W. H., Hennessey, P., Koch, W. M., Ochs, M. F., Califano, J. A. and 
Sun, W. (2014) Novel insight into mutational landscape of head and neck squamous 
cell carcinoma. PLoS One, 9(3), e93102. 
 
238 
 
Giaccone, G. (2000) Clinical perspectives on platinum resistance. Drugs, 59 Suppl 4, 
9-17; discussion 37-18. 
Gillison, M. L., Castellsague, X., Chaturvedi, A., Goodman, M. T., Snijders, P., 
Tommasino, M., Arbyn, M. and Franceschi, S. (2013) Comparative epidemiology of 
HPV infection and associated cancers of the head and neck and cervix. Int J Cancer, 
134(3), 497-507. 
 
Gillison, M. L., Koch, W. M., Capone, R. B., Spafford, M., Westra, W. H., Wu, L., 
Zahurak, M. L., Daniel, R. W., Viglione, M., Symer, D. E., Shah, K. V. and Sidransky, 
D. (2000) Evidence for a causal association between human papillomavirus and a 
subset of head and neck cancers. J Natl Cancer Inst, 92(9), 709-720. 
 
Glynn, S., Prueitt, R., Ridnour, L., Boersma, B., Dorsey, T., Wink, D., Goodman, J., 
Yfantis, H., Lee, D. and Ambs, S. (2010) COX-2 activation is associated with Akt 
phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. 
BMC Cancer, 10(1), 626. 
 
Goel, H. L. and Mercurio, A. M. (2013) VEGF targets the tumour cell. Nat Rev Cancer, 
13(12), 871-882. 
 
Gomperts, B. D., Kramer, I. M. and Tatham, P. E. R. (2009) Signal Transduction. 2 ed., 
London, Academic Press. 
 
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., 
Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H. and Hortobagyi, G. N. (2011) PI3K 
pathway mutations and PTEN levels in primary and metastatic breast cancer. 
Molecular cancer therapeutics, 10(6), 1093-1101. 
 
239 
 
Grandis, J. R., Drenning, S. D., Zeng, Q., Watkins, S. C., Melhem, M. F., Endo, S., 
Johnson, D. E., Huang, L., He, Y. and Kim, J. D. (2000) Constitutive activation of 
Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc 
Natl Acad Sci U S A, 97(8), 4227-4232. 
 
Grandis, J. R. and Tweardy, D. J. (1993) Elevated Levels of Transforming Growth 
Factor α and Epidermal Growth Factor Receptor Messenger RNA Are Early Markers 
of Carcinogenesis in Head and Neck Cancer. Cancer Research, 53(15), 3579-3584. 
 
Greaves, M. and Maley, C. C. (2012) Clonal evolution in cancer. Nature, 481(7381), 
306-313. 
 
Greenberg, J. S., El Naggar, A. K., Mo, V., Roberts, D. and Myers, J. N. (2003) 
Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. 
Implication for therapeutic decision making. Cancer, 98(3), 508-515. 
 
Grille, S. J., Bellacosa, A., Upson, J., Klein-Szanto, A. J., Van Roy, F., Lee-Kwon, W., 
Donowitz, M. and Larue, L. (2003) The protein kinase Akt induces epithelial 
mesenchymal transition and promotes enhanced motility and invasiveness of 
squamous cell carcinoma lines. Cancer Research, 63(9), 2172-2178. 
 
Grinspan, D. and Abulafia, J. (1979) Oral florid papillomatosis (verrucous 
carcinoma). Int J Dermatol, 18(8), 608-622. 
 
Grulich, A. E., van Leeuwen, M. T., Falster, M. O. and Vajdic, C. M. (2007) Incidence 
of cancers in people with HIV/AIDS compared with immunosuppressed transplant 
recipients: a meta-analysis. Lancet, 370(9581), 59-67. 
 
240 
 
Grunewald, F. S., Prota, A. E., Giese, A. and Ballmer-Hofer, K. (2010) Structure-
function analysis of VEGF receptor activation and the role of coreceptors in 
angiogenic signaling. Biochim Biophys Acta, 1804(3), 567-580. 
 
Guo, B. H., Feng, Y., Zhang, R., Xu, L. H., Li, M. Z., Kung, H. F., Song, L. B. and 
Zeng, M. S. (2011) Bmi-1 promotes invasion and metastasis, and its elevated 
expression is correlated with an advanced stage of breast cancer. Mol Cancer, 10(1), 
10. 
 
Ha, G.-H., Park, J.-S. and Breuer, E.-K. Y. (2013) TACC3 promotes epithelial–
mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK 
signaling pathways. Cancer Letters, 332(0), 63-73. 
 
Hackel, P. O., Zwick, E., Prenzel, N. and Ullrich, A. (1999) Epidermal growth factor 
receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol, 11(2), 
184-189. 
 
Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. 
Cell, 144(5), 646-674. 
 
Hancock, J. T. (2010) Cell Signalling. 3 ed., New York, Oxford University Press. 
 
Harris, R. C., Chung, E. and Coffey, R. J. (2003) EGF receptor ligands. Exp Cell Res, 
284(1), 2-13. 
 
Harrison, L. B., Sessions, R. B. and Hong, W. K. (2008) Head and Neck Cancer: A 
Multidisciplinary Approach. Lippincott Williams & Wilkins. 
 
 
241 
 
Hart, J. R. and Vogt, P. K. (2011) Phosphorylation of AKT: a mutational analysis. 
Oncotarget, 2(6), 467-476. 
 
Hase, T., Kawashiri, S., Tanaka, A., Nozaki, S., Noguchi, N., Kato, K., Nakaya, H. 
and Nakagawa, K. (2006) Correlation of basic fibroblast growth factor expression 
with the invasion and the prognosis of oral squamous cell carcinoma. Journal of Oral 
Pathology & Medicine, 35(3), 136-139. 
 
Hauptmann, M., Lubin, J. H., Stewart, P. A., Hayes, R. B. and Blair, A. (2004) 
Mortality from solid cancers among workers in formaldehyde industries. Am J 
Epidemiol, 159(12), 1117-1130. 
 
Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev, 
18(16), 1926-1945. 
 
Hayden, M. S. and Ghosh, S. (2008) Shared principles in NF-kappaB signaling. Cell, 
132(3), 344-362. 
 
Heck, J. E., Berthiller, J., Vaccarella, S., Winn, D. M., Smith, E. M., Shan'gina, O., 
Schwartz, S. M., Purdue, M. P., Pilarska, A., Eluf-Neto, J., Menezes, A., McClean, M. 
D., Matos, E., Koifman, S., Kelsey, K. T., Herrero, R., Hayes, R. B., Franceschi, S., 
Wunsch-Filho, V., Fernandez, L., Daudt, A. W., Curado, M. P., Chen, C., 
Castellsague, X., Ferro, G., Brennan, P., Boffetta, P. and Hashibe, M. (2010) Sexual 
behaviours and the risk of head and neck cancers: a pooled analysis in the 
International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J 
Epidemiol, 39(1), 166-181. 
 
Helfand, B. T., Chang, L. and Goldman, R. D. (2004) Intermediate filaments are 
dynamic and motile elements of cellular architecture. J Cell Sci, 117(Pt 2), 133-141. 
242 
 
Helliwell, T. and Woolgar, J. (2013) Dataset for histopathology reporting of mucosal 
malignancies of the oral cavity, London: The Royal College of Pathologists. 
 
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B. (2005) Exploiting the 
PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 4(12), 988-1004. 
 
Henson, B. J. and Gollin, S. M. (2010) Overexpression of KLF13 and FGFR3 in oral 
cancer cells. Cytogenet Genome Res, 128(4), 192-198. 
 
Hiatt, J. L. and Gartner, L. P. (2009) Textbook of Head and Neck Anatomy. 4 ed., New 
York, Lippincott Williams & Wilkins. 
 
Higashiyama, S., Iwabuki, H., Morimoto, C., Hieda, M., Inoue, H. and Matsushita, 
N. (2008) Membrane-anchored growth factors, the epidermal growth factor family: 
beyond receptor ligands. Cancer Sci, 99(2), 214-220. 
 
Hill, L., Browne, G. and Tulchinsky, E. (2013) ZEB/miR-200 feedback loop: at the 
crossroads of signal transduction in cancer. Int J Cancer, 132(4), 745-754. 
 
Ho, Y. P., Kuo, C. W., Hsu, Y. T., Huang, Y. S., Yew, L. P., Huang, W. F., Lin, K. C. 
and Hsu, J. H. (2011) beta-Actin is a downstream effector of the PI3K/AKT signaling 
pathway in myeloma cells. Mol Cell Biochem, 348(1-2), 129-139. 
 
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T. and De 
Bruijn, E. A. (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol 
Rev, 56(4), 549-580. 
 
 
243 
 
Homer, J. J., Prentice, M. G., Cawkwell, L., Birchall, M., Greenman, J. and Stafford, 
N. D. (2003) Angiogenesis and the expression of vascular endothelial growth factors 
A and C in squamous cell carcinoma of the piriform fossa. Arch Otolaryngol Head 
Neck Surg, 129(10), 1110-1114. 
 
Hong, K. O., Kim, J. H., Hong, J. S., Yoon, H. J., Lee, J. I., Hong, S. P. and Hong, S. D. 
(2009) Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting 
transition with restoring E-cadherin expression in KB and KOSCC-25B oral 
squamous cell carcinoma cells. J Exp Clin Cancer Res, 28, 28. 
 
Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W. (1991) The 
vascular endothelial growth factor family: identification of a fourth molecular 
species and characterization of alternative splicing of RNA. Mol Endocrinol, 5(12), 
1806-1814. 
 
Houlihan, C. F., Larke, N. L., Watson-Jones, D., Smith-McCune, K. K., Shiboski, S., 
Gravitt, P. E., Smith, J. S., Kuhn, L., Wang, C. and Hayes, R. (2012) Human 
papillomavirus infection and increased risk of HIV acquisition. A systematic review 
and meta-analysis. AIDS, 26(17), 2211-2222. 
 
Hsue, S. S., Wang, W. C., Chen, C. H., Lin, C. C., Chen, Y. K. and Lin, L. M. (2007) 
Malignant transformation in 1458 patients with potentially malignant oral mucosal 
disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med, 36(1), 
25-29. 
 
Huang, C., ed. (2010) Protein phosphorylation in human health. Rijeka, Croatia, Intech. 
 
Husten, C. G. (2009) How should we define light or intermittent smoking? Does it 
matter? Nicotine & Tobacco Research, 11(2), 111-121. 
244 
 
Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R. and Muller, W. J. (2001) 
Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical 
Cell Survival Signal Required for Tumor Progression. Molecular and Cellular Biology, 
21(6), 2203-2212. 
 
Hutchinson, J. N., Jin, J., Cardiff, R. D., Woodgett, J. R. and Muller, W. J. (2004) 
Activation of Akt-1 (PKB-α) Can Accelerate ErbB-2-Mediated Mammary 
Tumorigenesis but Suppresses Tumor Invasion. Cancer Research, 64(9), 3171-3178. 
 
Hynes, N. E. and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of 
targeted inhibitors. Nat Rev Cancer, 5(5), 341-354. 
 
IARC (2014) List of Classifications by cancer sites with sufficient or limited evidence 
in humans, Volumes 1 to 105. [online], available: 
http://monographs.iarc.fr/ENG/Classification/index.php [accessed 18 February 2014]. 
 
IARC (2015) Oral squamous cell carcinoma. [online], available: 
http://screening.iarc.fr/atlasoral_list.php?lang=1&cat=B2 [accessed 16 September 
2015]. 
 
Ihle, N. T. and Powis, G. (2010) Inhibitors of phosphatidylinositol-3-kinase in cancer 
therapy. Mol Aspects Med, 31(2), 135-144. 
 
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X. and Guan, K.-L. (2008) Essential function of 
TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. 
Embo J, 27(14), 1919-1931. 
 
245 
 
Iliopoulos, D., Polytarchou, C., Hatziapostolou, M., Kottakis, F., Maroulakou, I. G., 
Struhl, K. and Tsichlis, P. N. (2009) MicroRNAs differentially regulated by Akt 
isoforms control EMT and stem cell renewal in cancer cells. Sci Signal, 2(92), ra62. 
 
Inaki, M., Vishnu, S., Cliffe, A. and Rorth, P. (2012) Effective guidance of collective 
migration based on differences in cell states. Proc Natl Acad Sci U S A, 109(6), 2027-
2032. 
 
Inoki, K., Corradetti, M. N. and Guan, K. L. (2005a) Dysregulation of the TSC-mTOR 
pathway in human disease. Nat Genet, 37(1), 19-24. 
 
Inoki, K., Li, Y., Xu, T. and Guan, K. L. (2003) Rheb GTPase is a direct target of TSC2 
GAP activity and regulates mTOR signaling. Genes Dev, 17(15), 1829-1834. 
 
Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K. L. (2002) TSC2 is phosphorylated and 
inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol, 4(9), 648-657. 
 
Inoki, K., Ouyang, H., Li, Y. and Guan, K. L. (2005b) Signaling by target of 
rapamycin proteins in cell growth control. Microbiol Mol Biol Rev, 69(1), 79-100. 
 
Ip, C. K. M., Cheung, A. N. Y., Ngan, H. Y. S. and Wong, A. S. T. (2011) p70 S6 kinase 
in the control of actin cytoskeleton dynamics and directed migration of ovarian 
cancer cells. Oncogene, 30(21), 2420-2432. 
 
Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., 
Natesan, S. and Brugge, J. S. (2005) Distinct roles of Akt1 and Akt2 in regulating cell 
migration and epithelial–mesenchymal transition. The Journal of Cell Biology, 171(6), 
1023-1034. 
 
246 
 
Islam, M. R., Jones, S. J., Macluskey, M. and Ellis, I. R. (2014) Is there a pAkt between 
VEGF and oral cancer cell migration? Cellular Signalling, 26(6), 1294-1302. 
 
Itoh, N. and Ornitz, D. M. (2011) Fibroblast growth factors: from molecular evolution 
to roles in development, metabolism and disease. J Biochem, 149(2), 121-130. 
 
Iyer, N. G., Morris, L. G., Tuttle, R. M., Shaha, A. R. and Ganly, I. (2011) Rising 
incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who 
receive radioactive iodine therapy. Cancer, 117(19), 4439-4446. 
 
Jackson, J. L. and Young, M. R. (2003) Protein phosphatase-2A regulates protein 
tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. Clin Exp 
Metastasis, 20(4), 357-364. 
 
Jia, W. H., Luo, X. Y., Feng, B. J., Ruan, H. L., Bei, J. X., Liu, W. S., Qin, H. D., Feng, Q. 
S., Chen, L. Z., Yao, S. Y. and Zeng, Y. X. (2010) Traditional Cantonese diet and 
nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, 
China. BMC Cancer, 10, 446. 
 
Jiang, P., Enomoto, A., Jijiwa, M., Kato, T., Hasegawa, T., Ishida, M., Sato, T., Asai, 
N., Murakumo, Y. and Takahashi, M. (2008) An actin-binding protein Girdin 
regulates the motility of breast cancer cells. Cancer Res, 68(5), 1310-1318. 
 
Johnson, L. N. and Lewis, R. J. (2001) Structural basis for control by phosphorylation. 
Chem Rev, 101(8), 2209-2242. 
 
Johnson, N. (2001) Tobacco use and oral cancer: a global perspective. J Dent Educ, 
65(4), 328-339. 
 
247 
 
Johnstone, S. and Logan, R. M. (2007) Expression of vascular endothelial growth 
factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell 
carcinoma. Int J Oral Maxillofac Surg, 36(3), 263-266. 
 
Joo, Y. H., Jung, C. K., Kim, M. S. and Sun, D. I. (2009) Relationship between vascular 
endothelial growth factor and Notch1 expression and lymphatic metastasis in 
tongue cancer. Otolaryngol Head Neck Surg, 140(4), 512-518. 
 
Jordan, R. C., Catzavelos, G. C., Barrett, A. W. and Speight, P. M. (1996) Differential 
expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J 
Cancer B Oral Oncol, 32B(6), 394-400. 
 
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., 
Kalkkinen, N. and Alitalo, K. (1996) A novel vascular endothelial growth factor, 
VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine 
kinases. Embo J, 15(7), 1751. 
 
Joyce, J. A. and Pollard, J. W. (2009) Microenvironmental regulation of metastasis. 
Nat Rev Cancer, 9(4), 239-252. 
 
Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., van Roy, F., Dargemont, C., 
de Herreros, A. G., Bellacosa, A. and Larue, L. (2007) Activation of NF-kappaB by 
Akt upregulates Snail expression and induces epithelium mesenchyme transition. 
Oncogene, 26(53), 7445-7456. 
 
Junttila, M. R. and de Sauvage, F. J. (2013) Influence of tumour micro-environment 
heterogeneity on therapeutic response. Nature, 501(7467), 346-354. 
 
248 
 
Kakinuma, N., Roy, B. C., Zhu, Y., Wang, Y. and Kiyama, R. (2008) Kank regulates 
RhoA-dependent formation of actin stress fibers and cell migration via 14-3-3 in 
PI3K-Akt signaling. J Cell Biol, 181(3), 537-549. 
 
Kalluri, R. and Weinberg, R. A. (2009) The basics of epithelial-mesenchymal 
transition. J Clin Invest, 119(6), 1420-1428. 
 
Kalyankrishna, S. and Grandis, J. R. (2006) Epidermal Growth Factor Receptor 
Biology in Head and Neck Cancer. Journal of Clinical Oncology, 24(17), 2666-2672. 
 
Kamangar, F., Dores, G. M. and Anderson, W. F. (2006) Patterns of cancer incidence, 
mortality, and prevalence across five continents: defining priorities to reduce cancer 
disparities in different geographic regions of the world. J Clin Oncol, 24(14), 2137-
2150. 
 
Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. 
Nature, 441(7092), 431-436. 
 
Karin, M. and Greten, F. R. (2005) NF-kappaB: linking inflammation and immunity 
to cancer development and progression. Nat Rev Immunol, 5(10), 749-759. 
 
Karkkainen, M. J., Makinen, T. and Alitalo, K. (2002) Lymphatic endothelium: a new 
frontier of metastasis research. Nat Cell Biol, 4(1), E2-5. 
 
Katoh, M. and Katoh, M. (2006) Cross-talk of WNT and FGF signaling pathways at 
GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther, 
5(9), 1059-1064. 
 
249 
 
Katoh, M. and Nakagama, H. (2014) FGF receptors: cancer biology and therapeutics. 
Med Res Rev, 34(2), 280-300. 
 
Kawai, H., Kobayashi, M., Hiramoto-Yamaki, N., Harada, K., Negishi, M. and Katoh, 
H. (2013) Ephexin4-mediated promotion of cell migration and anoikis resistance is 
regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio, 3(0), 78-82. 
 
Kawamoto, T., Ohga, N., Akiyama, K., Hirata, N., Kitahara, S., Maishi, N., Osawa, T., 
Yamamoto, K., Kondoh, M., Shindoh, M., Hida, Y. and Hida, K. (2012) Tumor-
derived microvesicles induce proangiogenic phenotype in endothelial cells via 
endocytosis. PLoS One, 7(3), e34045. 
 
Kerr, D. J. (2004) Targeting angiogenesis in cancer: clinical development of 
bevacizumab. Nat Clin Pract Oncol, 1(1), 39-43. 
 
Kim, S. H., Cho, N. H., Kim, K., Lee, J. S., Koo, B. S., Kim, J. H., Chang, J. H. and 
Choi, E. C. (2006) Correlations of oral tongue cancer invasion with matrix 
metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) 
expression. J Surg Oncol, 93(4), 330-337. 
 
Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A. and 
Bartlett, J. M. (2005) AKT activation predicts outcome in breast cancer patients 
treated with tamoxifen. J Pathol, 207(2), 139-146. 
 
Kjaerheim, K., Gaard, M. and Andersen, A. (1998) The role of alcohol, tobacco, and 
dietary factors in upper aerogastric tract cancers: a prospective study of 10,900 
Norwegian men. Cancer Causes & Control, 9(1), 99-108. 
 
250 
 
Knight, Z. (2011) Small Molecule Inhibitors of the PI3-Kinase Family. in Rommel, C., 
Vanhaesebroeck, B. and Vogt, P. K., (eds). Phosphoinositide 3-kinase in Health and 
Disease. Springer Berlin Heidelberg, pp. 263-278. 
 
Koppikar, P., Lui, V. W., Man, D., Xi, S., Chai, R. L., Nelson, E., Tobey, A. B. and 
Grandis, J. R. (2008) Constitutive activation of signal transducer and activator of 
transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and 
resistance to epidermal growth factor receptor targeting. Clin Cancer Res, 14(23), 
7682-7690. 
 
Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M. K., Ng, K., 
Ma, J., Wienholds, E., Dunant, C., Pollett, A., Gallinger, S., McPherson, J., Mullighan, 
C. G., Shibata, D. and Dick, J. E. (2013) Variable Clonal Repopulation Dynamics 
Influence Chemotherapy Response in Colorectal Cancer. Science, 339(6119), 543-548. 
 
Krynitz, B., Edgren, G., Lindelof, B., Baecklund, E., Brattstrom, C., Wilczek, H. and 
Smedby, K. E. (2013) Risk of skin cancer and other malignancies in kidney, liver, 
heart and lung transplant recipients 1970 to 2008--a Swedish population-based 
study. Int J Cancer, 132(6), 1429-1438. 
 
Kyzas, P. A., Geleff, S., Batistatou, A., Agnantis, N. J. and Stefanou, D. (2005a) 
Evidence for lymphangiogenesis and its prognostic implications in head and neck 
squamous cell carcinoma. J Pathol, 206(2), 170-177. 
 
Kyzas, P. A., Stefanou, D., Batistatou, A. and Agnantis, N. J. (2005b) Potential 
autocrine function of vascular endothelial growth factor in head and neck cancer via 
vascular endothelial growth factor receptor-2. Mod Pathol, 18(4), 485-494. 
 
251 
 
Kyzas, P. A., Stefanou, D., Batistatou, A. and Agnantis, N. J. (2005c) Prognostic 
significance of VEGF immunohistochemical expression and tumor angiogenesis in 
head and neck squamous cell carcinoma. J Cancer Res Clin Oncol, 131(9), 624-630. 
 
Lahat, G., Zhu, Q. S., Huang, K. L., Wang, S., Bolshakov, S., Liu, J., Torres, K., 
Langley, R. R., Lazar, A. J., Hung, M. C. and Lev, D. (2010) Vimentin is a novel anti-
cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. 
PLoS One, 5(4), e10105. 
 
Lalla, R. V., Boisoneau, D. S., Spiro, J. D. and Kreutzer, D. L. (2003) Expression of 
vascular endothelial growth factor receptors on tumor cells in head and neck 
squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, 129(8), 882-888. 
 
Lansigan, F. and Foss, F. M. (2010) Current and emerging treatment strategies for 
cutaneous T-cell lymphoma. Drugs, 70(3), 273-286. 
 
Larue, L. and Bellacosa, A. (2005) Epithelial-mesenchymal transition in development 
and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene, 24(50), 
7443-7454. 
 
Lau, H. Y., Leung, C. M., Chan, Y. H., Lee, A. W., Kwong, D. L., Lung, M. L. and 
Lam, T. H. (2013) Secular trends of salted fish consumption and nasopharyngeal 
carcinoma: a multi-jurisdiction ecological study in 8 regions from 3 continents. BMC 
Cancer, 13, 298. 
 
Lauffenburger, D. A. and Horwitz, A. F. (1996) Cell migration: a physically 
integrated molecular process. Cell, 84(3), 359-369. 
 
252 
 
Lauffenburger, D. A. and Linderman, J. J. (1993) Receptors: models for  binding, 
trafficking and signalling. New York, Oxford University Press. 
 
Leber, M. F. and Efferth, T. (2009) Molecular principles of cancer invasion and 
metastasis (review). Int J Oncol, 34(4), 881-895. 
 
Lebwohl, D. and Canetta, R. (1998) Clinical development of platinum complexes in 
cancer therapy: an historical perspective and an update. Eur J Cancer, 34(10), 1522-
1534. 
 
Lee, Soria, J. C., Hassan, K. A., El-Naggar, A. K., Tang, X., Liu, D. D., Hong, W. K. 
and Mao, L. (2001a) Loss of PTEN expression as a prognostic marker for tongue 
cancer. Arch Otolaryngol Head Neck Surg, 127(12), 1441-1445. 
 
Lee, Thangada, S., Paik, J. H., Sapkota, G. P., Ancellin, N., Chae, S. S., Wu, M., 
Morales-Ruiz, M., Sessa, W. C., Alessi, D. R. and Hla, T. (2001b) Akt-mediated 
phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial 
cell chemotaxis. Mol Cell, 8(3), 693-704. 
 
Lee, J., Gray, A., Yuan, J., Luoh, S. M., Avraham, H. and Wood, W. I. (1996) Vascular 
endothelial growth factor-related protein: a ligand and specific activator of the 
tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A, 93(5), 1988-1992. 
 
Leslie, N. R., Maccario, H., Spinelli, L. and Davidson, L. (2009) The significance of 
PTEN's protein phosphatase activity. Adv Enzyme Regul, 49(1), 190-196. 
 
Levison, D. A., Reid, R., Burt, A. D., Harrison, D. J. and Fleming, S., eds. (2008) 
Muir's Textbook of Pathology. 14 ed., London, Edward Arnold Publishers Ltd. 
 
253 
 
Levy, L. and Hill, C. S. (2006) Alterations in components of the TGF-beta superfamily 
signaling pathways in human cancer. Cytokine Growth Factor Rev, 17(1-2), 41-58. 
 
Li, Ballif, B. A., Powelka, A. M., Dai, J., Gygi, S. P. and Hsu, V. W. (2005a) 
Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent recycling of 
integrin beta1 to control cell migration. Dev Cell, 9(5), 663-673. 
 
Li, Shintani, S., Terakado, N., Klosek, S. K., Ishikawa, T., Nakashiro, K. and 
Hamakawa, H. (2005b) Microvessel density and expression of vascular endothelial 
growth factor, basic fibroblast growth factor, and platelet-derived endothelial 
growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg, 34(5), 559-
565. 
 
Li, F., Zhao, C. and Wang, L. (2014) Molecular-targeted agents combination therapy 
for cancer: developments and potentials. Int J Cancer, 134(6), 1257-1269. 
 
Li, Y., Wang, X., Yue, P., Tao, H., Ramalingam, S. S., Owonikoko, T. K., Deng, X., 
Wang, Y., Fu, H., Khuri, F. R. and Sun, S. Y. (2013) Protein phosphatase 2A and 
DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt 
phosphorylation. J Biol Chem. 
 
Lim, J., Kim, J. H., Paeng, J. Y., Kim, M. J., Hong, S. D., Lee, J. I. and Hong, S. P. 
(2005) Prognostic value of activated Akt expression in oral squamous cell carcinoma. 
J Clin Pathol, 58(11), 1199-1205. 
 
Lin, H. K., Wang, G., Chen, Z., Teruya-Feldstein, J., Liu, Y., Chan, C. H., Yang, W. L., 
Erdjument-Bromage, H., Nakayama, K. I., Nimer, S., Tempst, P. and Pandolfi, P. P. 
(2009) Phosphorylation-dependent regulation of cytosolic localization and oncogenic 
function of Skp2 by Akt/PKB. Nat Cell Biol, 11(4), 420-432. 
254 
 
Lin, W. J., Jiang, R. S., Wu, S. H., Chen, F. J. and Liu, S. A. (2011) Smoking, alcohol, 
and betel quid and oral cancer: a prospective cohort study. J Oncol, 2011, 525976. 
 
Lindel, K., Beer, K. T., Laissue, J., Greiner, R. H. and Aebersold, D. M. (2001) Human 
papillomavirus positive squamous cell carcinoma of the oropharynx: a 
radiosensitive subgroup of head and neck carcinoma. Cancer, 92(4), 805-813. 
 
Lindquist, D., Romanitan, M., Hammarstedt, L., Nasman, A., Dahlstrand, H., 
Lindholm, J., Onelov, L., Ramqvist, T., Ye, W., Munck-Wikland, E. and Dalianis, T. 
(2007) Human papillomavirus is a favourable prognostic factor in tonsillar cancer 
and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol, 1(3), 
350-355. 
 
Lindsley, C. W. (2010) The Akt/PKB family of protein kinases: a review of small 
molecule inhibitors and progress towards target validation: a 2009 update. Curr Top 
Med Chem, 10(4), 458-477. 
 
Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. (1991) Cancer metastasis and 
angiogenesis: an imbalance of positive and negative regulation. Cell, 64(2), 327-336. 
 
Liu, Li, F., Cardelli, J. A., Martin, K. A., Blenis, J. and Huang, S. (2006a) Rapamycin 
inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. 
Oncogene, 25(53), 7029-7040. 
 
Liu, Radisky, D. C., Nelson, C. M., Zhang, H., Fata, J. E., Roth, R. A. and Bissell, M. J. 
(2006b) Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a 
protumorigenic role for TSC2. Proc Natl Acad Sci U S A, 103(11), 4134-4139. 
 
255 
 
Liu, L., Chen, L., Chung, J. and Huang, S. (2008) Rapamycin inhibits F-actin 
reorganization and phosphorylation of focal adhesion proteins. Oncogene, 27(37), 
4998-5010. 
 
Liu, L., Chen, L., Luo, Y., Chen, W., Zhou, H., Xu, B., Han, X., Shen, T. and Huang, S. 
(2010) Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. 
PLoS One, 5(5), e10578. 
 
Lodish, H., Berk, A., Kaiser, C. A., Krieger, M., Scott, M. P., Bretscher, A., Ploegh, H. 
and Matsudaira, P. (2007) Molecular Cell Biology. 6 ed., New York, W.H. Freeman and 
company. 
 
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. and Dennis, P. A. (2008) Targeting 
the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. 
Drug Resistance Updates, 11(1–2), 32-50. 
 
Lu, S. L., Herrington, H., Reh, D., Weber, S., Bornstein, S., Wang, D., Li, A. G., Tang, 
C. F., Siddiqui, Y., Nord, J., Andersen, P., Corless, C. L. and Wang, X. J. (2006) Loss of 
transforming growth factor-beta type II receptor promotes metastatic head-and-neck 
squamous cell carcinoma. Genes Dev, 20(10), 1331-1342. 
 
Lu, S. L., Reh, D., Li, A. G., Woods, J., Corless, C. L., Kulesz-Martin, M. and Wang, X. 
J. (2004) Overexpression of transforming growth factor beta1 in head and neck 
epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. 
Cancer Res, 64(13), 4405-4410. 
 
Luo, J., Manning, B. D. and Cantley, L. C. (2003) Targeting the PI3K-Akt pathway in 
human cancer: rationale and promise. Cancer Cell, 4(4), 257-262. 
 
256 
 
Lynch, D. K., Ellis, C. A., Edwards, P. A. and Hiles, I. D. (1999) Integrin-linked kinase 
regulates phosphorylation of serine 473 of protein kinase B by an indirect 
mechanism. Oncogene, 18(56), 8024-8032. 
 
Ma, J. and Waxman, D. J. (2008) Combination of antiangiogenesis with 
chemotherapy for more effective cancer treatment. Mol Cancer Ther, 7(12), 3670-3684. 
 
Machiels, J. P. and Schmitz, S. (2011) New advances in targeted therapies for 
squamous cell carcinoma of the head and neck. Anticancer Drugs, 22(7), 626-633. 
 
Maeda, G., Chiba, T., Okazaki, M., Satoh, T., Taya, Y., Aoba, T., Kato, K., Kawashiri, 
S. and Imai, K. (2005) Expression of SIP1 in oral squamous cell carcinomas: 
implications for E-cadherin expression and tumor progression. International journal of 
oncology., 27(6), 1535-1541. 
 
Maeda, T., Matsumura, S., Hiranuma, H., Jikko, A., Furukawa, S., Ishida, T. and 
Fuchihata, H. (1998) Expression of vascular endothelial growth factor in human oral 
squamous cell carcinoma: its association with tumour progression and p53 gene 
status. J Clin Pathol, 51(10), 771-775. 
 
Magalhaes, M. A., Larson, D. R., Mader, C. C., Bravo-Cordero, J. J., Gil-Henn, H., 
Oser, M., Chen, X., Koleske, A. J. and Condeelis, J. (2011) Cortactin phosphorylation 
regulates cell invasion through a pH-dependent pathway. J Cell Biol, 195(5), 903-920. 
 
Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. and Persico, M. G. (1991) 
Isolation of a human placenta cDNA coding for a protein related to the vascular 
permeability factor. Proc Natl Acad Sci U S A, 88(20), 9267-9271. 
 
257 
 
Maione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., Bussolino, 
F., Serini, G. and Giraudo, E. (2012) Semaphorin 3A overcomes cancer hypoxia and 
metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest, 
122(5), 1832-1848. 
 
Malik, S. N., Brattain, M., Ghosh, P. M., Troyer, D. A., Prihoda, T., Bedolla, R. and 
Kreisberg, J. I. (2002) Immunohistochemical demonstration of phospho-Akt in high 
Gleason grade prostate cancer. Clin Cancer Res, 8(4), 1168-1171. 
 
Mandal, M., Younes, M., Swan, E. A., Jasser, S. A., Doan, D., Yigitbasi, O., 
McMurphey, A., Ludwick, J., El-Naggar, A. K., Bucana, C., Mills, G. B. and Myers, J. 
N. (2006) The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and 
anoikis in squamous cell carcinoma of the head and neck. Oral Oncol, 42(4), 430-439. 
 
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., 
Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., 
Yang, J. and Weinberg, R. A. (2008) The epithelial-mesenchymal transition generates 
cells with properties of stem cells. Cell, 133(4), 704-715. 
 
Manning, B. D. and Cantley, L. C. (2003) Rheb fills a GAP between TSC and TOR. 
Trends Biochem Sci, 28(11), 573-576. 
 
Mao, L., Hong, W. K. and Papadimitrakopoulou, V. A. (2004) Focus on head and 
neck cancer. Cancer Cell, 5(4), 311-316. 
 
Mao, L., Lee, J. S., Fan, Y. H., Ro, J. Y., Batsakis, J. G., Lippman, S., Hittelman, W. and 
Hong, W. K. (1996) Frequent microsatellite alterations at chromosomes 9p21 and 
3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med, 
2(6), 682-685. 
258 
 
Margaritescu, C., Pirici, D., Simionescu, C., Mogoanta, L., Raica, M., Stinga, A., 
Ciurea, R., Stepan, A. and Ribatti, D. (2009) VEGF and VEGFRs expression in oral 
squamous cell carcinoma. Rom J Morphol Embryol, 50(4), 527-548. 
 
Marks, F., Klingmüller, U. and Müller-Decker, K. (2008) Cellular Signal Processing: An 
Introduction to the Molecular Mechanisms of Signal Transduction. New York, Garland 
Science. 
 
Marshall, M. E., Hinz, T. K., Kono, S. A., Singleton, K. R., Bichon, B., Ware, K. E., 
Marek, L., Frederick, B. A., Raben, D. and Heasley, L. E. (2011) Fibroblast growth 
factor receptors are components of autocrine signaling networks in head and neck 
squamous cell carcinoma cells. Clin Cancer Res, 17(15), 5016-5025. 
 
Martin, C., Pedersen, S. F., Schwab, A. and Stock, C. (2011) Intracellular pH gradients 
in migrating cells. Am J Physiol Cell Physiol, 300(3), C490-495. 
 
Massague, J. (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol, 1(3), 169-
178. 
 
Massague, J. (2008) TGFbeta in Cancer. Cell, 134(2), 215-230. 
 
Massague, J., Seoane, J. and Wotton, D. (2005) Smad transcription factors. Genes Dev, 
19(23), 2783-2810. 
 
Massarelli, Liu, D. D., Lee, J. J., El-Naggar, A. K., Lo Muzio, L., Staibano, S., De 
Placido, S., Myers, J. N. and Papadimitrakopoulou, V. A. (2005) Akt activation 
correlates with adverse outcome in tongue cancer. Cancer, 104(11), 2430-2436. 
 
259 
 
Mathers, C. D. and Loncar, D. (2006) Projections of global mortality and burden of 
disease from 2002 to 2030. PLoS Med, 3(11), e442. 
 
Matsuura, M., Onimaru, M., Yonemitsu, Y., Suzuki, H., Nakano, T., Ishibashi, H., 
Shirasuna, K. and Sueishi, K. (2009) Autocrine loop between vascular endothelial 
growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated 
lymphangiogenesis in oral squamoid cancer cells. Am J Pathol, 175(4), 1709-1721. 
 
McCoy, G. D. (1978) A biochemical approach to the etiology of alcohol related 
cancers of the head and neck. Laryngoscope, 88(1 Pt 2 Suppl 8), 59-62. 
 
McPhee, T. R., McDonald, P. C., Oloumi, A. and Dedhar, S. (2008) Integrin-linked 
kinase regulates E-cadherin expression through PARP-1. Dev Dyn, 237(10), 2737-
2747. 
 
Mehanna, H., Beech, T., Nicholson, T., El-Hariry, I., McConkey, C., Paleri, V. and 
Roberts, S. (2013) Prevalence of human papillomavirus in oropharyngeal and 
nonoropharyngeal head and neck cancer--systematic review and meta-analysis of 
trends by time and region. Head Neck, 35(5), 747-755. 
 
Mehanna, H., Paleri, V., West, C. M. L. and Nutting, C. (2010) Head and neck 
cancer—Part 1: Epidemiology, presentation, and prevention. Bmj, 341. 
 
Mehanna, H. M., Rattay, T., Smith, J. and McConkey, C. C. (2009) Treatment and 
follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck, 
31(12), 1600-1609. 
 
260 
 
Mehrotra, R. and Yadav, S. (2006) Oral squamous cell carcinoma: etiology, 
pathogenesis and prognostic value of genomic alterations. Indian J Cancer, 43(2), 60-
66. 
 
Meima, M. E., Webb, B. A., Witkowska, H. E. and Barber, D. L. (2009) The sodium-
hydrogen exchanger NHE1 is an Akt substrate necessary for actin filament 
reorganization by growth factors. J Biol Chem, 284(39), 26666-26675. 
 
Mendez, E. (2007) The Incidence of Oral Cancer Appears to be Increasing in the 
United Kingdom. Journal of Evidence Based Dental Practice, 7(4), 182-184. 
 
Mercurio, A. M., Lipscomb, E. A. and Bachelder, R. E. (2005) Non-angiogenic 
functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia, 10(4), 283-290. 
 
Messersmith, W., Oppenheimer, D., Peralba, J., Sebastiani, V., Amador, M., Jimeno, 
A., Embuscado, E., Hidalgo, M. and Iacobuzio-Donahue, C. (2005) Assessment of 
Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and 
normal colon tissue samples using computer-aided immunohistochemical analysis. 
Cancer Biol Ther, 4(12), 1381-1386. 
 
Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, H. G., 
Ziche, M., Lanz, C., Buttner, M., Rziha, H. J. and Dehio, C. (1999) A novel vascular 
endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via 
signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine 
kinases. Embo J, 18(2), 363-374. 
 
 
 
261 
 
Miao, H., Li, D. Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J. P., Sedor, 
J., Wu, J., Danielpour, D., Sloan, A. E., Cohen, M. L. and Wang, B. (2009) EphA2 
mediates ligand-dependent inhibition and ligand-independent promotion of cell 
migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell, 16(1), 
9-20. 
 
Minchinton, A. I. and Tannock, I. F. (2006) Drug penetration in solid tumours. Nat 
Rev Cancer, 6(8), 583-592. 
 
Mishra, A., Bharti, A. C., Varghese, P., Saluja, D. and Das, B. C. (2006) Differential 
expression and activation of NF-kappaB family proteins during oral carcinogenesis: 
Role of high risk human papillomavirus infection. Int J Cancer, 119(12), 2840-2850. 
 
Mitchison, T. J. and Cramer, L. P. (1996) Actin-based cell motility and cell 
locomotion. Cell, 84(3), 371-379. 
 
Mittal, K., Ebos, J. and Rini, B. (2014) Angiogenesis and the tumor 
microenvironment: vascular endothelial growth factor and beyond. Semin Oncol, 
41(2), 235-251. 
 
Miyazawa, J., Mitoro, A., Kawashiri, S., Chada, K. K. and Imai, K. (2004) Expression 
of Mesenchyme-Specific Gene HMGA2 in Squamous Cell Carcinomas of the Oral 
Cavity. Cancer Research, 64(6), 2024-2029. 
 
Moghal, N. and Sternberg, P. W. (1999) Multiple positive and negative regulators of 
signaling by the EGF-receptor. Curr Opin Cell Biol, 11(2), 190-196. 
 
262 
 
Mohamed, K. M., Le, A., Duong, H., Wu, Y., Zhang, Q. and Messadi, D. V. (2004) 
Correlation between VEGF and HIF-1alpha expression in human oral squamous cell 
carcinoma. Exp Mol Pathol, 76(2), 143-152. 
 
Mohan, C. (2009) Signal transduction: a short overview of its role in health and disease. 
Merck. 
 
Molinolo, A. A., Amornphimoltham, P., Squarize, C. H., Castilho, R. M., Patel, V. 
and Gutkind, J. S. (2009) Dysregulated molecular networks in head and neck 
carcinogenesis. Oral Oncol, 45(4-5), 324-334. 
 
Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., 
Meneses Garcia, A., Raimondi, A. R., Jufe, R., Itoiz, M., Gao, Y., Saranath, D., 
Kaleebi, G. S., Yoo, G. H., Leak, L., Myers, E. M., Shintani, S., Wong, D., Massey, H. 
D., Yeudall, W. A., Lonardo, F., Ensley, J. and Gutkind, J. S. (2007) Dissecting the 
Akt/mammalian target of rapamycin signaling network: emerging results from the 
head and neck cancer tissue array initiative. Clin Cancer Res, 13(17), 4964-4973. 
 
Molinolo, A. A., Marsh, C., El Dinali, M., Gangane, N., Jennison, K., Hewitt, S., Patel, 
V., Seiwert, T. Y. and Gutkind, J. S. (2012) mTOR as a molecular target in HPV-
associated oral and cervical squamous carcinomas. Clin Cancer Res, 18(9), 2558-2568. 
 
Moral, M. and Paramio, J. M. (2008) Akt pathway as a target for therapeutic 
intervention in HNSCC. Histol Histopathol, 23(10), 1269-1278. 
 
Morales-Ruiz, M., Fulton, D., Sowa, G., Languino, L. R., Fujio, Y., Walsh, K. and 
Sessa, W. C. (2000) Vascular endothelial growth factor-stimulated actin 
reorganization and migration of endothelial cells is regulated via the 
serine/threonine kinase Akt. Circ Res, 86(8), 892-896. 
263 
 
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K. and McDonald, D. M. 
(2002) Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in 
Tumors. The American Journal of Pathology, 160(3), 985-1000. 
 
Muro-Cacho, C. A., Anderson, M., Cordero, J. and Munoz-Antonia, T. (1999) 
Expression of transforming growth factor beta type II receptors in head and neck 
squamous cell carcinoma. Clin Cancer Res, 5(6), 1243-1248. 
 
Murugan, A. K., Hong, N. T., Fukui, Y., Munirajan, A. K. and Tsuchida, N. (2008) 
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell 
carcinomas. Int J Oncol, 32(1), 101-111. 
 
Nacerddine, K., Beaudry, J. B., Ginjala, V., Westerman, B., Mattiroli, F., Song, J. Y., 
van der Poel, H., Ponz, O. B., Pritchard, C., Cornelissen-Steijger, P., Zevenhoven, J., 
Tanger, E., Sixma, T. K., Ganesan, S. and van Lohuizen, M. (2012) Akt-mediated 
phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and 
DNA damage repair activity in mouse prostate cancer. J Clin Invest, 122(5), 1920-
1932. 
 
Nakanishi, C. and Toi, M. (2005) Nuclear factor-kappaB inhibitors as sensitizers to 
anticancer drugs. Nat Rev Cancer, 5(4), 297-309. 
 
Nakaya, H., Kawashiri, S., Tanaka, A., Noguchi, N., Kato, K., Hase, T. and 
Yamamoto, E. (2005) Influences of angiogenesis and lymphangiogenesis on 
cancerous invasion in experimentally induced tongue carcinoma. J Oral Pathol Med, 
34(2), 87-92. 
 
 
264 
 
Nallapalli, R. K., Ibrahim, M. X., Zhou, A. X., Bandaru, S., Sunkara, S. N., Redfors, B., 
Pazooki, D., Zhang, Y., Boren, J., Cao, Y., Bergo, M. O. and Akyurek, L. M. (2012) 
Targeting filamin A reduces K-RAS-induced lung adenocarcinomas and endothelial 
response to tumor growth in mice. Mol Cancer, 11, 50. 
 
Nankivell, P., Dunn, J., Langman, M. and Mehanna, H. (2012) Feasibility of 
recruitment to an oral dysplasia trial in the United Kingdom. Head Neck Oncol, 4, 40. 
 
Nathan, C. O., Amirghahari, N., Abreo, F., Rong, X., Caldito, G., Jones, M. L., Zhou, 
H., Smith, M., Kimberly, D. and Glass, J. (2004) Overexpressed eIF4E is functionally 
active in surgical margins of head and neck cancer patients via activation of the 
Akt/mammalian target of rapamycin pathway. Clin Cancer Res, 10(17), 5820-5827. 
 
Nathan, C. O., Amirghahri, N., Rice, C., Abreo, F. W., Shi, R. and Stucker, F. J. (2002) 
Molecular analysis of surgical margins in head and neck squamous cell carcinoma 
patients. Laryngoscope, 112(12), 2129-2140. 
 
Natsume, A., Kato, T., Kinjo, S., Enomoto, A., Toda, H., Shimato, S., Ohka, F., 
Motomura, K., Kondo, Y., Miyata, T., Takahashi, M. and Wakabayashi, T. (2012) 
Girdin maintains the stemness of glioblastoma stem cells. Oncogene, 31(22), 2715-
2724. 
 
Nawshad, A., Lagamba, D., Polad, A. and Hay, E. D. (2005) Transforming growth 
factor-beta signaling during epithelial-mesenchymal transformation: implications for 
embryogenesis and tumor metastasis. Cells Tissues Organs, 179(1-2), 11-23. 
 
NCI (2012) What is Cancer. [online], available: 
http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer [accessed 02 April 
2012]. 
265 
 
Neasta, J., Ben Hamida, S., Yowell, Q. V., Carnicella, S. and Ron, D. (2011) AKT 
signaling pathway in the nucleus accumbens mediates excessive alcohol drinking 
behaviors. Biol Psychiatry, 70(6), 575-582. 
 
Negri, E., Boffetta, P., Berthiller, J., Castellsague, X., Curado, M. P., Dal Maso, L., 
Daudt, A. W., Fabianova, E., Fernandez, L., Wunsch-Filho, V., Franceschi, S., Hayes, 
R. B., Herrero, R., Koifman, S., Lazarus, P., Lence, J. J., Levi, F., Mates, D., Matos, E., 
Menezes, A., Muscat, J., Eluf-Neto, J., Olshan, A. F., Rudnai, P., Shangina, O., Sturgis, 
E. M., Szeszenia-Dabrowska, N., Talamini, R., Wei, Q., Winn, D. M., Zaridze, D., 
Lissowska, J., Zhang, Z. F., Ferro, G., Brennan, P., La Vecchia, C. and Hashibe, M. 
(2009) Family history of cancer: pooled analysis in the International Head and Neck 
Cancer Epidemiology Consortium. Int J Cancer, 124(2), 394-401. 
 
Nelson, J. (2008) Structure and Function in Cell Signalling. 1 ed., West Sussex, John 
Wiley & Sons. 
 
Nelson, W. J. and Nusse, R. (2004) Convergence of Wnt, beta-catenin, and cadherin 
pathways. Science, 303(5663), 1483-1487. 
 
Neuchrist, C., Erovic, B. M., Handisurya, A., Steiner, G. E., Rockwell, P., Gedlicka, C. 
and Burian, M. (2001) Vascular endothelial growth factor receptor 2 (VEGFR2) 
expression in squamous cell carcinomas of the head and neck. Laryngoscope, 111(10), 
1834-1841. 
 
Neville, B., Damm, D., Allen, C. and Buquot, J. (2002) Oral and Maxillofacial Pathology. 
2 ed., Philadelphia, W B Saunders Company. 
 
Neville, B. W. and Day, T. A. (2002) Oral cancer and precancerous lesions. CA Cancer 
J Clin, 52(4), 195-215. 
266 
 
Newton, A. C. and Trotman, L. C. (2014) Turning off AKT: PHLPP as a drug target. 
Annu Rev Pharmacol Toxicol, 54, 537-558. 
 
Niaaa (2014) Moderate and Binge Drinking. [online], available: 
http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-
binge-drinking [accessed 12 May 2014]. 
 
Nicholson, R. I., Gee, J. M. and Harper, M. E. (2001) EGFR and cancer prognosis. Eur 
J Cancer, 37 Suppl 4, S9-15. 
 
Nieto, M. A. (2011) The ins and outs of the epithelial to mesenchymal transition in 
health and disease. Annu Rev Cell Dev Biol, 27, 347-376. 
 
Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., De Luca, A., 
Caponigro, F. and Salomon, D. S. (2005) The ErbB receptors and their ligands in 
cancer: an overview. Curr Drug Targets, 6(3), 243-257. 
 
Norton, N. S. (2007) Netter's Advanced Head and Neck Flash Cards. Philadelphia, 
Elsevier Science Health Science Division. 
 
O'Connor, C. M. and Adams, J. U. (2010) Essentials of Cell Biology, NPG Education 
[online], available: http://www.nature.com/scitable/ebooks/essentials-of-cell-biology-
14749010 [accessed 06 May 2014]. 
 
OCF (2012) Oral cancer facts. [online], available: 
http://www.oralcancerfoundation.org/facts/index.htm [accessed 12 April 2012]. 
 
 
267 
 
Ogino, S., Meyerhardt, J. A., Cantor, M., Brahmandam, M., Clark, J. W., Namgyal, C., 
Kawasaki, T., Kinsella, K., Michelini, A. L., Enzinger, P. C., Kulke, M. H., Ryan, D. P., 
Loda, M. and Fuchs, C. S. (2005) Molecular alterations in tumors and response to 
combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer 
Res, 11(18), 6650-6656. 
 
Ohno, F., Nakanishi, H., Abe, A., Seki, Y., Kinoshita, A., Hasegawa, Y., Tatematsu, 
M. and Kurita, K. (2007) Regional difference in intratumoral lymphangiogenesis of 
oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and 
podoplanin antibody: an analysis in comparison with angiogenesis. J Oral Pathol 
Med, 36(5), 281-289. 
 
Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., 
Orpana, A., Pettersson, R. F., Alitalo, K. and Eriksson, U. (1996) Vascular endothelial 
growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A, 
93(6), 2576-2581. 
 
Ondrey, F. G., Dong, G., Sunwoo, J., Chen, Z., Wolf, J. S., Crowl-Bancroft, C. V., 
Mukaida, N. and Van Waes, C. (1999) Constitutive activation of transcription factors 
NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma 
cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog, 
26(2), 119-129. 
 
Ongkeko, W. M., Altuna, X., Weisman, R. A. and Wang-Rodriguez, J. (2005) 
Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. 
Am J Clin Pathol, 124(1), 71-76. 
 
268 
 
Onishi, K., Higuchi, M., Asakura, T., Masuyama, N. and Gotoh, Y. (2007) The PI3K-
Akt pathway promotes microtubule stabilization in migrating fibroblasts. Genes 
Cells, 12(4), 535-546. 
 
Onoue, T., Uchida, D., Begum, N. M., Tomizuka, Y., Yoshida, H. and Sato, M. (2006) 
Epithelial-mesenchymal transition induced by the stromal cell-derived factor-
1/CXCR4 system in oral squamous cell carcinoma cells. International journal of 
oncology, 29(5), 1133-1138. 
 
Oommen, S., Gupta, S. K. and Vlahakis, N. E. (2011) Vascular Endothelial Growth 
Factor A (VEGF-A) Induces Endothelial and Cancer Cell Migration through Direct 
Binding to Integrin α9β1: IDENTIFICATION OF A SPECIFIC α9β1 BINDING SITE. 
Journal of biological chemistry, 286(2), 1083-1092. 
 
Ophardt, C. E. (2003) Virtual Chembook. [online], available: 
http://www.elmhurst.edu/~chm/vchembook/655cancer.html [accessed 20 April 
2014]. 
 
Ornitz, D. M. and Itoh, N. (2001) Fibroblast growth factors. Genome Biol, 2(3), 
REVIEWS3005. 
 
Ozaki, H., Hla, T. and Lee, M. J. (2003) Sphingosine-1-phosphate signaling in 
endothelial activation. J Atheroscler Thromb, 10(3), 125-131. 
 
Paget-Bailly, S., Cyr, D. and Luce, D. (2012) Occupational exposures to asbestos, 
polycyclic aromatic hydrocarbons and solvents, and cancers of the oral cavity and 
pharynx: a quantitative literature review. Int Arch Occup Environ Health, 85(4), 341-
351. 
 
269 
 
Palmer, T. D., Ashby, W. J., Lewis, J. D. and Zijlstra, A. (2011) Targeting tumor cell 
motility to prevent metastasis. Adv Drug Deliv Rev, 63(8), 568-581. 
 
Papadimitrakopoulou, V. A., Izzo, J., Mao, L., Keck, J., Hamilton, D., Shin, D. M., El-
Naggar, A., den Hollander, P., Liu, D., Hittelman, W. N. and Hong, W. K. (2001) 
Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper 
aerodigestive tract: role in response to chemoprevention and cancer development. 
Clin Cancer Res, 7(10), 3127-3134. 
 
Papaspyrou, G., Werner, J. A. and Dietz, A. (2011) Pharmacotherapy for squamous-
cell carcinoma of the head and neck. Expert Opin Pharmacother, 12(3), 397-409. 
 
Parkin, D. M. (2011a) 2. Tobacco-attributable cancer burden in the UK in 2010. Br J 
Cancer, 105(S2), S6-S13. 
 
Parkin, D. M. (2011b) 3. Cancers attributable to consumption of alcohol in the UK in 
2010. Br J Cancer, 105(S2), S14-S18. 
 
Parkin, D. M. (2011c) 11. Cancers attributable to infection in the UK in 2010. Br J 
Cancer, 105(S2), S49-S56. 
 
Pasquale, E. B. (2010) Eph receptors and ephrins in cancer: bidirectional signalling 
and beyond. Nat Rev Cancer, 10(3), 165-180. 
 
Patel, V., Lahusen, T., Leethanakul, C., Igishi, T., Kremer, M., Quintanilla-Martinez, 
L., Ensley, J. F., Sausville, E. A., Gutkind, J. S. and Senderowicz, A. M. (2002) 
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with 
altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res, 8(11), 3549-3560. 
 
270 
 
Pedrero, J. M., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, 
C. S. and Gonzalez, M. V. (2005) Frequent genetic and biochemical alterations of the 
PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer, 
114(2), 242-248. 
 
Pernick, N. (2012) Oral cavity. [online], available: 
http://www.pathologyoutlines.com/oralcavity.html [accessed 04 April 2012]. 
 
Perrot-Applanat, M. and Di Benedetto, M. (2012) Autocrine functions of VEGF in 
breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr, 6(6), 
547-553. 
 
Pickering, C. R., Zhang, J., Yoo, S. Y., Bengtsson, L., Moorthy, S., Neskey, D. M., 
Zhao, M., Ortega Alves, M. V., Chang, K., Drummond, J., Cortez, E., Xie, T. X., 
Zhang, D., Chung, W., Issa, J. P., Zweidler-McKay, P. A., Wu, X., El-Naggar, A. K., 
Weinstein, J. N., Wang, J., Muzny, D. M., Gibbs, R. A., Wheeler, D. A., Myers, J. N. 
and Frederick, M. J. (2013) Integrative genomic characterization of oral squamous 
cell carcinoma identifies frequent somatic drivers. Cancer Discov, 3(7), 770-781. 
 
Pietras, K. and Ostman, A. (2010) Hallmarks of cancer: interactions with the tumor 
stroma. Exp Cell Res, 316(8), 1324-1331. 
 
Pindborg, J. J., Reichart, P. A., Smith, C. J. and van der Waal, I. (1997) Histological 
typing of cancer and precancer of the oral mucosa. International Histological classification of 
tumours, 2 ed., Berlin, Springer. 
 
 
 
271 
 
Poeta, M. L., Manola, J., Goldwasser, M. A., Forastiere, A., Benoit, N., Califano, J. A., 
Ridge, J. A., Goodwin, J., Kenady, D., Saunders, J., Westra, W., Sidransky, D. and 
Koch, W. M. (2007) TP53 mutations and survival in squamous-cell carcinoma of the 
head and neck. N Engl J Med, 357(25), 2552-2561. 
 
Pollard, T. D. and Borisy, G. G. (2003) Cellular motility driven by assembly and 
disassembly of actin filaments. Cell, 112(4), 453-465. 
 
Polyak, K. and Weinberg, R. A. (2009) Transitions between epithelial and 
mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 
9(4), 265-273. 
 
Pontes, H. A., de Aquino Xavier, F. C., da Silva, T. S., Fonseca, F. P., Paiva, H. B., 
Pontes, F. S. and dos Santos Pinto, D., Jr. (2009) Metallothionein and p-Akt proteins 
in oral dysplasia and in oral squamous cell carcinoma: an immunohistochemical 
study. J Oral Pathol Med, 38(8), 644-650. 
 
Powar, C. B. (2010) Cell Signalling. 1 ed., Mumbai, Himalaya Publishing House. 
 
Prince, M. E. and Ailles, L. E. (2008) Cancer stem cells in head and neck squamous 
cell cancer. J Clin Oncol, 26(17), 2871-2875. 
 
Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, 
P., Weissman, I. L., Clarke, M. F. and Ailles, L. E. (2007) Identification of a 
subpopulation of cells with cancer stem cell properties in head and neck squamous 
cell carcinoma. Proc Natl Acad Sci U S A, 104(3), 973-978. 
 
Probst, R., Grevers, G. and Iro, H. S. (2006) Basic Otorhinolaryngology: A Step-by-Step 
Learning Guide. vii. New York, Georg Thieme Verlag. 
272 
 
Proby, C. M., Purdie, K. J., Sexton, C. J., Purkis, P., Navsaria, H. A., Stables, J. N. and 
Leigh, I. M. (2000) Spontaneous keratinocyte cell lines representing early and 
advanced stages of malignant transformation of the epidermis. Exp Dermatol, 9(2), 
104-117. 
 
Qian, Y., Corum, L., Meng, Q., Blenis, J., Zheng, J. Z., Shi, X., Flynn, D. C. and Jiang, 
B. H. (2004) PI3K induced actin filament remodeling through Akt and p70S6K1: 
implication of essential role in cell migration. Am J Physiol Cell Physiol, 286(1), C153-
163. 
 
Qian, Y., Zhong, X., Flynn, D. C., Zheng, J. Z., Qiao, M., Wu, C., Dedhar, S., Shi, X. 
and Jiang, B. H. (2005) ILK mediates actin filament rearrangements and cell 
migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene, 24(19), 3154-
3165. 
 
Quail, D. F. and Joyce, J. A. (2013) Microenvironmental regulation of tumor 
progression and metastasis. Nat Med, 19(11), 1423-1437. 
 
Ram, H., Sarkar, J., Kumar, H., Konwar, R., Bhatt, M. L. and Mohammad, S. (2011) 
Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg, 10(2), 
132-137. 
 
Ramadas, K., Lucas, E., Thomas, G., Mathew, B., Balan, A., Thara, S. and 
Sankaranarayanan, R., eds. (2012) A digital manual for the early diagnosis of oral 
neoplasia. Lyon, IARC. 
 
Rampias, T., Giagini, A., Siolos, S., Matsuzaki, H., Sasaki, C., Scorilas, A. and Psyrri, 
A. (2014) RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous 
cell carcinoma. Clin Cancer Res, 20(11), 2933-2946. 
273 
 
Rao, S. D., Fury, M. G. and Pfister, D. G. (2012) Molecular-targeted therapies in head 
and neck cancer. Semin Radiat Oncol, 22(3), 207-213. 
 
Ravid, D., Chuderland, D., Landsman, L., Lavie, Y., Reich, R. and Liscovitch, M. 
(2008) Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer 
cell migration. Exp Cell Res, 314(15), 2762-2773. 
 
Ravid, D., Maor, S., Werner, H. and Liscovitch, M. (2005) Caveolin-1 inhibits cell 
detachment-induced p53 activation and anoikis by upregulation of insulin-like 
growth factor-I receptors and signaling. Oncogene, 24(8), 1338-1347. 
 
Raza, S., Kornblum, N., Kancharla, V. P., Baig, M. A., Singh, A. B. and Kalavar, M. 
(2011) Emerging therapies in the treatment of locally advanced squamous cell 
cancers of head and neck. Recent Pat Anticancer Drug Discov, 6(2), 246-257. 
 
Rebucci, M., Peixoto, P., Dewitte, A., Wattez, N., De Nuncques, M. A., Rezvoy, N., 
Vautravers-Dewas, C., Buisine, M. P., Guerin, E., Peyrat, J. P., Lartigau, E. and 
Lansiaux, A. (2011) Mechanisms underlying resistance to cetuximab in the HNSCC 
cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol, 38(1), 189-
200. 
 
Regezi, J. A. and Jordan, R. C. (2001) Oral cancer in the molecular age. J Calif Dent 
Assoc, 29(8), 578-584. 
 
Reifman, E. (2012) Treating mouth cancer, oral cancer and dry mouth in Los Angeles. 
[online], available: http://encinosmiledr.com/treating-mouth-cancer-oral-cancer-and-
dry-mouth-in-los-angeles/ [accessed 8 May 2012]. 
 
274 
 
Ridge, J. A., Glisson, B., Lango, M. and Fiegenberg, S. (2008) Head and Neck Tumors. 
in Pazdur, R., Wagman, L., Camphausen, K. and Hoskins, W., (eds). Cancer 
management: A multidisciplinary approach. 11 ed., Norwalk, Cancer network, pp. 120-
143. 
 
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., 
Parsons, J. T. and Horwitz, A. R. (2003) Cell Migration: Integrating Signals from 
Front to Back. Science, 302(5651), 1704-1709. 
 
Ridnour, L. A., Barasch, K. M., Windhausen, A. N., Dorsey, T. H., Lizardo, M. M., 
Yfantis, H. G., Lee, D. H., Switzer, C. H., Cheng, R. Y., Heinecke, J. L., Brueggemann, 
E., Hines, H. B., Khanna, C., Glynn, S. A., Ambs, S. and Wink, D. A. (2012) Nitric 
oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. 
PLoS One, 7(9), e44081. 
 
Ringel, M. D., Hayre, N., Saito, J., Saunier, B., Schuppert, F., Burch, H., Bernet, V., 
Burman, K. D., Kohn, L. D. and Saji, M. (2001) Overexpression and overactivation of 
Akt in thyroid carcinoma. Cancer Res, 61(16), 6105-6111. 
 
Robert, J. (2013) Biology of cancer metastasis. Bull Cancer, available from: 
10.1684/bdc.2013.1724 [accessed 10 April 2013]. 
 
Robinson, C. J. and Stringer, S. E. (2001) The splice variants of vascular endothelial 
growth factor (VEGF) and their receptors. J Cell Sci, 114(Pt 5), 853-865. 
 
Robinson, K. L. and Macfarlane, G. J. (2003) Oropharyngeal cancer incidence and 
mortality in Scotland: are rates still increasing? Oral Oncology, 39(1), 31-36. 
 
275 
 
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. 
J., Waterfield, M. D. and Downward, J. (1994) Phosphatidylinositol-3-OH kinase as a 
direct target of Ras. Nature, 370(6490), 527-532. 
 
Rodriguez, L. G., Wu, X. and Guan, J. L. (2005) Wound-healing assay. Methods Mol 
Biol, 294, 23-29. 
 
Rorth, P. (2011) Whence directionality: guidance mechanisms in solitary and 
collective cell migration. Dev Cell, 20(1), 9-18. 
 
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, 
R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Garrido, P., 
Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, 
E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., 
Moreno, M. A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., 
Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-
Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., 
Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., 
Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J. L., Sanchez, J. J., Molina, M. 
A., Taron, M. and Paz-Ares, L. (2012) Erlotinib versus standard chemotherapy as 
first-line treatment for European patients with advanced EGFR mutation-positive 
non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 
3 trial. Lancet Oncol, 13(3), 239-246. 
 
Rosin, M. P., Cheng, X., Poh, C., Lam, W. L., Huang, Y., Lovas, J., Berean, K., Epstein, 
J. B., Priddy, R., Le, N. D. and Zhang, L. (2000) Use of allelic loss to predict malignant 
risk for low-grade oral epithelial dysplasia. Clin Cancer Res, 6(2), 357-362. 
 
276 
 
Rosner, M., Hanneder, M., Freilinger, A. and Hengstschlager, M. (2007) 
Nuclear/cytoplasmic localization of Akt activity in the cell cycle. Amino Acids, 32(3), 
341-345. 
 
Rowland, A. F., Larance, M., Hughes, W. E. and James, D. E. (2011) Identification of 
RhoGAP22 as an Akt-dependent regulator of cell motility in response to insulin. Mol 
Cell Biol, 31(23), 4789-4800. 
 
Ruddon, R. W. (2007) Cancer Biology. Oxford University Press, USA. 
 
Rudolf, E. and Cervinka, M. (2003) Topoisomerases and tubulin inhibitors: a 
promising combination for cancer treatment. Curr Med Chem Anticancer Agents, 3(6), 
421-429. 
 
Sadeghi, N. (2015) Malignant tumors of the palate. [online], available: 
http://emedicine.medscape.com/article/847807-overview#a5 [accessed 14 October 
2015]. 
 
Sailan, A. T. (2010) HPV and p16 in head and neck cancer, unpublished thesis ( PhD 
Thesis), University of Dundee. 
 
Sakakibara, K., Liu, B., Hollenbeck, S. and Kent, K. C. (2005) Rapamycin inhibits 
fibronectin-induced migration of the human arterial smooth muscle line (E47) 
through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol, 288(6), 
H2861-2868. 
 
Saki, M., Toulany, M. and Rodemann, H. P. (2013) Acquired resistance to cetuximab 
is associated with the overexpression of Ras family members and the loss of 
radiosensitization in head and neck cancer cells. Radiother Oncol, 108(3), 473-478. 
277 
 
Saku, T., Hayashi, Y., Takahara, O., Matsuura, H., Tokunaga, M., Tokunaga, M., 
Tokuoka, S., Soda, M., Mabuchi, K. and Land, C. E. (1997) Salivary gland tumors 
among atomic bomb survivors, 1950-1987. Cancer, 79(8), 1465-1475. 
 
Salven, P., Heikkila, P., Anttonen, A., Kajanti, M. and Joensuu, H. (1997) Vascular 
endothelial growth factor in squamous cell head and neck carcinoma: expression 
and prognostic significance. Mod Pathol, 10(11), 1128-1133. 
 
Samson, D., Ratko, T., Rothenberg, B., Brown, H., Bonnell, C., Ziegler, K. and 
NAronson (2010) Comparative Effectiveness and Safety of Radiotherapy Treatments for 
Head and Neck Cancer., Rockville, MD: Agency for Healthcare Research and Quality. 
 
Sanz-Moreno, V. (2012) Tumour invasion: a new twist on Rac-driven mesenchymal 
migration. Curr Biol, 22(11), R449-451. 
 
Sapkota, A., Gajalakshmi, V., Jetly, D. H., Roychowdhury, S., Dikshit, R. P., Brennan, 
P., Hashibe, M. and Boffetta, P. (2007) Smokeless tobacco and increased risk of 
hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. 
Int J Cancer, 121(8), 1793-1798. 
 
Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) 
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 
307(5712), 1098-1101. 
 
Satelli, A. and Li, S. (2011) Vimentin in cancer and its potential as a molecular target 
for cancer therapy. Cell Mol Life Sci, 68(18), 3033-3046. 
 
278 
 
Sawair, F. A., Irwin, C. R., Gordon, D. J., Leonard, A. G., Stephenson, M. and Napier, 
S. S. (2003) Invasive front grading: reliability and usefulness in the management of 
oral squamous cell carcinoma. J Oral Pathol Med, 32(1), 1-9. 
 
Sawhney, M., Rohatgi, N., Kaur, J., Shishodia, S., Sethi, G., Gupta, S. D., Deo, S. V., 
Shukla, N. K., Aggarwal, B. B. and Ralhan, R. (2007) Expression of NF-kappaB 
parallels COX-2 expression in oral precancer and cancer: association with smokeless 
tobacco. Int J Cancer, 120(12), 2545-2556. 
 
Sawka, A. M., Thabane, L., Parlea, L., Ibrahim-Zada, I., Tsang, R. W., Brierley, J. D., 
Straus, S., Ezzat, S. and Goldstein, D. P. (2009) Second primary malignancy risk after 
radioactive iodine treatment for thyroid cancer: a systematic review and meta-
analysis. Thyroid, 19(5), 451-457. 
 
Scanlon, C. S., Van Tubergen, E. A., Inglehart, R. C. and D'Silva, N. J. (2013) 
Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent 
Res, 92(2), 114-121. 
 
Scartozzi, M., Giampieri, R., Maccaroni, E., Mandolesi, A., Biagetti, S., Alfonsi, S., 
Giustini, L., Loretelli, C., Faloppi, L., Bittoni, A., Bianconi, M., Del Prete, M., Bearzi, I. 
and Cascinu, S. (2012) Phosphorylated AKT and MAPK expression in primary 
tumours and in corresponding metastases and clinical outcome in colorectal cancer 
patients receiving irinotecan-cetuximab. J Transl Med, 10(1), 71. 
 
Schartinger, V. H., Kacani, L., Andrle, J., Schwentner, I., Wurm, M., Obrist, P., 
Oberaigner, W. and Sprinzl, G. M. (2004) Pharmacodiagnostic value of the HER 
family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec, 
66(1), 21-26. 
 
279 
 
Schmidt, A. and Hall, M. N. (1998) Signaling to the actin cytoskeleton. Annu Rev Cell 
Dev Biol, 14, 305-338. 
 
Schmitz, K. J., Grabellus, F., Callies, R., Otterbach, F., Wohlschlaeger, J., Levkau, B., 
Kimmig, R., Schmid, K. W. and Baba, H. A. (2005) High expression of focal adhesion 
kinase (p125FAK) in node-negative breast cancer is related to overexpression of 
HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res, 
7(2), R194-203. 
 
Schmitz, S., Ang, K. K., Vermorken, J., Haddad, R., Suarez, C., Wolf, G. T., Hamoir, 
M. and Machiels, J. P. (2014) Targeted therapies for squamous cell carcinoma of the 
head and neck: current knowledge and future directions. Cancer Treat Rev, 40(3), 390-
404. 
 
Schmukler, E., Kloog, Y. and Pinkas-Kramarski, R. (2014) Ras and autophagy in 
cancer development and therapy. Oncotarget, 5(3), 577-586. 
 
Schor, S. L. (1994) Cytokine control of cell motility: modulation and mediation by the 
extracellular matrix. Prog Growth Factor Res, 5(2), 223-248. 
 
Schor, S. L., Allen, T. D. and Harrison, C. J. (1980) Cell migration through three-
dimensional gels of native collagen fibres: collagenolytic activity is not required for 
the migration of two permanent cell lines. J Cell Sci, 46, 171-186. 
 
Schor, S. L., Ellis, I. R., Jones, S. J., Baillie, R., Seneviratne, K., Clausen, J., Motegi, K., 
Vojtesek, B., Kankova, K., Furrie, E., Sales, M. J., Schor, A. M. and Kay, R. A. (2003) 
Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform 
expressed by carcinoma and tumor-associated stromal cells. Cancer Res, 63(24), 8827-
8836. 
280 
 
Schor, S. L., Grey, A. M., Picardo, M., Schor, A. M., Howell, A., Ellis, I. and Rushton, 
G. (1991) Heterogeneity amongst fibroblasts in the production of migration 
stimulating factor (MSF): implications for cancer pathogenesis. EXS, 59, 127-146. 
 
Sebens, S. and Schafer, H. (2012) The tumor stroma as mediator of drug resistance--a 
potential target to improve cancer therapy? Curr Pharm Biotechnol, 13(11), 2259-2272. 
 
Semenza, G. L. (2010) Defining the role of hypoxia-inducible factor 1 in cancer 
biology and therapeutics. Oncogene, 29(5), 625-634. 
 
Semenza, G. L. (2012) Hypoxia-inducible factors in physiology and medicine. Cell, 
148(3), 399-408. 
 
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, 
H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes 
accumulation of ascites fluid. Science, 219(4587), 983-985. 
 
Shah, J. P., Johnson, N. W. and Batsakis, J. G., eds. (2003) Oral Cancer. Illustrated ed., 
London, Thieme. 
 
Shah, J. P., Patel, S. G. and American Cancer, S. (2001) Cancer of the Head and Neck. BC 
Decker. 
 
Shang, Z. J. and Li, J. R. (2005) Expression of endothelial nitric oxide synthase and 
vascular endothelial growth factor in oral squamous cell carcinoma: its correlation 
with angiogenesis and disease progression. J Oral Pathol Med, 34(3), 134-139. 
 
281 
 
Shang, Z. J., Li, Z. B. and Li, J. R. (2006) VEGF is up-regulated by hypoxic stimulation 
and related to tumour angiogenesis and severity of disease in oral squamous cell 
carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg, 35(6), 533-538. 
 
Shao, Z., Zhang, W. F., Chen, X. M. and Shang, Z. J. (2008) Expression of EphA2 and 
VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis 
and clinical outcome. Oral Oncol, 44(12), 1110-1117. 
 
Sherr, C. J. and McCormick, F. (2002) The RB and p53 pathways in cancer. Cancer 
Cell, 2(2), 103-112. 
 
Shi, Y. and Massague, J. (2003) Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus. Cell, 113(6), 685-700. 
 
Shibata, T., Matsuo, Y., Shamoto, T., Hirokawa, T., Tsuboi, K., Takahashi, H., 
Ishiguro, H., Kimura, M., Takeyama, H. and Inagaki, H. (2013) Girdin, a regulator of 
cell motility, is a potential prognostic marker for esophageal squamous cell 
carcinoma. Oncol Rep, 29(6), 2127-2132. 
 
Shibuya, M. (2013) Vascular endothelial growth factor and its receptor system: 
physiological functions in angiogenesis and pathological roles in various diseases. J 
Biochem, 153(1), 13-19. 
 
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H. and 
Sato, M. (1990) Nucleotide sequence and expression of a novel human receptor-type 
tyrosine kinase gene (flt) closely related to the fms family. Oncogene, 5(4), 519-524. 
 
282 
 
Shiels, M. S., Cole, S. R., Kirk, G. D. and Poole, C. (2009) A meta-analysis of the 
incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic 
Syndr, 52(5), 611-622. 
 
Shiffman, S. (2009) Light and intermittent smokers: Background and perspective. 
Nicotine & Tobacco Research, 11(2), 122-125. 
 
Shin, D. M., Ro, J. Y., Hong, W. K. and Hittelman, W. N. (1994) Dysregulation of 
Epidermal Growth Factor Receptor Expression in Premalignant Lesions during 
Head and Neck Tumorigenesis. Cancer Research, 54(12), 3153-3159. 
 
Shintani, S., Li, C., Ishikawa, T., Mihara, M., Nakashiro, K. and Hamakawa, H. (2004) 
Expression of vascular endothelial growth factor A, B, C, and D in oral squamous 
cell carcinoma. Oral Oncol, 40(1), 13-20. 
 
Shojaei, A. H. (1998) Buccal Mucosa As A Route For Systemic Drug Delivery. Journal 
of Pharmacy and Pharmaceutical Sciences, 1(1), 15-30. 
 
Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992) Vascular endothelial growth 
factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 
359(6398), 843-845. 
 
Sia, D., Alsinet, C., Newell, P. and Villanueva, A. (2013) VEGF Signaling in Cancer 
Treatment. Curr Pharm Des. 
 
Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer statistics, 2013. CA Cancer J 
Clin, 63(1), 11-30. 
 
283 
 
Silverman, S., Jr., Gorsky, M. and Lozada, F. (1984) Oral leukoplakia and malignant 
transformation. A follow-up study of 257 patients. Cancer, 53(3), 563-568. 
 
Simard, E. P., Torre, L. A. and Jemal, A. (2014) International trends in head and neck 
cancer incidence rates: Differences by country, sex and anatomic site. Oral Oncology, 
50(5), 387-403. 
 
Sinha, N., Mukhopadhyay, S., Das, D. N., Panda, P. K. and Bhutia, S. K. (2013) 
Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in 
oral cancer. Oral Oncol, 49(9), 854-862. 
 
Siriwardena, B. S., Kudo, Y., Ogawa, I., Udagama, M. N., Tilakaratne, W. M. and 
Takata, T. (2008) VEGF-C is associated with lymphatic status and invasion in oral 
cancer. J Clin Pathol, 61(1), 103-108. 
 
Sitaramayya, A., ed. (2009) Signal Transduction: Pathway,Mechanisms and Diseases. 1 
ed., Hiedelberg, Springer. 
 
Slack, R., Young, C. and Rushton, L. (2012) Occupational cancer in Britain. 
Nasopharynx and sinonasal cancers. Br J Cancer, 107 Suppl 1, S49-55. 
 
Slaughter, D. P., Southwick, H. W. and Smejkal, W. (1953) Field cancerization in oral 
stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 
6(5), 963-968. 
 
Smeets, S. J., Braakhuis, B. J., Abbas, S., Snijders, P. J., Ylstra, B., van de Wiel, M. A., 
Meijer, G. A., Leemans, C. R. and Brakenhoff, R. H. (2006) Genome-wide DNA copy 
number alterations in head and neck squamous cell carcinomas with or without 
oncogene-expressing human papillomavirus. Oncogene, 25(17), 2558-2564. 
284 
 
Smith, Teknos, T. N. and Pan, Q. (2013) Epithelial to mesenchymal transition in head 
and neck squamous cell carcinoma. Oral Oncology, 49(4), 287-292. 
 
Smith, B. D., Smith, G. L., Carter, D., Sasaki, C. T. and Haffty, B. G. (2000) Prognostic 
significance of vascular endothelial growth factor protein levels in oral and 
oropharyngeal squamous cell carcinoma. J Clin Oncol, 18(10), 2046-2052. 
 
Snow, J., Wackym, P. and Ballenger, J. (2009) Ballenger's Otorhinolaryngology: Head 
and Neck Surgery. 17 ed., London, People's Medical Pub. House/ B C Decker. 
 
Song, L. B., Li, J., Liao, W. T., Feng, Y., Yu, C. P., Hu, L. J., Kong, Q. L., Xu, L. H., 
Zhang, X., Liu, W. L., Li, M. Z., Zhang, L., Kang, T. B., Fu, L. W., Huang, W. L., Xia, 
Y. F., Tsao, S. W., Li, M., Band, V., Band, H., Shi, Q. H., Zeng, Y. X. and Zeng, M. S. 
(2009) The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and 
induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. 
J Clin Invest, 119(12), 3626-3636. 
 
Song, M. S., Salmena, L. and Pandolfi, P. P. (2012) The functions and regulation of 
the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13(5), 283-296. 
 
Sorrells Jr, D. L., Ghali, G. E., De Benedetti, A., Nathan, C.-A. and Li, B. D. L. (1999) 
Progressive amplification and overexpression of the eukaryotic initiation factor 4E 
gene in different zones of head and neck cancers. Journal of Oral and Maxillofacial 
Surgery, 57(3), 294-299. 
 
Specenier, P. and Vermorken, J. B. (2013) Cetuximab: its unique place in head and 
neck cancer treatment. Biologics, 7, 77-90. 
 
285 
 
Speight, P. M. (2007) Update on Oral Epithelial Dysplasia and Progression to Cancer. 
Head and Neck Pathology, 1(1), 61-66. 
 
Spiegel, S. and Milstien, S. (2003) Sphingosine-1-phosphate: an enigmatic signalling 
lipid. Nat Rev Mol Cell Biol, 4(5), 397-407. 
 
Squarize, C. H., Castilho, R. M., Abrahao, A. C., Molinolo, A., Lingen, M. W. and 
Gutkind, J. S. (2013) PTEN deficiency contributes to the development and 
progression of head and neck cancer. Neoplasia, 15(5), 461-471. 
 
Squarize, C. H., Castilho, R. M. and Santos Pinto, D., Jr. (2002) Immunohistochemical 
evidence of PTEN in oral squamous cell carcinoma and its correlation with the 
histological malignancy grading system. J Oral Pathol Med, 31(7), 379-384. 
 
Squarize, C. H., Castilho, R. M., Sriuranpong, V., Pinto, D. S., Jr. and Gutkind, J. S. 
(2006) Molecular cross-talk between the NFkappaB and STAT3 signaling pathways 
in head and neck squamous cell carcinoma. Neoplasia, 8(9), 733-746. 
 
Squier, C. and Brogden, K. A., eds. (2011) Human Oral Mucosa: Development, 
Structure, and Function. Hobeken, NJ, John Wiley & Sons, Inc. 
 
Stal, O., Perez-Tenorio, G., Akerberg, L., Olsson, B., Nordenskjold, B., Skoog, L. and 
Rutqvist, L. E. (2003) Akt kinases in breast cancer and the results of adjuvant 
therapy. Breast Cancer Res, 5(2), R37-44. 
 
Stewart, B. W. and Wild, C. P., eds. (2014) World cancer report 2014. Lyon, France, 
IARC. 
 
286 
 
Stock, C. and Schwab, A. (2006) Role of the Na/H exchanger NHE1 in cell migration. 
Acta Physiol (Oxf), 187(1-2), 149-157. 
 
Stossel, T. P., Condeelis, J., Cooley, L., Hartwig, J. H., Noegel, A., Schleicher, M. and 
Shapiro, S. S. (2001) Filamins as integrators of cell mechanics and signalling. Nat Rev 
Mol Cell Biol, 2(2), 138-145. 
 
Stracke, M. L., Aznavoorian, S. A., Beckner, M. E., Liotta, L. A. and Schiffmann, E. 
(1991) Cell motility, a principal requirement for metastasis. EXS, 59, 147-162. 
 
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., 
Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., Shefler, E., Ramos, A. 
H., Stojanov, P., Carter, S. L., Voet, D., Cortes, M. L., Auclair, D., Berger, M. F., 
Saksena, G., Guiducci, C., Onofrio, R. C., Parkin, M., Romkes, M., Weissfeld, J. L., 
Seethala, R. R., Wang, L., Rangel-Escareno, C., Fernandez-Lopez, J. C., Hidalgo-
Miranda, A., Melendez-Zajgla, J., Winckler, W., Ardlie, K., Gabriel, S. B., Meyerson, 
M., Lander, E. S., Getz, G., Golub, T. R., Garraway, L. A. and Grandis, J. R. (2011) The 
mutational landscape of head and neck squamous cell carcinoma. Science, 333(6046), 
1157-1160. 
 
Sturgis, E. M., Wei, Q. and Spitz, M. R. (2004) Descriptive epidemiology and risk 
factors for head and neck cancer. Semin Oncol, 31(6), 726-733. 
 
Stuwe, L., Muller, M., Fabian, A., Waning, J., Mally, S., Noel, J., Schwab, A. and 
Stock, C. (2007) pH dependence of melanoma cell migration: protons extruded by 
NHE1 dominate protons of the bulk solution. J Physiol, 585(Pt 2), 351-360. 
 
 
287 
 
Sugiura, T., Inoue, Y., Matsuki, R., Ishii, K., Takahashi, M., Abe, M. and Shirasuna, K. 
(2009) VEGF-C and VEGF-D expression is correlated with lymphatic vessel density 
and lymph node metastasis in oral squamous cell carcinoma: Implications for use as 
a prognostic marker. Int J Oncol, 34(3), 673-680. 
 
Sulis, M. L. and Parsons, R. (2003) PTEN: from pathology to biology. Trends Cell Biol, 
13(9), 478-483. 
 
Sweeny, L., Zimmermann, T. M., Liu, Z. and Rosenthal, E. L. (2012) Evaluation of 
tyrosine receptor kinases in the interactions of head and neck squamous cell 
carcinoma cells and fibroblasts. Oral Oncol, 48(12), 1242-1249. 
 
Tae, K., El-Naggar, A. K., Yoo, E., Feng, L., Lee, J. J., Hong, W. K., Hittelman, W. N. 
and Shin, D. M. (2000) Expression of vascular endothelial growth factor and 
microvessel density in head and neck tumorigenesis. Clin Cancer Res, 6(7), 2821-2828. 
 
Taghavi, N. and Yazdi, I. (2007) Type of food and risk of oral cancer. Arch Iran Med, 
10(2), 227-232. 
 
Takes, R. P., Baatenburg de Jong, R. J., Schuuring, E., Litvinov, S. V., Hermans, J. and 
Van Krieken, J. H. (1998) Differences in expression of oncogenes and tumor 
suppressor genes in different sites of head and neck squamous cell. Anticancer Res, 
18(6B), 4793-4800. 
 
Taki, M., Kamata, N., Yokoyama, K., Fujimoto, R., Tsutsumi, S. and Nagayama, M. 
(2003) Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by 
epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer 
Science, 94(7), 593-597. 
 
288 
 
Tan, M., Myers, J. N. and Agrawal, N. (2013) Oral cavity and oropharyngeal 
squamous cell carcinoma genomics. Otolaryngol Clin North Am, 46(4), 545-566. 
 
Tang, J.-M., He, Q.-Y., Guo, R.-X. and Chang, X.-J. (2006) Phosphorylated Akt 
overexpression and loss of PTEN expression in non-small cell lung cancer confers 
poor prognosis. Lung Cancer, 51(2), 181-191. 
 
Tankere, F., Camproux, A., Barry, B., Guedon, C., Depondt, J. and Gehanno, P. (2000) 
Prognostic value of lymph node involvement in oral cancers: a study of 137 cases. 
Laryngoscope, 110(12), 2061-2065. 
 
Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L. and Shows, T. 
B. (1991) Identification of a new endothelial cell growth factor receptor tyrosine 
kinase. Oncogene, 6(9), 1677-1683. 
 
Testa, J. R. and Bellacosa, A. (2001) AKT plays a central role in tumorigenesis. Proc 
Natl Acad Sci U S A, 98(20), 10983-10985. 
 
Thariat, J., Etienne-Grimaldi, M. C., Grall, D., Bensadoun, R. J., Cayre, A., Penault-
Llorca, F., Veracini, L., Francoual, M., Formento, J. L., Dassonville, O., De Raucourt, 
D., Geoffrois, L., Giraud, P., Racadot, S., Moriniere, S., Milano, G. and Van 
Obberghen-Schilling, E. (2012) Epidermal growth factor receptor protein detection in 
head and neck cancer patients: a many-faceted picture. Clin Cancer Res, 18(5), 1313-
1322. 
 
Thiery, J. P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat 
Rev Cancer, 2(6), 442-454. 
 
289 
 
Thiery, J. P., Acloque, H., Huang, R. Y. and Nieto, M. A. (2009) Epithelial-
mesenchymal transitions in development and disease. Cell, 139(5), 871-890. 
 
Thiery, J. P. and Sleeman, J. P. (2006) Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol, 7(2), 131-142. 
 
Thompson, E. W. and Williams, E. D. (2008) EMT and MET in carcinoma--clinical 
observations, regulatory pathways and new models. Clin Exp Metastasis, 25(6), 591-
592. 
 
Tischer, E., Gospodarowicz, D., Mitchell, R., Silva, M., Schilling, J., Lau, K., Crisp, T., 
Fiddes, J. C. and Abraham, J. A. (1989) Vascular endothelial growth factor: a new 
member of the platelet-derived growth factor gene family. Biochem Biophys Res 
Commun, 165(3), 1198-1206. 
 
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C. and 
Abraham, J. A. (1991) The human gene for vascular endothelial growth factor. 
Multiple protein forms are encoded through alternative exon splicing. J Biol Chem, 
266(18), 11947-11954. 
 
Toker, A. and Marmiroli, S. (2014) Signaling specificity in the Akt pathway in 
biology and disease. Advances in Biological Regulation. 
 
Toker, A. and Newton, A. C. (2000) Akt/protein kinase B is regulated by 
autophosphorylation at the hypothetical PDK-2 site. J Biol Chem, 275(12), 8271-8274. 
 
Tokunaga, E., Kimura, Y., Mashino, K., Oki, E., Kataoka, A., Ohno, S., Morita, M., 
Kakeji, Y., Baba, H. and Maehara, Y. (2006) Activation of PI3K/Akt signaling and 
hormone resistance in breast cancer. Breast Cancer, 13(2), 137-144. 
290 
 
Tornes, K., Bang, G., Stromme Koppang, H. and Pedersen, K. N. (1985) Oral 
verrucous carcinoma. Int J Oral Surg, 14(6), 485-492. 
 
Tredan, O., Galmarini, C. M., Patel, K. and Tannock, I. F. (2007) Drug resistance and 
the solid tumor microenvironment. J Natl Cancer Inst, 99(19), 1441-1454. 
 
Troiani, T., Martinelli, E., Capasso, A., Morgillo, F., Orditura, M., De Vita, F. and 
Ciardiello, F. (2012) Targeting EGFR in pancreatic cancer treatment. Curr Drug 
Targets, 13(6), 802-810. 
 
Tsantoulis, P. K., Kastrinakis, N. G., Tourvas, A. D., Laskaris, G. and Gorgoulis, V. G. 
(2007) Advances in the biology of oral cancer. Oral Oncology, 43(6), 523-534. 
 
Tse, G. M., Chan, A. W., Yu, K. H., King, A. D., Wong, K. T., Chen, G. G., Tsang, R. 
K. and Chan, A. B. (2007) Strong immunohistochemical expression of vascular 
endothelial growth factor predicts overall survival in head and neck squamous cell 
carcinoma. Ann Surg Oncol, 14(12), 3558-3565. 
 
Turati, F., Garavello, W., Tramacere, I., Pelucchi, C., Galeone, C., Bagnardi, V., 
Corrao, G., Islami, F., Fedirko, V., Boffetta, P., La Vecchia, C. and Negri, E. (2013) A 
meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from 
subgroup analyses. Alcohol Alcohol, 48(1), 107-118. 
 
Turner, N. and Grose, R. (2010) Fibroblast growth factor signalling: from 
development to cancer. Nat Rev Cancer, 10(2), 116-129. 
 
Uehara, M., Sano, K., Ikeda, H., Sekine, J., Irie, A., Yokota, T., Tobita, T., Ohba, S. and 
Inokuchi, T. (2004) Expression of vascular endothelial growth factor and prognosis 
of oral squamous cell carcinoma. Oral Oncol, 40(3), 321-325. 
291 
 
Uribe and Gonzalez. (2011) Epidermal growth factor receptor (EGFR) and squamous 
cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res 
Pract, 207(6), 337-342. 
 
Uribe, P. and Gonzalez, S. (2011) Epidermal growth factor receptor (EGFR) and 
squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. 
Pathology - Research and Practice, 207(6), 337-342. 
 
van Leeuwen, M. T., Grulich, A. E., McDonald, S. P., McCredie, M. R., Amin, J., 
Stewart, J. H., Webster, A. C., Chapman, J. R. and Vajdic, C. M. (2009) 
Immunosuppression and other risk factors for lip cancer after kidney 
transplantation. Cancer Epidemiol Biomarkers Prev, 18(2), 561-569. 
 
VanderWalde, N. A., Meyer, A. M., Liu, H., Tyree, S. D., Zullig, L. L., Carpenter, W. 
R., Shores, C. D., Weissler, M. C., Hayes, D. N., Fleming, M. and Chera, B. S. (2013) 
Patterns of care in older patients with squamous cell carcinoma of the head and 
neck: a surveillance, epidemiology, and end results-medicare analysis. J Geriatr 
Oncol, 4(3), 262-270. 
 
Vasko, V., Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V., Miyakawa, M., 
Isozaki, O., Murakami, H., Tsushima, T., Burman, K. D., De Micco, C. and Ringel, M. 
D. (2004) Akt activation and localisation correlate with tumour invasion and 
oncogene expression in thyroid cancer. J Med Genet, 41(3), 161-170. 
 
Villagrasa, P., Diaz, V. M., Vinas-Castells, R., Peiro, S., Del Valle-Perez, B., Dave, N., 
Rodriguez-Asiain, A., Casal, J. I., Lizcano, J. M., Dunach, M. and Garcia de Herreros, 
A. (2012) Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene, 31(36), 
4022-4033. 
 
292 
 
Vivanco, I. and Sawyers, C. L. (2002) The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer, 2(7), 489-501. 
 
Vogelstein, B., Lane, D. and Levine, A. J. (2000) Surfing the p53 network. Nature, 
408(6810), 307-310. 
 
Wakulich, C., Jackson-Boeters, L., Daley, T. D. and Wysocki, G. P. (2002) 
Immunohistochemical localization of growth factors fibroblast growth factor-1 and 
fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and 
fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, 
and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 
93(5), 573-579. 
 
Waller, C. F. (2014) Imatinib mesylate. Recent Results Cancer Res, 201, 1-25. 
 
Walter, J. (1977) Radiation hazards and protection: Cytotoxic chemotherapy. in 
Walter, J., (ed). Cancer and Radiotherapy: A short guide to nurses and medical students. 
London, Churchil Livingstone, pp. 23-41. 
 
Wan, L., Pantel, K. and Kang, Y. (2013) Tumor metastasis: moving new biological 
insights into the clinic. Nat Med, 19(11), 1450-1464. 
 
Wang, H., Wang, H.-S., Zhou, B.-H., Li, C.-L., Zhang, F., Wang, X.-F., Zhang, G., Bu, 
X.-Z., Cai, S.-H. and Du, J. (2013) Epithelial–Mesenchymal Transition (EMT) Induced 
by TNF-α Requires AKT/GSK-3β-Mediated Stabilization of Snail in Colorectal 
Cancer. PLoS One, 8(2), e56664. 
 
Wang, R. and Brattain, M. G. (2006) AKT can be activated in the nucleus. Cell Signal, 
18(10), 1722-1731. 
293 
 
Wang, W., Goswami, S., Sahai, E., Wyckoff, J. B., Segall, J. E. and Condeelis, J. S. 
(2005a) Tumor cells caught in the act of invading: their strategy for enhanced cell 
motility. Trends Cell Biol, 15(3), 138-145. 
 
Wang, W., Goswami, S., Sahai, E., Wyckoff, J. B., Segall, J. E. and Condeelis, J. S. 
(2005b) Tumor cells caught in the act of invading: their strategy for enhanced cell 
motility. Trends Cell Biol, 15(3), 138-145. 
 
Wang, Y., Zang, Q. S., Liu, Z., Wu, Q., Maass, D., Dulan, G., Shaul, P. W., Melito, L., 
Frantz, D. E., Kilgore, J. A., Williams, N. S., Terada, L. S. and Nwariaku, F. E. (2011) 
Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive 
oxygen species. Am J Physiol Cell Physiol, 301(3), C695-704. 
 
Warburton, G., Nikitakis, N. G., Roberson, P., Marinos, N. J., Wu, T., Sauk, J. J., Jr., 
Ord, R. A. and Wahl, S. M. (2007) Histopathological and lymphangiogenic 
parameters in relation to lymph node metastasis in early stage oral squamous cell 
carcinoma. J Oral Maxillofac Surg, 65(3), 475-484. 
 
Warnakulasuriya, S. (2009) Global epidemiology of oral and oropharyngeal cancer. 
Oral Oncology, 45(4–5), 309-316. 
 
Weinberger, P. M., Yu, Z., Haffty, B. G., Kowalski, D., Harigopal, M., Brandsma, J., 
Sasaki, C., Joe, J., Camp, R. L., Rimm, D. L. and Psyrri, A. (2006) Molecular 
classification identifies a subset of human papillomavirus--associated oropharyngeal 
cancers with favorable prognosis. J Clin Oncol, 24(5), 736-747. 
 
Weng, L., Enomoto, A., Ishida-Takagishi, M., Asai, N. and Takahashi, M. (2010) 
Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression 
and angiogenesis. Cancer Science, 101(4), 836-842. 
294 
 
Wenig, B. M. (2002) Squamous Cell Carcinoma of the Upper Aerodigestive Tract: 
Precursors and Problematic Variants. Mod Pathol, 15(3), 229-254. 
 
Werning, J. W. (2007) Oral Cancer: Diagnosis, Management, and Rehabilitation. London, 
Thieme Medical Publishers. 
 
Wesche, J., Haglund, K. and Haugsten, E. M. (2011) Fibroblast growth factors and 
their receptors in cancer. Biochem J, 437(2), 199-213. 
 
West, K. A., Brognard, J., Clark, A. S., Linnoila, I. R., Yang, X., Swain, S. M., Harris, 
C., Belinsky, S. and Dennis, P. A. (2003) Rapid Akt activation by nicotine and a 
tobacco carcinogen modulates the phenotype of normal human airway epithelial 
cells. J Clin Invest, 111(1), 81-90. 
 
Wiseman, M. (2008) The second World Cancer Research Fund/American Institute for 
Cancer Research expert report. Food, nutrition, physical activity, and the prevention 
of cancer: a global perspective. Proc Nutr Soc, 67(3), 253-256. 
 
Wlodarski, P., Grajkowska, W., Lojek, M., Rainko, K. and Jozwiak, J. (2006) 
Activation of Akt and Erk pathways in medulloblastoma. Folia Neuropathol, 44(3), 
214-220. 
 
Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T. and 
Stahl, U. (2002) Genomic gain of PIK3CA and increased expression of p110alpha are 
associated with progression of dysplasia into invasive squamous cell carcinoma. J 
Pathol, 198(3), 335-342. 
 
 
295 
 
Wong, Y. K., Liu, C. J., Kwan, P. C. and Chao, S. Y. (2003) Microvascular density and 
vascular endothelial growth factor immunoreactivity as predictors of regional lymph 
node metastasis from betel-associated oral squamous cell carcinoma. J Oral Maxillofac 
Surg, 61(11), 1257-1262. 
 
Woodhouse, E. C., Chuaqui, R. F. and Liotta, L. A. (1997) General mechanisms of 
metastasis. Cancer, 80(8 Suppl), 1529-1537. 
 
Woolgar, J. A. and Triantafyllou, A. (2009) Pitfalls and procedures in the 
histopathological diagnosis of oral and oropharyngeal squamous cell carcinoma and 
a review of the role of pathology in prognosis. Oral Oncol, 45(4-5), 361-385. 
 
Wu, H. T., Ko, S. Y., Fong, J. H., Chang, K. W., Liu, T. Y. and Kao, S. Y. (2009) 
Expression of phosphorylated Akt in oral carcinogenesis and its induction by 
nicotine and alkaline stimulation. J Oral Pathol Med, 38(2), 206-213. 
 
Wu, K., Fan, J., Zhang, L., Ning, Z., Zeng, J., Zhou, J., Li, L., Chen, Y., Zhang, T., 
Wang, X., Hsieh, J.-T. and He, D. (2012) PI3K/Akt to GSK3β/β-catenin signaling 
cascade coordinates cell colonization for bladder cancer bone metastasis through 
regulating ZEB1 transcription. Cellular Signalling, 24(12), 2273-2282. 
 
Wu, R., Baker, S. J., Hu, T. C., Norman, K. M., Fearon, E. R. and Cho, K. R. (2013) 
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a 
More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer. The 
American Journal of Pathology, 182(4), 1391-1399. 
 
Wu, Y., Mohamed, H., Chillar, R., Ali, I., Clayton, S., Slamon, D. and Vadgama, J. 
(2008) Clinical significance of Akt and HER2/neu overexpression in African-
American and Latina women with breast cancer. Breast Cancer Research, 10(1), R3. 
296 
 
Wyszomierski, S. L. and Yu, D. (2005) A knotty turnabout?: Akt1 as a metastasis 
suppressor. Cancer Cell, 8(6), 437-439. 
 
Xi, S., Zhang, Q., Gooding, W. E., Smithgall, T. E. and Grandis, J. R. (2003) 
Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res, 
63(20), 6763-6771. 
 
Xu, W., Huang, J. J. and Cheung, P. C. (2012) Extract of Pleurotus pulmonarius 
suppresses liver cancer development and progression through inhibition of VEGF-
induced PI3K/AKT signaling pathway. PLoS One, 7(3), e34406. 
 
Xu, W., Liu, L. Z., Loizidou, M., Ahmed, M. and Charles, I. G. (2002) The role of 
nitric oxide in cancer. Cell Res, 12(5-6), 311-320. 
 
Xue, G. and Hemmings, B. A. (2013) PKB/Akt-Dependent Regulation of Cell 
Motility. J Natl Cancer Inst, 105(6), 393-404. 
 
Xue, G., Restuccia, D. F., Lan, Q., Hynx, D., Dirnhofer, S., Hess, D., Ruegg, C. and 
Hemmings, B. A. (2012) Akt/PKB-mediated phosphorylation of Twist1 promotes 
tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling 
axes. Cancer Discov, 2(3), 248-259. 
 
Yamaguchi, H., Wyckoff, J. and Condeelis, J. (2005) Cell migration in tumors. Curr 
Opin Cell Biol, 17(5), 559-564. 
 
Yanagawa, T., Hayashi, Y., Yoshida, H., Yura, Y., Nagamine, S., Bando, T. and Sato, 
M. (1986) An adenoid squamous carcinoma-forming cell line established from an 
oral keratinizing squamous cell carcinoma expressing carcinoembryonic antigen. Am 
J Pathol, 124(3), 496-509. 
297 
 
Yang, J. and Weinberg, R. A. (2008) Epithelial-mesenchymal transition: at the 
crossroads of development and tumor metastasis. Dev Cell, 14(6), 818-829. 
 
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X. M., Feldman, R. I., Hamilton, A. D., 
Polokoff, M., Nicosia, S. V., Herlyn, M., Sebti, S. M. and Cheng, J. Q. (2004) 
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt 
signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res, 
64(13), 4394-4399. 
 
Yang, M. H., Hsu, D. S., Wang, H. W., Wang, H. J., Lan, H. Y., Yang, W. H., Huang, 
C. H., Kao, S. Y., Tzeng, C. H., Tai, S. K., Chang, S. Y., Lee, O. K. and Wu, K. J. (2010) 
Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol, 
12(10), 982-992. 
 
Yang, W.-H., Lan, H.-Y., Huang, C.-H., Tai, S.-K., Tzeng, C.-H., Kao, S.-Y., Wu, K.-J., 
Hung, M.-C. and Yang, M.-H. (2012) RAC1 activation mediates Twist1-induced 
cancer cell migration. Nat Cell Biol, 14(4), 366-374. 
 
Yang, X. H., Man, X. Y., Cai, S. Q., Li, C. M., Zhou, J. and Zheng, M. (2009) Autocrine 
effect of vascular endothelial growth factor on the proliferation of HaCaT cells. 
Zhejiang Da Xue Xue Bao Yi Xue Ban, 38(4), 338-342. 
 
Yao, K., Ye, P. P., Tan, J., Tang, X. J. and Shen Tu, X. C. (2008) Involvement of 
PI3K/Akt pathway in TGF-beta2-mediated epithelial mesenchymal transition in 
human lens epithelial cells. Ophthalmic Res, 40(2), 69-76. 
 
Yarbro, C. H., Frogge, M. H. and Goodman, M., eds. (2005) Cancer nursing: principles 
and practice. 6 ed., Burlington, MA, Jones and Bartlett Publishers. 
 
298 
 
Yeh, Y.-Y., Chiao, C.-C., Kuo, W.-Y., Hsiao, Y.-C., Chen, Y.-J., Wei, Y.-Y., Lai, T.-H., 
Fong, Y.-C. and Tang, C.-H. (2008) TGF-β1 increases motility and αvβ3 integrin up-
regulation via PI3K, Akt and NF-κB-dependent pathway in human chondrosarcoma 
cells. Biochemical Pharmacology, 75(6), 1292-1301. 
 
Yoeli-Lerner, M. and Toker, A. (2006) Akt/PKB Signaling in Cancer: A Function in 
Cell Motility and Invasion. Cell Cycle, 5(6), 603-605. 
 
Yoeli-Lerner, M., Yiu, G. K., Rabinovitz, I., Erhardt, P., Jauliac, S. and Toker, A. 
(2005) Akt Blocks Breast Cancer Cell Motility and Invasion through the 
Transcription Factor NFAT. Molecular Cell, 20(4), 539-550. 
 
Yokoyama, K., Kamata, N., Hayashi, E., Hoteiya, T., Ueda, N., Fujimoto, R. and 
Nagayama, M. (2001) Reverse correlation of E-cadherin and snail expression in oral 
squamous cell carcinoma cells in vitro. Oral Oncology, 37(1), 65-71. 
 
Yokoyama, K., Kimoto, K., Itoh, Y., Nakatsuka, K., Matsuo, N., Yoshioka, H. and 
Kubota, T. (2012) The PI3K/Akt pathway mediates the expression of type I collagen 
induced by TGF-beta2 in human retinal pigment epithelial cells. Graefes Arch Clin 
Exp Ophthalmol, 250(1), 15-23. 
 
Yu, Z., Weinberger, P. M., Sasaki, C., Egleston, B. L., Speier, W. F., Haffty, B., 
Kowalski, D., Camp, R., Rimm, D., Vairaktaris, E., Burtness, B. and Psyrri, A. (2007) 
Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal 
squamous cell cancer. Cancer epidemiology, biomarkers & prevention, 16(3), 553-558. 
 
 
 
299 
 
Zangani, D., Darcy, K. M., Masso-Welch, P. A., Bellamy, E. S., Desole, M. S. and Ip, 
M. M. (1999) Multiple differentiation pathways of rat mammary stromal cells in 
vitro: acquisition of a fibroblast, adipocyte or endothelial phenotype is dependent on 
hormonal and extracellular matrix stimulation. Differentiation, 64(2), 91-101. 
 
Zeisberg, M. and Neilson, E. G. (2009) Biomarkers for epithelial-mesenchymal 
transitions. J Clin Invest, 119(6), 1429-1437. 
 
Zeng, X. T., Deng, A. P., Li, C., Xia, L. Y., Niu, Y. M. and Leng, W. D. (2013a) 
Periodontal disease and risk of head and neck cancer: a meta-analysis of 
observational studies. PLoS One, 8(10), e79017. 
 
Zeng, X. T., Luo, W., Huang, W., Wang, Q., Guo, Y. and Leng, W. D. (2013b) Tooth 
loss and head and neck cancer: a meta-analysis of observational studies. PLoS One, 
8(11), e79074. 
 
Zhang, X., Wang, Q., Ling, M. T., Wong, Y. C., Leung, S. C. and Wang, X. (2007) 
Anti-apoptotic role of TWIST and its association with Akt pathway in mediating 
taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer, 120(9), 1891-1898. 
 
Zhang, Y. E. (2009) Non-Smad pathways in TGF-beta signaling. Cell Res, 19(1), 128-
139. 
 
Zhang, Z., Filho, M. S. and Nor, J. E. (2012) The biology of head and neck cancer 
stem cells. Oral Oncol, 48(1), 1-9. 
 
Zheng, H. and Kang, Y. (2013) Multilayer control of the EMT master regulators. 
Oncogene. 
 
300 
 
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M. and Hung, M. C. (2004) 
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of 
epithelial-mesenchymal transition. Nat Cell Biol, 6(10), 931-940. 
 
Zhou, G. L., Zhuo, Y., King, C. C., Fryer, B. H., Bokoch, G. M. and Field, J. (2003) Akt 
phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration. 
Mol Cell Biol, 23(22), 8058-8069. 
 
Zhou, H. and Huang, S. (2011) Role of mTOR Signaling in Tumor Cell Motility, 
Invasion and Metastasis. Curr Protein Pept Sci, 12(1), 30-42. 
 
Zhu, Q. S., Rosenblatt, K., Huang, K. L., Lahat, G., Brobey, R., Bolshakov, S., Nguyen, 
T., Ding, Z., Belousov, R., Bill, K., Luo, X., Lazar, A., Dicker, A., Mills, G. B., Hung, 
M. C. and Lev, D. (2011) Vimentin is a novel AKT1 target mediating motility and 
invasion. Oncogene, 30(4), 457-470. 
 
Ziegler, B. L., Valtieri, M., Porada, G. A., De Maria, R., Muller, R., Masella, B., 
Gabbianelli, M., Casella, I., Pelosi, E., Bock, T., Zanjani, E. D. and Peschle, C. (1999) 
KDR receptor: a key marker defining hematopoietic stem cells. Science, 285(5433), 
1553-1558. 
 
Znaor, A., Brennan, P., Gajalakshmi, V., Mathew, A., Shanta, V., Varghese, C. and 
Boffetta, P. (2003) Independent and combined effects of tobacco smoking, chewing 
and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in 
Indian men. Int J Cancer, 105(5), 681-686. 
 
 
 
301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
302 
 
 
 
 
 
 
 
 
 
 
Chapter 8 Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
303 
 
Appendix 1.  Justification and validation of using cell lines 
 
Justification: 
Six cell lines of different stages (Normal-dysplastic-cancer) were selected in this 
project to investigate the phosphorylation status of Akt with their subsequent 
migration behaviour and compare with each other. We aimed to select all the cell 
lines (epithelial and fibroblasts) from Head and Neck origin.  Justification of using 
individual cell line is summarised below: 
 
Cell type 
HaCaT:  Normal skin keratinocyte (Squamous epithelial origin). First reason of 
selecting HaCaT cell is unavailability of oral mucosal keratinocytes in the laboratory. 
Although derived from skin squamous epithelial region their morphology and 
function is similar to oral mucosal squamous epithelial cells. 
TR 146: HNSCC (epithelial cells from buccal mucosa) 
TYS: Oral adenoid squamous cell carcinoma (An epithelial neoplastic cell line was 
derived from well-differentiated squamous cell carcinoma that arose in human oral 
mucosa. The cell line then treated with Sodium-butyrate and transplanted in nude 
mice. The resulting mass was then histopathologically tested and interpreted as 
human adenoid squamous cell carcinoma derived from minor salivary gland present 
in oral mucosa (Yanagawa T. et ai,1986). We selected this cell line to compare its  
pAkt status and migratory behaviour with that of squamous cell carcinoma. 
MM1: Normal oral mucosal fibroblast (fibroblast origin) 
304 
 
COM D25: Mouth cancer-associated fibroblast cell (fibroblast origin) 
PM1: Dysplastic cell (derived from forehead skin, squamous epithelial origin as 
described in the literature). The unavailability of dysplastic cell line from oral 
mucosal origin made us select this cell line. Also, their characteristics were similar to 
oral mucosal squamous l dysplastic cells. 
 
Validation of cells used:  
Cells were tested with epithelial and fibroblast marker to prove their origin. 
 
Experiment type: Immunofluorescence assay 
 
Primary antibodies: 
1. Rabbit anti-wide spectrum cytokeratin antibodies (Ab9377, Abcam, Cambridge, 
AM, USA, Dilution- 1:100)- Epithelial marker 
2. Vimentin (D21H3) XP rabbit mAb (#5741. Cell signalling technology, MA, USA. 
Dilution- 1:100)- Fibroblast marker 
Secondary antibody: Goat Anti Rabbit Alexa Fluor 488 conjugated (#4412, Cell 
signalling technology, Dilution- 1:1000) 
Methodology: All the cells were cultured in serum-free medium. 
Immunofluorescence  methods as described in Chapter 4. 
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Results: 
 
 
 
 
 
 
 
 
 
 
 
 
HaCaT, TR 146 and TYS showed higher cytokeratin and very low or no vimentin 
expression that proves their epithelial origin. 
 
 
 
 
 
 
HaCaT 
TR 146 
TYS 
Cytokeratin Vimentin 
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MM1 and COM D25 cells showed higher vimentin and very low or no cytokeratin 
expression that proves their fibroblast origin. PM1 (dysplastic cell) showed high 
vimentin and very low cytokeratin expression which opposed their origin as 
described in the literature (Proby et al, 2000). This is the reason why this cell line was 
described in this project as ‘cells from dysplastic lesion’. 
MM1 
COM D25 
PM1 
Cytokeratin Vimentin 
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Appendix 2.  Representative WB report (TR146, PM1, VEGF, pAkt 
S473, pAkt T308) 
 
 
 
 
 
 
DATE:  07.06.12 
Reducing ‘Any kD’ SDS PAGE  
BioRad Pre-cast Gels 
EXPERIMENTS 
Analysis of cell pAkt (Thr 308) and pAkt Ser 473. Cells were grown up (~confluent PM1 and TR146 80%) 
in 60mm dishes and then transferred to serum free (SF) medium overnight, prior to the experiment. 
Cells were then transferred to the test conditions (i.e. SF, or SF + VEGF) for 15 minutes. Cells were then 
washed with ice-cold PBS and lysed in RIPA buffer containing protease inhibitor. 
SAMPLE PREPARATION FOR GELS 
Frozen lysates were used for blot. Prior to use, the lysates were defrosted and spun at 13,000rpm for 5 
minutes. Samples were then mixed with an equal volume of Laemmli sample loading buffer (BioRAD) 
including 5% (v/v 2-mercaptoethanol). Samples were heated at 95C for 5 minutes. 
WESTERN BLOTTING 
As described in method, onto nitrocellulose using transfer buffer. 15V 42 minutes. 
PRIMARY ANTIBODIES 
1. anti pAkt Thr 308 #  2965 (Cell Signaling Technology Inc.). Diluted 1:1000 in TBST + 1% (w/v) dried 
milk (N.B. 5% w/v BSA was recommended by the manufacturer) 
 
 2. Anti-pAkt Ser 473 # 4060 (cell Signaling) .Diluted 1:2000 in TBST + 1% (w/v) dried milk. 
SECONDARY ANTIBODY 
1. Goat anti-rabbit HRP# 7074L (Cell Signaling) was used for at a 1:2,000 diluted in 1% (w/v) milk TBST 
.Washed with TBST . 
GEL 1 LOADING  
Lane  l  
1 MM 2.5 
Western Blot 
Anti pAkt Thr 308 
1:1000 
Biochem lab protocol 
 
2 Positive control (FCS) 15 
3 PM1 SF 15 
4 PM1 SF + 100pg/ml VEGF 15 
5 PM1 SF + 1ng/ml VEGF 15 
6 PM1 SF + 10ng/ml VEGF 15 
7 PM1 SF + 100ng/ml VEGF  15 
8   
9 TR146 SF + 100ng/ml VEGF 15 
10 TR146  SF + 10ng/ml VEGF 15 
11 TR146  SF + 1ng/ml VEGF 15 
12 TR146 SF + 100pg/ml VEGF 15 
13 TR146 SF 15 
14 Positive control (FCS) 15 
15 MM 2.5 
308 
 
GEL 2 LOADING  
Lane  l  
1 MM 2.5 
Western Blot 
Anti pAkt Ser 473 
1:2000 
Biochem lab protocol 
 
2 Positive control (FCS) 15 
3 PM1 SF 15 
4 PM1 SF + 100pg/ml VEGF 15 
5 PM1 SF + 1ng/ml VEGF 15 
6 PM1 SF + 10ng/ml VEGF 15 
7 PM1 SF + 100ng/ml VEGF  15 
8   
9 TR146 SF + 100ng/ml VEGF 15 
10 TR146  SF + 10ng/ml VEGF 15 
11 TR146  SF + 1ng/ml VEGF 15 
12 TR146 SF + 100pg/ml VEGF 15 
13 TR146 SF 15 
14 Positive control (FCS) 15 
15 MM 2.5 
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Gel1: pAkt T308 
 
 
 
 
 
 
 
 
Gel 2: pAkt S473 
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Appendix 3. Representative WB experiment report (TR 146 VEGF time 
course pAkt T308) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DATE:  10.10.13 
Reducing 7.5% SDS PAGE  
BioRad Pre-cast Gels 
EXPERIMENTS 
Analysis of cell  pAkt Thr308 and pAkt S473. Cells were grown up (~confluent TR146 80%) in 60mm 
dishes and then transferred to serum free (SF) medium overnight, prior to the experiment. Cells were 
then transferred to the test conditions (i.e. SF, VEGF)  for 15 minutes,5 hrs and 24 hrs. Cells were then 
washed with ice-cold PBS and lysed in RIPA buffer containing protease inhibitor. 
SAMPLE PREPARATION FOR GELS 
Cells were frozen at -20ºC. Prior to use, the lysates were thawed and then spun at 13,000rpm for 5 
minutes. Samples were then mixed with an equal volume of Laemmli sample loading buffer (BioRAD) 
including 5% (v/v 2-mercaptoethanol). Samples were heated at 95C for 5 minutes. 
 
WESTERN BLOTTING 
As described in method, onto nitrocellulose using transfer buffer. 15V 42 minutes. 
PRIMARY ANTIBODIES 
1. anti pAKT Thr 308 #  2965 (Cell Signalling Technology Inc.). Diluted 1:1000 in TBST + 1% (w/v) 
dried milk (N.B. 5% w/v BSA was recommended by the manufacturer) 
2. anti pAKT Ser 473 #  4060 (Cell Signalling Technology Inc.). Diluted 1:2000 in TBST + 1% (w/v) 
dried milk (N.B. 5% w/v BSA was recommended by the manufacturer) 
 
SECONDARY ANTIBODY 
1. Goat anti-rabbit HR #7074L (Cell signaling) was used for at a 1:2,000 diluted in 1% (w/v) milk TBST 
.Washed with TBST. 
  
 
GEL 1 LOADING  
Lane  l  
1 MM 2 
Western Blot 
Anti pAkt T308 
1:1000 
Biochem lab protocol 
 
2 TR146 SF 15 min 15 
3 TR146 FCS 15 min 15 
4 TR146 10n VEGF 15 min 15 
5 TR146 SF 5 hrs 15 
6 TR146 FCS 5 hrs 15 
7 TR146 10n VEGF 5 hrs 15 
8 TR146 SF 24 hrs 15 
9 TR146 FCS 24 hrs 15 
10 TR146 10n VEGF 24 hrs 15 
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GEL 2 LOADING  
Lane  l  
1 MM 2 
Western Blot 
Anti pAkt S473 
1:2000 
Biochem lab protocol 
 
2 TR146 SF 15 min 15 
3 TR146 FCS 15 min 15 
4 TR146 VEGF 15 min 15 
5 TR146 SF 5 hrs 15 
6 TR146 FCS 5 hrs 15 
7 TR146 VEGF 5 hrs 15 
8 TR146 SF 24 hrs 15 
9 TR146 FCS 24 hrs 15 
10 TR146 VEGF 24 hrs 15 
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313 
 
Appendix 4.  Representative WB experiment report (TR146, VEGF±LY, 
VEGF±PI103, pAkt S473, pAkt T308) 
 
 
DATE:  09.10.13 
Reducing ‘Any kD’ SDS PAGE  
BioRad Pre-cast Gels 
EXPERIMENTS 
Analysis of cell  pAkt ser 473 and pAkt T308. Cells were grown up (~confluent TR146 80%) in 60mm 
dishes and then transferred to serum free (SF) medium overnight, prior to the experiment. Cells were 
then transferred to the test conditions (i.e. SF, VEGF, inhibitors) for 15 minutes. Cells were then washed 
with ice-cold PBS and lysed in RIPA buffer containing protease inhibitor. 
SAMPLE PREPARATION FOR GELS 
Cells were frozen at -20ºC. Prior to use, the lysates were thawed and then spun at 13,000rpm for 5 
minutes. Samples were then mixed with an equal volume of Laemmli sample loading buffer (BioRAD) 
including 5% (v/v 2-mercaptoethanol). Samples were heated at 95C for 5 minutes. 
 
WESTERN BLOTTING 
As described in method, onto nitrocellulose using transfer buffer. 15V 42 minutes. 
PRIMARY ANTIBODIES 
1. anti pAKT Ser 473 #  4060 (Cell Signalling Technology Inc.). Diluted 1:2000 in TBST + 1% (w/v) 
dried milk (N.B. 5% w/v BSA was recommended by the manufacturer) 
2.  anti pAKT Thr 308 #  2965s (Cell Signalling Technology Inc.). Diluted 1:1000 in TBST + 1% 
(w/v) dried milk (N.B. 5% w/v BSA was recommended by the manufacturer) 
SECONDARY ANTIBODY 
1. Goat anti-rabbit HR #7074L (Cell signaling) was used for at a 1:2,000 diluted in 1% (w/v) milk TBST 
.Washed with TBST. 
GEL 1 LOADING  
Lane  l  
1 MM 2 
Western Blot 
Anti pAkt Thr 308  
1:1000 
Biochem lab protocol 
 
2 TR146 SF 15 
3 TR146 10ng/ml VEGF 15 
4 TR146 1µM LY 15 
5 TR146 6µM LY 15 
6 TR146 VEGF + 1µM LY 15 
7 TR146 VEGF + 6µM LY 15 
8   
9 TR146 VEGF+125nM PI103 15 
10 TR146 VEGF+ 75nM PI103 15 
11 TR146 125nM PI103 15 
12 TR146 75nM PI103 15 
13 TR146 10ng/ml VEGF 15 
14 TR146 SF 15 
15 MM 2 
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GEL 2 LOADING  
Lane  l  
1 MM 2 
Western Blot 
Anti pAkt S473  
1:2000 
Biochem lab protocol 
 
2 TR146 SF 15 
3 TR146 10ng/ml VEGF 15 
4 TR146 1µM LY 15 
5 TR146 6µM LY 15 
6 TR146 VEGF + 1µM LY 15 
7 TR146 VEGF + 6µM LY 15 
8   
9 TR146 VEGF+125nM PI103 15 
10 TR146 VEGF+ 75nM PI103 15 
11 TR146 125nM PI103 15 
12 TR146 75nM PI103 15 
13 TR146 10ng/ml VEGF 15 
14 TR146 SF 15 
15 MM 2 
 
 
 
 
 
 
 
Gel 1: pAkt T308 
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Gel 2: pAkt S473 
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Appendix 5.  Representative WB report (TR146, HaCaT, pPTEN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
DATE:  26.11.13 
Reducing 7.5% Mini Protean TGX     SDS PAGE  
BioRad Pre-cast Gels 
EXPERIMENTS 
Analysis of cell pPTEN (Ser 380) . Cells were grown up (~confluent HaCaT and TR146 80%) in 60mm 
dishes and then transferred to serum free (SF) medium overnight, prior to the experiment. Cells were 
then transferred to the test conditions (i.e. SF, VEGF) for 15 minutes, 5 hrs and 24 hrs. Cells were then 
washed with ice-cold PBS and lysed in RIPA buffer containing protease inhibitor. 
SAMPLE PREPARATION FOR GELS 
Cells were frozen at -20ºC. Prior to use, the lysates were thawed and then spun at 13,000rpm for 5 
minutes. Samples were then mixed with an equal volume of Laemmli sample loading buffer (BioRAD) 
including 5% (v/v 2-mercaptoethanol). Samples were heated at 95C for 5 minutes. 
 
WESTERN BLOTTING 
As described in method, onto nitrocellulose using transfer buffer. 15V 42 minutes. 
PRIMARY ANTIBODIES 
 
1.pPTEN antibody (#9552, Cell Signalling Tech. Inc) was used at 1:1000 diluted in 1% (w/v) milk TBST 
SECONDARY ANTIBODY 
1. Goat anti-rabbit HR #7074L (Cell signaling) was used at a 1:2,000 diluted in 1% (w/v) milk TBST 
.Washed with TBST. 
 
GEL 1 LOADING  
Lane  l  
1 MM 2 
Western Blot 
Anti pPTEN antibody 
1:1000 
Biochem lab protocol 
 
2 HacaT SF 15 min 30 
3 HaCaT FCS 15 min 30 
4 HaCaT VEGF 15 min 30 
5 HacaT SF 5hrs 30 
6 HaCaT FCS 5hrs 30 
7 HaCaT VEGF 5hrs 30 
8 HacaT SF 24 hrs 30 
9 HaCaT FCS 24 hrs 30 
10 HaCaT VEGF 24 hrs 30 
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GEL 2 LOADING  
Lane  l  
1 MM 2 
Western Blot 
Anti pPTEN antibody 
1:1000 
Biochem lab protocol 
 
2 TR146 SF 15 min 30 
3 TR146  FCS 15 min 30 
4 TR146 VEGF 15 min 30 
5 TR146 SF 5hrs 30 
6 TR146 FCS 5hrs 30 
7 TR146 VEGF 5hrs 30 
8 TR146 SF 24 hrs 30 
9 TR146 FCS 24 hrs 30 
10 TR146 VEGF 24 hrs 30 
 
 
Gel 1: HaCaT, pPTEN 
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Gel 2: TR146, pPTEN
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Appendix 6. 2D Chemotaxis assay 
 
To observe the chemotactical responses of adherent oral cancer cell the µ-slide 
chemotaxis 2D (IBIDI GmbH) was used. Chemotactical movement requires the linear 
concentration profile which is generated in this slide by diffusion and stable for 48 
hours. Two reservoirs in the slide contain different chemoattractant concentration 
and are connected by a thin slit. The configuration of this slide is given below: 
 
 
 
Materials required: 
1. Adherent cells: HaCaT and TR-146 
2. Chemoattractant ( VEGF, serum free medium) 
3. Tissue culture treated µ-slide chemotaxis 2D (80306) 
4. Heated stage 
5. A humid chamber ( 90mm petri dish with wet tissue) 
6. Inverted microscope (Olympus IX70) 
7. Time lapse video  equipment (CCD camera, acquisition software) 
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8. Beveled pipette tip  
9. Slant cosmetic tweezers 
 
Method 
1. Seeding cells 
a) All the media and µ-slide and plugs were placed into the incubator the day 
before conducting the experiment. µ-slide was placed in a humid chamber to 
reduce the evaporation. 
b) Cell suspension of 3×106 cells/ml concentration was then made and used for 
this experiment. 
c) Filling ports 6 & 7 were then closed by plugs. 
d) 6 µl of cell suspension was applied on top of filling port 5. 
 
 
e) Air was then gently aspirated from the opposite filling port 4 using the same 
pipette settings. The cell suspension on top of port 5 was flushed inside filling 
the entire observation area homogeneously. 
 
321 
 
 
f) Plugs from filling port 6 & 7 were then removed gently and all the ports were 
covered with cultivation caps. 
 
 
g) The slide with cell suspension was then placed in a humid chamber and 
incubated for 4-5 hours until cell attachment. 
 
2. Cell attachment 
a) After cell attachment, all the cultivation caps were removed and filling port 6 
& 7 were closed by plugs. 
b) 10 µl cell free medium was then placed onto filling port 5 and the same 
amount of was aspirated from filling port 4. 
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c) This step of washing was repeated twice. 
 
3. Filling the reservoirs 
a) Plug from filling port 7 was then transferred to port 4. 
b) 45 µl cell-free medium was then gently injected into port 5 to fill one 
reservoir. Medium was injected very slowly until port 7 was completely filled. 
 
 
c) The Plug from port 6 was then transferred to port 7. The other reservoir then 
filled by injecting 45 µl cell-free medium into port 5. 
 
4. Applying chemoattractant 
a) 18 µl of chemoattractant was applied onto port 6 and the same amount of 
liquid was aspirated from port 5. 
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b) Filling port 6 & 7 both were then closed by plugs. 
 
 
5. Video microscopy 
a) Slide with attached cells was then mounted in the heated stage on the 
microscope.  
b) A 4X objective lens was used to observe the cell movement for 24 hours. 
Time-lapse images capturing was set for every 15 minutes.  
c) After 24 hours images were exported as uncompressed single page .tif files. 
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Appendix 7. Tracking cells and analysing chemotaxis 
 
ImageJ plugin, ‘Manual tracking’ was used to track the cells after the chemotaxis 
experiment. This plugin was able to determine the movement of objects between 
frames of a sequential stack.  At least 30 cells in the observation field were tracked. 
Tracking of cells with Manual tracking Plugin was done as follows: 
1. ImageJ was opened and a movie as single page .tif files was imported by 
using File/import/image sequence. 
2. ‘Manual tracking’ plugin was then opened. 
3. ‘Add track’ was selected. 
4. First cell was then followed by clicking on the cell’s midpoint, through all the 
time points. The software created a data table after clicking first cells. The 
data table contains all tracked cells and time points with (x,y) positions. 
5. Data table was then saved after tracking is completed. 
6. Image sequences were also saved as a movie file (.avi). 
Tracked data was then analysed by IBIDI’s chemotaxis and migration tool. The 
detailed procedures followed as below: 
1. Data table from manual tracking was imported in chemotaxis tool software. 
2. Number of slices (number of pictures used for tracking) were then selected. 
3. The software was then calibrated by setting x/y calibration (length of one 
pixel in µm) and the time interval (15 min). 
4. ‘Apply settings’ was then pressed. 
325 
 
5. A trajectory plot was created and exported as an image file. 
6. The values for centre of mass, FMI and Rayleigh test were then exported. 
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Appendix 8.  Boyden Chamber: HacaT and VEGF121  
 
BD-Assay of  HacaT and VEGF121 
 
Exp. Code: MI 030511aHacaTVEGF121 
 
Aim: To compare the effect of VEGF121 on the migration of normal human Keratinocyte, 
HacaT  in the Boyden chamber. 
 
Cells: Normal Human Keratinocyte, HacaT 
Cells: semi-confluent, 5.68 x105cells/90mm dish 
Cells have been grown on 90 mm dishes in 10% FCS-MEM-Glu media 
Last farmed 1 day before the experiment on 03.05.11 
 
Protocol: 
VEGF121: Stock concentration 100µg/ml, Code no 10-1296C (Insight Biotechnology 
Ltd.UK) tested at final concentrations of 1 pg/ml, 10 pg/ml, 100pg/ml, 1ng/ml, 10ng/ml and 
100 ng/ml. 
Native Collagen: 100 µg/ml. 
Upper chamber: Cells in SF-BSA (2 µg/ml);  
5.0x104 cells/50µl/well (1.0 x 106 cells/ml) 
Filter: 8 µm pore filters coated with native collagen, 8°C O/N, Collagen used 1st time. 
Lower chamber: with SF-BSA (2 µg/ml) 
SF-BSA 10 pg/ml VEGF121 1 ng/ml VEGF121 100 ng/ml 
VEGF121 
1 pg/ml VEGF121 100 pg/ml VEGF121 10 ng/ml VEGF121 1ng/ml EGF 
Incubation time:  5 hours 
Staining time: Overnight 
 
Results: 
Chamber: 5 hours’ incubation 
x 200 (Objective x10, eye piece x20) 
 
 Well Migrated cell no. Mean Stdev 
SF-BSA 
5hr 
Nat.col 
8µm 
1 16 12 11 13 2.645751 
2 13 14 12 13 1 
3 16 13 11 13.33333 2.516611 
4 15 13 14 14 1 
5 16 14 15 15 1 
6 15 12 13 13.33333 1.527525 
Mean     13.61+/-0.77  
1pg/ml VEGF121 
5hr 
Nat.col 
8µm 
1 14 16 12 14 2 
2 12 14 16 14 2 
3 13 12 15 13.33333 1.527525 
4 14 16 19 16.33333 2.516611 
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5 13 14 12 13 1 
6 15 17 14 15.33333 1.527525 
Mean     14.33+/-1.32  
10pg/ml VEGF121 
5hr 
Nat.col 
8µm 
1 13 15 12 13.33333 1.527525 
2 13 14 12 13 1 
3 15 17 15 15.66667 1.154701 
4 17 14 16 15.66667 1.527525 
5 14 16 13 14.33333 1.527525 
6 11 15 12 12.66667 2.081666 
Mean     14.11+/-1.32  
100pg/ml VEGF121 
5hr 
Nat.col 
8µm 
1 13 16 15 14.66667 1.527525 
2 17 14 12 14.33333 2.516611 
3 11 14 13 12.66667 1.527525 
4 12 11 14 12.33333 1.527525 
5 18 12 13 14.33333 3.21455 
6 16 14 11 16 2.516611 
Mean     14.05+/-1.35  
1ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 15 16 14 15 1 
2 17 12 15 14.66667 2.516611 
3 14 13 12 13 1 
4 15 18 14 15.66667 2.081666 
5 13 12 11 12 1 
6 15 16 13 14.66667 1.527525 
Mean     14.16+/-1.37  
10 ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 18 16 15 16.33333 1.527525 
2 16 14 13 14.33333 1.527525 
3 14 17 12 14.33333 2.516611 
4 11 13 16 13.33333 2.516611 
5 13 16 17 15.33333 2.081666 
6 13 15 18 15.33333 2.516611 
Mean     14.83+/-1.04  
100ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 11 13 10 11.33333 1.527525 
2 15 16 14 15 1 
3 17 16 15 16 1 
4 14 16 18 16 2 
5 12 14 13 13 1 
6 15 17 18 16.66667 1.527525 
Mean     14.66+/-2.07  
1ng/ml EGF 
5hr 
Nat.col 
8µm 
1 66 72 78 72 6 
2 68 74 73 71.66667 3.21455 
3 72 75 77 74.66667 2.516611 
4 82 84 79 81.66667 2.516611 
5 70 69 78 72.33333 4.932883 
6 72 78 75 75 3 
Mean     74.55+/-3.75  
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Summary of Data: 
Chamber 1:  HacaT with VEGF121 
5 hours incubation 
8µm pore filter coated with native collagen 
Base medium: SF-BSA(2 µg/ml) 
 
 
  Mean SD 
% 
migration 
 
Significance? 
Bonferroni’s 
(P<0.05) 
Kruskal-
Wallis & 
Dunnet’s test 
(p<0.05) 
SF-BSA 13.61 +/-0.77 100   
1pg/ml 
VEGF121 14.33 +/- 1.26 105 
N N 
10pg/ml 
VEGF121 14.11 +/-1.32 104 
N N 
100pg/ml 
VEGF121 14.05 +/-1.35 103 
N N 
1ng/ml 
VEGF121 14.16 +/-1.37 104 
N N 
10ng/ml 
VEGF121 14.83 +/-1.04 109 
N N 
100ng/ml 
VEGF121 14.66 +/-2.07 108 
N N 
1ng/ml 
EGF 74.55 +/-3.75 548 
Y Y 
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Appendix 9.  Boyden Chamber: TYS and VEGF121 
 
BD-Assay of  TYS and VEGF121 
 
Exp. Code: MI 06.12.10bTYSVEGF121 
 
Aim: To compare the effect of VEGF121 on the migration of Oral tumour cell line, TYS in the 
Boyden chamber. 
 
Cells: Oral adeno-carcinoma cell line, TYS 
Cells: semi-confluent, 4.8x105cells/90mm dish 
Cells have been grown on 90 mm dishes in 15% DCS-MEM-Glu media 
Last farmed 1 day before the experiment on 06.12.10 
 
Protocol: 
VEGF121: Stock concentration 100µg/ml, Code no 10-1296C (Insight Biotechnology 
Ltd.UK) tested at final concentrations of 1 pg/ml, 10 pg/ml, 100pg/ml, 1ng/ml, 10ng/ml and 
100 ng/ml. 
Native Collagen: 100 µg/ml. 
Upper chamber: Cells in SF-BSA (2 µg/ml);  
5.0x104 cells/50µl/well (1.0 x 106 cells/ml) 
Filter: 8 µm pore filters coated with native collagen, 8°C O/N, Collagen used 2nd time. 
Lower chamber: with SF-BSA (2 µg/ml) 
SF-BSA(1) 10 pg/ml VEGF121 1 ng/ml VEGF121 100 ng/ml 
VEGF121 
1 pg/ml VEGF121 100 pg/ml VEGF121 10 ng/ml VEGF121 SF-BSA(2) 
Incubation time:  5 hours 
Staining time: Overnight 
 
Results: 
Chamber: 4 hours’ incubation 
x 200 (Objective x10, eye piece x20) 
 Well         Migrated cell no. Mean Stdev 
SF-BSA(1) 
5hr 
Nat.col 
8µm 
1 23 25 27 25 2 
2 25 26 26 25.66667 0.57735 
3 24 20 22 22 2 
4 25 21 20 22 2.645751 
5 25 22 23 23.33333 1.527525 
6 23 27 29 26.33333 3.05505 
Mean     24.05+/-0.86  
1pg/ml VEGF121 
5hr 
Nat.col 
1 37 36 34 35.66667 1.527525 
2 32 29 31 30.66667 1.527525 
3 29 27 25 27 2 
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5µm 4 36 35 33 34.66667 1.527525 
5 33 29 31 31 2 
6 30 36 33 33 3 
Mean     32.00+/-0.57  
10pg/ml VEGF121 
5hr 
Nat.col 
8µm 
1 33 36 39 36 3 
2 45 42 43 43.33333 1.527525 
3 42 38 44 41.33333 3.05505 
4 40 49 46 45 4.582576 
5 42 39 43 41.33333 2.081666 
6 38 44 47 43 4.582576 
Mean     41.66+/-1.25  
100pg/ml 
VEGF121 
5hr 
Nat.col 
8µm 
1 42 43 47 44 2.645751 
2 52 45 49 48.66667 3.511885 
3 48 45 44 45.66667 2.081666 
4 49 47 45 47 2 
5 50 47 46 47.66667 2.081666 
6 52 51 49 52 1.527525 
Mean     47.5+/-0.68  
1ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 52 48 53 51 2.645751 
2 56 58 54 56 2 
3 58 52 55 55 3 
4 54 56 52 54 2 
5 49 52 56 52.33333 3.511885 
6 48 52 51 50.33333 2.081666 
Mean     53.11+/-0.62  
10 ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 53 49 56 52.66667 3.511885 
2 52 50 48 50 2 
3 56 56 54 55.33333 1.154701 
4 66 62 64 64 2 
5 59 62 63 61.33333 2.081666 
6 54 58 55 55.66667 2.081666 
Mean     56.5+/-0.76  
100ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 32 35 30 32.33333 2.516611 
2 29 25 31 28.33333 3.05505 
3 26 32 29 29 3 
4 25 28 24 25.66667 2.081666 
5 32 27 30 29.66667 2.516611 
6 26 29 32 29 3 
Mean     29.00+/-0.38  
SF-BSA(2) 
5hr 
1 15 18 21 18 3 
2 17 19 23 19.66667 3.05505 
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Nat.col 
8µm 
3 20 22 16 19.33333 3.05505 
4 24 21 19 21.33333 2.516611 
5 23 18 16 19 3.605551 
6 19 21 24 21.33333 2.516611 
Mean     19.77+/-0.40  
 
Summary of Data: 
Chamber 1: TYS with VEGF121 
5 hours incubation 
8µm pore filter coated with native collagen 
Base medium: SF-BSA(2 µg/ml) 
 
 
  Mean SD 
% 
migration 
 
Significance? 
Bonferroni’s 
(P<0.05) 
Kruskal-
Wallis & 
Dunnet’s test 
(p<0.05) 
SF-BSA(1) 24.55 +/-0.86    
SF-BSA(2) 19.77 +/-0.40    
SF-BSA 22.16  100   
1pg/ml 
VEGF121 32.00 +/ 0.57 144 
Y N 
10pg/ml 
VEGF121 41.66 +/-1.25 188 
Y N 
100pg/ml 
VEGF121 47.50 +/-0.68 214 
Y Y 
1ng/ml 
VEGF121 53.11 +/-0.62 240 
Y Y 
10ng/ml 
VEGF121 56.50 +/-0.76 255 
Y Y 
100ng/ml 
VEGF121 29.00 +/-0.38 131 
N N 
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Appendix 10.  Boyden Chamber: COM D25 and VEGF121  
 
BD-Assay of  COM D25 and VEGF121 
 
Exp. Code: MI 11.09.12aCOM D25VEGF121 
 
Aim: To compare the effect of VEGF121 on the migration of mouth cancer associated 
fibroblast cell , COM D25 in the Boyden chamber. 
 
Cells: Mouth cancer associated fibroblast cell line, COM D25 
Cells: semi-confluent, 2.5 x105cells/90mm dish 
Cells have been grown on 90 mm dishes in 10% FCS-MEM-Glu media 
Last farmed 1 day before the experiment on 11.09.12 
 
Protocol: 
VEGF121: Stock concentration 100µg/ml, Code no 10-1296C (Insight Biotechnology 
Ltd.UK) tested at final concentrations of 1 pg/ml, 10 pg/ml, 100pg/ml, 1ng/ml, 10ng/ml and 
100 ng/ml. 
Native Collagen: 100 µg/ml. 
Upper chamber: Cells in SF-BSA (2 µg/ml);  
5.0x104 cells/50µl/well (1.0 x 106 cells/ml) 
Filter: 8 µm pore filters coated with native collagen, 8°C O/N, Collagen used 1st  time. 
Lower chamber: with SF-BSA (2 µg/ml) 
SF-BSA(1) 10 pg/ml VEGF121 1 ng/ml VEGF121 100 ng/ml 
VEGF121 
1 pg/ml VEGF121 100 pg/ml VEGF121 10 ng/ml VEGF121 SF-BSA(2) 
Incubation time:  5 hours 
Staining time: Overnight 
 
Results: 
Chamber: 5 hours’ incubation 
x 200 (Objective x10, eye piece x20) 
 
 Well         Migrated cell no. Mean Stdev 
SF-BSA(1) 
5hr 
Nat.col 
8µm 
1 16 14 18 16 2 
2 15 19 14 16 2.645751 
3 14 17 19 16.66667 2.516611 
4 20 22 18 20 2 
5 18 22 17 19 2.645751 
6 19 22 16 19 3 
Mean     17.77 0.39 
1pg/ml VEGF121 1 21 15 19 18.33333 3.05505 
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5hr 
Nat.col 
5µm 
2 26 20 24 23.33333 3.05505 
3 20 29 23 24 4.582576 
4 19 24 26 23 3.605551 
5 17 20 24 20.33333 3.511885 
 6 36 29 32 32.33333 3.511885 
Mean     23.55 0.55 
10pg/ml VEGF121 
5hr 
Nat.col 
8µm 
1 24 22 26 24 2 
2 29 21 23 24.33333 4.163332 
3 25 20 22 22.33333 2.516611 
4 25 24 20 23 2.645751 
5 26 23 21 23.33333 2.516611 
6 24 21 28 24.33333 3.511885 
Mean     23.56 0.79 
100pg/ml VEGF121 
5hr 
Nat.col 
8µm 
1 26 22 24 24 2 
2 21 20 29 23.33333 4.932883 
3 19 23 22 21.33333 2.081666 
4 26 22 24 24 2 
5 27 28 26 27 1 
6 24 29 22 24 3.605551 
Mean     23.94 1.41 
1ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 26 29 28 27.66667 1.527525 
2 32 26 24 27.33333 4.163332 
3 26 29 20 25 4.582576 
4 22 28 26 25.33333 3.05505 
5 24 26 27 25.66667 1.527525 
6 26 28 24 26 2 
Mean     26.16 1.34 
10 ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 19 24 27 23.33333 4.041452 
2 35 29 28 30.66667 3.785939 
3 25 24 29 26 2.645751 
4 25 28 27 26.66667 1.527525 
5 29 24 28 27 2.645751 
6 34 30 29 31 2.645751 
Mean     27.44 0.91 
100ng/ml VEGF121 
5hr 
Nat.col 
8µm 
1 15 19 20 18 2.645751 
2 17 19 18 18 1 
3 16 17 19 17.33333 1.527525 
4 19 22 17 19.33333 2.516611 
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5 17 20 19 18.66667 1.527525 
6 20 24 17 20.33333 3.511885 
Mean     18.6 0.93 
 
 
 
Summary of Data: 
Chamber 1:  COM D25 with VEGF121 
5 hours incubation 
8µm pore filter coated with native collagen 
Base medium: SF-BSA(2 µg/ml) 
 
 
  Mean SD 
% 
migration 
 
Significance? 
Bonferroni’s 
(P<0.05) 
Kruskal-
Wallis & 
Dunnet’s test 
(p<0.05) 
SF-BSA 17.77 +/-0.39 100   
1pg/ml 
VEGF121 23.55 +/ -0.55 132 
Y** N 
10pg/ml 
VEGF121 23.56 +/-0.79 133 
Y** N 
100pg/ml 
VEGF121 23.94 +/-1.41 134 
Y** N 
1ng/ml 
VEGF121 26.16 +/-1.34 147 
Y*** N 
10ng/ml 
VEGF121 27.44 +/-0.91 154 
Y*** Y 
100ng/ml 
VEGF121 18.6 +/-0.93 105 
N Y 
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Appendix 11.  Boyden Chamber: TYS and VEGF + PI103 
 
BD-Assay of TYS and VEGF+ PI103 
 
Exp. Code: MI 170511aHACATVEGFPI103 
 
Aim: To compare the effect of PI103 ( PI3Kinase and mTORC2 inhibitor)  on the migration 
effect of VEGF on the TYS cells in the Boyden chamber. 
 
Cells: TYS, Oral adeno-carcinoma cell line 
Cells: semi-confluent, 1.13x106 cells/90mm dish 
Cells have been grown on 90 mm dishes in 10% FCS-MEM-Glu media 
Last farmed 1 day before the experiment on 17.05.11 
 
Protocol: 
PI103: Stock concentration 10mM, Code no 528100 ( Merck Chemicals Ltd, UK) tested at 
final concentrations of 75nm, 125nm and 250nm. 
Native Collagen: 100 µg/ml. 
Upper chamber: Cells in SF-BSA (2 µg/ml);  
5.0x104 cells/50µl/well (1.0 x 106 cells/ml) 
Filter: 8 µm pore filters coated with native collagen, 8°C O/N, Collagen used 1st time. 
Lower chamber: with SF-BSA (2 µg/ml) 
SF-BSA 125nM PI103 10 ng/ml VEGF+ 
75nM PI103 
10 ng/ml VEGF+ 
250 nM PI103 
75nM PI103 250 nMPI103 10 ng/ml VEGF+ 
125nM PI103 
10ng/ml VEGF  
 
Incubation time: 5 hours 
Staining time: Overnight 
 
Results: 
Chamber: 5 hours’ incubation 
x 200 (Objective x10, eye piece x20) 
 
 Well         Migrated cell no. Mean Stdev 
SF-BSA 
5hr 
Nat.col 
8µm 
1 25 21 23 23 2 
2 25 25 22 24 1.732051 
3 28 30 26 28 2 
4 22 23 24 23 1 
5 26 25 23 24.66667 1.527525 
6 24 25 23 24 1 
Mean     24.44+/-1.85  
75nM PI103 
5hr 
Nat.col 
8µm 
1 17 18 16 17 1 
2 16 17 17 16.66667 0.57735 
3 12 14 13 13 1 
4 17 18 16 17 1 
5 16 18 17 17 1 
6 12 17 14 14.33333 2.516611 
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Mean     15.83+/-1.73  
125nM PI103 
5hr 
Nat.col 
8µm 
1 13 11 12 12 1 
2 12 11 10 11 1 
3 10 9 11 10 1 
4 13 12 12 12.33333 0.57735 
5 11 12 13 12 1 
6 14 21 17 17.33333 3.511885 
Mean     12.44+/-2.54  
250nM PI103 
5hr 
Nat.col 
8µm 
1 9 11 10 10 1 
2 11 11 10 10.66667 0.57735 
3 10 9 11 10 1 
4 9 10 10 9.666667 0.57735 
5 9 8 10 9 1 
6 13 12 14 13 1 
Mean     10.38+/-1.38  
10 ng/ml VEGF+ 75nM PI103 
5hr 
Nat.col 
8µm 
1 23 26 25 24.66667 1.527525 
2 18 21 24 21 3 
3 20 22 21 21 1 
4 24 24 26 24.66667 1.154701 
5 27 29 28 28 1 
6 22 23 25 23.33333 1.527525 
Mean     23.77+/-2.64  
10 ng/ml VEGF+ 125nM PI103 
5hr 
Nat.col 
8µm 
1 23 21 20 21.33333 1.527525 
2 23 25 26 24.66667 1.527525 
3 24 27 28 26.33333 2.081666 
4 31 28 27 28.66667 2.081666 
5 19 25 26 23.33333 3.785939 
6 23 25 27 25 2 
Mean     24.88+/-2.5  
10ng/ml VEGF+ 250nM PI103 
5hr 
Nat.col 
8µm 
1 20 26 24 23.33333 3.05505 
2 22 24 26 24 2 
3 30 25 28 27.66667 2.516611 
4 22 20 21 21 1 
5 24 27 25 25.33333 1.527525 
6 27 27 28 27.33333 0.57735 
Mean     24.77+/-2.53  
10 ng/ml VEGF 
5hr 
Nat.col 
8µm 
1 61 65 63 63 2 
2 74 67 69 70 3.605551 
3 62 64 60 62 2 
4 73 65 69 69 4 
5 59 63 65 62.33333 3.05505 
6 64 68 62 64.66667 3.05505 
Mean     65.16+/-3.49  
 
 
 
Summary of Data: 
Chamber 1: HACAT with VEGF and PI103 
5 hours incubation 
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8µm pore filter coated with native collagen 
Base medium: SF-BSA (2 µg/ml) 
 
 
  Mean SD 
% 
migration 
 
Significance? 
Bonferroni’s 
(P<0.05) 
Kruskal-
Wallis & 
Dunnet’s test 
(p<0.05) 
SF-BSA 24.44 +/-1.85 100   
75nM 
PI103 15.83 +/- 1.73 65 
Y N 
125nM 
PI103 12.44 +/-2.54 51 
Y N 
250nM 
PI103 10.38 +/-1.38 42 
Y N 
10 ng/ml 
VEGF+ 
75nM 
PI103 23.77 +/-2.64 97 
N N 
10 ng/ml 
VEGF+ 
125nM 
PI103 24.88 +/-2.5 102 
N N 
10 ng/ml 
VEGF+ 
250nM 
PI103 24.77 +/-2.53 101 
N N 
10 ng/ml  
VEGF 65.16 +/- 3.49 267 
Y N 
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Appendix 12.  Statistical Analysis: Boyden chamber Assay, TYS and 
VEGF 
 
 
Parameter           
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 0.05) Yes         
Number of groups 7         
F 96.89         
R square 0.9432         
            
Bartlett's test for equal variances           
Bartlett's statistic (corrected) 7.434         
P value 0.2826         
P value summary ns         
Do the variances differ signif. (P < 0.05) No         
            
ANOVA Table SS df MS     
Treatment (between columns) 5642 6 940.3     
Residual (within columns) 339.7 35 9.705     
Total 5982 41       
            
Bonferroni's Multiple Comparison Test Mean Diff. t Significant? P < 0.05? Summary 95% CI of diff 
SF-BSA vs 1pg/ml VEGF121 -7.944 4.417 Yes ** -13.84 to -2.053 
SF-BSA vs 10pg/ml VEGF121 -17.61 9.791 Yes *** -23.50 to -11.72 
SF-BSA vs 100pg/ml VEGF121 -23.44 13.03 Yes *** -29.34 to -17.55 
SF-BSA vs 1ng/ml VEGF121 -29.06 16.15 Yes *** -34.95 to -23.16 
SF-BSA vs 10ng/ml VEGF121 -32.44 18.04 Yes *** -38.34 to -26.55 
SF-BSA vs 100ng/ml VEGF121 -4.944 2.749 No ns -10.84 to 0.9474 
1pg/ml VEGF121 vs 10pg/ml VEGF121 -9.667 5.374 Yes *** -15.56 to -3.775 
1pg/ml VEGF121 vs 100pg/ml VEGF121 -15.50 8.618 Yes *** -21.39 to -9.608 
1pg/ml VEGF121 vs 1ng/ml VEGF121 -21.11 11.74 Yes *** -27.00 to -15.22 
1pg/ml VEGF121 vs 10ng/ml VEGF121 -24.50 13.62 Yes *** -30.39 to -18.61 
1pg/ml VEGF121 vs 100ng/ml VEGF121 3.000 1.668 No ns -2.892 to 8.892 
10pg/ml VEGF121 vs 100pg/ml VEGF121 -5.833 3.243 No ns -11.73 to 0.05850 
10pg/ml VEGF121 vs 1ng/ml VEGF121 -11.44 6.363 Yes *** -17.34 to -5.553 
10pg/ml VEGF121 vs 10ng/ml VEGF121 -14.83 8.247 Yes *** -20.73 to -8.941 
10pg/ml VEGF121 vs 100ng/ml VEGF121 12.67 7.042 Yes *** 6.775 to 18.56 
100pg/ml VEGF121 vs 1ng/ml VEGF121 -5.611 3.120 No ns -11.50 to 0.2807 
100pg/ml VEGF121 vs 10ng/ml VEGF121 -9.000 5.004 Yes *** -14.89 to -3.108 
100pg/ml VEGF121 vs 100ng/ml VEGF121 18.50 10.29 Yes *** 12.61 to 24.39 
1ng/ml VEGF121 vs 10ng/ml VEGF121 -3.389 1.884 No ns -9.281 to 2.503 
1ng/ml VEGF121 vs 100ng/ml VEGF121 24.11 13.41 Yes *** 18.22 to 30.00 
10ng/ml VEGF121 vs 100ng/ml VEGF121 27.50 15.29 Yes *** 21.61 to 33.39 
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Appendix 13. Legends of the chemotaxis video clips 
 
 
Video clip 4.1 Chemotaxis video of TR146 cells stimulated by VEGF. 
Oral cancer cells (TR146) were stimulated to migrate towards VEGF in µ-slide 
chemotaxis chamber and this migration of TR146 cells towards the chemoattractant 
(VEGF) was statistically significant (p<0.001).  
 
Video clip 4.2 Trajectory plot of TR146 cells migration towards VEGF. 
Around 40 cells were randomly tracked and a trajectory plot was generated. The plot 
showed the migration of TR146 cells towards VEGF. 
 
Video clip 4.3 Chemotaxis video of HaCaT cells treated with VEGF. 
Chemotaxis video of normal keratinocyte cells showed no migration towards VEGF. 
 
Video clip 4.4 Trajectory plot of HaCaT cell migration treated with VEGF. 
A trajectory plot was also generated by randomly tracked HaCaT cells. No 
movement was observed among the tracked HaCaT cells. 
 
Video clip 4.5 Chemotaxis video of TR146 cells treated with VEGF and PI103. 
Oral cancer cells were not migrated towards VEGF and PI103. PI103 effectively 
blocked VEGF stimulated oral cancer cell migration. 
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Video clip 4.6 Trajectory plot of TR146 cells treated with VEGF and PI103. 
Randomly selected TR146 cells were tracked and trajectory plot was created. Plot 
showed no migration of oral cancer cells towards VEGF and PI103. 
 
Video clip 4.7 Chemotaxis video of TR146 cells treated with VEGF and LY294002. 
TR146 cells showed no migration towards VEGF and LY294002, in contrast cells 
were migrated towards negative control (serum-free media). Statistical analysis 
showed directness of the migration was significant towards serum-free (P<0.05) but 
Cells were stayed inside the observation area of the chamber. 
 
Video clip 4.8 Trajectory plot of TR146 cells treated with VEGF and LY294002. 
Trajectory plot showed TR146 cells moved opposite to VEGF and LY294002 although 
a minimum distance. 
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Appendix 14.  Optimizing of Akt antibodies (pAkt Ser473 and pAkt 
Thr 308) for IHC in Oral tumour samples 
 
 
Plan of experiment 
 
Primary antibodies 
pAkt Thr 308: # 2965 ( Cell signalling) (1:20, 1:50, 1:100) 
pAkt Ser473: # 4060(Cell Signalling) (1:20, 1:50, 1:100) 
 
Secondary antibodies 
Goat anti-rabbit HRP conjugated (# 7074, Cell Signalling) (1:1000 and 1:3000)  
Signal stain boost antibody detection reagent (#8114, Cell signaling) 
 
Negative ctrl: No primary, Blocking peptide 
 
Pre-treatment: Microwave with citrate buffer (pH 6), No Pre-treatment, Trypsin 
digestion 
 
Diluent: 5%NGS-TBST, SS Antibody diluent (#8112, Cell signaling) 
 
Staining: DAB in PBS 
 
Results:  
 
pAkt T308 Ab 20 Ab Pre-treatment Result 
1:20 7074 Citrate, micro No Staining 
1:20 7074 No PT No Staining 
1:20 7074 Trypsin No Staining 
1:20 8114 Citrate, micro No Staining 
1:20 8114 No PT No Staining 
1:20 8114 Trypsin No Staining 
1:50 7074 Citrate, micro No Staining 
1:50 7074 No PT No Staining 
1:50 7074 Trypsin No Staining 
1:50 8114 Citrate, micro Very good staining 
1:50 8114 No PT No Staining 
1:50 8114 Trypsin No Staining 
1:100 7074 Citrate, micro No Staining 
1:100 7074 No PT No Staining 
1:100 7074 Trypsin No Staining 
346 
 
 
 
Suggestions: 1:50 dilution for pAkt T308 and 1:20 dilution for pAkt S473 was 
selected for optimal IHC result. Signal boost detection reagent and Citrate buffer 
(microwave heating) were also selected for both the antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1:100 8114 Citrate, micro Very weak staining 
1:100 8114 No PT No Staining 
1:100 8114 Trypsin No Staining 
pAkt S473 Ab 20 Ab Pre-treatment Result 
1:20 7074 Citrate, micro No Staining 
1:20 7074 No PT No Staining 
1:20 7074 Trypsin No Staining 
1:20 8114 Citrate, micro Very good Staining 
1:20 8114 No PT No Staining 
1:20 8114 Trypsin No Staining 
1:50 7074 Citrate, micro No Staining 
1:50 7074 No PT No Staining 
1:50 7074 Trypsin No Staining 
1:50 8114 Citrate, micro Weak staining 
1:50 8114 No PT No Staining 
1:50 8114 Trypsin No Staining 
1:100 7074 Citrate, micro No Staining 
1:100 7074 No PT No Staining 
1:100 7074 Trypsin No Staining 
1:100 8114 Citrate, micro No staining 
1:100 8114 No PT No Staining 
1:100 8114 Trypsin No Staining 
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Appendix 15.  HNSCC patient data with pAkt score 
 
Patholog
y ID 
Gen
der 
Age Site Tobac
co 
Alcoh
ol 
Tumour 
Size 
Nodal 
Status 
Tumour 
grade 
Recur
rence 
Follow-
up 
(months) 
Stat
us 
            pAkt Thr308 score             pAkt Ser473 Score HPV 
16 
status 
Obs 
1 
Obs 
2 
Obs  
3 
Avg 
score 
Obs
1 
Obs 
2 
Obs 
3 
Avg 
scor
e 
01371006
-1A 
F 75 tongue Y N T4 N2 3 N 4 D 9 6 7 7.3 3 2 1 2 Y 
0187207-
1HE 
F 65 supragl
ottis 
Y H T4 N0 2 N 31 A 7 8 5 6.5 1 1 0 0.6 N 
01353006
-1 
F 63 retrom
olar 
trigone 
Y H T4 N2 2 N 29 A 7 4 6 5.6 1 2 2 1.6 N 
0059407-
1 
M 55 tonsil Y H T3 N2 2 N 30 A 8 5 6 6.3 3 2 2 2.3 N 
0109407-
2F 
F 59 tongue Y H T2 N2 2 N 31 A 9 8 5 7.3 0 0 0 0 N 
023388 
05-1 
M 70 soft 
palate 
Y N T1 N0 2 N 35 A 8 5 4 5.6 2 2 2 2 N 
0338107-
2G 
M 75 tongue Y H T2 N0 2 N 30 A 6 6 2 4.6 1 1 1 1 N 
01864704
-1B 
F 78 retrom
olar 
trigone  
Y H T2 N0 2 N 57 A 4 8 3 5 0 0 0 0 N 
0164406-
3C 
M 65 tongue Y H T4 N1 2 N 43 A 10 8 6 8 1 0 0 0.3 N 
00148106
-1 
M 59 soft 
palate 
Y H T2 N0 3 Y 34 D 7 5 8 6.5 2 3 2 2.3 N 
01514806
-3D 
F 75 tongue Y N T4 N2 3 N 4 D 8 5 7 6.5 0 0 0    N 
01803103
-1 
M 67 floor of 
mouth 
Y M T1 N0 1 N 60 A 7 4 3 4.5 2 1 1 1.3 N 
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0671203-
1 
M 69 oropha
rynx 
Y M T4 N0 3 Y 44 D 6 8 4 6 0 0 0 0 N 
0711302-
1B 
F 55 tongue N M T2 N2 2 Y 60 A 4 4 4 4 3 3 1 2.3 N 
01399006
-1 
F 59 alveolu
s 
N M T4 N0 2 N 35 A 1 2 3 2 1 1 2 1.3 Y 
02579406
-1 
F 59 tongue Y H T2 N0 2 N 31 A 5 6 7 6 2 2 1 1.6 N 
00232207
-1 
F 63 floor of 
mouth 
Y H T1 N0 2 N 29 A 8 6 3 5.5 6 4 3 4.3 N 
0507307-
2B 
F 63 floor of 
mouth 
Y H T1 N0 2 N 29 A 5 8 4 5.5 0 0 0 0 N 
01290919
9-2 
M 64 tongue Y N T1 N0 2 N 55 A 2 2 1 1.5 0 0 0 0 N 
01020203
-3K 
M 62 tongue N H T2 N2 2 Y 66 A 12 7 9 9.5 0 0 0 0 N 
01258903
-1C 
M 64 floor of 
mouth 
Y H T4 N0 2 Y 60 A 6 4 8 6 0 0 0 0 N 
681/03-
1B 
M 74 retrom
olar 
trigone  
Y M T1 N0 1 N 60 A 8 5 3 5.2 0 0 0 0 Y 
00442204
-1L 
F 97 retrom
olar 
trigone  
N N T2 N0 2 Y 8 D 3 2 1 2 1 0 0 0.3 Y 
01642002
-1A 
M 60 tongue Y H T2 N2 2 Y 40 A 6 7 3 5.4 0 0 0 0 N 
00196904
-1 
F 97 retrom
olar 
trigone  
N N T2 N2 2 Y 8 D 3 2 1 2 1 0 0 0.3 N 
01404702
-1B 
M 60 tongue Y H T2 N2 2 Y 40 A 5 7 6 6 1 1 1 0.9 N 
0267305-
3E 
M 66 retrom
olar 
trigone  
Y H T1 N0 2 N 60 A 1 2 3 2 0 0 0 0 N 
0848002-
3D 
F 55 tongue N M T2 N2 2 Y 60 A 6 8 3 5.6 0 0 0 0 N 
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60315505
-1G 
M 52 tongue N M T1 N1 3 Y 54 A 8 7 5 6.5 0 0 0 0 N 
00629005
-1 
F 46 tongue Y M T1 N0 2 N 51 A 8 10 6 8 0 0 1 0.3 N 
006/4/04-
HED 
F 63 soft 
palate 
Y M T2 N2 3 N 60 A 1 3 2 2 1 1 1 1 N 
01291204
-1C 
M 77 tongue N M T1 N1 3 Y 37 D 6 7 7 6.6 0 1 1 0.6 N 
0139006-
1E 
F 62 tongue N M T1 N2 3 N 37 A 1 2 3 2 0 0 0 0 N 
01423506
3H 
F 59 alveolu
s 
N M T2 N0 2 N 35 A 1 1 4 2 0 0 0 0 N 
00642004
-1 
M 78 tongue Y H T2 N1 2 N 60 A 8 7 8 7.5 1 1 1 0.9 N 
0044505-
1 
M 52 tongue N M T1 N1 3 Y 54 A 8 4 5 5.5 1 1 2 1.3 N 
01076404
-1B 
M 67 floor of 
mouth 
Y M T1 N0 1 N 60 A 1 3 2 1.9 0 0 0 0 N 
02181410
5-2L 
M 62 tongue N M T1 N0 2 N 45 A 6 3 3 4 0 0 0 0 Y 
01218406
-1 
F 62 tongue N M T1 N2 3 N 37 A 7 5 5 5.5 1 0 0 0.3 N 
00624606
-1 
M 62 tongue N M T4 N0 3 N 41 A 4 3 1 2.6 1 2 1 1.3 N 
01399406
-4F 
F 81 floor of 
mouth 
Y H T1 N1 3 N 37 A 8 5 7 6.5 1 1 0 0.6 Y 
0958906-
1C 
M 67 tongue Y H T2 N1 2 N 39 A 7 7 6 6.5 0 0 0 0 N 
01298705
-1 
M 84 alveolu
s 
Y M T4 N0 2 Y 7 D 7 6 6 6.5 2 1 1 1.3 N 
0012706-
1 
M 65 tongue Y H T4 N1 2 N 43 A 8 5 7 6.5 0 0 0 0 Y 
01292806
-2K 
M 69 retrom
olar 
trigone  
Y M T4 N2 3 Y 38 A 9 5 7 7 0 0 0 0 N 
01596705 F 78 buccal N M T2 N0 2 Y 17 D 7 4 4 5 1 1 1 1 N 
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-1 mucosa 
40727066
-1 
M 67 tongue Y H T2 N1 2 N 39 A 8 8 6 7.3 0 0 1 0.3 N 
00965006
-3C 
F 66 floor of 
mouth 
Y N T2 N2 3 N 39 A 8 7 4 6.3 0 0 1 0.3 N 
02318405
-1 
M 62 soft 
palate 
Y H T2 N2 2 N 42 A 4 9 8 7 1 1 0 0.6 N 
02060804
-1 
F 66 alveolu
s 
N H T1 N2 2 Y 54 A 6 6 7 6.3 1 0 1 0.6 N 
01029003
-1 
M 64 floor of 
mouth 
Y H T4 N0 2 Y 60 D 6 5 4 5 1 1 1 1 N 
0055407-
1 
M 75 tongue Y H T2 N0 2 N 30 A 7 8 6 7 1 1 2 1.3 N 
1993205-
1 
M 84 soft 
palate 
Y M T4 N0 2 Y 30 D 8 6 10 8 4 2 2 2.6 N 
0213305-
1B 
F 62 floor of 
mouth 
Y H T1 N0 2 N 54 A 8 7 5 6.6 0 0 0 0 N 
0202204-
1 
F 62 floor of 
mouth 
Y H T1 N0 2 N 54 A 2 2 2 2 1 1 1 1 N 
1960104-
1 
M 66 retrom
olar 
trigone  
Y H T1 N0 2 N 60 A 9 4 4 5.6 0 0 0 0 N 
0279203-
1 
M 36 tongue Y H T1 N0 1 N 41 A 6 6 6 6 1 1 1 1 N 
00486606
-1A 
M 36 tongue Y H T1 N0 1 N 41 A 4 7 6 5.6 0 0 0 0 N 
Tobacco: Y-Yes, N-No; Alcohol: N-None drinker, M-Medium drinker and H-Heavy drinker; Status: D-Dead, A-Alive 
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Appendix 16.  Statistical analysis of pAkt IHC score and HNSCC patient data 
 
General Linear Model: Multivariate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Between-Subjects Factors 
 Value Label N 
Smoking 0 non-smoker 16 
1 Smoker 42 
Alcohol 0 Nondrinker 7 
1 meudim drinker 21 
2 heavy drinker 30 
Nodalstatusgr
p 
0 No lymph node metas 31 
1 Lymp node metas 1&2 27 
agegrp 0 <65 30 
1 >=65 28 
    
Tests of Between-Subjects Effects 
Dependent Variable: pAkt T308 
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected Model 138.717a 18 7.706 4.059 .000 
Intercept 518.039 1 518.039 272.876 .000 
Smoking 10.063 1 10.063 5.301 .027 
Alcohol 40.076 2 20.038 10.555 .000 
Nodalstatusgrp 2.479 1 2.479 1.306 .260 
agegrp 9.460 1 9.460 4.983 .031 
Smoking * Alcohol 12.144 2 6.072 3.198 .052 
Smoking * Nodalstatusgrp 7.815 1 7.815 4.116 .049 
Smoking * agegrp .020 1 .020 .011 .919 
Alcohol * Nodalstatusgrp 13.506 2 6.753 3.557 .038 
Alcohol * agegrp 20.155 2 10.077 5.308 .009 
Nodalstatusgrp * agegrp 5.317 1 5.317 2.801 .102 
Smoking * Alcohol * 
Nodalstatusgrp 
.323 1 .323 .170 .682 
Smoking * Alcohol * agegrp .158 1 .158 .083 .774 
Smoking * Nodalstatusgrp * 
agegrp 
11.391 1 11.391 6.000 .019 
Alcohol * Nodalstatusgrp * agegrp 10.874 1 10.874 5.728 .022 
Smoking * Alcohol * 
Nodalstatusgrp * agegrp 
.000 0 . . . 
Error 74.039 39 1.898   
Total 1894.330 58    
Corrected Total 212.756 57    
a. R Squared = .652 (Adjusted R Squared = .491) 
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                Cox Regression (Adjusted) 
Categorical Variable Codingsc,d,e,f,g 
 Frequency (1)b (2) 
Alcohola 0=Nondrinker 7 1 0 
1=meudim drinker 21 0 1 
2=heavy drinker 30 0 0 
Tumoursizegrpa 0=T1-T2 43 1  
1=T3-T4 15 0  
pAkts473grpa 0=No phosphorylation 23 1 0 
1=Low phosphorylation 30 0 1 
2=Medium phosphorylation 5 0 0 
agegrpa 0=<65 30 1  
1=>=65 28 0  
HPVa 0=negative 29 1  
1=positive 29 0  
a. Indicator Parameter Coding 
b. The (0,1) variable has been recoded, so its coefficients will not be the same as for 
indicator (0,1) coding. 
c. Category variable: Alcohol 
d. Category variable: Tumoursizegrp 
e. Category variable: pAkts473grp 
f. Category variable: agegrp 
g. Category variable: HPV 
 
 
     Block 1: Method = Backward Stepwise (Likelihood Ratio) 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
Step 1 HPV -4.493 1.578 8.103 1 .004 .011 .001 .247 
Tumoursizegrp -2.724 .970 7.895 1 .005 .066 .010 .439 
agegrp -3.847 1.436 7.176 1 .007 .021 .001 .356 
pAkts473grp   10.667 2 .005    
pAkts473grp(1) -6.081 1.883 10.426 1 .001 .002 .000 .092 
pAkts473grp(2) -3.068 1.461 4.410 1 .036 .047 .003 .815 
Alcohol   7.763 2 .021    
Alcohol(1) 3.900 1.422 7.523 1 .006 49.391 3.044 801.498 
Alcohol(2) .990 1.044 .900 1 .343 2.692 .348 20.829 
 
 
Omnibus Tests of Model Coefficientsb 
Step -2 Log Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
1a 37.254 37.016 7 .000 44.694 7 .000 44.694 7 .000 
a. Variable(s) Entered at Step Number 1: HPV  Tumoursizegrp  agegrp  pAkts473grp  Alcohol 
b. Beginning Block Number 1. Method = Backward Stepwise (Likelihood Ratio) 
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Appendix 17.  Published papers 
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